<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.63, http://www.edgar-online.com -->
<TITLE> LabStyle Innovations Corp. (Form: 10-K, Received: 02/08/2016 16:51:48) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_BUSINESS **FIS_RISK_FACTORS **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_PROPERTIES **FIS_LEGAL_PROCEEDINGS **FIS_MINE_SAFETY_DISCLOSURE **FIS_PART_II **FIS_MARKET **FIS_FINANCIAL_DATA **FIS_MANAGEMENTS_DISCUSSION **FIS_RESULTS_OF_OPERATIONS **FIS_LIQUIDITY_CAPITAL **FIS_MARKET_RISK **FIS_FINANCIAL_STATEMENTS **FIS_ACCOUNTING_CHANGES **FIS_CONTROL_AND_PROCEDURES **FIS_OTHER_INFORMATION **FIS_PART_III **FIS_DIRECTORS_AND_OFFICERS **FIS_NAME_AND_TITLE **FIS_COMPENSATION **FIS_COMPENSATION_TABLE **FIS_SECURITY_OWNERS **FIS_BENEFICIAL_OWNERS **FIS_OFFICER_TRANSACTIONS **FIS_ACCOUNTANT_FEES **FIS_PART_IV **FIS_EXHIBITS **FIS_AUDITORS_OPINION **FIS_BALANCE_SHEET **FIS_BALANCE_SHEET_2 **FIS_STOCKHOLDERS_EQUITY **FIS_CASH_FLOW **FIS_NOTES_TO_FINANCIAL_STATEMENT **FIS_SUBSEQUENT_EVENTS **FIS_SIGNATURES FIS_EXHIBIT_4 FIS_EXHIBIT_10 FIS_EXHIBIT_10_2 FIS_EXHIBIT_21 FIS_EXHIBIT_23 **FIS_EXPERTS_CONSENT FIS_EXHIBIT_31 **FIS_CERTIFICATION FIS_EXHIBIT_31_2 **FIS_CERTIFICATION_2 FIS_EXHIBIT_32 **FIS_CERTIFICATION_3 ">
<META NAME="DETECTED PAGES" CONTENT="158">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="V430703_10K_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	UNITED STATES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	SECURITIES AND EXCHANGE COMMISSION
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Washington, D.C. 20549
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	FORM 10-K
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	(Mark One)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 10PT">
	&thorn;
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	For the fiscal year ended December 31,
	2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 10PT">
	&uml;
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	TRANSITION
	REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 23.1PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	For the transition period from ______________to________________
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Commission File No.&nbsp;333-186054
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	LABSTYLE INNOVATIONS CORP.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	(Exact name of registrant as specified in
	its charter)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; WIDTH: 49%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Delaware
</B>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; WIDTH: 49%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	45-2973162
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	(State or other jurisdiction of
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	incorporation or organization)
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	(I.R.S. Employer
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Identification Number)
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	9 Halamish Street
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Caesarea Industrial Park
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	3088900, Israel
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	(Address of principal executive offices)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	972-4-770-4055
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Registrant&rsquo;s telephone number, including
	area code:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	None
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Securities Registered Pursuant to Section&nbsp;12(b)
	of the Act:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	None
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Securities Registered Pursuant to Section&nbsp;12(g)
	of the Act:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Indicate by check mark if the registrant
	is a well-known seasoned issuer, as defined in Rule&nbsp;405 of the Securities Act. Yes&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	No&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&thorn;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Indicate by check mark if the registrant
	is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Act.&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&thorn;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Indicate by check mark whether the registrant
	(1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the
	preceding 12&nbsp;months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been
	subject to such filing requirements for the past 90&nbsp;days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&thorn;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Indicate by check mark whether the registrant
	has submitted electronically and posted on it corporate Web site, if any, every Interactive Data File required to be submitted
	and posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T (&sect;&nbsp;232.405 of this chapter) during the preceding 12 months
	(or for such shorter time that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&thorn;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Indicate by check mark if disclosure of
	delinquent filers pursuant to Item&nbsp;405 of Regulation&nbsp;S-K is not contained herein, and will not be contained, to the best
	of registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference in Part&nbsp;III of this
	Form&nbsp;10-K or any amendment to this Form&nbsp;10-K.&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&thorn;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Indicate by check mark whether the registrant
	is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
	of &ldquo;large accelerated filer&rdquo;, &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company| in Rule&nbsp;12b-2
	of the Exchange Act. (Check one):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 25%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Large&nbsp;accelerated&nbsp;filer
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 2%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 36%">
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 10PT">
	&uml;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 2%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 30%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Accelerated&nbsp;filer
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 2%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 3%">
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 10PT">
	&uml;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Non-accelerated filer
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 10PT">
	&uml;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;(Do not check if a smaller reporting company)
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Smaller&nbsp;reporting&nbsp;company
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 10PT">
	&thorn;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT 0">
	Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the
	Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 10PT">
	&uml;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 10PT">
	&thorn;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The aggregate market value of the voting
	and non-voting common equity held by non-affiliates computed by reference to the closing price as of the last business day of the
	registrant&rsquo;s most recently completed second fiscal quarter is $9,323,900.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	As of February 8, 2016, the registrant
	had outstanding 53,498,649 shares of common stock, $0.0001 par value per share.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Documents Incorporated By Reference:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	None.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage2"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;TABLE OF
	CONTENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
<B>
	Item
	No.
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-BOTTOM: 1PT; WIDTH: 2%">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; WIDTH: 76%">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
<B>
	Description
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-BOTTOM: 1PT; WIDTH: 2%">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
<B>
	Page
</B>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD COLSPAN="3" STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY; COLOR: BLUE">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_001" STYLE="COLOR: BLUE">
	Cautionary
	Note Regarding Forward-Looking Statements
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	3
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; COLOR: BLUE">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<B>
<A HREF="#V430703_10K_HTM_A_002">
	PART
	I
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Item 1.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_003">
	Business.
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	4
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Item 1A.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_004">
	Risk Factors.
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	21
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Item 1B.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_005">
	Unresolved
	Staff Comments.
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	44
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Item 2.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_006">
	Properties.
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	44
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Item 3.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_007">
	Legal Proceedings.
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	45
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Item 4.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_008">
	Mine Safety
	Disclosures.
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	45
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_009">
	PART
	II
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Item 5.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_010">
	Market for
	Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	45
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Item 6.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_011">
	Selected
	Financial Data.
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	48
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Item 7.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_012">
	Management&rsquo;s
	Discussion and Analysis of Financial Condition and Results of Operations.
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	48
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Item 7A.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_013">
	Quantitative
	and Qualitative Disclosures About Market Risk.
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	56
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Item 8.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_014">
	Financial
	Statements and Supplementary Data.
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	57
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Item 9.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_015">
	Changes in
	and Disagreements with Accountants on Accounting and Financial Disclosure.
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	57
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Item 9A.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_016">
	Controls
	and Procedures.
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	57
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Item 9B.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_017">
	Other Information.
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	58
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_018">
	PART
	III
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Item 10.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_019">
	Directors,
	Executive Officers and Corporate Governance.
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	58
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Item 11.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_020">
	Executive
	Compensation.
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	64
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Item 12.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_021">
	Security
	Ownership of Certain Beneficial Owners and Management and Related&nbsp;Stockholder Matters.
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	70
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Item 13.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_022">
	Certain Relationships
	and Related Transactions, and Director Independence.
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	7
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	2
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Item 14.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_023">
	Principal
	Accounting Fees and Services.
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	72
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_024">
	PART
	IV
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Item 15.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_025">
	Exhibits,
	Financial Statement Schedules.
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	73
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLUE">
<A HREF="#V430703_10K_HTM_A_026">
	Signatures
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	76
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage3"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<A NAME="V430703_10K_HTM_A_001">
</A>
<B>
	CAUTIONARY NOTE REGARDING FORWARD-LOOKING
	STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	This Annual Report
	on Form 10-K contains &ldquo;forward-looking statements&rdquo;, which include information relating to future events, future financial
	performance, financial projections, strategies, expectations, competitive environment and regulation. Words such as &ldquo;may&rdquo;,
	&ldquo;should&rdquo;, &ldquo;could&rdquo;, &ldquo;would&rdquo;, &ldquo;predicts&rdquo;, &ldquo;potential&rdquo;, &ldquo;continue&rdquo;,
	&ldquo;expects&rdquo;, &ldquo;anticipates&rdquo;, &ldquo;future&rdquo;, &ldquo;intends&rdquo;, &ldquo;plans&rdquo;, &ldquo;believes&rdquo;,
	&ldquo;estimates&rdquo;, and similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking
	statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such
	performance or results will be achieved. Forward-looking statements are based on information we have when those statements are
	made or management&rsquo;s good faith belief as of that time with respect to future events, and are subject to significant risks
	and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the
	forward-looking statements. Important factors that could cause such differences include, but are not limited to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	our lack of operating history;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	our current and future capital requirements and our ability to satisfy our capital needs through financing transactions or otherwise;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	our ability to manufacture, market and sell our Dario&trade; diabetes management solution;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	our ability to maintain our relationships with key partners;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	our ability to complete required clinical trials of our product and obtain clearance or approval from the regulatory agents in different jurisdictions;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	our ability to maintain or protect the validity of our U.S. and other patents and other intellectual property;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	our ability to launch and penetrate markets in new locations;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	our ability to implement on-line distribution channels and to generate sales from such channels;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	our ability to retain key executive members;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	our ability to internally develop new inventions and intellectual property;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	interpretations of current laws and the passages of future laws; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	acceptance of our business model by investors.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The foregoing does
	not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors
	that we are faced with that may cause our actual results to differ from those anticipated in our forward-looking statements. Please
	see &ldquo;Risk Factors&rdquo; for additional risks which could adversely impact our business and financial performance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Moreover, new risks
	regularly emerge and it is not possible for our management to predict or articulate all risks we face, nor can we assess the impact
	of all risks on our business or the extent to which any risk, or combination of risks, may cause actual results to differ from
	those contained in any forward-looking statements. All forward-looking statements included in this Annual Report are based on information
	available to us on the date of this Annual Report. Except to the extent required by applicable laws or rules, we undertake no obligation
	to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
	All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified
	in their entirety by the cautionary statements contained above and throughout this Annual Report.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; OPTIONS: NEWSECTION; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage4"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<A NAME="V430703_10K_HTM_A_002">
</A>
	&nbsp;
<B>
	PART I
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_BUSINESS>
<A NAME="FIS_BUSINESS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<A NAME="V430703_10K_HTM_A_003">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
</B>
</FONT>
<B>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	1.
</FONT>
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Business
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Overview
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are a digital health
	(mHealth) company that is developing and commercializing a patented and proprietary technology providing consumers with laboratory-testing
	capabilities using smart phones and other mobile devices. Our principal operating subsidiary, LabStyle Innovation Ltd., is an Israeli
	company with its headquarters in Caesarea, Israel. We were formed on August 11, 2011 as a Delaware corporation. Our flagship product,
	Dario&trade;, which we also refer to as our Dario&trade; Smart Diabetes Management Solution is a mobile, real-time, cloud-based,
	diabetes management solution based on an innovative, multi-feature software application combined with a stylish, &lsquo;all-in-one&rsquo;,
	pocket-sized, blood glucose monitoring device, which we call the Dario&trade; Smart Meter.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Dario&trade; Smart
	Diabetes Management Solution is targeted at the mHealth app market currently estimated at $10 billion with expected growth of 15%
	to $31 billion by 2020 according to Research2Guidance. In addition, we are also focusing on the global diabetes care devices market
	for diabetic blood glucose self-monitoring, known as BGMS, that is expected to reach approximately $24.6 billion by 2020 according
	to researchandmarkets.com. Diabetes is a disease where insufficient levels, or a total absence, of the hormone insulin produces
	high levels of glucose in the bloodstream, which can lead to long term adverse effects on a patient&rsquo;s blood vessels, which
	in turn can lead to heart attack, stroke, high blood pressure, blindness, kidney disease and nerve damage. As part of controlling
	blood sugar, many patients must self-monitor their blood glucose levels using home testing kits (called glucose meters) and treat
	high and low blood sugar episodes accordingly to avoid the complications from the disease. We believe that by allowing patients
	to properly monitor the disease, provide actionable insights in real-time and create an online link to healthcare providers, this
	will ultimately improve patient outcomes and reduce healthcare costs - both critical advantages for the diabetes industry.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Dario&trade; is a comprehensive,
	digital diabetes management solution utilizing our patented and proprietary technology delivered through a cutting edge software
	application (commonly known as an &ldquo;app&rdquo;) available for iPhone or Android and cloud-based data services with a novel
	BGMS device (the Dario&trade; Smart Meter) that connect via a device&rsquo;s audio jack consisting of a lancet (to obtain a blood
	sample), a device-specific disposable test strip cartridge and a smart mobile device-driven glucose reader adaptor. Roughly the
	size of a pack of gum, we believe that the Dario&trade; Smart Meter has the potential to replace standalone glucose meters and
	their kits (lancing, lancets and strips vials) which are the current market standard, most of which have the necessary testing
	components separated from one another in what we believe is a cumbersome design. Moreover, all but a few glucose meters lack an
	interface with a smart mobile device, and none presently have the software features associated with Dario&trade;, each of which
	we believe will distinguish Dario&trade; as an alternative in the marketplace.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Beyond the benefits
	of individual diabetes management, we envision the Dario&trade; application becoming the centerpiece in a new era of interconnected
	devices and services, providing healthier and better lives for diabetic patients worldwide. With every single measurement captured
	and stored on a secure cloud data base, LabStyle&rsquo;s software driven, comprehensive data-management technology has the potential
	to deliver actionable insight and analytical tools to manage individual patients or large populations, as well as provide a complete
	and comprehensive &ldquo;big data&rdquo; solution for healthcare providers and payers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Beyond blood glucose
	testing, LabStyle&rsquo;s technology provides a body-fluid testing apparatus for performing metered measurement of samples utilizing:
	(i) a lancing device to obtain a test sample (blood in the case of Dario&trade;); and (ii) an adaptor specifically designed to
	connect a strip&nbsp;devised to absorb the sample, which then produces an electric signal indicating the level of the substance
	tested for in the sample.&nbsp;&nbsp;The adaptor is then connected to a smart mobile device via the headphone jack, which allows
	the test signal to be transmitted to the smart mobile device, which will then utilize our software application to obtain and display
	the test result on the device.&nbsp;&nbsp;This is coupled with a set of software features available via a smart mobile device application
	as well as cloud-based services, in real-time.&nbsp;&nbsp;We are presently pursuing patent applications in multiple jurisdictions
	covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body
	fluids using mobile devices and cloud-based services. On August 5, 2014, we were issued a U.S. patent (No. 8,797,180) relating
	to how the Dario&trade; blood glucose monitor draws power from and transmits data to a smart phone via the audio jack port and
	on September 8, 2015, we were issued a U.S. patent (No. 9,125,549) that broadens our registered patent No. 8,797,180 to include
	testing of other bodily fluids through an audio jack connection. We believe these represent critical intellectual property recognition
	and a significant initial validation of our intellectual property efforts.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage5"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	On September 23, 2013,
	we announced our receipt of CE Mark certification to market Dario&trade;. The receipt of the CE Mark (which incorporated positive
	data from clinical user performance studies undertaken in Israel) allows Dario&trade; to be marketed and sold in 32 countries across
	Europe as well as in certain other countries worldwide. On March 5, 2014, the Medical Device Safety Service, or MDSS, our European
	Authorized Representative, completed the registration of the Dario&trade; Smart Meter with the German Authority as required by
	Article 10 of Directive 98/79/EC on in vitro diagnostic medical devices.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	On December 22, 2015,
	we announced that the United States Food and Drug Administration (FDA) has granted 510(k) clearance for the Dario Blood Glucose
	Monitoring System, including its components, the Dario Blood Glucose Meter, Dario Blood Glucose Test Strips, Dario Glucose Control
	Solutions and the Dario app on the Apple iOS 6.1 platform and higher. The receipt of FDA clearance allows Dario&trade; to be marketed
	and sold in the United States and is a significant milestone towards marketing and commercialization of Dario in the United States
	in the first quarter 2016.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are also actively
	investigating regulatory clearance pathways for Dario&trade; in Asia and South America.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In December 2013, we
	began offering free downloads of the Dario&trade; software application in selected jurisdictions, and in March 2014, we commenced
	our global multi-market launch of the Dario&trade; Smart Diabetes Management Solution in selected regions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In June 2014, we were
	granted (effective September 1, 2014) reimbursement status in England, Wales, Scotland and Northern Ireland for strips and lancets
	to be utilized together with the Dario&trade; Smart Meter. We are actively pursuing reimbursement coverage in other jurisdictions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In July 2014, we received
	approval from Israel&rsquo;s Ministry of Health to sell the Dario&trade; Smart Meter for diabetes in Israel and also released the
	Dario&trade; Diabetes Management App for Android smartphone users. The Android mobile application will have the same user interface
	and features as the iOS Dario&trade; application and we are planning a soft launch in select markets, including the United Kingdom
	and New Zealand.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In December 2014, we
	received Therapeutic Goods Administration, or TGA, certification to market the Dario&trade; in Australia. We were also granted
	reimbursement status for the Dario&trade; test strips in Australia by the NDSS.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In December 2014, we
	entered into an agreement with Israel&rsquo;s leading Health Maintenance Organization (healthcare HMO), Maccabi Healthcare, or
	MOMA, to implement a comprehensive Dario&trade; digital suite for patients and professionals. The agreement with MOMA (Maccabi
	TeleCare unit) represents an additional revenue stream channel for Dario&trade;. We believe this revenue channel demonstrates the
	significant potential available in software-based services and value added services with HMOs and other strategic partners worldwide.
	The Dario&trade; application for MOMA is a proprietary customized diabetes management solution that enables remote treatment for
	diabetes and aims to improve overall outcomes for patients leveraging mHealth technology for effective engagement of health care
	professionals.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In February 2015, we
	obtained National Pharmaceutical Product Interface (known as NAPPI) approval and have registered Dario&trade; for sale in South
	Africa.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In March 2015, we started
	marketing the Dario&trade; Smart Diabetes Management Solution in the Netherlands and New Zealand as a private, out of pocket offering
	(no reimbursement).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage6"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In May 2015, we received
	Health Canada approval to market and sell Dario&trade; in Canada and we commenced sales in Canada in June 2015. The majority of
	Canadian medical plans are currently providing reimbursement coverage for Dario&trade;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In December 2015, we
	commenced registration for the Dario&trade; Lite in Italy.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Dario&trade; Smart
	Diabetes Management Solution has fully launched and begun penetrating most of the above mentioned markets with additional
	launch and market penetration plans for Italy, India, Panama, Costa Rica and the United States &ndash; all planned for the first
	half of 2016. We are consistently adding additional features and functionality in making Dario&trade; Smart Diabetes Management
	Solution the new standard of care in diabetes data management.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In the United States
	we plan to commence commercialization once our devices and test strips are packaged and labeled according to FDA guidelines. We
	intend to generate demand through a digital direct to consumer campaign. Customers will initially be able to purchase the product
	directly through our e-store or via Amazon. Third party distribution channels are expected to go live through the first and second
	quarters of 2016 to facilitate a subscription-based service via our proprietary store. We also intend to continue to broaden our
	reach via distribution agreements with national and regional durable medical equipment, or DME, and pharmacy chains.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In order to expand
	our global market reach in terms of smartphone support and lower pricing, we intend to expand our product offerings in three main
	areas: (1) we are developing Dario&trade; Lite, a less expensive version of our BGMS which includes the same blood glucose meter
	as our Dario&trade;, offers a 50 strip vial holder, and excludes a lancing device, (2) we are developing Dario for additional models
	of smartphones that operate the Android operating system and which are not typically available in western countries, and (3) we
	plan to package strips in vials containing 50 strips versus the existing product that contains 25 strips. We believe these additional
	offerings will assist us in penetrating additional cost sensitive markets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Although we are initially
	targeting only the large and growing BGMS market, we believe our invention has the potential to cover dozens of laboratory tests
	of bodily fluids (including blood, urine and saliva) that could potentially be undertaken using a smart mobile device, including
	blood coagulation, cholesterol, HIV and others.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Our Initial Product - Dario&trade;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We believe that the
	diabetic disease management market presents the most attractive initial application for our proprietary technology as there are
	millions of potential diabetic users of a smart mobile device-enabled glucose monitoring technology.&nbsp;&nbsp;As such, our first
	product,&nbsp;which we also refer to as the Dario&trade; Smart Diabetes Management Solution, will seek to revolutionize the way
	diabetic patients around the world manage their disease and connect with healthcare providers and others, making the Dario&trade;
	solution user-centric, engaging and accessible to all.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The full&nbsp;Dario&trade;
	diabetes management solution consists of a robust, real-time, cloud-based software application combined with the&nbsp;Dario&trade;
	Smart Meter.&nbsp;&nbsp;Roughly the size of a pack of gum, the&nbsp;Dario&trade; Smart Meter is an all-in-one device that includes
	the glucose reader which is connected to a smart mobile device via the device audio jack, along with a lancing device (a reusable
	blood-sampling device, when loaded with a disposable lancet) and an integrated, disposable cartridge for test strips. Beyond the
	benefits of individual diabetes management, we envision the Dario&trade; application becoming the centerpiece in a new era of interconnected
	devices and services, providing healthier and better lives for diabetic patients worldwide. With every single measurement captured
	and stored on a secure cloud data base, LabStyle&rsquo;s software driven, comprehensive data-management technology has the potential
	to deliver actionable insight and analytical tools to manage individual patients or large populations, as well as provide a complete
	and comprehensive &ldquo;big data&rdquo; solution for healthcare providers and payers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage7"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our revenues are derived
	from sales of&nbsp;Dario&trade;&rsquo;s components, including the&nbsp;
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Smart Meter
</FONT>
	&nbsp;itself,
	which is priced similarly to blood glucose monitors in the marketplace, and principally from the recurring sale of our disposable
	cartridges with 25 test strips.&nbsp;&nbsp;Our customers receive access to our smart mobile device application, which incorporate
	tools to help diabetic patients manage their disease.&nbsp;&nbsp;Importantly, our revenue model is driven by the fact that only
	our test strips, purchased through us and our partners, are able to be utilized with the&nbsp;Dario&trade;&nbsp;
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Smart
	Meter
</FONT>
	&nbsp;and software, so it is our expectation that we will be the sole source for&nbsp;Dario&trade; compatible test
	strips.&nbsp;In addition to&nbsp;
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Smart Meter
</FONT>
	&nbsp;and test strip related revenue,
	we anticipate to generate revenues in the future from our ability to offer&nbsp;Dario&trade;&rsquo;s subscribers additional products
	and services based on personalized recommendations, such as location-based, low-sugar food recommendations and the ability to send
	alerts to caregivers and family and friends.&nbsp;&nbsp;It is our intention to generate and sustain revenue not only from the consumables
	but also from software licensing and added value services so that the data monetization revenue channel becomes a significant contributor
	to the company&rsquo;s gross margin. We plan to monetize the comprehensive data that is collected in the Dario&trade; cloud as
	a result of various offerings such as a platform for diabetes&nbsp;
<FONT STYLE="COLOR: #333333; BACKGROUND-COLOR: WHITE">
	related
	clinical trials.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; COLOR: #333333">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We believe the following
	features of our&nbsp;Dario&trade; solution and the manner in which we plan to market and distribute the product will help position&nbsp;Dario&trade;
	to gain users and drive revenue growth:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Look and Feel
</I>
	.&nbsp;&nbsp;While
	utilizing the same state of the art electro-chemical, blood-based measurement techniques as standard glucose monitors offers familiar
	usability,&nbsp;the Dario&trade; blood glucose monitor is easily integrated with the patient&rsquo;s own smart mobile device that
	offers a distinctive look and feel.&nbsp;&nbsp;Furthermore, unlike the market standards,&nbsp;the Dario&trade;&nbsp;
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Smart
	Meter
</FONT>
	&nbsp;has an integrated lancing device and disposable strip cartridge.&nbsp;&nbsp;This eliminates the need for a separate
	glucose monitor, lancing device and strip vial and, we believe, will make&nbsp;Dario&trade; the&nbsp;
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Smart
	Meter
</FONT>
	&nbsp;among the smallest footprint in the market.&nbsp;&nbsp;Furthermore,&nbsp;Dario&trade; has novel applications
	incorporating software tools to help diabetic patients manage their disease.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Large Market of Potential Users
</I>
	.&nbsp;&nbsp;Our reliance on diabetics within the massive smart mobile device market gives us an established potential user-base. The most recent publicly available reports from Nielsen indicate that in the U.S., smartphone usage continues to climb.&nbsp;&nbsp;More than three out of five (61%) mobile subscribers in the U.S. owned a smartphone during the most recent three-month period for which data is available (March-May 2013), up more than 10% since smartphones became the mobile majority in early 2012.&nbsp;&nbsp;In March 2012, 50% of mobile subscribers used smartphones, making up the majority for the first time. &nbsp;Moreover, according to&nbsp;a Research2Guidance report from 2014, the percentage of people with diabetes who own a smartphone and will utilize apps to manage their condition is 1.2% or approximately 3.7 million people in 2014, growing to an anticipated 7.8%, or approximately 24 million people, by 2018, which would represent an increase of 650%.&nbsp;&nbsp;In many countries (including the U.S.), smart mobile devices are also typically subsidized by the cellular providers through discounted pricing associated with related plan subscriptions, enabling&nbsp;Dario&trade; to benefit from the extensive marketing by cellular companies of these devices.&nbsp;&nbsp;We believe that it is reasonable to assume that the percentage of smart mobile device users with diabetes mirrors that of the general population.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Marketing and Distribution
</I>
	.&nbsp;&nbsp;We primarily use distribution partners to market and sell&nbsp;Dario&trade; in Europe as well as in New Zealand, Australia and Canada.&nbsp;&nbsp;In the U.S. we are planning to use online distribution channels to sell directly to customers and to also contract with nonexclusive distributors and partners. &nbsp;In addition, we have initiated our own direct to consumer marketing channel to support our sales efforts. In Israel, we have developed a direct sales and marketing channel through e-commerce. &nbsp;Our direct to consumer, online distribution plan will continue to supplement our distributors&rsquo; efforts and enables a direct communication channel with the market and the diabetic community. &nbsp;This approach is also designed to effectively create brand awareness with a significantly reduced use of our capital resources versus the amounts required via the traditional, offline retail channels.&nbsp;&nbsp;In some additional jurisdictions, we may adopt a direct sales model in addition to utilizing local distributors.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	&ldquo;Expanding the Pie&rdquo;
</I>
	.&nbsp;&nbsp;Our goal is to obtain significant market share using technological innovations and by expanding the total BGMS market size &ldquo;pie&rdquo; through offering a user-friendly diabetes management solution that utilizes an existing platform and installed potential user base (smart mobile devices and smart mobile device users, respectively).&nbsp;&nbsp;We will endeavor to emphasize the user friendly nature of Dario&trade; to expand the total BGMS market size by encouraging existing diabetes patients to test their glucose levels more frequently and by encouraging the &ldquo;non-testing&rdquo; population to adopt glucose monitoring.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage8"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Competitive Cost of Goods Sold.&nbsp;&nbsp;
</I>
	&nbsp;Based on our market research and discussions with our test strip manufacturer, we believe that our anticipated outsourced manufacturing cost of the test strips will be similar to our estimate of our competitors&rsquo; cost for existing single-use disposable strips.&nbsp;&nbsp;In addition, we believe the manufacturing costs of our&nbsp;Dario&trade;&nbsp;
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Smart Meter
</FONT>
	&nbsp;will be competitive with those of the leading glucose meters.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Opportunities for Commercialization Partnerships.
</I>
	&nbsp; Healthcare and pharmaceutical company entrants into the BGMS market (such as Perigo and Sanofi) are licensing and/or acquiring technologies, seeking differentiation, thereby providing us with opportunities for more rapid commercialization through partnerships.&nbsp;&nbsp;Therefore, we plan to explore the possibility of entering into commercialization agreements, including an upfront payment, supply agreement and royalty payments, with strategic partners.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Currently
	there are a few new market entrants in the BGMS space that are attempting to utilize computer or smart mobile device connectivity,
	including the Sanofi IBGStar, Medisana GlucoDock, Philosys Gmate Smart, and iHealth Align.&nbsp;&nbsp;We believe that none of these
	devices offer the integration of an all-in-one unit that includes a lancing device and strip cartridge as Dario&trade; does. We
	further believe that these competitors provide limited capabilities over their diabetes management apps as compared to the Dario&trade;
	application.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	As a result, we believe&nbsp;Dario&trade;
	will bring an entirely new dynamic to the BGMS device market.&nbsp;&nbsp;We believe that our primary business model for&nbsp;Dario&trade;
	is clean and simple - sales of proprietary glucose test strips (the disposable component) directly to consumers, leveraging an
	installed base of mobile phones. The entire mechanism consists of a small and simple adaptor combined with a strip which is connected
	to the smart mobile device&rsquo;s headphone jack, with the strip test results being read by the smart mobile device.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	We
	also believe that this business model is the foundation for a broader push to improve the health care system. An application that
	is always in your pocket and used multiple times per day is an ideal platform to support people living with diabetes, their health
	care providers, and health systems. Our application is designed to improve health outcomes and reduce costs through increased insights,
	motivating tools and automation.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Background on Diabetes
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Diabetes
	is a chronic disease that arises when the pancreas does not produce enough (or ceases to produce) insulin, or when the body cannot
	effectively use the insulin it produces.&nbsp;&nbsp;Insulin is a hormone made by the pancreas that enables cells to take in glucose
	from the blood and use it for energy.&nbsp;&nbsp;Failure to produce insulin, or of insulin to act properly, or both, leads to raised
	glucose (sugar) levels in the blood (hyperglycemia), which can be detected with a blood test.&nbsp;&nbsp;Excess glucose in the
	blood has been shown to cause damage to blood vessels and is thus associated with long-term damage to the body and failure of various
	organs and tissues, including the retina and the kidneys.&nbsp;There are three main types of diabetes:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Type 1 diabetes
</I>
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	,
	sometimes called insulin-dependent, or juvenile, diabetes, is caused by an auto-immune reaction where the body&rsquo;s defense
	system attacks the insulin-producing cells located in a person&rsquo;s pancreas.&nbsp;&nbsp;The reason why this occurs is not fully
	understood.&nbsp;&nbsp;People with Type 1 diabetes produce very little or no insulin.&nbsp;&nbsp;The disease can affect people
	of any age, but usually occurs in children or young adults.&nbsp;&nbsp;People with this form of diabetes need injections or infusions
	of insulin every day in order to control the levels of glucose in their blood.&nbsp;&nbsp;Type 1 diabetes patients constitute approximately
	10% of the overall number of patients, but are much more extensive users of BGMS, as these diabetics need to measure their glucose
	levels 4-10 times day (versus once or twice a day for most Type 2 diabetic patients).&nbsp;&nbsp;The vast majority of Type 1 diabetes
	patients are insulin dependent.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Type 2 diabetes
</I>
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;is
	sometimes called adult-onset diabetes and accounts for at least 90% of all cases of diabetes.&nbsp;&nbsp;It is characterized by
	insulin resistance and relative insulin deficiency, either of which may be present at the time that diabetes becomes clinically
	manifest. The diagnosis of Type 2 diabetes usually occurs after the age of 40 but can occur earlier, especially in populations
	with high diabetes incidence.&nbsp;&nbsp;Type 2 diabetes can remain undetected for many years and the diagnosis is often made from
	associated complications or incidentally through an abnormal blood or urine glucose test.&nbsp;&nbsp;It is often, but not always,
	associated with obesity, which may contribute to insulin resistance and lead to elevated blood glucose levels.&nbsp;&nbsp;A growing
	portion of the Type 2 diabetes patients are insulin dependent or use insulin as part of their treatment.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage9"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Gestational diabetes
	(GDM)
</I>
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;is a form of diabetes consisting of high blood glucose levels during pregnancy.&nbsp;&nbsp;It
	develops in one in 25 pregnancies worldwide and is associated with complications in the time period immediately before and after
	birth.&nbsp;&nbsp;GDM usually disappears after pregnancy but women with GDM and their offspring are at an increased risk of developing
	Type 2 diabetes later in life.&nbsp;&nbsp;Approximately half of women with a history of GDM go on to develop Type 2 diabetes within
	five to ten years after delivery.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	We
	also believe we will be able to support patients with&nbsp;
<I>
	pre-diabetes
</I>
	, also called metabolic syndrome.&nbsp;&nbsp;Metabolic
	syndrome is a combination of medical disorders that increase the risk of developing cardiovascular disease and diabetes.&nbsp;&nbsp;According
	to the National Institutes of Health, during the years 2009-2012, 37% of U.S. adults ages 20 years or older had pre-diabetes, with
	51% of those ages 65 years or older, leading the NIH to estimate that approximately 86 million persons in the U.S. had pre-diabetes
	in 2012.&nbsp; This population is typically prescribed with periodic lab-based glucose level testing (which requires a doctor visit,
	significantly reducing the compliance level) and typically does not involve the utilization of self-monitoring glucose devices.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	The Diabetic and BGMS Markets and the&nbsp;Dario&trade;
	Solution
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Diabetes is a growing epidemic for which
	no cure exists, but for which treatments (including a regimen of frequent blood glucose testing) are available.&nbsp; The medical
	journal Lancet has reported that number of worldwide diabetics has doubled over the past thirty years.&nbsp; While about 70% of
	the increase has been attributed in the Lancet report to population growth and aging, the balance was linked to changing diets,
	rising obesity levels and less physical activity.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	According to the International Diabetes
	Foundation (IDF), approximately 382 million people worldwide were estimated to have diabetes in 2013. The greatest number are between
	40 and 59 years old. If these trends continue, by 2035, some 592 million people, or almost one adult in 10, will have diabetes.&nbsp;In
	Europe, there were 56.3 million people with diabetes in 2013 according to IDF. There were approximately 29.1 million diabetics
	in the U.S. in 2012 according to the American Diabetes Association (ADA), or 9.3% of the population.&nbsp; In the U.S., one in
	four adults have diabetes.&nbsp; An additional 86 million U.S. adults had pre-diabetes in 2012, which puts them at high risk for
	developing Type 2 diabetes.&nbsp; Approximately 138 million adult diabetics live in China and India, with approximately 12 million
	in Brazil and 10 million in Russia.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	It is estimated that
	the costs of diabetes complications account for between 5% and 10% of total healthcare spending in the world. In the United States,
	the ADA estimates that the total cost of diagnosed diabetes has risen from $174 billion in 2007 to $245 billion in 2012. &nbsp;Early
	diagnosis of warning signs and ongoing monitoring of diabetes are the keys to the prevention and treatment of the disease, with
	blood glucose monitoring being the primary method of diagnosis and disease management, coupled with matching blood glucose readings
	with food (i.e., carbohydrate) and insulin or other medication intake.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Since blood glucose
	self-monitoring is a key part of managing diabetes, the market for BGMS products required to service these many patients is also
	large.&nbsp; As reported in a press release published by Transparency Market Research, the blood glucose self-monitoring market
	is currently estimated to be $12 billion and is expected to grow to an estimated $27 billion by 2022.&nbsp;&nbsp;The same source
	also notes that the total diabetes management market was $50.8 billion in 2011 and is estimated to reach $98.4 billion by 2018.&nbsp;&nbsp;The
	biggest drivers for growth in the diabetes device market will be the increased prevalence and awareness of diabetes.&nbsp;&nbsp;The
	U.S. is the largest market, contributing close to 40% of the global market for these devices.&nbsp; In fact, the BGMS testing market,
	which barely existed in 1980, now accounts for approximately a quarter of the entire in vitro diagnostics industry.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Key factors driving
	market growth include increasing number of people with diabetes, growing patient awareness, technological advancements and increasing
	number of patients adopting blood glucose self-monitoring.&nbsp;&nbsp;In addition, the affordable cost of blood glucose test strips,
	and increase in daily monitoring, are also expected to contribute to market growth.&nbsp;&nbsp;As such, BGMS represents a large
	market that has grown significantly over the past 30 years and is expected to continue to grow.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 9; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage10"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	It is important to
	note that the diabetic market is a first point of entry for LabStyle and the goal of providing mHealth/Digital health solution
	for a variety of chronic and wellness related conditions based on mobile device testing will grant us access to a much larger market.
	The Dario
<SUP>
	TM
</SUP>
	Smart Diabetes Management Solution is targeted at the mHealth app market currently estimated at $10 billion
	with expected growth of 15% to $31 billion by 2020.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Industry Background and the&nbsp;Dario&trade; Opportunity
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	From a competition
	perspective, four companies currently dominate the BGMS business, controlling approximately 90% of the market: Roche Diagnostics
	(part of Hoffman-LaRoche), LifeScan (a Johnson &amp; Johnson company), Bayer Healthcare Division, and Abbott Laboratories.&nbsp;&nbsp;These
	&ldquo;big four&rdquo; offer a wide variety of BGMS products and have led the market since the late 1990s.&nbsp;&nbsp;Numerous
	second-tier and third-tier competitors, including several in Asia, hold the remaining 10% of the market.&nbsp;&nbsp;We believe
	that the BGMS offerings by all vendors are comparable, with mild differentiation of the main feature sets of the devices.&nbsp;&nbsp;This
	is akin to the differentiation among personal computers (PCs) during the 1990s and 2000s, where most of them had the same key feature
	set of Microsoft Windows and Intel Processors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We believe that the
	increasing global adoption of mobile phones has created an opportunity for disruption in BGMS market. The&nbsp;Dario&trade; solution,
	which features a compact all-in-one&nbsp;
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Smart Meter
</FONT>
	&nbsp;coupled with iOS, Android
	and web-based apps, is intended to eliminate the need for separate glucose monitors, carb-calculators and cumbersome dependency
	on wired, computer-based logging tools.&nbsp;&nbsp;Our intention is for&nbsp;Dario&trade; to not only deliver the best blood glucose
	monitoring experience, but also use the unique capabilities of mobile smart mobile devices to deliver better health outcomes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	With respect to the U.S. BGMS market, the
	principal barriers to entry (all of which we believe the features of&nbsp;Dario&trade; can overcome) can be summarized as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Achieving significant
	product differentiation in the eyes of diabetes patients or insurance payers
</I>
	.&nbsp;&nbsp;We believe that&nbsp;Dario&trade;
	offers a novel design that is compatible with the usability of the current devices, yet offers a modern look and feel when compared
	to products in the marketplace.&nbsp;&nbsp;Marketing of the product directly to consumers will emphasize the product&rsquo;s distinguishing
	attributes, without incurring the significant product introduction expenses typically incurred for the marketing of a standard
	glucose meter via traditional retail channels.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Costs.&nbsp;
</I>
	&nbsp;We anticipate that low manufacturing costs for the&nbsp;Dario&trade; dongle (the part of the Smart Meter that attaches to the phone jack) and the similarity to our competitors&rsquo; estimated cost of manufacturing the strips, when coupled with the direct-to-consumer marketing, creates the potential for providing us with a meaningful cost advantage versus most vendors of traditional glucose meters.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Difficulty obtaining shelf space at the pharmacy
</I>
	.&nbsp;&nbsp;With many products on the market, a new entrant has to battle for visibility on the shelf.&nbsp;&nbsp;Dario&trade; will limit this obstacle by emphasizing Internet based direct-to-consumer marketing and sales.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	The challenge of influencing diabetes specialists to recommend another BGMS product to patients
</I>
	.&nbsp;&nbsp;We will seek to introduce and present&nbsp;Dario&trade; to the medical community through our participation in academic and professional conferences.&nbsp;&nbsp;Dario&trade; will mainly be marketed directly to our target users, who we believe are increasingly becoming the primary decision makers in choosing their glucose monitoring equipment.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We believe that&nbsp;Dario&trade;&rsquo;s
	specific features and trends in the marketplace create a significant opportunity to penetrate the market and effectively compete
	with and gain market share against the established players.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 10; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage11"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Utilization of Mobile Health Applications
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Smart mobile device
	applications combine easy-to-use interfaces with continuous Internet access to create transformational mobile health solutions
	(often called mHealth).&nbsp;&nbsp;Although the potential benefits of mHealth solutions have been widely discussed for over a decade,
	the market is now starting to emerge from the trial phase.&nbsp;&nbsp;According to a publicly available 2010 study by Research2Guidance,
	smart mobile device applications will enable the mHealth industry to reach 500 million of a total 1.4 billion worldwide smart mobile
	device users in 2015.&nbsp; We believe that&nbsp;Dario&trade; is designed to play directly into this trend.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Currently more than
	70% of the mHealth applications in major &ldquo;app stores&rdquo; are adhering to the paid business model according to Research2Guidance.
	With more and more traditional healthcare providers joining the mobile applications market, we expect the business models will
	broaden to include healthcare services, advertising and drug sales revenues.&nbsp;&nbsp;According to Research2Guidance, with the
	growing sophistication level of mHealth applications, only 14% of the total market revenue in the next 5 years will come from application
	download, advertisement and transaction revenue, whereas 76% of total mHealth application market revenue will come from related
	services and products.&nbsp; We believe that&nbsp;Dario&trade; is well-positioned to benefit from that trend.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The&nbsp;Dario&trade;
	diabetes management solution includes the Dario&trade;&nbsp;
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Smart Meter
</FONT>
	&nbsp;and software
	application for people with diabetes.&nbsp;Dario&trade; currently allows users to easily record, analyze, transmit and store key
	data points such as glucose level, insulin and carbohydrate intake. Moreover, the&nbsp;Dario&trade; application provides knowledge
	and motivation with an aim of improving health outcomes. In addition, we are developing software for health care providers and
	payers to help better support patients and intelligently manage large patient populations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Sales and Marketing
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our initial marketing
	has been focused on the early adopter diabetics, and we expect to gradually broaden our marketing efforts (and benefitting from
	viral marketing) toward the entire diabetic population. We plan to initially focus on insulin dependent diabetic patients. While
	this population constitutes about 20-30%&nbsp;of the diabetic patient population, we estimate it to be responsible for over 60%
	of the revenue from blood glucose monitoring.&nbsp; Dario&trade;&rsquo;s ease of use and the lack of need for a special glucometer
	are also expected to be of major appeal to the entire Type 2 diabetes population. With our initial market launch, we are addressing
	the European market, as well as Australia and New Zealand, and we plan to expand to the U.S. in 2016. This will be followed, possibly
	through marketing collaborations, by targeting additional large markets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Dario&trade; will also
	be an Internet-driven product.&nbsp;Dario&trade; was designed for the mobile age and will be powered by the Internet as an effective
	route of launching and marketing new consumer products.&nbsp;&nbsp;We plan to sell directly to consumers and also collaborate with
	distributors and online marketing firms in various jurisdictions. It is estimated that a typical Type 1 diabetes patient, who is
	testing his or her blood sugar 4 to 10 times a day, uses 120 to 300 strips each month, which creates the potential for a substantial
	and predictable revenue stream.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	On the marketing side,
	we plan to primarily utilize online marketing in order to create awareness of&nbsp;Dario&trade;. Rather than solely rely on online
	advertisement, we will also consider revenue sharing with affiliate networks and a variety of other pay-for-performance methods
	commonly used in online commerce.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In December 2014, we
	entered into an agreement with Israel's leading healthcare HMO, Maccabi Healthcare, to implement a comprehensive Dario&trade; digital
	suite for patients and professionals. The agreement with MOMA (Maccabi TeleCare unit) represents an additional channel of revenue
	stream for Dario&trade;. We believe this channel for revenues indicates the huge potential available which is based on software
	licensing and added value services with HMOs and other strategic partners worldwide. The Dario&trade; application for MOMA is a
	proprietary customized diabetes management solution that enables remote treatment for diabetes which aims to improve overall outcomes
	for patients leveraging mHealth technology for effective engagement of health care professionals.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We also expect to collaborate with the medical
	community to showcase what we expect will be&nbsp;Dario&trade;&rsquo;s clinical equivalence and usability superiority.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 11; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage12"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Manufacturing
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	As we do not plan to
	engage in manufacturing activity ourselves, we plan to have supply agreements with manufacturers for the&nbsp;Dario&trade; Smart
	Meter, glucose test strips, lancing devices and lancets.&nbsp;&nbsp;We have arrangements in place with commercial scale manufacturers
	for both the&nbsp;Dario&trade; Smart Meters and for our test strips. As a result of investments we have made over the past several
	years, we own the specialized equipment used to manufacture&nbsp;Dario&trade; Smart Meters.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	During 2015, we commenced
	manufacturing of our Dario&trade; Smart Meter with a Chinese manufacturer as part of our efforts to further reduce manufacturing
	costs of the Dario&trade; Smart Meter. We are currently transitioning our manufacturing to a new Chinese manufacturer as part of
	our effort to increase our manufacturing capacity and improve cost savings.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Insurance Reimbursement
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In the United States
	and in other jurisdictions such as Germany and England, we expect that&nbsp;Dario&trade;&rsquo;s test strips should generally be
	available for full or partial patient reimbursement by third-party payers.&nbsp; We expect to work with third-party payers in the
	countries into which we expect to market&nbsp;Dario&trade; in order to establish coverage for test strips, although we cannot be
	sure of this being obtained.&nbsp; In April 2014, we announced the receipt of reimbursement coverage for the use of the Dario&trade;
	Smart Meter in Italy, making 600,000 Italians eligible for reimbursement coverage. In June 2014, we were&nbsp;
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	granted
	(effective September 1, 2014) reimbursement status in England, Wales, Scotland and Northern Ireland for strips and lancets to be
	utilized together with the Dario&trade; Smart Meter. In December 2014, we were granted reimbursement
</FONT>
	status for the Dario&trade;
	test strips Australia.&nbsp;In May 2015 we launched Dario&trade; in Canada and the majority of Canadian medical plans are now covering
	Dario&trade; test strips with reimbursement. We expect the balance of Canadian insurance plans to provide reimbursement coverage
	in the near future. We are actively pursuing reimbursement coverage in other jurisdictions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Clinical Trials
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 40.5PT">
	As part of our CE
	Mark clearance, in 2013 we conducted positive User Performance studies for the Dario&trade; Smart Meter in Israel with 161 diabetic
	patients. The aim of this study was to collect measurement data from capillary blood with defined distribution of glucose concentrations
	in order to perform system accuracy evaluation according to ISO 15197:2013, the current international standard requirements for
	BGMS systems. The results of this study showed that the Dario&trade; strips are well within the limits for system accuracy defined
	by ISO 15197:2013 in that 100% of results fell within zones A and B of the Consensus Error Grid for all systems, which means that
	the system accuracy requirements of the ISO 15197:2013 have been met. The acceptance criteria for accuracy of BGMS per ISO 15197:2013
	is &ldquo;95 % of the individual glucose measured values shall fall within &plusmn; 0,83 mmol/l (&plusmn;15 mg/dl) of the measured
	values of the manufacturer&rsquo;s measurement procedure at glucose concentrations &lt; 5,55 mmol/l (&lt;100 mg/dl) and within
	&plusmn; 15% at glucose concentrations &ge; 5,55 mmol/l (&ge;100 mg/dl)&rdquo;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 40.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 40.5PT">
	In January 2015, we
	completed, and in March 2015, we announced positive results from, a required User Performance evaluation study in the U.S. to evaluate
	the accuracy of blood glucose level results obtained from fingertip using&nbsp;Dario&trade; compared to reference equipment (YSI
	2300 STATPLUS) and to evaluate the ease of use of the&nbsp;Dario&trade; device by the first time user.&nbsp;&nbsp;This study was
	in connection with our regulatory submissions for the product in the U.S. and Canada and in accordance with ISO 15197:2013.&nbsp;&nbsp;The
	study was performed at Remington Davis Clinical Research in Columbus, Ohio with the&nbsp;Dario&trade; device and included 368 participants
	with varying demographics.&nbsp;&nbsp;As required by FDA, the study was approved by the institutional review board (IRB) which
	supervise the clinical studies performed in their institutions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 40.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 40.5PT">
	The purpose of the
	study was to demonstrate the accuracy of the&nbsp;Dario&trade; compared with the YSI reference standard and to evaluate how the
	first time users of the&nbsp;Dario&trade; (1) use it under the Dario&trade; guidance materials (i.e., quick user guide and video
	clip) in an effort to demonstrate how the use of the&nbsp;Dario&trade; device and related software could potentially improve patient
	care and diabetic compliance, (2) to understand the potential weaknesses of the device and introduce methods of overcoming them
	to the users and (3) to&nbsp;establish the proposition that lay users can operate the device.
</P>
<!-- FIELD: PAGE; SEQUENCE: 12; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage13"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We evaluated accuracy
	and user performance in this clinical trial with 368 diabetic patients, each of whom tested fresh capillary finger prick blood
	glucose levels while using Dario&trade; for the first time, as instructed at Dario&trade;'s instruction material. System accuracy
	was determined with samples obtained from each subject measured both on the Dario&trade; by individual subjects and by a reference
	YSI analyzer. We documented sample collection or measurement errors. When required, repeated sampling by each subject was limited
	to three per subject. The interval of glucose levels tested were within BGMS range 43.0-477.0 mg/dL, and YSI range 42.3-435.5 mg/dL.
	There were no outliers. Accuracy for Dario&trade; met ISO 15197:2013 criteria, as can be seen in the accuracy tables below. Below
	100 mg/dL, 97.8% of values were within &plusmn;15mg/d of YSI reference glucose values. For samples with glucose above or equal
	to 100 mg/dL, 96.4% of values were within &plusmn; 15% of YSI glucose levels. Lay subject performance assessment of the Dario&trade;&rsquo;s
	instruction clarity and usefulness showed that 100% successfully obtained a measurement result, and 97.1% of subjects found instructions
	easy to follow with 70.7% rating they were very satisfied (5/5) and 26.4% rating they were satisfied (4/5). Reading the result
	on the smart mobile device was rated easy to understand by 99.1% of lay subjects, with 86.1% rated it very easy (5/5) and 13% rated
	it easy (4/5). If an error message displayed on the report screen, 100% of lay subjects were clear about how to resolve the error,
	with 56.5% reporting is was very clear (5/5) and 43.5% reported it was clear (4/5).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="21" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	System&nbsp;accuracy&nbsp;results:&nbsp;DBGMS&nbsp;platform
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="9" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	System&nbsp;accuracy&nbsp;results&nbsp;for&nbsp;glucose&nbsp;
<BR>
	concentrations&nbsp;&lt;100&nbsp;mg/dL
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	System&nbsp;accuracy&nbsp;results&nbsp;for&nbsp;glucose&nbsp;
<BR>
	concentrations&nbsp;&ge;100&nbsp;mg/dL
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Within&nbsp;&plusmn;&nbsp;5
<BR>
	mg/dL
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Within&nbsp;&plusmn;&nbsp;10
<BR>
	mg/dL
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Within&nbsp;&plusmn;&nbsp;15
<BR>
	mg/dL
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Within&nbsp;&plusmn;&nbsp;5&nbsp;%
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Within&nbsp;&plusmn;&nbsp;10&nbsp;%
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Within&nbsp;&plusmn;&nbsp;15&nbsp;%
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 35%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	42/93
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	73/93
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	91/93
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	111/275
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	211/275
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	265/275
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	45.2
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	%
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	78.5
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	97.8
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	40.4
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	76.7
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	96.4
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="10" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	System&nbsp;accuracy&nbsp;results&nbsp;for&nbsp;glucose&nbsp;concentrations&nbsp;between&nbsp;42.3&nbsp;mg/dL&nbsp;and&nbsp;435.5&nbsp;mg/dL
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Within&nbsp;&plusmn;&nbsp;5&nbsp;mg/dL&nbsp;or&nbsp;&plusmn;&nbsp;5&nbsp;%
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Within&nbsp;&plusmn;&nbsp;10&nbsp;mg/dL&nbsp;or&nbsp;&plusmn;&nbsp;10&nbsp;%
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Within&nbsp;&plusmn;&nbsp;15&nbsp;mg/dL&nbsp;or&nbsp;&plusmn;&nbsp;15&nbsp;%
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 31%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	153/368
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 31%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	284/368
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 30%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	356/368
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	41.5
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	77.2
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	96.7
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	To conclude, the Dario&trade;
	meets ISO 15197:2013 standards for clinical performance as determined by lay user accuracy and by satisfactory experience with
	the Dario&trade; instructions clarity and system utility.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 40.5PT">
	In November 2015,
	we completed an additional User Performance evaluation study in the U.S. as requested by FDA. We evaluated the accuracy of blood
	glucose level results obtained from fingertip using&nbsp;Dario&trade; compared to reference equipment (YSI 2300 STATPLUS). We also
	assessed the usability of the&nbsp;Dario&trade; device by first time users.&nbsp;&nbsp; The study was performed at the University
	of Colorado Barbara Davis Center for Diabetes in Aurora, Colorado with the&nbsp;Dario&trade; device and included 100 participants
	with varying demographics.&nbsp;&nbsp;As required by the FDA, the study was approved by the Western Institutional Review Board
	(WIRB) which supervises clinical studies performed in their institutions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 40.5PT">
	The purpose of the
	study was to demonstrate the accuracy of the&nbsp;Dario&trade; compared with the YSI reference standard and to evaluate how first
	time users of the&nbsp;Dario&trade; (1) use it under the Dario&trade; guidance materials (i.e., quick user guide and user guide)
	in an effort to demonstrate how the use of the&nbsp;Dario&trade; device and related software could potentially improve patient
	care and diabetic compliance, (2) to understand the potential weaknesses of the device and introduce methods of overcoming them
	to the users and (3) to&nbsp;establish the proposition that lay users can operate the device.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 40.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 13; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage14"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The acceptance criteria
	for accuracy of BGMS per ISO 15197:2003 is &ldquo;Ninety-five percent (95%) of the individual glucose results shall fall within
	&plusmn; 15mg/dL of the results of the Dario&rsquo;s measurement at glucose concentrations &lt; 75mg/dL and within &plusmn; 20%
	at glucose concentrations greater than or equal to 75mg/dL&rdquo;. The study evaluated accuracy and user performance in this clinical
	trial with 100 diabetic patients, each of whom tested fresh capillary finger prick blood glucose levels while using Dario&trade;
	for the first time, as instructed at Dario&trade;'s instruction material. System accuracy was determined with samples obtained
	from each subject measured both on the Dario&trade; by individual subjects and by a reference YSI analyzer. We documented sample
	collection or measurement errors. When required, repeated sampling by each subject was limited to three per subject. The interval
	of glucose levels tested were within BGMS range 42-396 mg/dL, and YSI range 37-386 mg/dL. There were no outliers. Accuracy for
	Dario&trade; met ISO 15197:2003 criteria, as can be seen in the accuracy tables below. Below 75 mg/dL, 100% of values were within
	&plusmn;15mg/dL of YSI reference glucose values. For samples with glucose above or equal to 75 mg/dL, 98.88% of values were within
	&plusmn; 20% of YSI glucose levels. Lay subject performance assessment of the Dario&trade;&rsquo;s instruction clarity and usefulness
	showed that 100% successfully obtained a measurement result. The average rating of the users for successful operation of the Dario
	was 4.35 (out of 5 when 1 is &ldquo;completely failed&rdquo; and 5 is &ldquo;very successful&rdquo;) and an average rate of 3.66
	(out of 5 when 1 is &ldquo;very hard&rdquo; and 5 is &ldquo;very easy&rdquo;) for operating the Dario&trade; for the first time.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="25" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 9PT">
	System&nbsp;accuracy&nbsp;results:&nbsp;DBGMS&nbsp;platform
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="9" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 9PT">
	System&nbsp;accuracy&nbsp;results&nbsp;for&nbsp;glucose
<BR>
	concentrations&nbsp;&lt;75&nbsp;mg/dL
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="14" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 9PT">
	System&nbsp;accuracy&nbsp;results&nbsp;for&nbsp;glucose&nbsp;
<BR>
	concentrations&nbsp;&ge;75&nbsp;mg/dL
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 9PT">
	Within&nbsp;&plusmn;&nbsp;5
<BR>
	mg/dL
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 9PT">
	Within&nbsp;&plusmn;&nbsp;10
<BR>
	mg/dL
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 9PT">
	Within&nbsp;&plusmn;&nbsp;15
<BR>
	mg/dL
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 9PT">
	Within&nbsp;&plusmn;&nbsp;5&nbsp;%
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 9PT">
	Within&nbsp;&plusmn;&nbsp;10&nbsp;%
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 9PT">
	Within&nbsp;&plusmn;&nbsp;15&nbsp;%
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 9PT">
<B>
	Within&nbsp;&plusmn;&nbsp;20&nbsp;%
</B>
</FONT>
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 9PT">
	4/11
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 9PT">
	9/11
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 9PT">
	11/11
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 9PT">
	39/89
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 9PT">
	68/89
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 9PT">
	85/89
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 9PT">
	88/89
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; WIDTH: 13%">
<FONT STYLE="FONT-SIZE: 9PT">
	36.36
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 9PT">
	%
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 9PT">
	81.82
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 9PT">
	%
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 9PT">
	100
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 9PT">
	%
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 9PT">
	40.4
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 9PT">
	%
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 9PT">
	76.7
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 9PT">
	%
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 9PT">
	96.4
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 9PT">
	%
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 9PT">
	98.88
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 9PT">
	%
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	To conclude, the Dario&trade;
	meets the requirements of ISO 15197:2003 for clinical performance as determined by lay user accuracy and by satisfactory experience
	with the Dario&trade; instructions clarity and system utility.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Government Regulation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The principal markets
	that we are initially targeting for&nbsp;Dario&trade; are the United States, the European Union, Australia and New Zealand. The
	following is an overview of the regulatory regimes in these jurisdictions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	United States Regulation
	Generally
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In the United States,
	devices are subject to varying levels of regulatory control, the most comprehensive of which requires that a clinical evaluation
	be conducted before a device receives clearance for commercial distribution.&nbsp;&nbsp;Under Section 201(h) of the Food, Drug,
	and Cosmetic Act, a medical device is an article, which, among other things, is intended for use in the diagnosis of disease or
	other conditions, or in the cure, mitigation, treatment or prevention of disease, in man or other animals.&nbsp;&nbsp;We believe
	that Dario&trade; will be classified as a medical device and subject to regulation by numerous agencies and legislative bodies,
	including the FDA and its foreign counterparts.&nbsp;&nbsp;FDA regulations govern product design and development, pre-clinical
	and clinical testing, manufacturing, labeling, storage, pre-market clearance or approval, advertising and promotion, and sales
	and distribution.&nbsp;&nbsp;Specifically, the FDA classifies medical devices into one of three classes.&nbsp;&nbsp;Class I devices
	are relatively simple and can be manufactured and distributed with general controls.&nbsp;&nbsp;Class II devices are somewhat more
	complex and require greater scrutiny.&nbsp;&nbsp;Class III devices are new and frequently help sustain life.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Unless an exemption
	applies, each medical device commercially distributed in the United States will require a 510(k) clearance, 510(k)+ &ldquo;de-novo&rdquo;
	clearance, or a pre-market approval (or PMA) from the FDA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	510(k) Clearance
	Process.
</I>
	&nbsp;&nbsp; After a device receives 510(k) clearance, any modification that could significantly affect its safety
	or effectiveness, or that would constitute a major change in its intended use, requires a new 510(k) clearance or could even require
	a premarket application approval.&nbsp;&nbsp;The FDA requires each manufacturer to make this determination in the first instance,
	but the FDA can review any such decision.&nbsp;&nbsp;If the FDA disagrees with the determination, the agency may retroactively
	require the manufacturer to seek 510(k) clearance or premarket application approval.&nbsp;&nbsp;The FDA also can require the manufacturer
	to cease marketing and/or recall the modified device until 510(k) clearance or premarket application approval is obtained.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	De Novo Classification
</I>
	.&nbsp;&nbsp;&nbsp;If
	the FDA denies 510(k) clearance of a device because it is novel and an adequate predicate device does not exist, the &ldquo;de
	novo classification&rdquo; procedure can be invoked based upon reasonable assurance that the device is safe and effective for its
	intended use.&nbsp;&nbsp;This procedure approximates the level of scrutiny in the 510(k) process but may add several months to
	the clearance process. If the FDA grants the request, the device is permitted to enter commercial distribution in the same manner
	as if 510(k) clearance had been granted.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 14; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage15"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Premarket Application
	Approval Process
</I>
	.&nbsp;&nbsp; After approval of a premarket application, a new premarket application or premarket application
	supplement is required in the event of a modification to the device, its labeling or its manufacturing process.&nbsp;&nbsp;The
	premarket application approval pathway is much more costly, lengthy and uncertain.&nbsp;&nbsp;It generally takes from one to three
	years or longer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	European and Non-European
	Regulation Generally
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Sales of medical devices
	outside the United States are subject to foreign regulatory requirements that vary widely from country to country. These laws and
	regulations range from simple product registration requirements in some countries to complex clearance and production controls
	in others.&nbsp;&nbsp;As a result, the processes and time periods required to obtain foreign marketing clearance may be longer
	or shorter than those necessary to obtain FDA clearance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Commercialization of
	medical devices in Europe is regulated by the European Union. The European Union presently requires that all medical products bear
	the CE mark, an international symbol of adherence to quality assurance standards and demonstrated clinical effectiveness.&nbsp;&nbsp;Compliance
	with the Medical Device Directive (MDD) or the Active Implantable Medical Device Directive (AIMD) or the In Vitro Diagnostic Medical
	Device Directive (IVDD) as audited by a notified body and certified by a recognized European Competent Authority, permits the manufacturer
	to affix the CE mark on its products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In September 2013,
	we obtained&nbsp;ISO 13485 certification for our quality management system and CE Mark certification to market&nbsp;Dario&trade;
	and in May 2015 Dario&trade; was cleared to fulfil the criteria according to EN ISO 15197:2013&nbsp;&nbsp;The granting of the CE
	Mark allows&nbsp;Dario&trade;&nbsp;to be marketed and sold in 32 countries across Europe as well as in certain other countries
	worldwide. On November 21, 2014, MDSS, our European Authorized Representative, completed the registration of the Dario&trade; Smart
	Meter with the German Authority as required by Article 10 of Directive 98/79/EC on in vitro diagnostic medical devices. We commenced
	an initial soft launch of the product in Europe in 2014, created initial demand for the product and established brand awareness
	and marketing techniques to reach our target market with a goal to continue expansion to new markets and territories.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We achieved regulatory
	clearance to market Dario&trade; in other countries that do not rely on the CE Mark. To date, the non-CE Mark jurisdictions which
	we have begun to market Dario&trade; include New Zealand, Canada and Australia.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In January 2014, we
	completed the registration with Medsafe, the New Zealand Medicines and Medical Devices Safety Authority, through their WAND (Web
	Assisted Notification of Devices) system allowing us to sell the Dario&trade; in New Zealand. We also have completed the process
	of registering the Dario&trade; with the Australian TGA, in the ARTG (Australian Register of Therapeutic Goods), which is required
	in order to bring and sell the Dario&trade; in Australia and effective March 3, 2015 our product is approved for reimbursement
	in Australia. In February 2015, we also gained National Pharmaceutical Product Interface (known as NAPPI) approval and registered
	the Dario&trade; in South Africa. In May 2015, we also received Health Canada approval to market the Dario&trade; blood glucose
	monitoring system and commenced marketing the product. We have also received reimbursement status from the majority of insurance
	plans in Canada.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are currently pursuing
	regulatory clearance in other jurisdictions, including Costa Rica, India, Italy and Panama. To the extent that we seek to market
	our product in other non-CE Mark countries in the future, we will be required to comply with the applicable regulatory requirements
	in each such country.&nbsp;&nbsp;Such regulatory requirements vary by country and may be tedious.&nbsp;&nbsp;As a result, no assurance
	can be given that we will be able to satisfy the regulatory requirements to sell our products in any such country.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Clinical Studies
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Even when a clinical
	study has an approved Investigational Device Exemption (IDE) from FDA under significant risk (SR) determination, has been approved
	by an Institutional Review Board (IRB) under non-significant risk (NSR) determination and/or has been approved by local or regional
	Ethic Committee,&nbsp;&nbsp;the study is subject to factors beyond a manufacturer&rsquo;s control, including, but not limited to
	the fact that the institutional review board at a given clinical site might not approve the study, might decline to renew approval
	which is required annually, or might suspend or terminate the study before the study has been completed. There is no assurance
	that a clinical study at any given site will progress as anticipated; the interim results of a study may not be satisfactory leading
	the sponsor or others to terminate the study, there may be an insufficient number of patients who qualify for the study or who
	agree to participate in the study, or the investigator at the site may have priorities other than the study.&nbsp;&nbsp;Also, there
	can be no assurance that the clinical study will provide sufficient evidence to assure regulatory authorities that the product
	is safe, effective and performs as intended as a prerequisite for granting market clearance. See &ldquo;Clinical Trials&rdquo;
	above for clinical trials performed to date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 15; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage16"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	Post-Clearance Matters
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Even if the FDA or
	other non-US regulatory authorities approve or clear a device, they may limit its intended uses in such a way that manufacturing
	and distributing the device may not be commercially feasible. After clearance or approval to market is given, the FDA and foreign
	regulatory agencies, upon the occurrence of certain events, are authorized under various circumstances to withdraw the clearance
	or approval or require changes to a device, its manufacturing process or its labeling or additional proof that regulatory requirements
	have been met.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	A manufacturer of a
	device approved through the premarket approval&nbsp;application&nbsp;process is not permitted to make changes to the device which
	affects its safety or effectiveness without first submitting a supplement application to its premarket approval&nbsp;application
	and obtaining FDA clearance for that supplement.&nbsp;&nbsp;In some instances, the FDA may require a clinical trial to support
	a supplement application.&nbsp;&nbsp;A manufacturer of a device cleared through a 510(k) submission or a 510(k)+ &ldquo;de-novo&rdquo;
	submission must submit another premarket notification if it intends to make a change or modification in the device that could significantly
	affect the safety or effectiveness of the device, such as a significant change or modification in design, material, chemical composition,
	energy source or manufacturing process.&nbsp;&nbsp;Any change in the intended uses of a premarket approval&nbsp;application device
	or a 510(k) device requires an approval supplement or cleared premarket notification.&nbsp;&nbsp;Exported devices are subject to
	the regulatory requirements of each country to which the device is exported, as well as certain FDA export requirements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	Mobile Medical Applications Guidance
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	On September 23, 2013,
	the FDA issued final Guidance for developers of mobile medical applications, or apps, which are software programs that run on mobile
	communication devices and perform the same functions as traditional medical devices.&nbsp;&nbsp;The Guidance outlines the FDA&rsquo;s
	tailored approach to mobile apps. &nbsp;The FDA plans to exercise enforcement discretion (meaning it will not enforce requirements
	under the Federal Food, Drug &amp; Cosmetic Act) for the majority of mobile apps as they pose minimal risk to consumers.&nbsp;&nbsp;The
	FDA plans to focus its regulatory oversight on a subset of mobile medical apps that present a greater risk to patients if they
	do not work as intended.&nbsp;&nbsp;The FDA is focusing its oversight on mobile medical apps that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	are intended to be used as
	an accessory to a regulated medical device &ndash; for example, an application that allows a health care professional to make
	a specific diagnosis by viewing a medical image from a picture archiving and communication system (PACS) on a smart mobile device
	or a mobile tablet;&nbsp;or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	transform a mobile platform into a regulated medical device &ndash; for example, an application that turns a smart mobile device into an electrocardiography (ECG) machine to detect abnormal heart rhythms or determine if a patient is experiencing a heart attack.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	Ongoing Regulation by FDA
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Even after a device
	receives clearance or approval and is placed on the market, numerous regulatory requirements apply.&nbsp;&nbsp;These include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	establishment registration and device listing;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	quality system regulation, which requires manufacturers, including third party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all phases of the product life-cycle;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 16; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage17"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	labeling regulations and FDA prohibitions against the promotion of products for uncleared, unapproved or &ldquo;off-label&rdquo; uses, and other requirements related to promotional activities;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	medical device reporting regulations, which require that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	corrections and removals reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the Federal Food, Drug and Cosmetic Act that may present a risk to health;&nbsp;and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Failure to comply with
	applicable regulatory requirements can result in enforcement action by the FDA, which may include any of the following sanctions:
	fines, injunctions, civil or criminal penalties, recall or seizure of our current or future products, operating restrictions, partial
	suspension or total shutdown of production, refusing our request for 510(k) clearance or PMA approval of new products, rescinding
	previously granted 510(k) clearances or withdrawing previously granted PMA approvals.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We may be subject to
	announced and unannounced inspections by the FDA, and these inspections may include the manufacturing facilities of our subcontractors.
	If, as a result of these inspections, the FDA determines that our or our subcontractor&rsquo;s equipment, facilities, laboratories
	or processes do not comply with applicable FDA regulations and conditions of product clearance, the FDA may seek civil, criminal
	or administrative sanctions and/or remedies against us, including the suspension of our manufacturing and selling operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Ongoing Regulation
	by International Regulators
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	International sales
	of medical devices are subject to foreign government regulations, which may vary substantially from country to country.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In order to maintain
	the right to affix the CE Mark to sell medical devices in the European Union, an annual surveillance audit in the company premises
	and, if needed, at major subcontractors&rsquo; premises needs to be carried out by the notified body.&nbsp;&nbsp;Additionally,
	the European Directives dictate the following requirements:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Vigilance system, which requires the manufacturer to immediately notify the relevant Competent Authority when a company product has been involved in an incident that led to a death; led to a serious injury or serious deterioration in the state of health of a patient, user or other person; or might have led to death, serious injury or serious deterioration in health; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Post market surveillance including a documented procedure to review experience gained from devices on the market and to implement any necessary corrective action, commensurate with the nature and risks involved with the product
</FONT>
	.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Failure to comply with
	applicable regulatory requirements can result in enforcement action be the regulatory agency, which may include any of the following
	sanctions: fines, injunctions, civil or criminal penalties, recall or seizure of our current or future products, operating restrictions,
	partial suspension or total shutdown of production, refusing our request for renewing clearance and/or registration of our products
	or granting clearance/registration for new products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 17; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage18"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	State Licensure
	Requirements
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Several states require
	that DME providers be licensed in order to sell products to patients in that state. Certain of these states require that DME providers
	maintain an in-state location. If these rules are determined to be applicable to us and if we were found to be noncompliant, we
	could lose our licensure in that state, which could prohibit us from selling our current or future products to patients in that
	state.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Federal Anti-Kickback
	and Self-Referral Laws
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Federal Anti-Kickback
	Statute prohibits the knowing and willful offer, payment, solicitation or receipt of any form of remuneration in return for, or
	to induce the:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	referral of a person;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	furnishing or arranging for the furnishing of items or services reimbursable under Medicare, Medicaid or other governmental programs;&nbsp;or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	purchase, lease, or order of, or the arrangement or recommendation of the purchasing, leasing, or ordering of any item or service reimbursable under Medicare, Medicaid or other governmental programs.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	To the extent we are
	required to comply with these regulations, it is possible that regulatory authorities could allege that we have not complied, which
	could subject us to sanction.&nbsp;&nbsp;Noncompliance with the federal anti-kickback legislation can result in exclusion from
	Medicare, Medicaid or other governmental programs, restrictions on our ability to operate in certain jurisdictions, as well as
	civil and criminal penalties, any of which could have an adverse effect on our business and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Federal law also includes
	a provision commonly known as the &ldquo;Stark Law&rdquo;, which prohibits a physician from referring Medicare or Medicaid patients
	to an entity providing &ldquo;designated health services&rdquo;, including a company that furnishes durable medical equipment,
	in which the physician has an ownership or investment interest or with which the physician has entered into a compensation arrangement.
	Violation of the Stark Law could result in denial of payment, disgorgement of reimbursements received under a noncompliant arrangement,
	civil penalties, and exclusion from Medicare, Medicaid or other governmental programs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Federal False Claims
	Act
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Federal False Claims
	Act provides, in part, that the federal government may bring a lawsuit against any person whom it believes has knowingly presented,
	or caused to be presented, a false or fraudulent request for payment from the federal government, or who has made a false statement
	or used a false record to get a claim approved.&nbsp;&nbsp;In addition, amendments in 1986 to the Federal False Claims Act have
	made it easier for private parties to bring &ldquo;qui tam&rdquo; whistleblower lawsuits against companies.&nbsp;&nbsp;Penalties
	include fines ranging from $5,500 to $11,000 for each false claim, plus three times the amount of damages that the federal government
	sustained because of the act of that person.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Civil Monetary Penalties
	Law
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Federal Civil Monetary
	Penalties Law prohibits the offering or transferring of remuneration to a Medicare or Medicaid beneficiary that the person knows
	or should know is likely to influence the beneficiary&rsquo;s selection of a particular supplier of Medicare or Medicaid payable
	items or services. Noncompliance can result in civil money penalties of up to $10,000 for each wrongful act, assessment of three
	times the amount claimed for each item or service and exclusion from the Federal healthcare programs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	State Fraud and Abuse Provisions
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Many states have also
	adopted some form of anti-kickback and anti-referral laws and false claims acts. A determination of liability under such laws could
	result in fines and penalties and restrictions on our ability to operate in these jurisdictions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 18; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage19"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Administrative Simplification
	of the Health Insurance Portability and Accountability Act of 1996
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Health Insurance
	Portability and Accountability Act of 1996, or HIPAA, mandated the adoption of standards for the exchange of electronic health
	information in an effort to encourage overall administrative simplification and enhance the effectiveness and efficiency of the
	healthcare industry. Ensuring privacy and security of patient information is one of the key factors driving the legislation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Intellectual Property
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Patent applications
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	On May 8, 2011, certain
	of our founders filed Patent Cooperation Treaty (or PCT) Application No. PCT/IL2011/000369, titled &ldquo;Fluids Testing Apparatus
	and Methods of Use&rdquo;.&nbsp;&nbsp;This PCT took priority from two preceding U.S. provisional applications filed by our founders,
	with the earliest priority date being May 9, 2010. The PCT application was transferred to us by our founders on October 27, 2011.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	This application covers
	the novel blood glucose measurement device, comprising the glucose meter; and an adaptor that connects the glucose meter to a smart-phone
	to receive power supply and data display, storage and analysis.&nbsp;&nbsp;A PCT search report and written opinion on patentability
	that we received from World Intellectual Property Organization (known as WIPO) was very positive, including only two &ldquo;Y&rdquo;
	citations, meaning no significant prior art was found with regards to novelty and inventiveness of the application.&nbsp;&nbsp;Corresponding
	national applications of our PCT were filed in November 2012 in the U.S., Europe, and other major territories.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	On May 1, 2014 we announced
	the receipt of a U.S. Notice of Allowance for a key patent relating to how the Dario&trade; blood glucose monitor draws power from
	and transmits data to a smart phone via the audio jack port. This patent was issued in August 2014, and in September 2015, we were
	issued a U.S. patent (No. 9,125,549) that broadens our registered patent No. 8,797,180 to include testing of other bodily fluids
	through an audio jack connection. We believe this represents a critical intellectual property recognition and a significant initial
	validation of our intellectual property efforts.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Additionally, a provisional
	application was filed covering a feature related to future Dario&trade;&nbsp;generations. Additional patent applications are expected
	to be filed covering additional aspects of the core Dario&trade; technology.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are further seeking
	to develop and protect new intellectual property around future generations of Dario&trade; hardware and software with the goal
	of achieving enhanced functionality, user interface and data usability.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Design patents and
	patent applications on the Dario&trade; device
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	To create market distinction
	and branding for Dario&trade;, three U.S. Design Applications have been filed covering the glucose meter and the cartridge. These
	applications were granted and registered in the United States. We have filed national applications for the cartridge in major territories.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Design patents and
	patent applications on the Dario&trade; App
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In addition, three
	U.S. Design Applications have been filed covering our smart mobile device display screens with graphical user interface. These
	design application were granted and registered in the United States. We have filed national applications also in in major territories.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Trademark applications
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have also filed
	four trademark applications covering the Dario&trade; name, logo and the &ldquo;Nothing Holds Me Back&rdquo; slogan for Dario&trade;,
	as well as our company&rsquo;s name.&nbsp;&nbsp;The marks were granted and registered in the United States; national applications
	were filed in major territories.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 19; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage20"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Protection on disposable
	test strip cartridge
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Dario&trade; device
	includes a disposable part containing the test strips. To protect the disposable part and prevent generic competition, we have
	sought several complementary protection means, including recognition of the Dario&trade; strips by the device as well as for ensuring
	that the strips are kept in appropriate conditions of humidity and expiry.&nbsp;&nbsp;There are additional design elements used
	to recognize the cartridge for which protection is also being sought.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Utility Models
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have filed several
	Utility Model applications in several key markets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Other intangible
	assets
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	As the number of Dario&trade;
	users grows, large amount of data will be collected from diabetic patients, comprising their blood sugar levels, meal composition
	and timing, physical exercise (intensity and duration) as well as many other factors, which are useful for creating meaningful
	correlations between these factors and insulin use.&nbsp;&nbsp;We expect that this database will be highly valuable and may be
	capitalized in many ways. The accumulation of this type of know-how and related algorithms are protected as trade secrets using
	specialized confidentiality protocols.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Competition
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We face competition
	principally from two arenas:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Direct competition
	from existing companies in the blood based glucose monitors market
</I>
	.&nbsp;&nbsp;We compete directly and primarily with large
	pharmaceutical and medical device companies, including, but not limited to, Abbott Laboratories, Bayer Healthcare Division, Johnson
	&amp; Johnson LifeScan, Roche Diagnostics and Sanofi.&nbsp;&nbsp;While the market is highly competitive, we believe that Dario&trade;
	has important comparative advantages versus other devices in the market. Some of these devices are now offered as connected devices
	to smart mobile devices, such as the Sanofi IBGStar, Medisana GlucoDock, Philosys Gmate Smart, and iHealth Align.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Dario&trade; Smart
	Meter offers an all-in-one glucose monitoring system, including a small form factor glucose reader, lancing device and a strip
	cartridge connected to existing smart mobile devices, which enables Dario&trade; to offer features that are similar to or superior
	to the most advanced meters in the market (such as Sanofi IBGStar, Gmate Smart and iHealth Align) while having a smaller form factor
	than the compact meters in the market (Abbott FreeStyle Lite and OneTouch UltraMini).&nbsp;&nbsp;We believe this design will be
	attractive to diabetic patients.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Non-invasive and
	continuous blood glucose monitors.
</I>
	&nbsp;&nbsp;While there are numerous continuous blood glucose monitoring technologies in
	the market, we believe they are expensive to use and are therefore offered mainly for temporary usage and in medical settings (such
	as hospitals) or to limited population at high risk for hypoglycemia.&nbsp;&nbsp;There have been a wealth of attempts for noninvasive
	glucose monitors, but we are not aware of any that are available in the market or are expected to reach the market with significant
	presence over the next few years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Gearing up for the
	expansion of LabStyle and potential growth into the mHealth space, we are currently analyzing key players in the mobile health/digital
	health arena. Big Data and analytical insights are the key offerings for all segments of the market &ndash; patients, healthcare
	providers and payers. Our technology development focus and marketing efforts are all geared at placing us as a major player in
	this global market.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Employees
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We currently have 19 full time employees
	and 2 part time employees.&nbsp;&nbsp;We have employment agreements with our two executive officers.&nbsp;&nbsp;See &ldquo;Management
	&ndash; Employment Agreements&rdquo;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 20; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_BUSINESS>
<A NAME="eolPage21"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<EFX_RISK_FACTORS>
<A NAME="FIS_RISK_FACTORS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V430703_10K_HTM_A_004">
</A>
	Item
	1A.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Risk
	Factors
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Investing in our
	securities is highly speculative and involves a high degree of risk. You should carefully consider the following factors and other
	information in this Annual Report and our other SEC filings before making a decision to invest in our securities. Additional risks
	and uncertainties that we are unaware of may become important factors that affect us. If any of the following events occur, our
	business, financial conditions and operating results may be materially and adversely affected. In that event, the trading price
	of our common stock and warrants may decline, and you could lose all or part of your investment.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<B>
	Risks Related to
	Our Financial Position and Capital Requirements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	We were formed in August 2011 and are thus subject to
	the risks associated with new businesses.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We were formed in August
	2011 as a new business and only recently entered the commercialization stage of our technology. As such, &nbsp;this limited operating
	history may not be adequate to enable you to fully assess our ability to develop and commercialize Dario&trade;, achieve market
	acceptance of Dario&trade; and respond to competition. We commenced an initial &ldquo;soft&rdquo; launch of the Dario&trade; application
	in December 2013 in the United Kingdom and the Dario&trade; Smart Meter in March 2014 in targeted jurisdictions and continued into
	scaled up launch during 2014 in the United Kingdom, the Netherlands and New Zealand, and during 2015 in Australia, Israel and Canada.
	These efforts have not generated material revenue, and it is still too early to predict if we will be able to generate significant
	revenues over the next 12 months. Therefore, we are, and expect for the foreseeable future to be, subject to all the risks and
	uncertainties, inherent in a new business and the development and sale of new medical devices and related software applications.
	As a result, we may be unable to fully develop, obtain regulatory approval for, commercialize, manufacture, market, sell and derive
	material revenues from Dario&trade; in the timeframes we project, if at all, and our inability to do so would materially and adversely
	impact our viability as a company. In addition, we still must establish many functions necessary to operate a business, including
	finalizing our managerial and administrative structure, continuing product and technology development, assessing and commencing
	our marketing activities, implementing financial systems and controls and personnel recruitment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Accordingly, you should
	consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by companies in their
	initial revenue generating stages, particularly those in the medical device and mobile heath fields. In particular, potential investors
	should consider that there is a significant risk that we will not be able to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	implement or execute our
	current business plan, or that our business plan is sound;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	maintain our management team and Board of Directors;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	raise sufficient funds in the capital markets or otherwise to effectuate our business plan;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	determine that our technologies that we have developed&nbsp;are commercially viable; and/or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	attract, enter into or maintain contracts with, and retain customers.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In the event that we do not successfully
	address these risks, our business, prospects, financial condition, and results of operations could be materially and adversely
	affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Given our limited revenue and lack
	of positive cash flow, we will need to raise additional capital, which may be unavailable to us or, even if consummated, may cause
	dilution or place significant restrictions on our ability to operate.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	According to our management&rsquo;s
	estimates, based on our current cash on hand and further based on our budget and the assumption that initial commercial sales will
	commence during our anticipated timeframes, we believe that we will have sufficient resources to continue our activities only into
	April 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 21; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage22"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Since we might be unable
	to generate sufficient revenue or cash flow to fund our operations for the foreseeable future, we will need to seek additional
	equity or debt financing to provide the capital required to maintain or expand our operations. We may also need additional funding
	for developing products and services, increasing our sales and marketing capabilities, and promoting brand identity, as well as
	for working capital requirements and other operating and general corporate purposes. Moreover, the regulatory compliance arising
	out of being a publicly registered company has dramatically increased our costs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We do not currently
	have any arrangements or credit facilities in place as a source of funds, and there can be no assurance that we will be able to
	raise sufficient additional capital on acceptable terms, or at all. If such financing is not available on satisfactory terms, or
	is not available at all, we may be required to delay, scale back or eliminate the development of business opportunities and our
	operations and financial condition may be materially adversely affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	If we raise additional
	capital by issuing equity securities, the percentage ownership of our existing stockholders may be reduced, and accordingly these
	stockholders may experience substantial dilution. We may also issue equity securities that provide for rights, preferences and
	privileges senior to those of our common stock. Given our need for cash and that equity raising is the most common type of fundraising
	for companies like ours, the risk of dilution is particularly significant for stockholders of our company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Debt financing, if
	obtained, may involve agreements that include liens on our assets, covenants limiting or restricting our ability to take specific
	actions, such as incurring additional debt, could increase our expenses and require that our assets be provided as a security for
	such debt. Debt financing would also be required to be repaid regardless of our operating results.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	If we raise additional
	funds through collaborations and licensing arrangements, we may be required to relinquish some rights to our technologies or candidate
	products, or to grant licenses on terms that are not favorable to us.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Funding from any source
	may be unavailable to us on acceptable terms, or at all, particularly due to certain offering participation rights afforded to
	investors in a private placement which closed in February 2014 (which we refer to as the February 2014 Private Placement) as well
	as preemptive rights held by the lead investor in our private placement which closed in September 2014 (which we refer to as the
	September 2014 Private Placement). If we do not have sufficient capital to fund our operations and expenses, we may not be able
	to achieve or maintain competitiveness, which could lead to the failure of our business and the loss of your investment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We have incurred significant losses
	since inception. As such, you cannot rely upon our historical operating performance to make an investment decision regarding our
	company.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Since our inception,
	we have engaged primarily in research and development activities and only recently entered the commercialization stage. We have
	financed our operations primarily through private placements of common stock and convertible debt and have incurred losses in each
	year since inception including net losses of $7,296,000 and $16,055,000 in 2015 and 2014, respectively. Our accumulated deficit
	at December 31, 2015 was approximately $43,354,000. We do not know whether or when we will become profitable. Our ability to generate
	revenue and achieve profitability depends upon our ability, alone or with others, to launch Dario&trade; in additional European
	countries, and elsewhere and manufacture, market and sell Dario&trade; where approved. We may be unable to achieve any or all of
	these goals.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Our independent registered public
	accounting firm has expressed in its report to our 2015 audited financial statements a substantial doubt about our ability to continue
	as a going concern
</I>
</B>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We only recently entered
	the commercialization stage, and the development and commercialization of Dario&trade; is uncertain and expected to require substantial
	expenditures. We have not yet generated sufficient revenues from our operations to fund our activities, and are therefore dependent
	upon external sources for financing our operations. There is a risk that we will be unable to obtain necessary financing to continue
	our operations on terms acceptable to us or at all. As a result, our independent registered public accounting firm has expressed
	in its auditors&rsquo; report on the financial statements for December 31, 2015 a substantial doubt regarding our ability to continue
	as a going concern. Our financial statements do not include any adjustments that might result from the outcome of the uncertainty
	regarding our ability to continue as a going concern. This going concern opinion could materially limit our ability to raise additional
	funds through the issuance of equity or debt securities or otherwise. Future reports on our financial statements may include an
	explanatory paragraph with respect to our ability to continue as a going concern. If we cannot continue as a going concern, our
	stockholders may lose their entire investment in the common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 22; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage23"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Risks Related to Our Business
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
<I>
	We only recently
	began commercializing Dario&trade; and our success will depend on the acceptance of Dario&trade; in the healthcare market.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Dario
<I>
	&trade;
</I>
	has been CE marked since 2013, enabling us to commercialize
</FONT>
	in 32 countries across Europe as well as in certain other countries
	worldwide
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	. It was also approved by the regulatory authorities in Australia, New Zealand,
	Canada, Israel and South Africa, and most recently in December 2015, we received FDA clearance. As a result, we have a limited
	history of commercializing Dario&trade; and no history of selling Dario&trade; in the United States. We have limited experience
	engaging in commercial activities and limited established relationships with physicians and hospitals as well as third-party suppliers
	on whom we depend for the manufacture of our product.&nbsp;
</FONT>
	We are faced with the risk that the marketplace will not be receptive
	to Dario&trade; over competing products and that we will be unable to compete effectively. Factors that could affect our ability
	to establish Dario&trade; or any potential future product include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	the development of products or devices which could result in a shift of customer preferences away from our device and services and significantly decrease revenue;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	the increased use of improved diabetes drugs that could encourage certain diabetics to test less often, resulting in less usage of self-monitoring test device for certain types of diabetics;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	the challenges of developing (or acquiring externally-developed) technology solutions that are adequate and competitive in meeting the requirements of next-generation design challenges;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	the significant number of current competitors in BGMS market who have significantly greater brand recognition and more recognizable trademarks and who have established relationships with diabetics healthcare providers and payors; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	intense competition to attract acquisition targets, which may make it more difficult for us to acquire companies or technologies at an acceptable price or at all.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We cannot assure you
	that Dario&trade; or any future product will gain broad market acceptance. If the market for Dario&trade; or any future product
	fails to develop or develops more slowly than expected, or if any of the technology and standards supported by us do not achieve
	or sustain market acceptance, our business and operating results would be materially and adversely affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We cannot accurately predict the
	volume or timing of any future sales, making the timing of any revenues difficult to predict.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We may be faced with
	lengthy customer evaluation and approval processes associated with Dario&trade;. Consequently, we may incur substantial expenses
	and devote significant management effort and expense in developing customer adoption of Dario&trade;, which may not result in revenue
	generation. We must also obtain regulatory approvals of Dario&trade; in certain jurisdictions as well as approval for insurance
	reimbursement in order to initiate sales of Dario&trade;, each of which is subject to risk and potential delays, and neither of
	which may actually occur. As such, we cannot accurately predict the volume or timing of any future sales.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 23; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage24"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	&nbsp;&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	If Dario&trade; fails to satisfy
	current or future customer requirements, we may be required to make significant expenditures to redesign the product, and we may
	have insufficient resources to do so.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Dario&trade; is being
	designed to address an evolving marketplace and must comply with current and evolving customer requirements in order to gain market
	acceptance. There is a risk that Dario&trade; will not meet anticipated customer requirements or desires. If we are required to
	redesign our products to address customer demands or otherwise modify our business model, we may incur significant unanticipated
	expenses and losses, and we may be left with insufficient resources to engage in such activities. If we are unable to redesign
	our products, develop new products or modify our business model to meet customer desires or any other customer requirements that
	may emerge, our operating results would be materially adversely affected and our business might fail.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We expect to derive substantially
	all of our revenues from our principal technology, which leaves us subject to the risk of reliance on such technology.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We expect to derive
	substantially all of our revenues from sales of products derived from our principal technology. Our initial product utilizing this
	technology is Dario&trade;. As such, any factor adversely affecting sales of Dario&trade;, including the product release cycles,
	regulatory issues, market acceptance, product competition, performance and reliability, reputation, price competition and economic
	and market conditions, would likely harm our operating results. We may be unable to develop other products utilizing our technology,
	which would likely lead to the failure of our business. Moreover, in spite of our efforts related to the registration of our technology,
	if patent protection is not available for our principal technology, the viability of Dario&trade; and any other products that may
	be derived from such technology would likely be adversely impacted to a significant degree, which would materially impair our prospects.&nbsp;
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<B>
<I>
	We are dependent
	upon third-party manufacturers and suppliers making us vulnerable to supply shortages and problems and price fluctuations, which
	could harm our business.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	We
	do not own or operate manufacturing facilities for clinical or commercial production of Dario&trade; and we lack the resources
	and the capability to manufacture Dario&trade; on a commercial scale. Therefore, we rely on a limited number of suppliers who manufacture
	and assemble certain components of Dario&trade;. Our suppliers may encounter problems during manufacturing for a variety of reasons,
	including, for example, failure to follow specific protocols and procedures, failure to comply with applicable legal and regulatory
	requirements, equipment malfunction and environmental factors, failure to properly conduct their own business affairs, and infringement
	of third-party intellectual property rights, any of which could delay or impede their ability to meet our requirements. Our reliance
	on these third-party suppliers also subjects us to other risks that could harm our business, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	we are not a major customer
	of many of our suppliers, and these suppliers may therefore give other customers&rsquo; needs higher priority than ours;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	third parties may threaten
	or enforce their intellectual property rights against our suppliers, which may cause disruptions or delays in shipment, or may
	force our suppliers to cease conducting business with us;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	we may not be able to obtain
	an adequate supply in a timely manner or on commercially reasonable terms;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	our suppliers, especially
	new suppliers, may make errors in manufacturing that could negatively affect the efficacy or safety of Dario&trade; or cause delays
	in shipment;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	we may have difficulty locating
	and qualifying alternative suppliers;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	switching components or suppliers
	may require product redesign and possibly submission to FDA, European Economic Area Notified Bodies, or other foreign regulatory
	bodies, which could significantly impede or delay our commercial activities;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	one or more of our sole-
	or single-source suppliers may be unwilling or unable to supply components of Dario&trade;;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	other customers may use fair
	or unfair negotiation tactics and/or pressures to impede our use of the supplier;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	the occurrence of a fire,
	natural disaster or other catastrophe impacting one or more of our suppliers may affect their ability to deliver products to us
	in a timely manner; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	our suppliers may encounter
	financial or other business hardships unrelated to our demand, which could inhibit their ability to fulfill our orders and meet
	our requirements.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 24; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage25"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	We
	may not be able to quickly establish additional or alternative suppliers if necessary, in part because we may need to undertake
	additional activities to establish such suppliers as required by the regulatory approval process. Any interruption or delay in
	obtaining products from our third-party suppliers, or our inability to obtain products from qualified alternate sources at acceptable
	prices in a timely manner, could impair our ability to meet the demand of our customers and cause them to switch to competing products.
	Given our reliance on certain single-source suppliers, we are especially susceptible to supply shortages because we do not have
	alternate suppliers currently available.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<B>
<I>
	We rely
	in part on a small group of third-party distributors to effectively distribute our products.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	We
	depend in part on medical device distributors for the marketing and selling of our products in certain territories in which we
	have launched product sales. We depend on these distributors&rsquo; efforts to market our products, yet we are unable to control
	their efforts completely. These distributors typically sell a variety of other, non-competing products that may limit the resources
	they dedicate to selling Dario&trade;. In addition, we are unable to ensure that our distributors comply with all applicable laws
	regarding the sale of our products. If our distributors fail to effectively market and sell Dario&trade;, in full compliance with
	applicable laws, our operating results and business may suffer. Recruiting and retaining qualified third-party distributors and
	training them in our technology and product offering requires significant time and resources. To develop and expand our distribution,
	we must continue to scale and improve our processes and procedures that support our distributors. Further, if our relationship
	with a successful distributor terminates, we may be unable to replace that distributor without disruption to our business. If we
	fail to maintain positive relationships with our distributors, fail to develop new relationships with other distributors, including
	in new markets, fail to manage, train or incentivize existing distributors effectively, or fail to provide distributors with competitive
	products on attractive terms, or if these distributors are not successful in their sales efforts, our revenue may decrease and
	our operating results, reputation and business may be harmed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Failure in our online and digital
	marketing efforts could significantly impact our ability to generate sales.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In several of our principal
	target markets, we plan to utilize online and digital marketing in order to create awareness to Dario&trade;. Our management believes
	that using online advertisement through affiliate networks and a variety of other pay-for-performance methods will be superior
	for marketing and generating sales of Dario&trade; rather than utilizing traditional, expensive retail channels. However, there
	is a risk that our marketing strategy could fail. Because we plan to use non-traditional retail sales tools and to rely on healthcare
	providers to educate our customers about Dario&trade;, we cannot predict the level of success, if any, that we may achieve by marketing
	Dario&trade; via the Internet. The failure of our online marketing efforts would significantly and negatively impact our ability
	to generate sales.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Our Dario&trade; smart mobile application,
	which is a key to our business model, is available via Apple&rsquo;s iOS and via Google&rsquo;s Android platforms and maybe in
	the future via additional platforms. If we are unable to achieve or maintain a good relationship with each of Apple and Google
	or similar platforms, or if the Apple App Store or the Google Play Store or any other applicable platform were unavailable for
	any prolonged period of time, our business will suffer.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	A key component of
	the Dario&trade; solution is an iPhone or Android application which includes tools to help diabetic patients manage their disease.
	This application is compatible with Apple&rsquo;s iOS and with Google&rsquo;s Android platforms and may in the future become compatible
	via additional platforms. If we are unable to make our Dario&trade; application compatible with these platforms, or if there is
	any deterioration in our relationship with either Apple or Google or others after our application is available, our business would
	be materially harmed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are subject to each
	of Apple&rsquo;s and Google&rsquo;s standard terms and conditions for application developers, which govern the promotion, distribution
	and operation of games and other applications on their respective storefronts. Each of Apple and Google has broad discretion to
	change its standard terms and conditions, including changes which could require us to pay to have our Dario&trade; application
	available for downloading. In addition, these standard terms and conditions can be vague and subject to changing interpretations
	by Apple or Google. We may not receive any advance warning of such changes. In addition, each of Apple and Google have the right
	to prohibit a developer from distributing its applications on its storefront if the developer violates its standard terms and conditions.
	In the event that either Apple or Google ever determines that we are in violation of its standard terms and conditions, including
	by a new interpretation, and prohibits us from distributing our Dario&trade; application on its storefront, it would materially
	harm our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 25; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage26"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Additionally, we will
	rely on the continued function of the Apple App Store and the Google Play Store as digital storefronts where our Dario&trade; application
	may be obtained. There have been occasions in the past when these digital storefronts were unavailable for short periods of time
	or where there have been issues with the in-app purchasing functionality within the storefront. In the event that either the Apple
	App Store or the Google Play Store is unavailable or if in-app purchasing functionality within the storefront is non-operational
	for a prolonged period of time, it would have a material adverse effect on the ability of our customers to secure the Dario&trade;
	application, which would materially harm our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	As we conduct business internationally,
	we are susceptible to risks associated with international relationships.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Outside of the United
	States, we operate our business internationally, presently in Europe, Australia, New Zealand, Canada, Israel and other markets.
	The international operation of our business requires significant management attention, which could negatively affect our business
	if it diverts their attention from their other responsibilities. In the event that we are unable to manage the complications associated
	with international operations, our business prospects could be materially and adversely affected. In addition, doing business with
	foreign customers subjects us to additional risks that we do not generally face in the United States. These risks and uncertainties
	include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	management, communication
	and integration problems resulting from cultural differences and geographic dispersion;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	localization of products and services, including translation of foreign languages;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	delivery, logistics and storage costs;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	longer accounts receivable payment cycles and difficulties in collecting accounts receivable;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	difficulties supporting international operations;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	difficulties supporting customer services;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	changes in economic and political conditions;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	impact of trade protection measures;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	complying with import or export licensing requirements;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	exchange rate fluctuations;
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 10PT">
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	competition from companies with international operations, including large international competitors and entrenched local companies;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	potentially adverse tax consequences, including foreign tax systems and restrictions on the repatriation of earnings;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	maintaining and servicing computer hardware in distant locations;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	keeping current and complying with a wide variety of foreign laws and legal standards, including local labor laws;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	securing or maintaining protection for our intellectual property; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	reduced or varied protection for intellectual property rights, including the ability to transfer such rights to third parties, in some countries.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 26; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage27"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The occurrence of any
	or all of these risks could adversely affect our international business and, consequently, our results of operations and financial
	condition.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We expect to be exposed to fluctuations
	in currency exchange rates, which could adversely affect our results of operations.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Because we expect to
	conduct a material portion of our business outside of the United States but report our financial results in U.S. Dollars, we face
	exposure to adverse movements in currency exchange rates. Our foreign operations will be exposed to foreign exchange rate fluctuations
	as the financial results are translated from the local currency into U.S. Dollars upon consolidation. Specifically, the U.S. Dollar
	cost of our operations in Israel is influenced by any movements in the currency exchange rate of the New Israeli Shekel (NIS).
	Such movements in the currency exchange rate may have a negative effect on our financial results. If the U.S. Dollar weakens against
	foreign currencies, the translation of these foreign currency denominated transactions will result in increased revenue, operating
	expenses and net income. Similarly, if the U.S. Dollar strengthens against foreign currencies, the translation of these foreign
	currency denominated transactions will result in decreased revenue, operating expenses and net income. As exchange rates vary,
	sales and other operating results, when translated, may differ materially from our or the capital market&rsquo;s expectations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Non-U.S. governments often impose
	strict price controls, which may adversely affect our future profitability.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We intend to seek approval
	to market Dario&trade; and any future product in both the U.S. and in non-U.S. jurisdictions. If we obtain approval in one or more
	non-U.S. jurisdictions, we will be subject to rules and regulations in those jurisdictions relating to our products. In some countries,
	particularly countries of the European Union, each of which has developed its own rules and regulations, pricing may be subject
	to governmental control under certain circumstances. In these countries, pricing negotiations with governmental authorities can
	take considerable time after the receipt of marketing approval for a medical device candidate. To obtain reimbursement or pricing
	approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product
	to other available products.
<B>
	&nbsp;
</B>
	If reimbursement of our product candidates is unavailable or limited in scope or amount,
	or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Our Dario&trade; Smart Meter, software
	application and associated business processes may contain undetected errors, which could limit our ability to provide our services
	and diminish the attractiveness of our service offerings.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Dario&trade; (including
	the Smart Meter and software application) may contain undetected errors, defects or bugs. As a result, our customers or end users
	may discover errors or defects in our products, software or the systems we design, or the products or systems incorporating our
	designs and intellectual property may not operate as expected. We may discover significant errors or defects in the future that
	we may not be able to fix. Our inability to fix any of those errors could limit our ability to provide our products, impair the
	reputation of our brand and diminish the attractiveness of our product offerings to our customers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In addition, we may
	utilize third party technology or components in our products and we rely on those third parties to provide support services to
	us. Failure of those third parties to provide necessary support services could materially adversely impact our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Our future performance will depend
	on the continued engagement of key members of our management team.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our future performance
	depends to a large extent on the continued services of members of our current management including, in particular, Erez Raphael,
	our Chief Executive Officer and Chairman of our Board of Directors, and Zvi Ben David, our Chief Financial Officer, Treasurer and
	Secretary. In the event that we lose the continued services of such key personnel for any reason, this could have a material adverse
	effect on our business, operations and prospects.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 27; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage28"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	If we are not able to attract and
	retain highly skilled managerial, scientific and technical personnel, we may not be able to implement our business model successfully.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We believe that our
	management team must be able to act decisively to apply and adapt our business model in the rapidly changing markets in which we
	will compete. In addition, we will rely upon technical and scientific employees or third party contractors to effectively establish,
	manage and grow our business. Consequently, we believe that our future viability will depend largely on our ability to attract
	and retain highly skilled managerial, sales, scientific and technical personnel. In order to do so, we may need to pay higher compensation
	or fees to our employees or consultants than we currently expect and such higher compensation payments would have a negative effect
	on our operating results. Competition for experienced, high-quality personnel is intense and we cannot assure that we will be able
	to recruit and retain such personnel. We may not be able to hire or retain the necessary personnel to implement our business strategy.
	Our failure to hire and retain such personnel could impair our ability to develop new products and manage our business effectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Risks Related to Product Development
	and Regulatory Approval
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	The regulatory clearance process
	which we must navigate is expensive, time-consuming, and uncertain and may prevent us from obtaining clearance for the commercialization
	of Dario&trade;
</I>
</B>
	&nbsp;
<B>
<I>
	or our any future product.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 42PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are not permitted
	to market Dario&trade; until we receive regulatory clearance. To date, we have received regulatory clearance in Australia, Canada,
	Israel, the Netherlands, New Zealand, the United Kingdom and the United States and we are currently seeking approval in Costa Rica,
	India and Panama.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The research, design,
	testing, manufacturing, labeling, selling, marketing and distribution of medical devices are subject to extensive regulation by
	the FDA and non-U.S. regulatory authorities, which regulations differ from country to country.
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	There can be no assurance that, even after such time and expenditures, we will be able to obtain necessary regulatory approvals
	for clinical testing or for the manufacturing or marketing of any products.&nbsp;&nbsp;In addition, during the regulatory process,
	other companies may develop other technologies with the same intended use as our products.&nbsp;&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are also subject
	to numerous post-marketing regulatory requirements, which include labeling regulations and medical device reporting regulations,
	which may require us to report to different regulatory agencies if our device causes or contributes to a death or serious injury,
	or malfunctions in a way that would likely cause or contribute to a death or serious injury. In addition, these regulatory requirements
	may change in the future in a way that adversely affects us. If we fail to comply with present or future regulatory requirements
	that are applicable to us, we may be subject to enforcement action by regulatory agencies, which may include, among others, any
	of the following sanctions:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	untitled letters, warning
	letters, fines, injunctions, consent decrees and civil penalties;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	customer notification, or orders for repair, replacement or refunds;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	voluntary or mandatory recall or seizure of our current or future products;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	imposing operating restrictions, suspension or shutdown of production;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	refusing our requests for 510(k) clearance or pre-market approval of new products, new intended uses or modifications to Dario&trade; or future products;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	rescinding 510(k) clearance or suspending or withdrawing pre-market approvals that have already been granted;&nbsp;and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	criminal prosecution.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 28; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage29"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The occurrence of any
	of these events may have a material adverse effect on our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In addition, on September
	23, 2013, the FDA issued final guidance (which we refer to herein as the Guidance) for developers of mobile medical applications,
	or apps, which are software programs that run on mobile communication devices and perform the same functions as traditional medical
	devices. The Guidance outlines the FDA&rsquo;s tailored approach to mobile apps. &nbsp;The FDA plans to exercise enforcement discretion
	(meaning it will not enforce requirements under the Federal Food, Drug and Cosmetic Act) for the majority of mobile apps as they
	pose minimal risk to consumers. The FDA plans to focus its regulatory oversight on a subset of mobile medical apps that present
	a greater risk to patients if they do not work as intended. We anticipate that the Dario&trade; application will be subject to
	the FDA regulation as a &ldquo;mobile medical app.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<B>
<I>
	We have
	conducted limited clinical studies of Dario&trade;. Clinical and pre-clinical data is susceptible to varying interpretations, which
	could delay, limit or prevent additional regulatory clearances.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	To
	date, we have conducted limited clinical studies on Dario&trade;.&nbsp;&nbsp; There can be no assurance that we will successfully
	complete additional clinical studies necessary to receive additional regulatory approvals in certain jurisdictions. While studies
	conducted by us have produced results we believe to be encouraging and indicative of the potential efficacy of Dario&trade;, data
	already obtained, or in the future obtained, from pre-clinical studies and clinical studies do not necessarily predict the results
	that will be obtained from later pre-clinical studies and clinical studies. Moreover, pre-clinical and clinical data are susceptible
	to varying interpretations, which could delay, limit or prevent additional regulatory approvals. A number of companies in the medical
	device and pharmaceutical industries have suffered significant setbacks in advanced clinical studies, even after promising results
	in earlier studies. The failure to adequately demonstrate the safety and effectiveness of an intended product under development
	could delay or prevent regulatory clearance of the device, resulting in delays to commercialization, and could materially harm
	our business.&nbsp;&nbsp;Even though we have received CE mark and FDA clearance of Dario&trade;, there can be no assurance that
	we will be able to receive approval for other potential applications of our principal technology, or that we will receive regulatory
	clearances from other targeted regions or countries.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We may be unable to complete required
	clinical trials, or we may experience significant delays in completing such clinical trials, which could significantly delay our
	targeted product launch timeframe and impair our viability and business plan.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The completion of any
	future clinical trials for Dario&trade; or other trials that we may be required to undertake in the future could be delayed, suspended
	or terminated for several reasons, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	our failure or inability to conduct the clinical trial in accordance with regulatory requirements;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	sites participating in the trial may drop out of the trial, which may require us to engage new sites for an expansion of the number of sites that are permitted to be involved in the trial;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	patients may not enroll in, remain in or complete, the clinical trial at the rates we expect; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	clinical investigators may not perform our clinical trial on our anticipated schedule or consistent with the clinical trial protocol and good clinical practices.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	If our clinical trial
	is delayed it will take us longer to ultimately commercialize Dario&trade; and generate revenues. Moreover, our development costs
	will increase if we have material delays in our clinical trial or if we need to perform more or larger clinical trials than planned.
	We may be faced with similar risks in connection with future trials we conduct. See &ldquo;Business - Clinical Trials&rdquo; for
	a description of our clinical trials performed to date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	If we or our manufacturers fail to
	comply with the FDA&rsquo;s Quality System Regulation or any applicable state equivalent, our operations could be interrupted and
	our operating results could suffer.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We, our manufacturers
	and suppliers must, unless specifically exempt by regulation, follow the FDA&rsquo;s Quality System Regulation (QSR) and are also
	subject to the regulations of foreign jurisdictions regarding the manufacturing process. If our affiliates, our manufacturers or
	suppliers are found to be in significant non-compliance or fail to take satisfactory corrective action in response to adverse QSR
	inspectional findings, the FDA could take enforcement actions against us and our manufacturers which could impair our ability to
	produce our products in a cost-effective and timely manner in order to meet our customers&rsquo; demands. Accordingly, our operating
	results could suffer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 29; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage30"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We are subject to the risk of reliance
	on third parties to conduct our clinical trial work.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We depend on independent
	clinical investigators to conduct our clinical trials. Contract research organizations may also assist us in the collection and
	analysis of data. These investigators and contract research organizations will not be our employees and we will not be able to
	control, other than by contract, the amount of resources, including time that they devote to products that we develop. If independent
	investigators fail to devote sufficient resources to our clinical trials, or if their performance is substandard, it will delay
	the approval or clearance and commercialization of any products that we develop. Further, the FDA and other regulatory bodies around
	the world require that we comply with standards, commonly referred to as good clinical practice, for conducting, recording and
	reporting clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and
	confidentiality of trial subjects are protected. If our independent clinical investigators and contract research organizations
	fail to comply with good clinical practice, the results of our clinical trials could be called into question and the clinical development
	of our product candidates could be delayed. Failure of clinical investigators or contract research organizations to meet their
	obligations to us or comply with federal regulations could adversely affect the clinical development of our product candidates
	and harm our business. Moreover, we intend to have several clinical trials in order to support our marketing efforts and business
	development purposes. Such clinical trials will be conducted by third parties as well. Failure of such clinical trials to meet
	their primary endpoints could adversely affect our marketing efforts.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<B>
<I>
	Legislative
	reforms to the United States healthcare system may adversely affect our revenues and business.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	From
	time to time, legislative reform measures are proposed or adopted that would impact healthcare expenditures for medical services,
	including the medical devices used to provide those services. For example, in March 2010, U.S. President Barack Obama signed the
	Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively referred
	to as the Affordable Care Act. The Affordable Care Act made a number of substantial changes in the way health care is financed
	by both governmental and private insurers and the way that Medicare providers are reimbursed. Among other things, the Affordable
	Care Act requires certain medical device manufacturers and importers to pay an excise tax equal to 2.3% of the price for which
	such medical devices are sold, beginning January&nbsp;1, 2013.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	In
	addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted.&nbsp;On August&nbsp;2,
	2011, the President signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee
	on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted
	deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation&rsquo;s automatic reduction
	to several government programs. This includes reductions to Medicare payments to providers of 2.0%&nbsp;per fiscal year. On January&nbsp;2,
	2013, President Obama signed into law the American Taxpayer Relief Act of 2012, or the ATRA, which delayed for another two months
	the budget cuts mandated by these sequestration provisions of the Budget Control Act of 2011. On March&nbsp;1, 2013, the President
	signed an executive order implementing sequestration, and on April&nbsp;1, 2013, the 2% Medicare payment reductions went into effect.
	The Bipartisan Budget Act of 2013, enacted on December&nbsp;26, 2013, extends these cuts to 2023. The ATRA also, among other things,
	reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased
	the statute of limitations period for the government to recover overpayments to providers from three to five years. In December
	2014, Congress passed an omnibus funding bill (the Consolidated and Further Continuing Appropriations Act, 2015) and a tax extenders
	bill, both of which may negatively impact coverage and reimbursement of healthcare items and services.&nbsp;We expect that additional
	state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and
	state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional
	pricing pressure.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 30; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage31"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	Government
	and private sector initiatives to limit the growth of health care costs, including price regulation, competitive pricing, coverage
	and payment policies, comparative effectiveness reviews of therapies, technology assessments, and managed-care arrangements, are
	continuing. Government programs, including Medicare and Medicaid, private health care insurance and managed-care plans have attempted
	to control costs by limiting the amount of reimbursement they will pay for particular procedures or treatments, tying reimbursement
	to outcomes, and other mechanisms designed to constrain utilization and contain costs, including delivery reforms such as expanded
	bundling of services. Hospitals are also seeking to reduce costs through a variety of mechanisms, which may increase price sensitivity
	among customers for our products, and adversely affect sales, pricing, and utilization of our products. Some third-party payors
	must also approve coverage for new or innovative devices or therapies before they will reimburse health care providers who use
	the medical devices or therapies. We cannot predict the potential impact of cost-containment trends on future operating results.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We may be subject to federal, state
	and foreign healthcare fraud and abuse laws and regulations.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Many federal, state
	and foreign healthcare laws and regulations apply to the BGMS business and medical devices. We may be subject to certain federal
	and state regulations, including the federal healthcare programs&rsquo; Anti-Kickback Law, the federal Health Insurance Portability
	and Accountability Act of 1996, and other federal and state false claims laws. The medical device industry has been under heightened
	scrutiny as the subject of government investigations and enforcement actions involving manufacturers who allegedly offered unlawful
	inducements to potential or existing customers in an attempt to procure their business, including arrangements with physician consultants.
	If our operations or arrangements are found to be in violation of such governmental regulations, we may be subject to civil and
	criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs and the curtailment of our operations. All
	of these penalties could adversely affect our ability to operate our business and our financial results.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Product liability suits, whether
	or not meritorious, could be brought against us due to an alleged defective product or for the misuse of Dario&trade; or our potential
	future products. These suits could result in expensive and time-consuming litigation, payment of substantial damages, and an increase
	in our insurance rates.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	If Dario&trade; or
	any of our future products are defectively designed or manufactured contain defective components or are misused, or if someone
	claims any of the foregoing, whether or not meritorious, we may become subject to substantial and costly litigation. Misusing our
	device or failing to adhere to the operating guidelines or the device producing inaccurate meter readings could cause significant
	harm to patients, including death. In addition, if our operating guidelines are found to be inadequate, we may be subject to liability.
	Product liability claims could divert management&rsquo;s attention from our core business, be expensive to defend and result in
	sizable damage awards against us. While we maintain product liability insurance, we may not have sufficient insurance coverage
	for all future claims. Any product liability claims brought against us, with or without merit, could increase our product liability
	insurance rates or prevent us from securing continuing coverage, could harm our reputation in the industry and could reduce revenue.
	Product liability claims in excess of our insurance coverage would be paid out of cash reserves harming our financial condition
	and adversely affecting our results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	If we are found to have violated
	laws protecting the confidentiality of patient health information, we could be subject to civil or criminal penalties, which could
	increase our liabilities and harm our reputation or our business.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Part of our business
	plan includes the storage and potential monetization of medical data of users of Dario&trade;. There are a number of federal and
	state laws protecting the confidentiality of certain patient health information, including patient records, and restricting the
	use and disclosure of that protected information. In particular, the U.S.&nbsp;Department of Health and Human Services promulgated
	patient privacy rules under the Health Insurance Portability and Accountability Act of 1996 (which we refer to as HIPAA). These
	privacy rules protect medical records and other personal health information by limiting their use and disclosure, giving individuals
	the right to access, amend and seek accounting of their own health information and limiting most use and disclosures of health
	information to the minimum amount reasonably necessary to accomplish the intended purpose. We may face difficulties in holding
	such information in compliance with applicable law. If we are found to be in violation of the privacy rules under HIPAA, we could
	be subject to civil or criminal penalties, which could increase our liabilities, harm our reputation and have a material adverse
	effect on our business, financial condition and results of operations.
</P>
<!-- FIELD: PAGE; SEQUENCE: 31; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage32"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Risks Related to Our Intellectual Property
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	The failure to obtain or maintain patents, licensing agreements
	and other intellectual property could materially impact our ability to compete effectively.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In order for our business
	to be viable and to compete effectively, we need to develop and maintain, and we will heavily rely on, our proprietary position
	with respect to our technologies and intellectual property. We filed a Patent Cooperation Treaty (or PCT) application for a &ldquo;Fluids
	Testing Apparatus and Methods of Use&rdquo; in May 2011 which incorporates two U.S. provisional applications submitted in the preceding
	year. The PCT covers the specific processes related to blood glucose level measurement as well as more general methods of rapid
	tests of body fluids and has subsequently been converted into several national phase patent applications. We have also filed a
	significant number of other patent applications for aspects of both the Dario&trade; Smart Meter and software. We have also obtained
	numerous Web domains.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	However, to date, we
	have only been issued two patents (which were issued in the United States) relating to how the Dario&trade; blood glucose monitor
	draws power from and transmits data to a smart phone via the audio jack port. None of our other patents have been granted by a
	patent office. In addition, there are significant risks associated with our actual or proposed intellectual property. The risks
	and uncertainties that we face with respect to our pending patent and other proprietary rights principally include the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	pending patent applications we have filed or will file may not result in issued patents or may take longer than we expect to result in issued patents;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	we may be subject to interference proceedings;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	we may be subject to opposition proceedings in foreign countries;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	any patents that are issued to us may not provide meaningful protection;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	we may not be able to develop additional proprietary technologies that are patentable;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	other companies may challenge patents licensed or issued to us;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	other companies may have independently developed and/or patented (or may in the future independently develop and patent) similar or alternative technologies, or duplicate our technologies;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	other companies may design their technologies around technologies we have licensed or developed; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	enforcement of patents is complex, uncertain and very expensive.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We cannot be certain
	that patents will be issued as a result of any of our pending or future applications, or that any of our patents, once issued,
	will provide us with adequate protection from competing products. For example, issued patents may be circumvented or challenged,
	declared invalid or unenforceable, or narrowed in scope. In addition, since publication of discoveries in scientific or patent
	literature often lags behind actual discoveries, we cannot be certain that we were the first to make our inventions or to file
	patent applications covering those inventions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	It is also possible
	that others may have or may obtain issued patents that could prevent us from commercializing our products or require us to obtain
	licenses requiring the payment of significant fees or royalties in order to enable us to conduct our business. As to those patents
	that we have licensed, our rights depend on maintaining our obligations to the licensor under the applicable license agreement,
	and we may be unable to do so.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 32; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage33"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	&nbsp;&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Costly litigation may be necessary
	to protect our intellectual property rights and we may be subject to claims alleging the violation of the intellectual property
	rights of others.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We may face significant
	expense and liability as a result of litigation or other proceedings relating to patents and intellectual property rights of others.
	In the event that another party has also filed a patent application or been issued a patent relating to an invention or technology
	claimed by us in pending applications, we may be required to participate in an interference proceeding declared by the United States
	Patent and Trademark Office to determine priority of invention, which could result in substantial uncertainties and costs for us,
	even if the eventual outcome was favorable to us. We, or our licensors, also could be required to participate in interference proceedings
	involving issued patents and pending applications of another entity. An adverse outcome in an interference proceeding could require
	us to cease using the technology, substantially modify it or to license rights from prevailing third parties.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The cost to us of any
	patent litigation or other proceeding relating to our licensed patents or patent applications, even if resolved in our favor, could
	be substantial, especially given our early stage of development. Our ability to enforce our patent protection could be limited
	by our financial resources, and may be subject to lengthy delays. A third party may claim that we are using inventions claimed
	by their patents and may go to court to stop us from engaging in our normal operations and activities, such as research, development
	and the sale of any future products. Such lawsuits are expensive and would consume significant time and other resources. There
	is a risk that a court will decide that we are infringing the third party&rsquo;s patents and will order us to stop the activities
	claimed by the patents. In addition, there is a risk that a court will order us to pay the other party damages for having infringed
	their patents.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Moreover, there is
	no guarantee that any prevailing patent owner would offer us a license so that we could continue to engage in activities claimed
	by the patent, or that such a license, if made available to us, could be acquired on commercially acceptable terms. In addition,
	third parties may, in the future, assert other intellectual property infringement claims against us with respect to our services,
	technologies or other matters.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We have limited foreign intellectual
	property rights and may not be able to protect our intellectual property rights throughout the world.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have limited intellectual
	property rights outside the United States. Filing, prosecuting and defending patents on devices in all countries throughout the
	world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be
	less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property
	to the same extent as laws in the United States. Consequently, we may not be able to prevent third parties from practicing our
	inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into
	the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patents
	to develop their own products and further, may export otherwise infringing products to territories where we have patents, but enforcement
	is not as strong as that in the United States.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Many companies have
	encountered significant problems in protecting and defending intellectual property in foreign jurisdictions. The legal systems
	of certain countries, particularly China and certain other developing countries, do not favor the enforcement of patents, trade
	secrets and other intellectual property, particularly those relating to medical devices and biopharmaceutical products, which could
	make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary
	rights generally. To date, we have not sought to enforce any issued patents in these foreign jurisdictions. Proceedings to enforce
	our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects
	of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk
	of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate
	and the damages or other remedies awarded, if any, may not be commercially meaningful. The requirements for patentability may differ
	in certain countries, particularly developing countries. Certain countries in Europe and developing countries, including China
	and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those
	countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant
	a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue
	opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain
	a significant commercial advantage from the intellectual property that we develop or license.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 33; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage34"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We rely on confidentiality agreements
	that could be breached and may be difficult to enforce, which could result in third parties using our intellectual property to
	compete against us.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Although we believe
	that we take reasonable steps to protect our intellectual property, including the use of agreements relating to the non-disclosure
	of confidential information to third parties, as well as agreements that purport to require the disclosure and assignment to us
	of the rights to the ideas, developments, discoveries and inventions of our employees and consultants while we employ them, the
	agreements can be difficult and costly to enforce. Although we seek to enter into these types of agreements with our contractors,
	consultants, advisors and research collaborators, to the extent that employees and consultants utilize or independently develop
	intellectual property in connection with any of our projects, disputes may arise as to the intellectual property rights associated
	with our technology. If a dispute arises, a court may determine that the right belongs to a third party. In addition, enforcement
	of our rights can be costly and unpredictable. We also rely on trade secrets and proprietary know-how that we seek to protect in
	part by confidentiality agreements with our employees, contractors, consultants, advisors or others. Despite the protective measures
	we employ, we still face the risk that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	these agreements may be breached;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	these agreements may not provide adequate remedies for the applicable type of breach;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our proprietary know-how will otherwise become known; or
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our competitors will independently develop similar technology or proprietary information.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We may be subject to claims challenging
	the inventorship of our patents and other intellectual property.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We may be subject to
	claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property
	as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants
	or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other
	claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable
	intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome
	could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could
	result in substantial costs and be a distraction to management and other employees. In addition, the Israeli Supreme Court ruled
	in 2012 that an employee who receives a patent or contributes to an invention during his employment may be allowed to seek compensation
	for such contributions from his or her employer, even if the employee&rsquo;s contract of employment specifically states otherwise
	and the employee has transferred all intellectual property rights to the employer. The Israeli Supreme Court ruled that the fact
	that a contract revokes an employee&rsquo;s right for royalties and compensation, does not rule out the right of the employee to
	claim their right for royalties. As a result, it is unclear whether and, if so, to what extent our employees may be able to claim
	compensation with respect to our future revenue. We may receive less revenue from future products if any of our employees successfully
	claim for compensation for their work in developing our intellectual property, which in turn could impact our future profitability.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Risks Related to Our Industry
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	We face intense competition in the self-monitoring of
	blood glucose market, and as a result we may be unable to effectively compete in our industry.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	With our first product,
	Dario&trade;, we expect to compete directly and primarily with large pharmaceutical and medical device companies such as Abbott
	Laboratories, Bayer Healthcare Division, Johnson &amp; Johnson LifeScan, Roche Diagnostics and Sanofi. The first four of these
	companies have more than 90% combined market share of the BGMS business and strong research and development capacity for next generation
	products. Their dominant market position since the late 1990s and significant control over the market could significantly limit
	our ability to introduce Dario&trade; or effectively market and generate sales of the product. We will also compete with numerous
	second-tier and third-tier competitors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 34; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	34
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage35"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We recently entered
	the commercial stage, and most of our competitors have long histories and strong reputations within the industry. They have significantly
	greater brand recognition, financial and human resources than we do. They also have more experience and capabilities in researching
	and developing testing devices, obtaining and maintaining regulatory clearances and other requirements, manufacturing and marketing
	those products than we do. There is a significant risk that we may be unable to overcome the advantages held by our competition,
	and our inability to do so could lead to the failure of our business and the loss of your investment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Competition in the
	BGMS markets is extremely intense, which can lead to, among other things, price reductions, longer selling cycles, lower product
	margins, loss of market share and additional working capital requirements. To succeed, we must, among other critical matters, gain
	consumer acceptance for Dario&trade; and potential future devices incorporating our principal technology and offer better strategic
	concepts, technical solutions, prices and response time, or a combination of these factors, than those of other competitors. If
	our competitors offer significant discounts on certain products, we may need to lower our prices or offer other favorable terms
	in order to compete successfully. Moreover, any broad-based changes to our prices and pricing policies could make it difficult
	to generate revenues or cause our revenues, if established, to decline. Some of our competitors may bundle certain software products
	offering competing applications for diabetes management at low prices for promotional purposes or as a long-term pricing strategy.
	These practices could significantly reduce demand for Dario&trade; or potential future products or constrain prices we can charge.
	Moreover, if our competitors develop and commercialize products that are more effective or desirable than Dario&trade; or the other
	products that we may develop, we may not convince our customers to use our products. Any such changes would likely reduce our commercial
	opportunity and revenue potential and could materially adversely impact our operating results.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;&nbsp;
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	If we fail to respond quickly to
	technological developments our products may become uncompetitive and obsolete.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The BGMS market and
	other markets in which we plan to compete experience rapid technology developments, changes in industry standards, changes in customer
	requirements and frequent new product introductions and improvements. If we are unable to respond quickly to these developments,
	we may lose competitive position, and Dario&trade; or any other device or technology may become uncompetitive or obsolete, causing
	revenues and operating results to suffer. In order to compete, we must develop or acquire new devices and improve our existing
	device on a schedule that keeps pace with technological developments and the requirements for products addressing a broad spectrum
	and designers and designer expertise in our industries. We must also be able to support a range of changing customer preferences.
	For instance, as non-invasive technologies become more readily available in the market, we may be required to adopt our platform
	to accommodate the use of non-invasive or continuous blood glucose sensors. We cannot guarantee that we will be successful in any
	manner in these efforts.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
<I>
	If third-party payors do not
	provide adequate coverage and reimbursement for the use of Dario&trade;, our revenue will be negatively impacted.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	In
	the United States and in other jurisdictions such as Germany and England, we expect that&nbsp;Dario&trade;&rsquo;s test strips
	should generally be available for full or partial patient reimbursement by third-party payers.&nbsp; Our success in marketing Dario&trade;
	depends and will depend in large part on whether U.S. and international government health administrative authorities, private health
	insurers and other organizations adequately cover and reimburse customers for the cost of our products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	In
	the United States, we expect to derive nearly all our sales from sales of Dario&trade; from direct to consumer cash sales as well
	as retail pharmacy and DME distributors who typically bill various third-party payors, including Medicare, Medicaid, private commercial
	insurance companies, health maintenance organizations and other healthcare-related organizations, to cover all or a portion of
	the costs and fees associated with Dario&trade; and bill patients for any applicable deductibles or co-payments. Access to adequate
	coverage and reimbursement for Center for Medicare and Medicaid Services (CMS) procedures using Dario&trade; (and our other products
	in development) by third-party payors is essential to the acceptance of our products by our customers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 35; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	35
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage36"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	Third-party
	payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling
	healthcare costs. In addition, in the United States, no uniform policy of coverage and reimbursement for medical device products
	and services exists among third-party payors. Therefore, coverage and reimbursement for medical device products and services can
	differ significantly from payor to payor. In addition, payors continually review new technologies for possible coverage and can,
	without notice, deny coverage for these new products and procedures. As a result, the coverage determination process is often a
	time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to
	each payor separately, with no assurance that coverage and adequate reimbursement will be obtained, or maintained if obtained.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	Reimbursement
	systems in international markets vary significantly by country and by region within some countries, and reimbursement approvals
	must be obtained on a country-by-country basis. In many international markets, a product must be approved for reimbursement before
	it can be approved for sale in that country. Further, many international markets have government-managed healthcare systems that
	control reimbursement for new devices and procedures. For example, the governmental healthcare system in the Netherlands, New Zealand
	and Israel have not yet approved reimbursement of Dario&trade;. In most markets there are private insurance systems as well as
	government-managed systems. If sufficient coverage and reimbursement is not available for our current or future products, in either
	the United States or internationally, the demand for our products and our revenues will be adversely affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Risks Related to Our Operations in Israel
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Potential political, economic and
	military instability in the State of Israel, where our management team and our research and development facilities are located,
	may adversely affect our results of operations.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our operating subsidiary,
	along with our management team and our research and development facilities, is located in Israel. Accordingly, political, economic
	and military conditions in Israel and the surrounding region may directly affect our business and operations. Since the establishment
	of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its neighboring countries. Any
	hostilities involving Israel or the interruption or curtailment of trade between Israel and its trading partners could adversely
	affect our operations and results of operations. The hostilities involved missile strikes against civilian targets in various parts
	of Israel, including areas in which our employees and some of our consultants are located, and negatively affected business conditions
	in Israel. Our offices, located in Caesarea, Israel, are within the range of the missiles and rockets that have been fired at Israeli
	cities and towns from Gaza sporadically since 2006, with escalations in violence (such as the recent escalation in July 2014) during
	which there were a substantially larger number of rocket and missile attacks aimed at Israel. In addition, since February 2011,
	Egypt has experienced political turbulence and an increase in terrorist activity in the Sinai Peninsula. Such political turbulence
	and violence may damage peaceful and diplomatic relations between Israel and Egypt, and could affect the region as a whole. Similar
	civil unrest and political turbulence has occurred in other countries in the region, including Syria which shares a common border
	with Israel, and is affecting the political stability of those countries. This instability and any outside intervention may lead
	to deterioration of the political and economic relationships that exist between the State of Israel and some of these countries,
	and may have the potential for causing additional conflicts in the region. In addition, Iran has threatened to attack Israel and
	is widely believed to be developing nuclear weapons. Iran is also believed to have a strong influence among extremist groups in
	the region, such as Hamas in Gaza, Hezbollah in Lebanon, and various rebel militia groups in Syria. Additionally, a violent jihadist
	group named Islamic State of Iraq and Levant (ISIL) is involved in hostilities in Iraq and Syria and have been growing in influence.
	Although ISIL&rsquo;s activities have not directly affected the political and economic conditions in Israel, ISIL&rsquo;s stated
	purpose is to take control of the Middle East, including Israel. These situations may potentially escalate in the future to more
	violent events which may affect Israel and us. Any armed conflicts, terrorist activities or political instability in the region
	could adversely affect business conditions and could harm our results of operations and could make it more difficult for us to
	raise capital. Parties with whom we do business may decline to travel to Israel during periods of heightened unrest or tension,
	forcing us to make alternative arrangements when necessary in order to meet our business partners face to face. In addition, the
	political and security situation in Israel may result in parties with whom we have agreements involving performance in Israel claiming
	that they are not obligated to perform their commitments under those agreements pursuant to force majeure provisions in such agreements.
	Further, in the past, the State of Israel and Israeli companies have been subjected to economic boycotts. Several countries still
	restrict business with the State of Israel and with Israeli companies. These restrictive laws and policies may have an adverse
	impact on our operating results, financial condition or the expansion of our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 36; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	36
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage37"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our commercial insurance
	does not cover losses that may occur as a result of events associated with the security situation in the Middle East. Although
	the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts
	of war, we cannot assure you that this government coverage will be maintained. Any losses or damages incurred by us could have
	a material adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively affect
	business conditions and could harm our results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Further, the State
	of Israel and Israeli companies have been subjected to an economic boycott. Several countries still restrict business with the
	State of Israel and with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating results,
	financial condition or the expansion of our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Our operations may be disrupted as
	a result of the obligation of Israeli citizens to perform military service.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Many Israeli citizens
	are obligated to perform several days, and in some cases more, of annual military reserve duty each year until they reach the age
	of 40 (or older, for reservists who are military officers or who have certain occupations) and, in the event of a military conflict,
	may be called to active duty. In response to increases in terrorist activity, there have been periods of significant call-ups of
	military reservists. It is possible that there will be military reserve duty call-ups in the future. Our operations could be disrupted
	by such call-ups, which may include the call-up of members of our management. Such disruption could materially adversely affect
	our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Investors may have difficulties enforcing
	a U.S. judgment, including judgments based upon the civil liability provisions of the U.S. federal securities laws, against us,
	or our executive officers and directors or asserting U.S. securities laws claims in Israel.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Certain of our directors
	and officers are not residents of the United States and whose assets may be located outside the United States. Service of process
	upon us or our non-U.S. resident directors and officers and enforcement of judgments obtained in the United States against us or
	our non-U.S. our directors and executive officers may be difficult to obtain within the United States. We have been informed by
	our legal counsel in Israel that it may be difficult to assert claims under U.S. securities laws in original actions instituted
	in Israel or obtain a judgment based on the civil liability provisions of U.S. federal securities laws. Israeli courts may refuse
	to hear a claim based on a violation of U.S. securities laws against us or our officers and directors because Israel may not be
	the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine
	that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable
	U.S. law must be proved as a fact, which can be a time-consuming and costly process. Certain matters of procedure will also be
	governed by Israeli law. There is little binding case law in Israel addressing the matters described above. Israeli courts might
	not enforce judgments rendered outside Israel, which may make it difficult to collect on judgments rendered against us or our officers
	and directors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Moreover, among other
	reasons, including but not limited to, fraud or absence of due process, or the existence of a judgment which is at variance with
	another judgment that was given in the same matter if a suit in the same matter between the same parties was pending before a court
	or tribunal in Israel, an Israeli court will not enforce a foreign judgment if it was given in a state whose laws do not provide
	for the enforcement of judgments of Israeli courts (subject to exceptional cases) or if its enforcement is likely to prejudice
	the sovereignty or security of the State of Israel.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 37; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	37
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage38"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Risks Related to the Ownership of Our
	Common Stock and Warrants
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Our officers, directors and founding stockholders may
	exert significant influence over our affairs, including the outcome of matters requiring stockholder approval.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	As of the date of this
	Annual Report, our officers, directors and affiliated stockholders (including&nbsp;
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Dicilyon
	Consulting and Investment Ltd., or Dicilyon,&nbsp;
</FONT>
	an affiliate of David Edery, and Shmuel Farhi) collectively have an approximately
	61.2% beneficial ownership of our company. As a result, such individuals will have the ability, acting together, to control the
	election of our directors and the outcome of corporate actions requiring stockholder approval, such as: (i) a merger or a sale
	of our company, (ii) a sale of all or substantially all of our assets, and (iii) amendments to our certificate of incorporation
	and bylaws. This concentration of voting power and control could have a significant effect in delaying, deferring or preventing
	an action that might otherwise be beneficial to our other stockholders and be disadvantageous to our stockholders with interests
	different from those individuals. Certain of these individuals also have significant control over our business, policies and affairs
	as officers or directors of our company. Therefore, you should not invest in reliance on your ability to have any control over
	our company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Dicilyon Consulting and Investment Ltd., an affiliate
	of investor David Edery, has the right to appoint up to three members of our Board of Directors, which affords such investor the
	potential for control over our business.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Dicilyon, an affiliate
	of investor David Edery (who was the lead investor in our September 2014 Private Placement), has the right, for so long as such
	investor holds 25%, 15% and 10% of our outstanding shares of common stock, to appoint, respectively, three, two or one member of
	our seven person Board of Directors. Mr. Edery is the sole shareholder of Dicilyon. To date, such investor has appointed three
	members of our Board of Directors (Rami Yehudiha, Hila Karah and Peter Kash, although as of the date of this Annual Report, Dr.
	Kash is not serving on our Board of Directors following his resignation during February 2015 for personal reasons). As a result,
	such investor has significant influence over the composition of our Board of Directors which, in turn, affords such investor the
	potential for material control over our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	We have broad discretion in the use of the net proceeds
	from any offering of our securities and may use the net proceeds in ways with which you disagree.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our management will have broad discretion
	in the application of the net proceeds from any offering of our securities and could spend the proceeds in ways that do not improve
	our results of operations or enhance the value of our securities. You will be relying on the judgment of our management with regard
	to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether
	the net proceeds are being used appropriately. The failure by our management to apply these funds effectively could result in financial
	losses that could have a material adverse effect on our business, cause the price of our securities to decline and delay the development
	of our product candidates. Pending the application of these funds, we may invest the net proceeds from any offering of our securities
	in a manner that does not produce income or that loses value.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We may be unable to establish a liquid
	market for our common stock or warrants due to the manner in which we became a publicly reporting company.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Because we did not
	become an SEC reporting company by the traditional means of conducting an initial public offering of our common stock, but rather
	through a self-registration process, we may be unable to establish a liquid market for our common stock. Moreover, we do not expect
	security analysts of brokerage firms to provide coverage of our company in the near future. In addition, investment banks may be
	less likely to agree to underwrite primary or secondary offerings on behalf of our company or its stockholders in the future than
	they would if we had become a public reporting company by means of an initial public offering of common stock. If all or any of
	the foregoing risks occur, it would have a material adverse effect on our company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	If securities or industry analysts
	do not publish or cease publishing research or reports about us, our business or our market, or if they change their recommendations
	regarding our common stock or warrants adversely, the price of our common stock or warrants and trading volume could decline.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The trading market
	for our common stock or warrants may be influenced by the research and reports that securities or industry analysts may publish
	about us, our business, our market or our competitors. If any of the analysts who may cover us change their recommendation regarding
	our common stock or warrants adversely, or provide more favorable relative recommendations about our competitors, the price of
	our common stock or warrants would likely decline. If any analyst who may cover us were to cease coverage of our company or fail
	to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause the price of our
	common stock or warrants or trading volume to decline.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 38; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	38
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage39"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	A sustained, active trading market
	for our common stock or warrants may not develop or be maintained.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	As we are in our early
	stages, an investment in our company will likely require a long-term commitment, with no certainty of return. Although our common
	stock is quoted on the OTCQB market under the symbol DRIO, and although in 2014 we have experienced historically periods of high
	trading volume in our common stock, we cannot predict whether an active market for our common stock or warrants will ever develop
	or be sustained in the future.&nbsp; None of our warrants are currently listed or trading on any market or trading venue. In the
	absence of an active trading market:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	investors may have difficulty
	buying and selling or obtaining market quotations;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	market visibility for shares of our common stock and our warrants may be limited; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	a lack of visibility for shares of our common stock and our warrants may have a depressive effect on the market price for shares of our common stock.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The OTCQB market is
	relatively unorganized, inter-dealer, over-the-counter markets that provide significantly less liquidity than NASDAQ or the NYSE
	MKT (formerly known as the NYSE AMEX). In this event, there would be a highly illiquid market for our common stock and you may
	be unable to dispose of your common stock at desirable prices or at all. Moreover, there is a risk that our common stock could
	be delisted from the OTCQB, in which case it might be listed on the OTC Pink, which is even more illiquid than the OTCQB.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The lack of an active
	market impairs your ability to sell your shares or warrants at the time you wish to sell them or at a price that you consider reasonable.
	The lack of an active market may also reduce the fair market value of your shares or warrants. An inactive market may also impair
	our ability to raise capital to continue to fund operations by selling securities and may impair our ability to acquire additional
	intellectual property assets by using our securities as consideration.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	The market price of our common stock and warrants may
	be significantly volatile.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The market price for
	our common stock and warrants may be significantly volatile and subject to wide fluctuations in response to factors including the
	following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	actual or anticipated fluctuations in our quarterly or annual operating results;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	changes in financial or operational estimates or projections;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	conditions in markets generally;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	changes in the economic performance or market valuations of companies similar to ours; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	general economic or political conditions in the United States or elsewhere.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In particular, the
	market prices for securities of mHealth and medical device have historically been particularly volatile. Some of the factors that
	may cause the market price of our common stock and warrants to fluctuate include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	any delay in or the results of our clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	any delay in manufacturing of our products;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	any delay with the approval for reimbursement for the patients from their insurance companies;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	our failure to comply with regulatory requirements;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 39; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	39
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage40"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the announcements of clinical trial data, and the investment community&rsquo;s perception of and reaction to those data;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the results of clinical trials conducted by others on products that would compete with ours;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	any delay or failure to receive clearance or approval from regulatory agencies or bodies;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	our inability to commercially launch products or market and generate sales of our products, including Dario&trade;;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	failure of Dario&trade; or any other products, even if approved for marketing, to achieve any level of commercial success;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	our failure to obtain patent protection for any of our technologies and products (including those related to Dario&trade;) or the issuance of third party patents that cover our proposed technologies or products;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	developments or disputes concerning our product&rsquo;s intellectual property rights;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	our or our competitors&rsquo; technological innovations;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	general and industry-specific economic conditions that may affect our expenditures;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	changes in market valuations of similar companies;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures, capital commitments, new technologies, or patents;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	failure to adequately manufacture Dario&trade; or any other products through third parties;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	future sales of our common stock or other securities, including shares issuable upon the exercise of outstanding warrants or otherwise issued pursuant to certain contractual rights;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	period-to-period fluctuations in our financial results; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	low or high trading volume of our common stock due to many factors, including the terms of our financing arrangements.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In addition, if we
	fail to reach an important research, development or commercialization milestone or result by a publicly expected deadline, even
	if by only a small margin, there could be significant impact on the market price of our common stock and warrants. Additionally,
	as we approach the announcement of anticipated significant information and as we announce such information, we expect the price
	of our common stock and warrants to be particularly volatile, and negative results would have a substantial negative impact on
	the price of our common stock and warrants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In some cases, following
	periods of volatility in the market price of a company&rsquo;s securities, stockholders have often instituted class action securities
	litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management
	attention and resources, which could significantly harm our business operations and reputation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 40; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	40
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage41"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Shares eligible for future sale may adversely affect the
	market for our common stock and warrants.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have a material
	number of shares of common stock underlying outstanding warrants and options of our company as well as underlying the shares of
	our Series A Convertible Preferred Stock issued in our September 2014 Private Placement, the future sale of which could depress
	the price of our publicly-traded stock. As of the date of this Annual Report: (i)&nbsp;11,378,436 shares of common stock are issuable
	upon exercise of outstanding stock options at a weighted average exercise price of $0.87 per share; (ii)&nbsp;43,269,306 shares
	of common stock issuable upon exercise of our outstanding warrants at a weighted average exercise price of $0.65 per share and
	(iii) 8,980,832 shares of common stock are issuable upon the conversion of our Series A Convertible Preferred Stock. If and when
	these securities are exercised or converted into shares of our common stock, our outstanding shares will increase. Such increase
	in our outstanding securities, and any sales of such shares, could have a material adverse effect on the market for our common
	stock and warrants and the market price of our common stock and warrants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In addition, from time
	to time, certain of our stockholders may be eligible to sell all or some of their shares of common stock by means of ordinary brokerage
	transactions in the open market pursuant to Rule 144, promulgated under the Securities Act, subject to certain limitations. In
	general, pursuant to Rule 144, after satisfying a six month holding period: (i) affiliated stockholder (or stockholders whose shares
	are aggregated) may, under certain circumstances, sell within any three month period a number of securities which does not exceed
	the greater of 1% of the then outstanding shares of common stock or the average weekly trading volume of the class during the four
	calendar weeks prior to such sale and (ii) non-affiliated stockholders may sell without such limitations, provided we are current
	in our public reporting obligations. Rule 144 also permits the sale of securities by non-affiliates that have satisfied a one year
	holding period without any limitation or restriction. Any substantial sale of our common stock pursuant to Rule 144 or pursuant
	to any resale report may have a material adverse effect on the market price of our securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	The right of the investors in our February 2014 Private
	Placement and the lead investor in our September 2014 Private Placement to participate in future financings of ours could impair
	our ability to raise capital.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Under the securities
	purchase agreement with the investors in our February 2014 Private Placement, as amended, for a period ending on February 12, 2016,
	in the event that we seek to raise money through the offer and sale of debt or equity securities, we must first offer such investors
	a right to participate in at least 35% of the securities we propose to offer in such funding. In addition, Dicilyon, an affiliate
	of David Edery, the lead investor in our September 2014 Private Placement, holds preemptive rights until September 23, 2016 that
	allow such investor to participate in future financings of our company in an amount necessary to maintain its fully-diluted percentage
	interest in our company. The existence of such right of participation or preemptive rights, or the exercise of such rights, may
	in the deter potential investors from providing us needed financing, or may deter investment banks from working with, which would
	have a material adverse effect on our ability to finance our company which, in turn, could lead to our inability to continue our
	business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Our shares of common stock and warrants are not yet listed
	for trading on a national securities exchange.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Although we intend to apply to have our
	common stock and warrants listed for trading on The NASDAQ Capital Market, there is no assurance that such listing will be approved
	or how long such approval could take. Currently, our common stock only trades on the OTCQB and is not listed for trading on any
	national securities exchange. Investments in securities trading on the OTCQB are generally less liquid than investments in securities
	trading on a national securities exchange. The pool of potential investors who may buy and sell on the OTCQB is limited. Many institutional
	investors have policies which preclude them from doing so. You may not be able to sell your securities at the time desired or at
	the price desired. The failure of our securities to be approved for trading on a national securities exchange may have the effect
	of limiting the trading activity of our securities and reducing the liquidity of an investment in our common stock. The effects
	of not being able to list our securities on a national exchange include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 3PT; PADDING-BOTTOM: 3PT; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-TOP: 3PT; PADDING-BOTTOM: 3PT; WIDTH: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 3PT; PADDING-BOTTOM: 3PT">
<FONT STYLE="FONT-SIZE: 10PT">
	limited dissemination of the market price of our securities,
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 3PT; PADDING-BOTTOM: 3PT; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-TOP: 3PT; PADDING-BOTTOM: 3PT; WIDTH: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 3PT; PADDING-BOTTOM: 3PT">
<FONT STYLE="FONT-SIZE: 10PT">
	limited news coverage,
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 3PT; PADDING-BOTTOM: 3PT; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-TOP: 3PT; PADDING-BOTTOM: 3PT; WIDTH: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 3PT; PADDING-BOTTOM: 3PT">
<FONT STYLE="FONT-SIZE: 10PT">
	limited interest by investors in our securities,
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 3PT; PADDING-BOTTOM: 3PT; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-TOP: 3PT; PADDING-BOTTOM: 3PT; WIDTH: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 3PT; PADDING-BOTTOM: 3PT">
<FONT STYLE="FONT-SIZE: 10PT">
	volatility of our stock and warrant prices due to low trading volume,
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 41; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	41
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage42"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 3PT; PADDING-BOTTOM: 3PT; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-TOP: 3PT; PADDING-BOTTOM: 3PT; WIDTH: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 3PT; PADDING-BOTTOM: 3PT">
<FONT STYLE="FONT-SIZE: 10PT">
	increased difficulty in selling our securities in certain states due to &ldquo;blue sky&rdquo; restrictions, and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 3PT; PADDING-BOTTOM: 3PT; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-TOP: 3PT; PADDING-BOTTOM: 3PT; WIDTH: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 3PT; PADDING-BOTTOM: 3PT">
<FONT STYLE="FONT-SIZE: 10PT">
	limited ability to issue additional securities or to secure additional financing.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	As an &ldquo;emerging growth company&rdquo; under applicable
	law, we will be subject to lessened disclosure requirements, which could leave our stockholders without information or rights available
	to stockholders of more mature companies.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	For as long as we remain
	an &ldquo;emerging growth company&rdquo; as defined in the JOBS Act, we have elected to take advantage of certain exemptions from
	various reporting requirements that are applicable to other public companies that are not &ldquo;emerging growth companies&rdquo;
	including, but not limited to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	not being required to comply
	with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	taking advantage of an extension of time to comply with new or revised financial accounting standards;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We expect to take advantage
	of these reporting exemptions until we are no longer an &ldquo;emerging growth company&rdquo;. Because of these lessened regulatory
	requirements, our stockholders would be left without information or rights available to stockholders of more mature companies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Because we have elected to use the
	extended transition period for complying with new or revised accounting standards for an &ldquo;emerging growth company&rdquo;
	our financial statements may not be comparable to companies that comply with public company effective dates.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have elected to
	use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.
	This election allows us to delay the adoption of new or revised accounting standards that have different effective dates for public
	and private companies until those standards apply to private companies. While we are not currently delaying the implementation
	of any relevant accounting standards, in the future we may avail ourselves of this rights, and as a result of this election, our
	financial statements may not be comparable to companies that comply with public company effective dates. Because our financial
	statements may not be comparable to companies that comply with public company effective dates, investors may have difficulty evaluating
	or comparing our business, performance or prospects in comparison to other public companies, which may have a negative impact on
	the value and liquidity of our common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Our common stock may be considered
	a &ldquo;penny stock&rdquo;, and thereby be subject to additional sale and trading regulations that may make it more difficult
	to sell.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our common stock
	may be considered to be a &ldquo;penny stock&rdquo; if it does not qualify for one of the exemptions from the definition of
	&ldquo;penny stock&rdquo; under Section 3a51-1 of the Securities Exchange Act of 1934, as amended, or the Exchange Act.
	Our common stock may be a &ldquo;penny stock&rdquo; if it meets one or more of the following conditions: (i) the stock trades
	at a price less than $5 per share; (ii) it is not traded on a &ldquo;recognized&rdquo; national exchange; or (iii) is issued
	by a company that has been in business less than three years with net tangible assets less than $5 million.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 42; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	42
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage43"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The principal result or
	effect of being designated a &ldquo;penny stock&rdquo; is that securities broker-dealers participating in sales of our common stock
	will be subject to the &ldquo;penny stock&rdquo; regulations set forth in Rules 15g-2 through 15g-9 promulgated under the Exchange
	Act. For example, Rule 15g-2 requires broker-dealers dealing in penny stocks to provide potential investors with a document disclosing
	the risks of penny stocks and to obtain a manually signed and dated written receipt of the document at least two business days
	before effecting any transaction in a penny stock for the investor&rsquo;s account. Moreover, Rule 15g-9 requires broker-dealers
	in penny stocks to approve the account of any investor for transactions in such stocks before selling any penny stock to that investor.
	This procedure requires the broker-dealer to: (i) obtain from the investor information concerning his or her financial situation,
	investment experience and investment objectives; (ii) reasonably determine, based on that information, that transactions in penny
	stocks are suitable for the investor and that the investor has sufficient knowledge and experience as to be reasonably capable
	of evaluating the risks of penny stock transactions; (iii) provide the investor with a written statement setting forth the basis
	on which the broker-dealer made the determination in (ii) above; and (iv) receive a signed and dated copy of such statement from
	the investor, confirming that it accurately reflects the investor&rsquo;s financial situation, investment experience and investment
	objectives. Compliance with these requirements may make it more difficult and time consuming for holders of our common stock to
	resell their shares to third parties or to otherwise dispose of them in the market or otherwise.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	FINRA sales practice requirements may
	also limit your ability to buy and sell our common stock, which could depress the price of our shares.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Financial Industry Regulatory
	Authority, Inc. (FINRA) rules require broker-dealers to have reasonable grounds for believing that an investment is suitable for
	a customer before recommending that investment to the customer. Prior to recommending speculative low-priced securities to their
	non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer&rsquo;s financial
	status, tax status and investment objectives, among other things. Under interpretations of these rules, FINRA believes that there
	is a high probability such speculative low-priced securities will not be suitable for at least some customers. Thus, FINRA requirements
	make it more difficult for broker-dealers to recommend that their customers buy our common stock, which may limit your ability
	to buy and sell our shares, have an adverse effect on the market for our shares, and thereby depress our share price.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Our compliance with complicated U.S.
	regulations concerning corporate governance and public disclosure is expensive. Moreover, our ability to comply with all applicable
	laws, rules and regulations is uncertain given our management&rsquo;s relative inexperience with operating U.S. public companies.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	As a publicly reporting
	company, we are faced with expensive and complicated and evolving disclosure, governance and compliance laws, regulations and standards
	relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act and the Dodd-Frank Act, and, to the extent
	we complete our anticipated public offering, the rules of the NASDAQ Stock Market. New or changing laws, regulations and standards
	are subject to varying interpretations in many cases due to their lack of specificity, and, as a result, their application in practice
	may evolve over time as new guidance is provided by regulatory and governing bodies, which could result in continuing uncertainty
	regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. As a result,
	our efforts to comply with evolving laws, regulations and standards of a U.S. public company are likely to continue to result in
	increased general and administrative expenses and a diversion of management time and attention from revenue-generating activities
	to compliance activities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Moreover, our executive
	officers have little experience in operating a U.S. public company, which makes our ability to comply with applicable laws, rules
	and regulations uncertain. Our failure to company with all laws, rules and regulations applicable to U.S. public companies could
	subject us or our management to regulatory scrutiny or sanction, which could harm our reputation and stock price.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	If we fail to maintain effective internal
	control over financial reporting, the price of our common stock may be adversely affected.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 45PT">
	Our internal control over
	financial reporting may have weaknesses and conditions that could require correction or remediation, the disclosure of which may
	have an adverse impact on the price of our common stock.&nbsp; We are required to establish and maintain appropriate internal control
	over financial reporting.&nbsp; Failure to establish those controls, or any failure of those controls once established, could adversely
	affect our public disclosures regarding our business, prospects, financial condition or results of operations.&nbsp; In addition,
	management&rsquo;s assessment of internal control over financial reporting may identify weaknesses and conditions that need to
	be addressed in our internal control over financial reporting or other matters that may raise concerns for investors.&nbsp; Any
	actual or perceived weaknesses and conditions that need to be addressed in our internal control over financial reporting or disclosure
	of management&rsquo;s assessment of our internal control over financial reporting may have an adverse impact on the price of our
	common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 45PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 43; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	43
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage44"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Anti-takeover provisions in our charter
	documents and Delaware law could discourage, delay or prevent a change in control of our company and may affect the trading price
	of our common stock and warrants.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are a Delaware corporation
	and the anti-takeover provisions of the Delaware General Corporation Law may discourage, delay or prevent a change in control by
	prohibiting us from engaging in a business combination with an interested stockholder for a period of three years after the person
	becomes an interested stockholder, even if a change in control would be beneficial to our existing stockholders. In addition, our
	certificate of incorporation and bylaws may discourage, delay or prevent a change in our management or control over us that stockholders
	may consider favorable. Our certificate of incorporation and bylaws:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	authorize the issuance of
	&ldquo;blank check&rdquo; preferred stock that could be issued by our Board of Directors to thwart a takeover attempt;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	provide that vacancies on
	our Board of Directors, including newly created directorships, may be filled only by a majority vote of directors then in office;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	provide that special meetings
	of stockholders may only be called by our Chairman, Chief Executive Officer and/or President or other executive officer, our Board
	of Directors or a super-majority (66 2/3%) of our stockholders;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	place restrictive requirements
	(including advance notification of stockholder nominations and proposals) on how special meetings of stockholders may be called
	by our stockholders;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	do not provide stockholders
	with the ability to cumulate their votes; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	provide that our Board of
	Directors or a super-majority of our stockholders (66 2/3%) may amend our bylaws.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We do not currently intend to pay dividends
	on our common stock in the foreseeable future, and consequently, your ability to achieve a return on your investment will depend
	on appreciation in the price of our common stock.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have never declared
	or paid cash dividends on our common stock and do not anticipate paying any cash dividends to holders of our common stock in the
	foreseeable future. Consequently, investors must rely on sales of their common stock after price appreciation, which may never
	occur, as the only way to realize any future gains on their investments. There is no guarantee that shares of our common stock
	will appreciate in value or even maintain the price at which our stockholders have purchased their shares.
</P>
</EFX_RISK_FACTORS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A NAME="V430703_10K_HTM_A_005">
</A>
	Item&nbsp;1B.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Unresolved Staff Comments
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Not applicable.
</P>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_PROPERTIES>
<A NAME="FIS_PROPERTIES"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD">
<A NAME="V430703_10K_HTM_A_006">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item&nbsp;2.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Properties
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	We
	do not own any real property. Currently, we maintain our headquarters at 9 Halamish Street, Caesarea Industrial Park, 3088900,
	Israel
</FONT>
	. On December 30, 2013, we signed a lease agreement for our headquarters facilities for a period of 3 years commencing
	January 1, 2014 for a monthly rent and management services of approximately $9,000.
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	In December
	2015, we signed a lease agreement for our U.S. headquarters facilities in Burlington, Massachusetts for a period of 1 year commencing
	February 1, 2016 for a monthly rent and management services of approximately $1,200.
</FONT>
	We believe our facilities are adequate
	for our current operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 44; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	44
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_PROPERTIES>
<A NAME="eolPage45"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
</P>
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD">
<A NAME="V430703_10K_HTM_A_007">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item&nbsp;3.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Legal Proceedings
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are currently not a
	party to any pending legal proceeding, nor is our property the subject of a pending legal proceeding, that we believe is not ordinary
	routine litigation incidental to our business or otherwise material to the financial condition of our business.
</P>
</EFX_LEGAL_PROCEEDINGS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD">
<A NAME="V430703_10K_HTM_A_008">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item&nbsp;4.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Mine Safety Disclosures
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Not applicable.
</P>
</EFX_MINE_SAFETY_DISCLOSURE>
</EFX_PART_I>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<A NAME="V430703_10K_HTM_A_009">
</A>
<B>
	PART II
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_MARKET>
<A NAME="FIS_MARKET"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD">
<A NAME="V430703_10K_HTM_A_010">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item&nbsp;5.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Market Information
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our common stock is quoted on the OTCQB market
	under the symbol &ldquo;DRIO&rdquo;. Our common stock began trading on April 9, 2013. The following table sets forth the high and
	low sales prices per share of our common stock for the periods indicated as reported by the OTCQB. The share values reflected below
	have been adjusted to give effect to the 1-for-5 reverse split which we implemented on October 6, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Price&nbsp;Range
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	Period
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	High
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Low
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	Year Ended December 31, 2014:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 74%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	First Quarter
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13.10
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8.00
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Second Quarter
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9.05
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4.05
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Third Quarter
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.70
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.25
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Fourth Quarter
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.65
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.10
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	Year Ended December 31, 2015:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	First Quarter
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.26
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.17
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Second Quarter
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.45
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.28
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Third Quarter
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.37
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.29
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Fourth Quarter
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.65
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.27
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	Year Ended December 31, 2016:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.49
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.30
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	First Quarter (through February 8, 2016)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	As of February
	8, 2016, the last reported price of our common stock quoted on the OTCQB was $0.45 per share. The
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	OTCQB prices set forth above represent inter-dealer quotations, without adjustment for retail mark-up, mark-down
	or commission, and may not represent the prices of actual transactions.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Record Holders
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	As of February 8, 2016,
	we had 233
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	stockholders of record of our common stock.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Dividends
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We have never paid any cash dividends on our
	common stock. We anticipate that we will retain funds and future earnings to support operations and to finance the growth and development
	of our business. Therefore, we do not expect to pay cash dividends in the foreseeable future. Any future determination to pay dividends
	will be at the discretion of our Board of Directors and will depend on our financial condition, results of operations, capital
	requirements and other factors that our Board of Directors deems relevant. In addition, the terms of any future debt or credit
	financings may preclude us from paying dividends.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 45; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	45
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage46"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
<B>
	Securities
	Authorized for Issuance Under Equity Compensation Plans as of December 31, 2015:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The following table provides information as
	of December 31, 2015 with respect to options outstanding:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Number&nbsp;of&nbsp;securities
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	to&nbsp;be&nbsp;issued&nbsp;upon
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Weighted-average
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	exercise&nbsp;of
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	exercise&nbsp;price&nbsp;of
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Number&nbsp;of&nbsp;securities
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	outstanding&nbsp;options,
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	outstanding&nbsp;options,
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	remaining&nbsp;available
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	Plan&nbsp;category
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	warrants&nbsp;and&nbsp;rights
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	warrants&nbsp;and&nbsp;rights
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	for&nbsp;future&nbsp;issuance
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 0.1IN">
	Equity compensation plans approved by security holders
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9,206,334
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.78
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,473,713
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 0.1IN">
	Equity compensation plans not approved by security holders *
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	251,400
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7.07
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 0.1IN">
	Equity compensation plans not approved by security holders **
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	76,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.95
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 0.1IN">
	Equity compensation plans not approved by security holders ***
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	980,800
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.32
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 0.1IN">
	Equity compensation plans not approved by security holders ****
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	863,902
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.023
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Total
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	11,378,436
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.87
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,473,713
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%">
<FONT STYLE="FONT-SIZE: 10PT">
	*
</FONT>
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	In March 2013, our Board of Directors adopted a non-employee director&rsquo;s remuneration policy. For further details refer to &ldquo;Non-Employee Director Remuneration Policy&rdquo; below.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	**
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	In May 2014, our Board of Directors approved the grant of non-plan options to our
	Scientific Advisory Board, or SAB. These options have an exercise price of $6.95 per share, vest over 4 quarterly
	installments, have a cashless exercise feature and a ten year term.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	***
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	In September 2015, our Board of Directors approved the grant of non-plan options to our Board members and members of our SAB. These options have an exercise price of $0.32 per share, one third vesting immediately and the balance vest over 8 quarterly installments, have a cashless exercise feature and a six year term.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	****
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	In December 2015, our Board of Directors approved the grant of non-plan options to a
	member of the SAB and to a finder. The options to the SAB member have an exercise price of $0.39 per share, and will vest
	over a three year period. One third vesting after one year and the balance vest over 8 quarterly installments after the
	first anniversary; these options have a cashless exercise feature and a six year term. The options to the finder have an
	exercise price of $0.0001 and are fully vested and exercisable after the lapse of four months from the grant
	date.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	On January 23, 2012,
	our Board of Directors and a majority of the holders of our then outstanding shares of our common stock adopted our 2012
	Equity Incentive Plan (which includes both U.S. and Israeli sub-plans). On January&nbsp;23, 2012, an Israeli sub-plan was
	adopted under our 2012 Equity Incentive Plan, which sets forth the terms for the grant of stock awards to Israeli employees
	or Israeli non-employees. The sub-plan was adopted in accordance with the amended sections 102 and 3(i) of Israel&rsquo;s
	Income Tax Ordinance. The sub-plan is part of the 2012 Equity Incentive Plan and subject to the same terms and conditions.
	Following amendments, there are currently 13,425,000 shares of common stock reserved for issuance under the 2012 Equity
	Incentive Plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The purpose of our 2012 Equity Incentive Plan
	is to attract and retain directors, officers, consultants, advisors and employees whose services are considered valuable, to encourage
	a sense of proprietorship and to stimulate an active interest of such persons in our development and financial achievements. The
	2012 Equity Incentive Plan will be administered by the Compensation Committee of our Board of Directors or by the full board, which
	may determine, among other things, the (a) terms and conditions of any option or stock purchase right granted, including the exercise
	price and the vesting schedule, (b) persons who are to receive options and stock purchase rights and (c) the number of shares to
	be subject to each option and stock purchase right. The 2012 Equity Incentive Plan will provide for the grant of (i)&nbsp;&rdquo;incentive&rdquo;
	options (qualified under section 422 of the Internal Revenue Code of 1986, as amended) to employees of our company and (ii)&nbsp;non-qualified
	options to directors and consultants of our company. In addition, our Board of Directors has authorized the appointment of Tamir
	Fishman Equity Plan Services to act as a trustee for grants of options under the Israeli sub-plan to Israeli residents.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 46; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	46
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage47"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	In connection with the administration of our
	2012 Equity Incentive Plan, our Compensation Committee will:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	determine which employees and other persons will be granted
	awards under our 2012 Equity Incentive Plan;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	grant the awards to those
	selected to participate;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	determine the exercise price
	for options; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	prescribe any limitations,
	restrictions and conditions upon any awards, including the vesting conditions of awards.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our Compensation Committee will: (i) interpret
	our 2012 Equity Incentive Plan; and (ii) make all other determinations and take all other action that may be necessary or advisable
	to implement and administer our 2012 Equity Incentive Plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The 2012 Equity Incentive Plan provides that
	in the event of a change of control event, the Compensation Committee or our Board of Directors shall have the discretion to determine
	whether and to what extent to accelerate the vesting, exercise or payment of an award.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	In addition, our Board of Directors may amend
	our 2012 Equity Incentive Plan at any time. However, without stockholder approval, our 2012 Equity Incentive Plan may not be amended
	in a manner that would:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	increase the number of shares
	that may be issued under our 2012 Equity Incentive Plan;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	materially modify the requirements
	for eligibility for participation in our 2012 Equity Incentive Plan;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	materially increase the benefits
	to participants provided by our 2012 Equity Incentive Plan; or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	otherwise disqualify our
	2012 Equity Incentive Plan for coverage under Rule 16b-3 promulgated under the Exchange Act.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Awards previously granted under our 2012 Equity
	Incentive Plan may not be impaired or affected by any amendment of our 2012 Equity Incentive Plan, without the consent of the affected
	grantees.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Option Exercises
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	To date, no options have been exercised by our
	directors or officers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Unregistered Sales of Equity Securities and Use of Proceeds
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	As of December 31, 2015, since September 30,
	2015 we issued an aggregate of 128,716 shares of our common stock to officers and directors under the 2012 Equity Incentive Plan
	as equity compensation according to the Israeli sub-plan and we also issued an aggregate of 96,138 shares of our common stock to
	directors under the 2012 Equity Incentive Plan as equity compensation. We claimed exemption from registration under the Securities
	Act of 1933, as amended, or the Securities Act, for the foregoing transactions pursuant to Section 4(a)(2) of the Securities Act
	and/or under Regulation S under the Securities Act.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On December 24, 2015, we consummated a private
	placement pursuant to which we issued 1,461,988 shares of common stock and a warrant exercisable for an aggregate of 1,461,988
	shares of common stock for an aggregate gross consideration of $500,000. The warrant is immediately exercisable at an exercise
	price of $0.34 per share and expires 6 months from the date of the closing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 47; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	47
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage48"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The securities issued in the offering are exempt
	from the registration requirements of the Securities Act pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506(b) of
	Regulation D promulgated thereunder because, among other things, the transaction did not involve a public offering, the investors
	are accredited investors, the investors are taking the securities for investment and not resale and we took appropriate measures
	to restrict the transfer of the securities, and pursuant to Regulation S of the Securities Act to non-U.S. investors.
</P>
</EFX_MARKET>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD">
<A NAME="V430703_10K_HTM_A_011">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item&nbsp;6.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Selected Financial Data
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	Not applicable.
</P>
</EFX_FINANCIAL_DATA>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_MANAGEMENTS_DISCUSSION>
<A NAME="FIS_MANAGEMENTS_DISCUSSION"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD">
<A NAME="V430703_10K_HTM_A_012">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item&nbsp;7.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operation
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Readers are advised
	to review the following discussion and analysis of our financial condition and results of operations together with our consolidated
	financial statements and the related notes and other financial information included elsewhere in this Annual Report. Some of the
	information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with
	respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. See
	&ldquo;Cautionary Note Regarding Forward-Looking Statements&rdquo;. You should review the &ldquo;Risk Factors&rdquo; section of
	this Annual Report for a discussion of important factors that could cause actual results to differ materially from the results
	described in or implied by the forward-looking statements contained in the following discussion and analysis
</I>
	.
<I>
	The share
	and per share numbers in the following discussion reflect a 1-for-5 reverse stock split that we effected on October 6, 2014.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Overview
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We are a digital health (mHealth) company that
	is developing and commercializing a patented and proprietary technology providing consumers with laboratory-testing capabilities
	using smart phones and other mobile devices. Our principal operating subsidiary, LabStyle Innovation Ltd., is an Israeli company
	with its headquarters in Caesarea, Israel. We were formed on August 11, 2011 as a Delaware corporation. Our flagship product, Dario&trade;,
	is a mobile, real-time, cloud-based, diabetes management solution based on an innovative, multi-feature software application combined
	with a stylish, &lsquo;all-in-one&rsquo;, pocket-sized, blood glucose monitoring device, which we call the Dario&trade; Smart Meter.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We commenced a commercial launch of the free
	Dario&trade; application in the United Kingdom in late 2013 and commenced an initial soft launch of the full Dario&trade; solution
	(including the app and the Smart Meter) in selected jurisdictions in March 2014 and continued to scale up launch during 2014 in
	the United Kingdom, the Netherlands and New Zealand, and during 2015 in Australia, Israel and Canada, with the goal of collecting
	customer feedback to refine our longer-term roll-out strategy. We are consistently adding new additional features and functionality
	in making Dario&trade; the new standard of care in diabetes data management. We currently have over 35,000 installs of our iOS
	app and over 10,000 installs of our Android app.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Through our Israeli subsidiary, Labstyle Innovation
	Ltd., our plan of operations is to continue the development of our software and hardware offerings and related technology. During
	2015, we successfully launched the Dario&trade; Smart Diabetes Management Solution according to plan and are currently expanding
	the launch to other jurisdictions. In support of these goals, we intend to utilize our funds for the following activities:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	ramp up of mass production,
	marketing and distribution and sales efforts related to the Dario&trade; application, Smart Meters and test strips;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	continued product development
	and related activities (including costs associated with application development and data storage capabilities as well as any necessary
	design modifications to the various elements of the Dario&trade; solution);
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	continued work on registration
	of our patents worldwide;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 48; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	48
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage49"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	regulatory matters;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	professional fees associated
	with being a publicly reporting company; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	general and administrative
	matters.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Readers are cautioned that, according to our
	management&rsquo;s estimates, based on our budget and the initial launch of our commercial sales, we believe that we will have
	sufficient resources to continue our activity only into April 2016 without raising additional capital. This includes a small amount
	of anticipated inflows from sales of Dario&trade; through distribution partners. As such, we have a significant present need for
	capital. If we are unable to scale up our commercial launch of Dario&trade; or meet our commercial sales targets (or if we are
	unable to ramp up revenues), and if we are unable to obtain additional capital resources in the near term, we may be unable to
	continue activities, absent a material alternations in our business plans and our business might fail.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Critical Accounting Policies
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our consolidated financial statements are prepared
	using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States (or US GAAP).&nbsp;Our
	fiscal year ends December 31.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	This Management&rsquo;s Discussion and Analysis
	of Financial Condition and Results of Operations discuss our consolidated financial statements, which have been prepared in accordance
	with US GAAP. The preparation of these consolidated financial statements requires making estimates and assumptions that affect
	the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated
	financial statements, as well as the reported revenues and expenses for the reporting periods. On an ongoing basis, we evaluate
	such estimates and judgments. We base our estimates on historical experience and on various other factors that we believe are reasonable
	under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities
	that are not readily apparent from other sources. Actual results may differ (perhaps significantly) from these estimates under
	different assumptions or conditions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	While all the accounting policies impact the
	consolidated financial statements, certain policies may be viewed to be critical. Our management believes that the accounting policies
	which involve more significant judgments and estimates used in the preparation of our consolidated financial statements, include
	revenue recognition, inventories, liability related to certain warrants, and accounting for production lines and its related useful
	life and impairment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Revenue Recognition
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We derive revenues from the sale of our device-specific
	disposables test strip cartridges, lancets and our Dario&trade; Smart Meters through distributors or directly to end users. The
	Dario&trade; software application is offered for a free download and we do not have a recurring hosting commitment with our end
	users relating specifically to the application.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Revenues from product sales are recognized in
	accordance with ASC 605-10, &ldquo;Revenue Recognition&rdquo;, when delivery has occurred, persuasive evidence of an agreement
	exists, the vendor&rsquo;s fee is fixed or determinable, no further obligation exists and collectability is probable. We generally
	do not grant a right of return. We assess whether the fee is fixed or determinable based on the nature of the fee charged for the
	products delivered, the existing contractual arrangements and the distributor&rsquo;s consistency of payments. When evaluating
	collectability, we consider whether we have sufficient history to reliably estimate the distributor&rsquo;s payment patterns.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Through December 31, 2015, product sales to
	distributors are only recognized as revenues upon receipt of payment. We will apply this policy until we will have sufficient historical
	experience with each distributor in order to conclude that fee is fixed or determinable and collectability is probable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 49; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	49
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage50"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We also generate revenues from arrangements
	with health care providers which include supply of Dario&trade; Smart Meters and software platform that requires certain customization
	followed by monthly service, support and maintenance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	When a sales arrangement contains multiple elements,
	such as software and non-software components, we allocate revenue to each element based on a selling price hierarchy as required
	according to ASC 605-25, &ldquo;Multiple-Element Arrangements&rdquo;, or ASC 605-25. The selling price for a deliverable is based
	on its Vendor Specific Objective Evidence, or VSOE, or, if available, third party evidence, or TPE, if VSOE is not available, or
	estimated selling price, or ESP, if neither VSOE nor TPE is available. The best estimate of selling price is established considering
	several internal factors including, but not limited to, historical sales, pricing practices and geographies in which we offer our
	products. The determination of ESP is judgmental.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Revenues from software components in sales arrangements
	containing multiple elements are recognized when all criteria outlined in ASC 985-605, &ldquo;Software Revenue Recognition&rdquo;,
	or ASC 985-605, are met (when persuasive evidence of an arrangement exists, delivery of the product has occurred or the services
	have been rendered, the fee is fixed or determinable and collectability is probable).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	For multiple element arrangements within ASC
	985-605, revenues are allocated to the different elements in the arrangement under the &ldquo;residual method&rdquo; when VSOE
	of fair value exists for all undelivered elements and no VSOE exists for the delivered elements. Under the residual method, at
	the outset of the arrangement with the customer, we defer revenue for the fair value of its undelivered elements and recognize
	revenue for the remainder of the arrangement fee attributable to the elements initially delivered in the arrangement when the basic
	criteria in ASC 985-605 have been met. Any discount in the arrangement is allocated to the delivered element.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Since VSOE does not exist for undelivered elements,
	revenues are recognized as one unit of accounting, on a straight-line basis over the term of the last deliverable based on ASC
	605-15 and ASC 985-605.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Liability Related to Certain Warrants
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The fair value of the liability for certain
	warrants issued to investors and our previous placement agents in connection with our financings to date was calculated using the
	Binomial option-pricing model. We accounted for these warrants according to the provisions of ASC 815, &ldquo;Derivatives and Hedging
	- Contracts in Entity&rsquo;s Own Equity&rdquo; and, based on the anti-dilution protections contained in part of the warrants and
	net settlement cash feature contained in other warrants, we classified them as non-current liabilities, measured at fair value
	each reporting period until they will be exercised or expired, with changes in the fair values being recognized in our statement
	of comprehensive loss as financial income or expense. The anti-dilution protections feature for certain warrants was valued by
	calculating a put option. The value of these warrants was calculated using the call option value in addition with the put option
	value, which reflects the anti-dilution protection, multiplied by the probability that a down round will occur. The value of warrants
	with net settlement cash feature and liquidated damages penalties which do not include anti-dilution provision was calculated using
	a call option value.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Fair value for each reporting period was calculated
	based on the following assumptions:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Risk-free interest rate -
	based on yield rates of non-index linked U.S. Federal Reserve treasury bonds.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	(2)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Expected volatility - was
	calculated based on actual historical stock price movements of the Company together with companies in the same industry over a
	term that is equivalent to the expected term of the option.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	(3)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Expected life - the expected
	life was based on the expiration date of the warrants.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	(4)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Expected dividend yield -
	was based on the fact that the Company has not paid dividends to its shareholders in the past and does not expect to pay dividends
	to its shareholders in the future.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our net loss for the year ended December 31,
	2015 and 2014 included finance income in the amount of $571,000 and $2,194,000, respectively, with connection to the above-mentioned
	warrants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 50; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	50
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage51"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Inventories
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 35.45PT">
	Inventory write-down is also measured as the
	difference between the cost of the inventory and net realized value based upon assumptions about future demand, and is charged
	to the cost of sales. At the point of the loss recognition, a new, lower-cost basis for that inventory is established, and subsequent
	changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	If there were to be a sudden and significant
	decrease in demand for our products or if there were a higher incidence of inventory obsolescence because of rapidly changing technology
	and customer requirements, we could be required to increase our inventory write-downs and our gross margin could be adversely affected.
	Inventory and supply chain management remain areas of focus as we balance the need to maintain supply chain flexibility, to help
	ensure competitive lead times with the risk of inventory obsolescence.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	During the year ended December 31, 2015, total
	inventory write-off expenses amounted to $193,000.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Production Lines
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Capitalization of Costs
</I>
	. We capitalize
	direct incremental costs of third party manufacturers related to the equipment in our production lines. We cease construction cost
	capitalization relating to our production lines once they are ready for its intended use and held available for occupancy. All
	renovations and betterments that extend the economic useful lives of assets and/or improve the performance of the production lines
	are capitalized.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Useful Lives of Assets
</I>
	. We are required
	to make subjective assessments as to the useful lives of our production lines for purposes of determining the amount of depreciation
	to record on an annual basis with respect to our construction of the production lines. These assessments have a direct impact on
	our net income (loss). Production lines are usually depreciated on a straight-line basis over a period of up to five years, except
	any renovations and betterments which are depreciated over the remaining life of the production lines.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Impairment of production lines.
</I>
	&nbsp;We
	are required to review our production lines for impairment in accordance with ASC 360, &ldquo;Property, Plant and Equipment,&rdquo;
	whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability
	of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows
	expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured
	by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Based on such review, during the
	year ended December 31, 2014, we recorded a non-cash charge with respect to an impairment of production equipment in the amount
	of $489,000. During the year ended December 31, 2015, no impairment losses have been recorded.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Extended Transition Period for &ldquo;Emerging
	Growth Companies&rdquo;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We have elected to use the extended transition
	period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. This election allows us
	to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies
	until those standards apply to private companies. As a result of this election, our financial statements may not be comparable
	to companies that comply with public company effective dates. Because our financial statements may not be comparable to companies
	that comply with public company effective dates, investors may have difficulty evaluating or comparing our business, performance
	or prospects in comparison to other public companies, which may have a negative impact on the value and liquidity of our common
	stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 51; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	51
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage52"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_RESULTS_OF_OPERATIONS>
<A NAME="FIS_RESULTS_OF_OPERATIONS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Results of Operations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Comparison of the Year Ended December 31, 2015 to Year Ended
	December 31, 2014
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Revenues
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Revenues for the year ended December 31, 2015
	amounted to $823,000, compared to $51,000 during the year ended December 31, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Revenues generated during the year ended December
	31, 2015 were derived mainly from the sales of Dario&trade;&rsquo;s components, including the Smart Meter itself, through distributers.
	We recognize revenues on a cash basis, when all revenue recognition criteria are met, until we are able to determine the
	ability of the distributer to honor its commitment to complete payment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Cost of Revenues and ramp up of manufacturing
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	During the years ended December 31, 2015 and
	2014, we recorded costs related to revenues and ramp up of manufacturing in the amount of $1,678,000 and $2,274,000, respectively,
	out of which $193,000 and $1,046,000, respectively, was recorded to cover inventory write-downs due to net realized value which
	was lower than original cost. In addition, during the year ended December 31, 2014, we recorded an amount of $489,000 in a separate
	line due to impairment of one of our production lines when we decided to cease its operation. The decrease in cost of revenues
	and ramp up of manufacturing was mainly due to a decrease in our production costs as well as depreciation costs that were recorded
	in the fourth quarter of 2014 as a result of the cessation of operation of our old production line.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Cost of revenues consist mainly of cost of device
	production, employees' salaries and related overhead costs, depreciation of production line and related cost of equipment used
	in production, shipping and handling costs and inventory write-downs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Research and Development Expenses
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our research and development expenses decreased
	by $1,378,000 to $2,565,000 for the year ended December 31, 2015 compared to $3,943,000 for the year ended December 31, 2014. This
	decrease was mainly due to decreases in employee payroll and related costs, stock-based compensation expenses, development costs
	and other costs due to our product launch in 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Research and development expenses consist mainly
	of payroll expenses to employees involved in research and development activities, expenses related to our Dario&trade; software
	application and related Smart Meter device, labor contractors and engineering expenses, depreciation and maintenance fees related
	to equipment and software tools used in research and development, clinical trials performed in the United States to satisfy the
	FDA product approval requirements and facilities expenses associated with and allocated to research and development activities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Sales, Marketing and Pre-production Costs
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our sales, marketing and pre-production costs
	increased by $267,000 to $1,330,000 for the year ended December 31, 2015 compared to $1,063,000 for the year ended December 31,
	2014. This increase was mainly due to an increase in headcount of marketing personnel and public relations efforts towards initiation
	of sales in the United States in connection with the receipt of FDA certification in December 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Sales and marketing expenses consist mainly
	of payroll expenses, trade show expenses and on-line marketing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	General and Administrative Expenses
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our general and administrative expenses decreased
	by $692,000 to $2,948,000 for the year ended December 31, 2015 compared to $3,640,000 for the year ended December 31, 2014. The
	decrease is mainly due to decreases in employee payroll and related costs due to a change in management structure, stock-based
	compensation expenses of employees and directors, office maintenance and employee welfare, legal and professional expenses and
	other expenses.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 52; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	52
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage53"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our general and administrative expenses consist
	mainly of payroll and stock-based compensation expenses for management, employees, directors and consultants, legal fees, expenses
	related to investor relations, as well as our office rent and related expenses.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
<I>
	Finance Income (expenses), net
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our finance income, net, increased by $2,075,000
	to $556,000 for the year ended December 31, 2015 compared to ($1,519,000) for the year ended December 31, 2014. Finance income
	includes mainly the results of a revaluation of warrants to investors and a former placement agent, which are recorded as liability
	and presented at fair value each reporting period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Net loss
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Net loss for the year ended December 31, 2015
	was $7,142,000. Net loss for the year ended December 31, 2014 was $12,877,000. The decrease from 2014 was mainly due to commencement
	of revenues in the fourth quarter of 2014 and continuing increases in revenues during 2015 coupled with a decrease of $3,660,000,
	or 32%, in operating costs during 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Net operating loss carryforwards
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We had U.S. federal net operating loss carryforwards
	of approximately $4,877,000 at December 31, 2015. This loss carryforwards expire principally beginning in 2031 through 2035.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our Israeli subsidiary has accumulated net operating
	losses for Israeli income tax purposes as of December&nbsp;31, 2015 in the amount of approximately $18,675,000. The net operating
	losses may be carried forward and offset against taxable income in the future for an indefinite period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	In accordance with GAAP, it is required that
	a deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence it is more likely than not
	(a likelihood of more than 50 percent) that some portion or all of the deferred tax assets will not be realized. The valuation
	allowance should be sufficient to reduce the deferred tax asset to the amount which is more likely than not to be realized. As
	a result, we recorded a valuation allowance with respect to our deferred tax asset. Under Sections 382 and 383 of the Internal
	Revenue Code, if an ownership change occurs with respect to a &ldquo;loss corporation&rdquo; (as defined in the Internal Revenue
	Code), there are annual limitations on the amount of the net operating loss and other deductions which are available to us.
</P>
</EFX_RESULTS_OF_OPERATIONS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_LIQUIDITY_CAPITAL>
<A NAME="FIS_LIQUIDITY_CAPITAL"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Liquidity and Capital Resources
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	As of December 31, 2015, we had approximately
	$2,671,000 in cash and cash equivalents compared to $1,453,000 at December 31, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We have experienced cumulative losses of $43,354,000
	from inception (August 11, 2011) through December 31, 2015, and have a stockholders&rsquo; deficiency of $1,580,000 at December
	31, 2015. In addition, we have not completed our efforts to establish a stable recurring source of revenues sufficient to cover
	our operating costs and expect to continue to generate losses for the foreseeable future. There is no assurances that we will be
	able to obtain an adequate level of financing needed for our near term requirements or the long-term development and commercialization
	of our product. These conditions raise substantial doubt about our ability to continue as a &ldquo;going concern&rdquo;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Since inception, we have financed our operations
	primarily through private placements of our common stock and warrants to purchase shares of our common stock, receiving aggregate
	net proceeds totaling $31,100,000 as of December 31, 2015, approximately $2,000,000 of which was raised during February and March
	2015 pursuant to a private placement, or the February 2015 Private Placement, pursuant to which we issued 11,286,444 shares of
	our common stock and warrants to purchase an aggregate of 5,643,226 shares of our common stock, $453,000 which was raised following
	the entry on May 15, 2015 into warrant exercise and replacement agreements, or the Exercise and Replacement Agreements, with certain
	of the investors and the placement agent, or the Buyers, in our February 2015 Private Placement. The purpose of the Exercise and
	Replacement Agreements was to induce the exercise of the warrants issued in the February 2015 Private Placement, or the Warrants,
	into 1,923,636 shares of our common stock at an exercise price of $0.24 per share. In connection with the Exercise and Replacement
	Agreements and the exercise of the Warrants, we issued to the Buyers additional warrants to purchase an aggregate of 1,923,636
	shares of our common stock at an exercise price of $0.24 per share. In connection with the issuance of the Warrants to purchase
	an aggregate of 1,923,636 shares of our common stock we recorded in the second quarter of 2015 a deemed dividend in the amount
	of $154,000.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 53; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	53
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage54"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	In July and August 2015, we consummated a private
	placement, or the July 2015 Private Placement, pursuant to which we issued 8,350,870 shares of our common stock, Series A Warrants
	to purchase 4,175,440 shares of our common stock at an exercise price of $0.35 per share and Series B Warrants to purchase 4,175,440
	shares of our common stock at an exercise price of $0.40 per share for an aggregate gross consideration of approximately $2,500,000.
	With respect to the July 2015 Private Placement our issuance costs were approximately $181,000 ($122,000 out of which related to
	commissions and fees of the placement agent). In addition, we agreed to grant to the placement agent 50,000 restricted shares of
	our common stock, to the placement agent and a selected dealer an aggregate of 898,313 warrants at exercise prices of $0.30, $0.35
	and $0.40 per share, and to certain finders that assisted with the July 2015 Private Placement 245,333 restricted shares of our
	common stock, 374,272 non-plan stock options to purchase 374,272 shares of common stock and 619,606 warrants at exercise prices
	of $0.35 and $0.40 per share.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On November 19, 2015, we consummated a private
	placement, or the November 2015 Private Placement, pursuant to which we issued 7,648,267 shares of common stock and warrants exercisable
	for an aggregate of 7,648,267 shares of common stock for an aggregate gross consideration of approximately $2,300,000. The warrants
	issued in the November 2015 Private Placement consisted of a Series A warrant to purchase 0.7 shares of our common stock, immediately
	exercisable at an exercise price of $0.37 per share and expiring 16 months from the date of the closing and a Series B warrant
	to purchase 0.3 shares of common stock, immediately exercisable at an exercise price of $0.43 per share and expiring 36 months
	from the date of the closing. In connection with the November 2015 Private Placement we agreed to issue to certain finders 383,467
	restricted shares of common stock, 439,630 non-plan stock options to purchase 439,630 shares of common stock and 823,097 warrants
	subject to the same terms as those issued to investors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On December 24, 2015, we consummated a private
	placement, or the December 2015 Private Placement, pursuant to which we issued 1,461,988 shares of common stock and a warrant exercisable
	for an aggregate of 1,461,988 shares of common stock for an aggregate gross consideration of approximately $500,000. The warrant
	issued in the December 2015 Private Placement consisted of a warrant to purchase shares of our common stock, immediately exercisable
	at an exercise price of $0.34 per share and expiring 6 months from the date of the closing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	According to our
	management&rsquo;s estimates, based on our budget and the initial launch of our commercial sales, we believe that we will have
	sufficient resources to continue our activity into April 2016
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	without raising additional capital.
	This includes an amount of anticipated inflows from sales of Dario&trade; through distribution partners and to direct customers.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	As such, we have a significant present need
	for capital. If we are unable to scale up our commercial launch of Dario&trade; or meet our commercial sales targets (or if we
	are unable to generate any revenue at all), and if we are unable to obtain additional capital resources in the near term, we may
	be unable to continue activities absent material alterations in our business plans and our business might fail.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Additionally, readers are advised that available
	resources may be consumed more rapidly than currently anticipated, resulting in the need for additional funding sooner than expected.
	Should this occur, we will need to seek additional capital earlier than anticipated in order to fund (1) further development and,
	if needed, testing of our Dario&trade; Smart Meter and its related application and data storage components, (2)&nbsp;our efforts
	to obtain regulatory clearances or approvals necessary to be able to commercially launch Dario&trade;, (3) expenses which will
	be required in order to start and expand production of Dario&trade;, (4) sales and marketing efforts and (5) general working capital.
	Such funding may be unavailable to us on acceptable terms, or at all. Our failure to obtain such funding when needed could create
	a negative impact on our stock price or could potentially lead to the failure of our company. This would particularly be the case
	if we are unable to commercially launch Dario&trade; in the jurisdictions and in the timeframes we expect.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 54; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	54
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage55"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Cash Flows
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The following tables sets forth selected cash
	flow information for the periods indicated:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	December&nbsp;31,
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 74%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Cash used in operating activities:
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(6,277,000
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(8,581,000
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Cash used in investing activities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(113,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(429,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Cash provided by financing activities:
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,608,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,200,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,218,000
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(810,000
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Net cash used in operating activities
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Net cash used in operating activities was $6,277,000
	for the year ended December 31, 2015 compared to $8,581,000 used in operations for the same period in 2014. Cash used in operations
	decreased mainly due to decreases in employee payroll and related costs, overhead costs, legal and professional expenses and other
	expenses, coupled with an increase in cash due to ramp-up of revenues during the twelve month period ended December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Net cash used in investing activities
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Net cash used in investing activities was $113,000
	for the year ended December 31, 2015 compared to $429,000 for the year ended December 31, 2014. Cash used in investing activities
	decreased mainly due to the decrease in the purchase of property and equipment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.5IN">
<I>
	Net cash provided by financing
	activities
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Net cash provided by financing activities was
	$7,608,000 for the year ended December 31, 2015 compared to $8,200,000 for the year ended December 31, 2014. During the year ended
	December 31, 2015, we raised net proceeds in an amount of $7,075,000, of which $1,956,000 was raised through our February 2015
	Private Placement, $2,325,000 was raised through our July 2015 Private Placement, $2,294,000 was raised through our November 2015
	Private Placement and $500,000 was raised through our December 2015 Private Placement. In addition, we raised $453,000 in May 2015
	through our Warrant Exercise and Replacement Agreements with the Buyers from our February 2015 Private Placement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Contractual Obligations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Set forth below is a summary of our current
	obligations as of December 31, 2015 to make future payments due by the period indicated below, excluding payables and accruals.
	We expect to be able to meet our obligations in the ordinary course. Operating lease obligations are for&nbsp;motor vehicle and
	real property leases which we use in our business. Purchasing obligations consists of outstanding purchase orders for materials
	and services from our vendors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;&#9;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	Payments&nbsp;due&nbsp;by&nbsp;period&nbsp;(U.S.&nbsp;dollars)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Contractual&nbsp;Obligations
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	Less&nbsp;than&nbsp;1&nbsp;year
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	1-3&nbsp;years
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Operating Lease Obligations
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	274
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	220
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	54
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9PT">
	Purchasing Obligations
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,395
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,395
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Total contractual cash obligations
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,669
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,615
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	54
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 55; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	55
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage56"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Off-Balance Sheet Arrangements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We did not have during the periods presented,
	and we do not currently have, any off-balance sheet arrangements as defined under Securities and Exchange Commission rules.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Contingencies
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We account for our contingent
	liabilities in accordance with ASC 450 &ldquo;Contingencies&ldquo;. A provision is recorded when it is both probable that a
	liability has been incurred and the amount of the loss can be reasonably estimated.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	With respect to legal matters, provisions are
	reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and
	other information and events pertaining to a particular matter. Currently, we are not a party to any ligation that we believe could
	have a material adverse effect on our business, financial position, results of operations or cash flows.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Recently Issued and Adopted Accounting Pronouncements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	In May 2014, the Financial Accounting Standards
	Board, or FASB, issued Accounting Standards Update (&ldquo;ASU&rdquo;) No. 2014-09, &ldquo;Revenue from Contracts with Customers&rdquo;,
	which will replace most of the existing revenue recognition guidance under U.S. Generally Accepted Accounting Principles. The core
	principle of the ASU is that an entity should recognize revenue for the transfer of goods or services equal to the amount that
	it expects to be entitled to receive for those goods or services. The ASU requires additional disclosure about the nature, amount,
	timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in
	judgments. In August&nbsp;2015, the FASB issued ASU 2015-14, &ldquo;Revenue from Contracts with Customers (Topic 606),&rdquo; which
	defers the effective date of ASU 2014-09 by one year to fiscal years beginning after December&nbsp;15, 2018, and interim reporting
	periods within annual reporting periods beginning after December 15, 2019 with early adoption permitted. We are in the process
	of determining the method of adoption and assessing the impact of this ASU on our consolidated financial position, results of operations
	and cash flows.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	In August 2014, the FASB issued Accounting Standards
	Update No. 2014-15 (ASU 2014-15), &ldquo;Presentation of Financial Statements-Going Concern&rdquo; (Subtopic 205-40): &ldquo;Disclosure
	of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern&rdquo;, which defines management&rsquo;s responsibility
	to assess an entity&rsquo;s ability to continue as a going concern, and to provide related footnote disclosures if there is substantial
	doubt about its ability to continue as a going concern. ASU 2014-15 is effective for annual reporting periods ending after December
	15, 2016 with early adoption permitted. The adoption of this guidance is not expected to have a material impact on our financial
	statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	In July 2015, the FASB issued ASU No. 2015-11,
	&ldquo;Inventory (Topic 330): Simplifying the Measurement of Inventory.&rdquo; Under this accounting guidance, inventory will be
	measured at the lower of cost and net realizable value and other options that currently exist for market value will be eliminated.
	ASU No. 2015-11 defines net realizable value as the estimated selling prices in the ordinary course of business, less reasonably
	predictable costs of completion, disposal, and transportation. No other changes were made to the current guidance on inventory
	measurement. ASU 2015-11 is effective for fiscal years beginning after December&nbsp;15, 2016, and interim periods within fiscal
	years beginning after December 15, 2017 with early adoption permitted. The adoption of this guidance is not expected to have a
	material impact on the Company&rsquo;s financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	In November 2015, the FASB issued ASU No. 2015-17,
	&ldquo;Income Taxes &ndash; Balance Sheet Classification of Deferred Taxes.&rdquo; The purpose of the standard is to simplify the
	presentation of deferred taxes on a classified balance sheet.&nbsp;&nbsp;Under current GAAP, deferred income tax assets and liabilities
	are separated into current and noncurrent amounts in the balance sheet.&nbsp;&nbsp;The amendments in ASU 2015-17 require that all
	deferred tax assets and liabilities be classified as noncurrent in the balance sheet.&nbsp; ASU 2015-17 is effective for interim
	and annual periods beginning after December 15, 2016. &nbsp;Early application is permitted and should be applied prospectively.
	&nbsp; We do not expect the adoption of ASU 2015-17 to have a material impact on its consolidated financial statements or presentation.
</P>
</EFX_LIQUIDITY_CAPITAL>
</EFX_MANAGEMENTS_DISCUSSION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD">
<A NAME="V430703_10K_HTM_A_013">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 7A.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Quantitative and Qualitative Disclosure About Market Risk
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 56; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	56
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_MARKET_RISK>
<A NAME="eolPage57"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD">
<A NAME="V430703_10K_HTM_A_014">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 8.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Financial Statements and Supplementary Data
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Our Consolidated
	Financial Statements and Notes thereto and the report of
</FONT>
	Kost Forer Gabbay &amp; Kasierer, a member of Ernst &amp; Young
	Global
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	, our independent registered public accounting firm, are set forth on pages F-1 through
	F-39 of this Annual Report.
</FONT>
</P>
</EFX_FINANCIAL_STATEMENTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_ACCOUNTING_CHANGES>
<A NAME="FIS_ACCOUNTING_CHANGES"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD">
<A NAME="V430703_10K_HTM_A_015">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 9.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Not applicable.
</P>
</EFX_ACCOUNTING_CHANGES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD">
<A NAME="V430703_10K_HTM_A_016">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item&nbsp;9A.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Controls and Procedures
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; BACKGROUND-COLOR: WHITE">
<I>
	Evaluation of Disclosure Controls and
	Procedures
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	Under the supervision
	and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, we carried
	out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules&nbsp;13a-15(e)
	and 15d-15(e) under the Exchange Act. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have
	concluded that, at December&nbsp;31, 2015, such disclosure controls and procedures were effective.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	Disclosure controls
	and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports
	filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in
	the SEC&rsquo;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed
	to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and
	communicated to management, including our Chief Executive Officer and Chief Financial Officer, or persons performing similar functions,
	as appropriate, to allow timely decisions regarding required disclosure.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; BACKGROUND-COLOR: WHITE">
<I>
	Limitations on the Effectiveness of
	Internal Controls
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; BACKGROUND-COLOR: WHITE">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Readers are cautioned that our management does
	not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent
	all fraud and material error. An internal control system, no matter how well conceived and operated, can provide only reasonable,
	not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems,
	no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our control
	have been detected. The design of any system of controls also is based in part upon certain assumptions about the likelihood of
	future events, and there can be no assurance that any control design will succeed in achieving its stated goals under all potential
	future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with
	the policies or procedures may deteriorate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Changes in Internal Control over Financial Reporting
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	There were no changes
	in our internal control over financial reporting that occurred during the quarter ended December&nbsp;31, 2015 that have materially
	affected, or are reasonably likely to materially affect, our internal control over financial reporting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; BACKGROUND-COLOR: WHITE">
<I>
	Management&rsquo;s Report on Internal
	Control Over Financial Reporting
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	As required by the
	SEC rules and regulations, our management is responsible for
	establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting
	is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our consolidated
	financial statements for external reporting purposes in accordance with U.S. GAAP. Our internal control over financial reporting
	includes those policies and procedures that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 57; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	57
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage58"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	pertain to the maintenance
	of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of our company;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	(2)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	provide reasonable assurance
	that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with accounting
	principles generally accepted in the United States of America, and that our receipts and expenditures are being made only in accordance
	with authorizations of our management and directors; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	(3)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	provide reasonable assurance
	regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material
	effect on the consolidated financial statements.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	Because of its inherent
	limitations, internal control over financial reporting may not prevent or detect errors or misstatements in our consolidated financial
	statements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become
	inadequate because of changes in conditions, or that the degree or compliance with the policies or procedures may deteriorate.
	Management assessed the effectiveness of our internal control over financial reporting at December&nbsp;31, 2015. In making these
	assessments, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (2013
	Framework). Based on our assessments and those criteria, management determined that we maintained effective internal control over
	financial reporting at December&nbsp;31, 2015.
</P>
</EFX_CONTROL_AND_PROCEDURES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<EFX_OTHER_INFORMATION>
<A NAME="FIS_OTHER_INFORMATION"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD">
<A NAME="V430703_10K_HTM_A_017">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 9B.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Other Information
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	None.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<A NAME="V430703_10K_HTM_A_018">
</A>
<B>
	PART II
</B>
</P>
</EFX_OTHER_INFORMATION>
</EFX_PART_II>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD">
<A NAME="V430703_10K_HTM_A_019">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 10.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Directors, Executive Officers and Corporate Governance
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The following sets forth
	information regarding our executive officers and the members of our Board of Directors as of the date of this Annual Report. All
	directors hold office for one-year terms until the election and qualification of their successors. Officers are appointed by our
	Board of Directors and serve at the discretion of our Board of Directors, subject to applicable employment agreements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_NAME_AND_TITLE>
<A NAME="FIS_NAME_AND_TITLE"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Name
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Age
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Position(s)
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Erez Raphael
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	42
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Chairman of the Board of Directors and Chief Executive Officer
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	Zvi Ben David
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	55
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	Chief Financial Officer, Treasurer and Secretary
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	Malcolm Hoenlein
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	71
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	Director
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	Dennis M. McGrath
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	59
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	Director
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	Prof. Richard B. Stone
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	72
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	Director
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	Rami Yehudiha
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	45
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	Director
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	Hila Karah
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	47
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	Director
</FONT>
</TD>
</TR>
</TABLE>
</EFX_NAME_AND_TITLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Erez Raphael
</I>
</B>
	&nbsp;has served as
	our Chief Executive Officer since August 9, 2013 and as a director of our company since December 2013. Mr. Raphael has served as
	Chairman of the Board of Directors since November 2014. He previously and since October 2012 served as our Vice President of Research
	and Development. Mr. Raphael has over 17 years of industry experience, having been responsible in his career for product delivery,
	technology and business development. Prior to joining us, from 2010 to 2012, Mr. Raphael served as Head of Business Operations
	for Nokia Siemens Networks, where he was responsible for establishing and implementing a new portfolio business unit directed towards
	marketing and sales of complimentary products. Prior to that, from 1998 to 2010, he held increasingly senior positions at Amdocs
	Limited (NYSE:DOX) where he was ultimately responsible for advising the Chief Technology Officer and implementing matters of overall
	business strategy. Mr. Raphael holds a B.A. in economics and business management from Haifa University. We believe Mr. Raphael
	is qualified to serve on our Board of Directors because of his extensive experience with technology companies and in sales and
	marketing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 58; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	58
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage59"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Zvi Ben David&nbsp;
</I>
</B>
	has served
	as our Chief Financial Officer, Treasurer and Secretary since January 7, 2015. Mr. Ben David has over 25 years of experience in
	corporate and international financial management, including at both publicly-listed and private companies. Since 2012, he has acted
	as an independent entrepreneur with, and investor in, various medical device ventures. From 2005 to 2012, Mr. Ben David served
	as the Chief Financial Officer of UltraShape Medical Ltd., a&nbsp;
<FONT STYLE="COLOR: #161925">
	developer, manufacturer and marketer
	of innovative non-invasive technologies for fat cell destruction and body sculpting. While with UltraShape, he helped lead the
	company through $35 million in private financing, followed by the company&rsquo;s merger with a Tel Aviv Stock Exchange company
	and ultimately the company&rsquo;s sale to Syneron Medical Ltd. (NASDAQ:ELOS). From 2000 to 2005,&nbsp;
</FONT>
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	he
	served as Vice President and Chief Financial Officer of Given Imaging Ltd., where he was part of the management team that led that
	company&rsquo;s 2001 initial public offering and 2004 follow-on offering, and served as a director of that company from its establishment
	in 1998 to 2000. From 1995 to June 2000, Mr. Ben David served as Vice President and Chief Financial Officer of RDC Rafael Development
	Corporation, one of Given Imaging Ltd.&rsquo;s principal shareholders. From 1994 to 1995, Mr. Ben David served as manager of the
	finance division of Electrochemical Industries (Frutarom) Ltd., an Israeli company traded on the Tel-Aviv Stock Exchange and the
	American Stock Exchange, and from 1989 to 1993, Mr. Ben David served as the manager of that company&rsquo;s economy and control
	department. From 1984 to 1988, Mr. Ben David worked at Avigosh &amp; Kerbs, an accounting firm in Haifa, Israel. Mr. Ben David
	is a certified public accountant in Israel and holds a B.A. in economics and accounting from Haifa University.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Malcolm Hoenlein
</I>
</B>
	&nbsp;has been
	a director of our company since August 31, 2011. Since 1986, Mr. Hoenlein has served as Chief Executive Officer and Executive Vice
	Chairman of the Conference of Presidents of Major American Jewish Organizations, the coordinating body on international and national
	concerns for 52 national American Jewish organizations. Previously, he served as the founding Executive Director of the Jewish
	Community Relations Council of Greater New York. Prior to that, he was the founding Executive Director of the Greater New York
	Conference on Soviet Jewry. A National Defense Fellow at the Near East Center of the University of Pennsylvania, Mr. Hoenlein taught
	International Relations in the Political Science Department and served as a Middle East specialist at the Foreign Policy Research
	Institute. In addition, he served on the editorial staff of ORBIS, the Journal of International Affairs. He serves as a director
	of several companies, Coronado Biosciences Inc. (NASDAQ: CNDO), Nanox Technologies, Data to Life, Nuvo Corp and WellSense Technologies.
	Mr. Hoenlein has a B.A. in Political Science from Temple University and a Master's Degree in International Relations from the University
	of Pennsylvania, as well as an honorary Doctorate of Laws from Touro College and an honorary Doctorate of Humane Letters from Yeshiva
	University. He was appointed by Presidents Clinton and Bush as a U.S. delegate to the Organization for Security and Cooperation
	in Europe. In 2013, he received the highest civilian decoration from King Mohamad VI of Morocco. We believe Mr. Hoenlein is qualified
	to serve on our Board of Directors because of his extensive experience serving on the boards of public and private companies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Dennis M. McGrath
</I>
</B>
	&nbsp;has
	been a director of our company since November 12, 2013. Mr. McGrath is the President and Chief Financial Officer, and a
	member of the Board of Directors, of PhotoMedex, Inc. (NASDAQ: PHMD), a global medical device and specialty pharmaceutical
	company. Upon completion of the PhotoMedex&rsquo;s 2011 merger with Radiancy, Inc., Mr. McGrath reassumed his role of Chief
	Financial Officer in addition to President and director of PhotoMedex, to which he was appointed in July 2009. Mr. McGrath
	was the Chief Executive Officer of PhotoMedex from July 2009 through December 2011, the date of the merger. He had previously
	served as Chief Financial Officer and vice president, finance and administration of PhotoMedex from January 2000 through June
	2009. He has held several senior-level positions in prior endeavors of public companies, including, from February 1999 to
	January 2000, serving as the Chief Operating Officer of Internet Practice, the largest division for AnswerThink Consulting
	Group, Inc., a company specializing in business consulting and technology integration. Concurrently, from August 1999 until
	January 2000, Mr. McGrath served as Chief Financial Officer of Think New Ideas, Inc., a company specializing in interactive
	marketing services and business solutions. In addition to the financial reporting responsibilities, he was responsible for
	the merger integration of Think New Ideas, Inc. and AnswerThink Consulting Group, Inc. Prior to that, from September 1996 to
	February 1999, Mr. McGrath was Chief Financial Officer and executive vice-president of operations of TriSpan, Inc., an
	internet commerce solutions and technology consulting company that was acquired by AnswerThink Consulting Group, Inc. in
	1999. Mr. McGrath is currently a director of Noninvasive Medical Technologies, Inc., Cagent Vascular, LLC and serves on the
	Board of Advisors of Taylor University and the Board of Trustees of Manor College. We believe Mr. McGrath is qualified to serve on
	our Board of Directors because of his accounting expertise and his experiences serving as an officer and director of public
	and private companies. Mr. McGrath began his career at the accounting firm Arthur Andersen in Philadelphia, PA. Upon
	graduating maxima cum laude with a B.S. in accounting from LaSalle University in 1979 he became a certified public accountant
	in 1981.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 59; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	59
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage60"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Prof. Richard B. Stone
</I>
</B>
	has been
	a director of our company since July 7, 2014. For more than twenty-five years, Prof. Stone has been active participant in early
	stage business enterprises as a director or investor, including technology and biotechnology companies. He currently serves on
	the board of directors of multiple technology companies, including Powermat, Espro-Accoustiguide Group, Wellsense Technologies,
	NanoX Imaging Plc, Illumigyn Ltd, Cardiologic Innovations, Quality Inflow Ltd., and Check-Cap. Since 1974, Prof. Stone has been
	a member of the faculty of Columbia Law School, where he held the Wilbur Friedman Chair in Tax Law for twenty years. In addition
	to basic and advanced tax courses, Prof. Stone has taught in the areas of contracts, business planning and real estate planning.
	Among other not-for-profit organizations he has been associated with, from 2011 to 2013, Prof. Stone served as Chairman of the
	Conference of Presidents of Major American Jewish Organizations. Prof. Stone began his career in 1967 in private practice in Washington,
	D.C, and thereafter joined the staff of the Solicitor General of the United States, where from 1969 to 1973 he was Assistant to
	the Solicitor General. We believe Prof. Stone is qualified to serve on our Board of Directors because of his legal expertise and
	experience with life sciences companies. He is a graduate of Harvard College and Harvard Law School.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Rami Yehudiha
</I>
</B>
	&nbsp;has been a
	director of our company since September 23, 2014.&nbsp; Mr. Yehudiha is a marketing and advertising executive with a particular
	expertise in developing and implementing campaigns utilizing cutting edge technologies and methods.&nbsp; From 2004 to the present,
	he has served as the Founder and Chief Executive Officer of LEAD, a top ten Israeli advertising firm.&nbsp; From 1997 to 2003,
	he served as the Chief Executive Officer at Ogilvy One Israel, a part of the WPP Group. &nbsp;&nbsp;We believe Mr. Yehudiha is
	qualified to serve on our Board of Directors because of his experience in technology-based marketing. Mr. Yehudiha received his
	B.A. in Political Science and Economics from Tel Aviv University and an M.B.A. in Marketing from Manchester University.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Hila Karah
</I>
</B>
	&nbsp;has been a director
	of our company since November 23, 2014. Ms. Karah is an independent business consultant and an investor in several high-tech, biotech
	and internet companies.&nbsp; From 2006 to 2013, she served as a partner and Chief Investment Officer of Eurotrust Ltd., a family
	office.&nbsp; From 2002 to 2005, she served as a research analyst at Perceptive Life Sciences Ltd., a New York-based hedge fund.&nbsp;
	Prior to that, Ms. Karah served as research analyst at Oracle Partners Ltd., a health care-focused hedge fund.&nbsp; Ms. Karah
	has served as a director in several private and public companies including Intec Pharma, since 2009 and Cyren Ltd since 2008. We
	believe Ms. Karah is qualified to serve on our Board of Directors because of her experience as an investor in and advisor to high-tech,
	biotech and Internet companies. Ms. Karah holds a B.A. in Molecular and Cell Biology from the University of California, Berkeley,
	and studied at the University of California, Berkeley-University of California, San Francisco Joint Medical Program.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Scientific Advisory Board
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We have established a Scientific Advisory Board
	(SAB), whose members will be available to us to advise on our scientific and business plans and operational strategies.&nbsp;&nbsp;Below
	are the biographies of our SAB members.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Prof. Itamar Raz
</I>
</B>
	&nbsp;is a world
	renowned expert in diabetes care and research. He currently services as the head of the Diabetes Unit of Hadassah Hebrew University
	Medical Center in Jerusalem, the head of the Israel National Council of Diabetes of the Israel Ministry of Health (which is responsible
	for formulating Israeli national policies), the President of D-Cure, a diabetes not-for-profit organization and the head of the
	Israel Diabetes Research Group.&nbsp;&nbsp;He also serves as a member of Advisory Boards at Novo Nordisk (NYSE: ADR), Astra Zeneca/Bristol-Myers
	Squibb (NYSE: BMY), Sanofi (NYSE: SNY), Merck Sharp &amp; Dohme (NYSE: MRK), and Eli Lilly (NYSE: LLY) and as a consultant for
	InsuLine Medical Ltd, Andromeda Biotech Ltd and Astra Zeneca/Bristol-Myers Squibb. Prof. Raz has published over 260 research papers
	including biennial publications of a Supplement to Diabetes Care summarizing proceedings of the European Controversies to Consensus
	in Obesity, Diabetes and Hypertension (CODHy) meeting.&nbsp;&nbsp;He also holds editorial positions on a number of medical journals.&nbsp;&nbsp;Prof.
	Raz&rsquo;s medical career began in 1985 at Hadassah University Hospital as Senior Physician, specializing in Internal Medicine.&nbsp;&nbsp;From
	1986 to 1992, Prof. Raz was head of Hebrew University Student Services, and in 1988 he was appointed Senior Lecturer at Hadassah
	University Hospital&rsquo;s Department of Internal Medicine.&nbsp;&nbsp;In 1989, Prof. Raz was appointed Chief Physician of Internal
	Medicine, and as head of the Diabetes Clinic at Hadassah University Hospital in 1992.&nbsp;&nbsp;In 1995, Prof. Raz became an Associate
	Professor at the Department of Internal Medicine, Hadassah University Hospital.&nbsp;&nbsp;In 2001, he was appointed Director of
	the hospital&rsquo;s Center for Prevention of Diabetes and its Complications.&nbsp;&nbsp;Since 2003, Prof. Raz has served as Professor
	of Internal Medicine at the Department of Internal Medicine, Hadassah University Hospital.&nbsp;&nbsp;Prof. Raz graduated from
	Hebrew University &amp; Hadassah School of Pharmacy with a Bachelor of Science in 1973.&nbsp;&nbsp;In 1981, he graduated from Hebrew
	University &amp; Hadassah School of Medicine with an M.D. and completed his residency at Hadassah University Hospital from 1981
	to 1985, specializing in internal medicine.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 60; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	60
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage61"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Dr. William Polonsky, PhD, CDE
</I>
</B>
	&nbsp;is
	an internationally recognized expert in the behavioral aspects of diabetes management. Dr. Polonsky is the Founder of the Behavioral
	Diabetes Institute and serves as its Chief Executive Officer. Dr. Polonsky is also an Associate Clinical Professor of Psychiatry
	at University of California, San Diego. He served as Senior Psychologist at the Joslin Diabetes Center in Boston, faculty member
	at Harvard Medical School and Chairman of the National Certification Board for Diabetes Educators. Dr. Polonsky serves as a Member
	of Advisory Board at SweetSpot&nbsp;Diabetes Care, Inc. He has served on the editorial boards of numerous professional and lay
	publications, including Diabetes Care, Diabetes Forecast, Clinical Diabetes, Diabetes Self-Management and Diabetes Health. In addition
	to his professional publications, he is the author of&nbsp;
<I>
	Diabetes Burnout: What to Do When You Can't Take it Anymore
</I>
	,
	a popular book for patients published by the American Diabetes Association. In addition, he was co-editor of A CORE Curriculum
	for Diabetes Education and Diabetes Education Goals. Dr. Polonsky received his PhD in clinical psychology from Yale University.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Mr. Robert G. Faissal
</I>
</B>
	is a Managing
	Partner of Lebita Consulting Services LLC, a Toronto based business development and investment group with emphasis on commercial
	relationships in North America, Europe, Africa and the Middle East. Lebita Consulting focuses on healthcare, technology, finance,
	oil and gas and real estate. Mr. Faissal was the Managing Partner of Richmond Development, an Abu Dhabi based multi-disciplinary
	investment group. From 1997 until 2000, Mr. Faissal served as the Managing Director/Middle East &amp; Africa for the Philadelphia
	based Wharton Econometrics Forecasting Associates (WEFA Group, currently IHS Global Insight) advising various governments and private
	sector clients on economics and financial matters in the Middle East and Africa. He holds a Master of Arts degree in Economics
	&amp; International Finance from McMaster University in Canada and an undergraduate Honors Degree in Economics from the University
	of Western Ontario.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Mr. Erez Levy
</I>
</B>
	attended the Technion
	Institution in Haifa and graduated with a B.Sc. degree in Industrial Engineering and Management in 1996. He then started to work
	as a Manufacturing Program Manager, Missile Division in Rafael, Israel. He joined GE Healthcare in 2000 as a Material Site Manager
	in Haifa, Israel and became a certified Six Sigma Green belt in 2001. In 2003, he became certified Lean Manufacturing Leader. During
	2004 he relocated with his family to Cleveland, Ohio as an Operation manager in GE Coils. In 2006, he returned to Israel as VCP
	leader in Nuclear Medicine, Engineering drive design for cost in NPI process. During 2008 to 2010 he led the evaluation, due diligence
	and negotiation process the acquisition of Orbotech by GE and become the integration manager after deal closing. In 2011, he was
	appointed as General Manager of Global Direct Conversion Detector, CZT solid-state Center of Excellence located in Rehovot, Israel.
	Mr. Levy brings with him 18 years of broad leadership experience with growing responsibilities, and strong leadership background
	in medical device design, process engineering, manufacturing and supply chain. He has completed his M.B.A. studies at the Technion
	institution, Haifa, Israel.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Dr. Paolo Pozzilli
</I>
</B>
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;is
	a Professor of Endocrinology and Metabolic Diseases, Head of Department at the University Campus Bio-Medico in Rome, Italy where
	he is in charge of the Post-Graduate School and PhD program in Endocrinology and Diabetes. &nbsp;He is also Professor of Diabetes
	Research at St. Bartholomew's and the London School of Medicine, Queen Mary, University of London.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Hope Warchaw, MMSc, RD, CDE, BC-ADM
</I>
</B>
	&nbsp;is
	a dietitian and diabetes educator for thirty-five years and is author of professional articles in leading diabetes journals and
	co-author of several American Diabetes Association books for healthcare professionals. &nbsp;Among diabetes educators, Ms. Warshaw
	is a leading promoter of the Diabetes Online Community and its value to people with diabetes and their caregivers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Dr. Paul Rosman, DO FACP FACE FACOI&nbsp;
</I>
</B>
	has
	served roles in industry, academia and non-profit leadership. He was Former Senior Medical Advisor at Eli Lilly &amp; Company,
	has held teaching positions at Ohio University and Northeastern Ohio Universities College of Medicine, as well as served as President
	or Chair of American Diabetes Association, Ohio Chapter, American Association of Clinical Endocrinologists, Ohio River Chapter,
	and the Ohio Diabetes Prevention and Control Program at Ohio Department of Health.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 61; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	61
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage62"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Gary Scheiner, CDE MS&nbsp;
</I>
</B>
	has
	dedicated his professional life to improving the lives of people with insulin-dependent diabetes. Scheiner has authored six books:
	You Can Control Diabetes (1997), Think Like A Pancreas (2004), The Ultimate Guide to Accurate Carb Counting (2007), Get Control
	of Your Blood Sugar (2009), Think Like A Pancreas, 2nd edition (2011), and Until There&rsquo;s A Cure (2012). Mr. Scheiner holds
	a B.A. in Psychology, an M.S. in Exercise Physiology, and is a Certified Diabetes Educator who trained at the Joslin Diabetes Center.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Board Composition
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our
	business is managed under the direction of our Board of Directors. Our Board of Directors currently consists of seven members.
	Under the Securities Purchase Agreement we entered into in connection with our September 2014 Private Placement, we are required
	to maintain a Board of Directors with seven members. Each director is elected to the board for a one-year term until the following
	annual meeting of stockholders and until his successor has been elected and qualified or until the director's earlier resignation
	or removal.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Under the terms
	of the Securities Purchase Agreement of the September 2014 Private Placement, for so long as David Edery or his controlled affiliates
	holds 25%, 15% and 10% of the outstanding shares of our common stock, Mr. Edery shall have the right to nominate, respectively,
	three, two or one member of our seven-member Board of Directors.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	However, Mr. Edery shall
	not be entitled to designate an individual as a nominee to the Board of Directors upon a written determination by our Nominating
	and Corporate Governance Committee or the Board of Directors that such individual would not be qualified under any applicable law,
	rule or regulation to serve on our Board of Directors.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Mr. Yehudiha and Ms. Karah were appointed to
	our Board of Directors as nominees of David Edery. Except for the foregoing, there are no arrangements between our directors and
	any other person pursuant to which our directors were nominated or elected for their positions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	There are no family relationships between any
	of our directors or executive officers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Board Committees
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our Board of Directors has three standing committees:
	an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Audit Committee
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our Audit Committee is comprised of Messrs.
	Hoenlein and McGrath, each of whom is an independent director. Mr. McGrath is the Chairman of the Audit Committee. Mr. McGrath
	is an &ldquo;audit committee financial expert&rdquo; as defined in Item 407(d)(5)(ii) of Regulation S-K.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our Audit Committee oversees our corporate accounting,
	financial reporting practices and the audits of financial statements.&nbsp; For this purpose, the Audit Committee has a charter
	(which is reviewed annually) and performs several functions.&nbsp; The Audit Committee charter is available on our website at www.mydario.com
	under the Investors / Governance section. The Audit Committee:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	evaluates the independence
	and performance of, and assesses the qualifications of, our independent auditor and engage such independent auditor;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	approves the plan and fees
	for the annual audit, quarterly reviews, tax and other audit-related services and approve in advance any non-audit service to
	be provided by our independent auditor;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	monitors the independence
	of our independent auditor and the rotation of partners of the independent auditor on our engagement team as required by law;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 62; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	62
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage63"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	reviews the financial statements
	to be included in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and reviews with management and our independent
	auditor the results of the annual audit and reviews of our quarterly financial statements; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	oversees all aspects our
	systems of internal accounting control and corporate governance functions on behalf of the board.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Compensation Committee
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our Compensation Committee is comprised of Messrs.
	Hoenlein and Yehudiha and Ms. Karah. Mr. Hoenlein is the Chairman of the Compensation Committee. Under the terms of the Securities
	Purchase Agreement in our September 2014 Private Placement, we agreed to appoint two nominees of our lead investor, David Edery,
	to the Compensation Committee. Both Mr. Yehudiha and Ms. Karah are nominees of Mr. Edery.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The Compensation Committee reviews or recommends
	the compensation arrangements for our management and employees and also assists our Board of Directors in reviewing and approving
	matters such as company benefit and insurance plans, including monitoring the performance thereof. The Compensation Committee has
	a charter (which is reviewed annually) and performs several functions. The Compensation Committee charter is available on our website
	at www.mydario.com under the Investors / Governance section.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The Compensation Committee has the authority
	to directly engage, at our expense, any compensation consultants or other advisers as it deems necessary to carry out its responsibilities
	in determining the amount and form of employee, executive and director compensation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Nominating and Corporate Governance Committee
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our Nominating and Corporate Governance Committee
	is currently comprised of Prof. Stone and Messrs. Hoenlein and Yehudiha. Prof. Stone is the Chairman of the Nominating and Corporate
	Governance Committee.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Under the terms of the Securities Purchase Agreement
	in our September 2014 Private Placement, we agreed to appoint two nominees of our lead investor, David Edery to the Nominating
	and Corporate Governance Committee. Mr. Yehudiha is the current nominee of Mr. Edery serving on this committee.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	The Nominating
	and Corporate Governance Committee is charged with the responsibility of reviewing our corporate governance policies and with proposing
	potential director nominees to the Board of Directors for consideration. This committee also has the authority to oversee the hiring
	of potential executive positions in our company.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	The Nominating and Corporate Governance Committee
	operates under a written charter, which will be reviewed and evaluated at least annually.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Director Independence
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our Board of Directors has reviewed the materiality
	of any relationship that each of our directors has with us, either directly or indirectly. Based on this review, our Board of Directors
	has determined that Prof. Stone, Messrs. Hoenlein, Yehudiha and McGrath and Ms. Karah are &ldquo;independent directors&rdquo; as
	defined in the NASDAQ Listing Rules and Rule 10A-3 promulgated under the Exchange Act.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Code of Ethics
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On March 5, 2013, our Board of Directors adopted
	a Code of Business Conduct and Ethics and Insider Trading Policy. Our Code of Business Conduct and Ethics is available on our website
	at mydario.com under the Investors/Governance section.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 63; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	63
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage64"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Limitation of Directors Liability and Indemnification
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The Delaware General Corporation Law authorizes
	corporations to limit or eliminate, subject to certain conditions, the personal liability of directors to corporations and their
	stockholders for monetary damages for breach of their fiduciary duties. Our certificate of incorporation limits the liability of
	our directors to the fullest extent permitted by Delaware law.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We have director and officer liability insurance
	to cover liabilities our directors and officers may incur in connection with their services to us, including matters arising under
	the Securities Act. Our certificate of incorporation and bylaws also provide that we will indemnify our directors and officers
	who, by reason of the fact that he or she is one of our officers or directors, is involved in a legal proceeding of any nature.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	There is no pending litigation or proceeding
	involving any of our directors, officers, employees or agents in which indemnification will be required or permitted. We are not
	aware of any threatened litigation or proceeding that may result in a claim for such indemnification.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Section 16(a) Beneficial Ownership Reporting Compliance
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Since our common stock is not registered under
	Section 12 of the Exchange Act, our directors and executive officers and persons who beneficially own more than 10% of our common
	stock are not required to file with the SEC various reports as to their ownership of and activities relating to our common stock.
</P>
</EFX_DIRECTORS_AND_OFFICERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_COMPENSATION>
<A NAME="FIS_COMPENSATION"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD">
<A NAME="V430703_10K_HTM_A_020">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 11.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Executive Compensation
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The following table summarizes compensation
	of our named executive officers, as of December 31, 2015 and 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<EFX_COMPENSATION_TABLE>
<A NAME="FIS_COMPENSATION_TABLE"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Summary Compensation
	Table
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	Name&nbsp;and&nbsp;
<BR>
	Principal&nbsp;Position
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Year
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Salary&nbsp;
<BR>
	($)*
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Bonus
<BR>
	($)
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Stock
<BR>
	Awards
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Option
<BR>
	Awards
<BR>
	($)**
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Non-equity&nbsp;
<BR>
	incentive&nbsp;plan
<BR>
	compensation
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Non-qualified
<BR>
	incentive&nbsp;plan
<BR>
	compensation
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	All&nbsp;Other
<BR>
	Compensation
<BR>
	($)
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Total&nbsp;($)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Erez Raphael
<BR>
	(Chairman and
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	2015
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	113,802
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	(1)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	541,813
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	(2)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	608,053
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	(3)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	69,388
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	(4)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	$1,333,057
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Chief Executive
</FONT>
<FONT STYLE="FONT-SIZE: 8PT">
	Officer)***
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	2014
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	147,610
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	(1)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	307,400
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	(3)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	78,147
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	(4)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	$533,157
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Zvi Ben David (Chief Financial Officer)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	2015
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	89,769
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	(5)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	32,146
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	(6)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	155,060
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	(7)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	27,688
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	(8)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	$304,663
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	2014
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_COMPENSATION_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%">
<FONT STYLE="FONT-SIZE: 10PT">
	*
</FONT>
</TD>
<TD STYLE="WIDTH: 95%">
<FONT STYLE="FONT-SIZE: 10PT">
	Certain compensation paid by the company is denominated in New Israeli Shekel (or the NIS). Such compensation is calculated for purposes of this table based on the annual average currency exchange for such period.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	**
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Amount shown does not reflect dollar amount actually received. Instead, this amount
	reflects the aggregate grant date fair value of each stock option granted in the fiscal years ended December 31, 2014 and
	December 31, 2015, computed in accordance with the provisions of ASC 718 &ldquo;Compensation - Stock Compensation&rdquo;, or
	ASC 718. Assumptions used in accordance with ASC 718 are included in Note 9 to our consolidated
	financial statements included in this Annual Report.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	***
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Since August 2013, Mr. Raphael has served as Chief Executive Officer and since November 2014 as Chairman of the Board of Directors.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	In accordance with his second amendment to the employment agreement with our company effective August 11, 2013, Mr. Raphael is entitled to a monthly salary of NIS 44,000).&nbsp;&nbsp;During 2015, Mr. Raphael agreed to a waiver of 16% of his cash salary according to our salary program (see further details in &ldquo;Employment and Related Agreements&rdquo; below).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(2)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	On October 7, 2015, Mr. Raphael was granted 33,990 shares of our common stock under our 2012 Equity Incentive Plan, on September 3, 2015, Mr. Raphael was granted 1,520,133 shares of our common stock under our 2012 Equity Incentive Plan, and on August 27, 2015, Mr. Raphael was granted 52,621 shares of our common stock under our 2012 Equity Incentive Plan.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 64; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	64
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage65"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%">
<FONT STYLE="FONT-SIZE: 10PT">
	(3)
</FONT>
</TD>
<TD STYLE="WIDTH: 95%">
<FONT STYLE="FONT-SIZE: 10PT">
	Mr. Raphael, upon his nomination as the Chief Executive Officer of our company, was granted 60,000 options pursuant to our 2012 Equity Incentive Plan. The options granted vested as follows: 30,000 vested on August 29, 2013 (grant date) and 30,000 vested on August 30, 2014. During 2014, Mr. Raphael was granted an additional 16,000 and 84,000 options which vest over a period of 2 years commencing January 7, 2014 and July 7, 2014, respectively. During 2015, Mr. Raphael was granted 3,040,267 options to purchase shares of our common stock. 1,013,422 of such options are immediately vested and the balance shall vest in eight equal quarterly installments from the grant date during a two year period. We may grant Mr. Raphael additional options to purchase shares of common stock from time to time at the discretion of our Board of Directors or the Compensation Committee thereof (see further details in &ldquo;Employment and Related Agreements&rdquo; below).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(4)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	In addition to his salary, Mr. Raphael is entitled to receive a leased automobile and mobile phone during his employment as well as reimbursements for expenses accrued. These benefits as well as other social benefits under Israeli law are included as part of his &ldquo;All Other Compensation&rdquo;.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(5)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	In accordance with his employment agreement with our company effective January 8, 2015, Mr. Ben David was initially entitled to a monthly salary and additional compensation (excluding social benefits under applicable Israeli law) of NIS 31,200 for providing eighty percent of his working time to our company. Beginning on March 1, 2015, Mr. Ben David began working for us on a full time basis pursuant to the terms of his employment agreement at which point Mr. Ben David&rsquo;s salary was increased to NIS 39,000 per month. During 2015, Mr. Ben David agreed to a waiver of 21.9% of his cash salary according to our salary program (see further details in &ldquo;Employment and Related Agreements&rdquo; below).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(6)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	On October 7, 2015, Mr. Ben David was granted 30,900 shares of our common stock under our 2012 Equity Incentive Plan and on August 27, 2015, Mr. Ben David was granted 68,416 shares of our common stock under our 2012 Equity Incentive Plan.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(7)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	During 2015, Mr. Ben David was granted 775,300 options to purchase shares of our common stock. 258,433 of such options are immediately vested and the balance shall vest in eight equal quarterly installments from the grant date during a two year period. We may grant Mr. Ben David additional options to purchase shares of common stock from time to time at the discretion of our Board of Directors or the Compensation Committee thereof (see further details in &ldquo;Employment and Related Agreements&rdquo; below).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(8)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	In addition to his salary, Mr. Ben David is entitled to receive a mobile phone during his employment as well as reimbursements for expenses accrued. These benefits as well as other social benefits under Israeli law are included as part of his &ldquo;All Other Compensation&rdquo;.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	All compensation awarded to our executive officers
	were independently reviewed by our Compensation Committee.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Employment and Related Agreements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Except as set forth below, we currently have
	no other written employment agreements with any of our officers and directors. The following is a description of our current executive
	employment agreements:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Erez Raphael
</I>
	,
<I>
	Chief Executive Officer
	and Chairman of our Board of Directors
</I>
	&ndash; On August 30, 2013, LabStyle Innovation Ltd., our Israeli subsidiary, entered
	into an amendment to a Personal Employment Agreement with Mr. Raphael in connection with his August 2013 appointment as our President
	and Chief Executive Officer. Pursuant to the terms of his employment agreement as amended, Mr. Raphael is entitled to a monthly
	salary of NIS 44,000. During 2015, Mr. Raphael agreed to a waiver of 16% of his cash salary according to our salary program pursuant
	to which Mr. Raphael shall receive compensation shares of restricted common stock as consideration for cash salary waived. Mr.
	Raphael&rsquo;s employment agreement may be terminated by either party at will upon 180 days prior written notice or terminated
	by us or for cause, as defined under the employment agreement. In the event the employment agreement is terminated by us at will,
	Mr. Raphael shall be entitled to receive 6 months base salary and severance payment pursuant to applicable Israeli severance law.
	In the event the employment agreement is terminated by us for cause, Mr. Raphael will only be entitled to severance payment under
	applicable Israeli severance law. Mr. Raphael&rsquo;s employment agreement also includes a one year non-competition and non-solicitation
	provision, certain confidentiality covenants and assignment of any of his company-related inventions to us. Under the terms of
	the agreement, Mr. Raphael is entitled to certain expense reimbursements and other standard benefits, including vacation, sick
	leave, contributions to a manager&rsquo;s insurance policy and study fund and car and mobile phone allowances.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 65; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	65
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage66"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On March 15, 2013, the Compensation Committee
	of our Board of Directors approved a grant under our 2012 Equity Incentive Plan to Mr. Raphael of 36,000 options to purchase shares
	of our common stock for an exercise price of $6.75 per share. 6,000 of these options vested on March 31, 2013 and the remaining
	vested in five equal quarterly increments commencing June 30, 2013.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On June 6, 2013, the Compensation Committee
	of our Board of Directors approved a grant under our 2012 Equity Incentive Plan to Mr. Raphael of 4,000 options to purchase shares
	of our common stock for an exercise price of $15.00 per share. 800 of these options vested on June 30, 2013 and the remaining vested
	in four equal quarterly increments commencing September 30, 2013.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	In August 2013, the Compensation Committee of
	our Board of Directors approved a grant under our 2012 Equity Incentive Plan to Mr. Raphael of 60,000 options to purchase shares
	of our common stock for an exercise price of $13.35 per share. 30,000 of these options vested on August 29, 2013 and the remaining
	options vested on August 30, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	In January 2014, the Compensation Committee
	of our Board of Directors approved a grant under our 2012 Equity Incentive Plan to Mr. Raphael of 16,000 options to purchase shares
	of our common stock for an exercise price of $9.25 per share. Those options vest in eight equal quarterly increments commencing
	April 7, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On July 7, 2014, the Board of Directors approved
	a grant under our 2012 Equity Incentive Plan to Mr. Raphael of 84,000 options to purchase shares of our common stock for an exercise
	price of $4.90 per share. Those options vest in eight equal quarterly increments commencing October 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On August 27, 2015, the Compensation Committee
	of our Board of Directors approved the issuance to Mr. Raphael of 52,621 shares of our common stock under our 2012 Equity Incentive
	Plan. Such shares were issued in lieu of the waiver of $17,091 salary otherwise payable to Mr. Raphael from April to September
	2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On September 3, 2015, our Board of Directors
	approved the issuance to Mr. Raphael of 1,520,133 shares of our common stock under our 2012 Equity Incentive Plan and to grant
	to Mr. Raphael 3,040,267 options to purchase shares of our common stock for an exercise price of $0.32 per share. 1,013,422 of
	such options are immediately vested and the balance will vest in eight equal quarterly installments from the grant date during
	a two year period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On October 7, 2015, the Compensation Committee
	of our Board of Directors approved the issuance to Mr. Raphael of 33,990 shares of our common stock under our 2012 Equity Incentive
	Plan. Such shares were issued in lieu of the waiver of $10,917 salary otherwise payable to Mr. Raphael from October to December
	2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On January 27, 2016, the Compensation Committee
	of our Board of Directors approved the issuance to Mr. Raphael of 24,548 shares of our common stock under our 2012 Equity Incentive
	Plan. Such shares were issued in lieu of the waiver of $10,637 salary otherwise payable to Mr. Raphael from January to March 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Zvi Ben David
</I>
	,
<I>
	Chief Financial Officer,
	Treasurer and Secretary
</I>
	&ndash; On January 8, 2015, LabStyle Innovation Ltd., our Israeli subsidiary, entered into a Personal
	Employment Agreement with Mr. Ben David. Pursuant to his employment agreement, Mr. Ben David was initially entitled to a monthly
	salary and additional compensation (excluding social benefits under applicable Israeli law) of NIS 31,200 for providing eighty
	percent of his working time to our company. Beginning on March 1, 2015, Mr. Ben David began working for us on a full time basis
	pursuant to the terms of his employment agreement at which point Mr. Ben David&rsquo;s salary was increased to NIS 39,000 per month.
	During 2015, Mr. Ben David agreed to a waiver of 21.9% of his cash salary according to our salary program pursuant to which Mr.
	Ben David shall receive compensation shares of restricted common stock as consideration for cash salary waived.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Mr. Ben David's employment agreement may be
	terminated by either party at will upon 90 days prior written notice or terminated by us for cause, as defined under the employment
	agreement. In the event the employment agreement is terminated by us at will, Mr. Ben David shall be entitled to receive 6 months
	base salary and severance payment pursuant to applicable Israeli severance law. In the event the employment agreement is terminated
	by us at will,&nbsp;Mr. Ben David shall be entitled to receive 90 days of severance plus any required severance payment pursuant
	to applicable Israeli severance law. In the event the employment agreement is terminated by us for cause, Mr.&nbsp;Ben David will
	only be entitled to severance payment under applicable Israeli severance law.
<I>
</I>
	The employment agreement also includes a twelve
	month non-competition and non-solicitation provision, certain confidentiality covenants and assignment of any of his company-related
	inventions to the company. Under the terms of the employment agreement, Mr. Ben David is entitled to certain expense reimbursements
	and other standard benefits, including vacation, sick leave, contributions to a manager&rsquo;s insurance policy and study fund
	and mobile phone allowances.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 66; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	66
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage67"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On August 27, 2015, the Compensation Committee
	of our Board of Directors approved the issuance to Mr. Ben David of 68,416 shares of our common stock under our 2012 Equity Incentive
	Plan. Such shares were issued in lieu of the waiver of $22,222 salary otherwise payable to Mr. Ben David from March to September
	2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On September 3, 2015, the Board of Directors
	approved a grant to Mr. Ben David of 775,300 options to purchase shares of our common stock for an exercise price of $0.32 per
	share. 258,433 of such options are immediately vested and the balance will vest in eight equal quarterly installments from the
	grant date during a two year period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On October 7, 2015, the Compensation Committee
	of our Board of Directors approved the issuance to Mr. Ben David of 30,900 shares of our common stock under our 2012 Equity Incentive
	Plan. Such shares were issued in lieu of the waiver of $9,925 salary otherwise payable to Mr. Ben David from October to December
	2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On January 27, 2016, the Compensation Committee
	of our Board of Directors approved the issuance to Mr. Ben David of 31,242 shares of our common stock under our 2012 Equity Incentive
	Plan. Such shares were issued in lieu of the waiver of $13,538 salary otherwise payable to Mr. Ben David from January to March
	2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Outstanding Equity Awards at December 31,
	2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
</B>
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	Name
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number&nbsp;of
<BR>
	securities
<BR>
	underlying
<BR>
	unexercised
<BR>
	options&nbsp;(#)
<BR>
	exercisable
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number&nbsp;of
<BR>
	securities
<BR>
	underlying
<BR>
	unexercised
<BR>
	options&nbsp;(#)
<BR>
	unexercisable
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Equity
<BR>
	incentive
<BR>
	plan&nbsp;awards:&nbsp;
<BR>
	Number&nbsp;of
<BR>
	securities
<BR>
	underlying
<BR>
	unexercised
<BR>
	unearned
<BR>
	options&nbsp;(#)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Option
<BR>
	exercise
<BR>
	price
<BR>
	($)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Option
<BR>
	expiration
<BR>
	date
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 30%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Erez Raphael (Chairman and
<BR>
	Chief Executive Officer)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	36,000
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.75
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 17%; FONT-SIZE: 10PT">
	March 14, 2023
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	15.00
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	June 5, 2023
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	60,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13.35
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	August 28, 2023
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	14,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2,000
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	(1)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9.25
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	January 6, 2024
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	52,500
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	31,500
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	(2)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4.90
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	July 6, 2024
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,266,778
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,773,489
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	(3)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.32
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	September 3, 2021
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Zvi Ben David (Chief Financial Officer, Secretary and Treasurer)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	323,041
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	452,259
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	(4)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.32
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	September 3, 2021
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
	Total Option Shares
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,756,319
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,259,248
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD>
	Vests in 8 equal quarterly installments commencing April 4, 2014.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)
</TD>
<TD>
	Vests in 8 equal quarterly installments commencing October 7, 2014.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 67; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	67
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage68"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(3)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	Following vesting of 1,013,422 options on September 3, 2015, vests in 8 equal quarterly installments commencing December 3,
	2015.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(4)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	Following vesting of 258,433 options on September 3, 2015, vests in 8 equal quarterly installments commencing December 3, 2015.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Non-Employee Director Remuneration Policy
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	In March 2013, our Board of Directors adopted
	the following non-employee director remuneration policy:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Cash Awards
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our non-employee directors (currently Messrs.
	Hoenlein, McGrath and Yehudiha, Prof. Stone and Ms. Karah) will receive the following cash payments for each fiscal year: (i) $25,000
	per year, to be paid quarterly in arrears and (ii) $16,000 for Board committee service, to be paid quarterly in arrears;
<I>
	provided,
	however,
</I>
	that such quarterly payments and committee meeting fees shall accrue and shall be payable upon the approval of Mr.
	Raphael at such time when our company is adequately capitalized in his reasonable discretion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Stock and Option Awards
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Each of our non-employee directors may receive
	5,000 options to purchase shares of common stock (which we refer to as the Annual Director Options) for each fiscal year. The Annual
	Director Options will be confirmed (together with the exercise price for such options) at the first meeting of our Board of Directors
	for each fiscal year and shall vest quarterly in arrears. Annual Director Options shall have ten year terms and, unless otherwise
	approved by Compensation Committee of our Board of Directors, shall not be issued under our 2012 Equity Incentive Plan or any successor
	to such plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Both the Annual Directors Options as well as
	the one-time options granted were not issued under our 2012 Equity Incentive Plan. All annual director options or other equity
	incentives issued under our non-employee director remuneration policy shall be deemed to have been issued under an &ldquo;employee
	benefit plan&rdquo; as defined in Rule 405 promulgated under the Securities Act.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On April 3, 2015, our Board of Directors approved
	a compensation plan under which the executive officers have been granted the authority (in their discretion from time to time with
	the concurrence of the impacted individuals, and subject to applicable laws, rules and regulations) to cause the issuance of shares
	of common stock to our directors, officers and employees as consideration for a reduction in cash salary or fees owed to such individuals.
	For that purpose a pool of up to 2,200,000 shares of common stock is reserved under a shares for salary program.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On April 20, 2015, 88,749, 89,539 and 221,805
	shares were respectively issued to Prof. Stone, Mr. McGrath and Mr. Hoenlein in lieu of $23,988, $24,201 and $61,500 fees otherwise
	payable to each of Prof. Stone for the period from July 7, 2014 to March 31, 2015, Mr. McGrath for the period from November 12,
	2013 to March 31, 2015 and Mr. Hoenlein for the period from October 1, 2013 to March 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On August 13, 2015, 30,723 shares were issued
	to each of Prof. Stone, Mr. Hoenlein and Mr. McGrath in lieu of $10,250 in fees otherwise payable to each of them for the period
	from April 1, 2015 to June 30, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On August 27, 2015, the Compensation Committee
	of our Board of Directors approved the issuance to Ms. Karah and Mr. Yehudiha 63,116 and 97,134 shares of our common stock under
	our 2012 Equity Incentive Plan, respectively. Such shares were issued in lieu of $20,500 and $31,549 of fees, respectively, otherwise
	payable to each of Ms. Karah for the period from January 2015 to June 2015 and Mr. Yehudiha, for the period from September 23,
	2014 to June 30, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 68; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	68
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage69"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On September 3, 2015, our Board of Directors
	approved a grant of an aggregate of 1,368,000 options to our non-employee directors. These options have an exercise price of $0.32
	per share. 456,000 of such options are immediately vested and the balance shall vest in quarterly arrears.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On October 6, 2015, 32,046 shares were issued
	to each of Prof. Stone, Mr. Hoenlein and Mr. McGrath, in lieu of $10,250 in fees otherwise payable to each of them for the period
	from July 1, 2015 to September 30, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On October 7, 2015, the Compensation Committee
	of our Board of Directors approved the issuance to each of Ms. Karah and Mr. Yehudiha of 31,913 shares of our common stock under
	our 2012 Equity Incentive Plan. Such shares were issued in lieu of $10,250 in fees otherwise payable to each of Ms. Karah and Mr.
	Yehudiha for the period from July 1, 2015 to September 30, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On January 3, 2016, 24,266 shares were issued
	to each of Prof. Stone, Mr. Hoenlein and Mr. McGrath in lieu of $10,250 in fees otherwise payable to each of them for the period
	from October 1, 2015 to December 31, 2015 (this grant included a correction to the grant made on October 6, 2015).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On January 3, 2016, the Compensation Committee
	of our Board of Directors approved the issuance to each of Ms. Karah and Mr. Yehudiha of 24,314 shares of our common stock under
	our 2012 Equity Incentive Plan. Such shares were issued in lieu of $10,250 in fees otherwise payable to each of Ms. Karah and Mr.
	Yehudiha for the period from October 1, 2015 to December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Compensation Committee Review
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The Compensation Committee shall, if it deems
	necessary or prudent in its discretion, reevaluate and approve in January of each such year (or in any event prior to the first
	board meeting of such fiscal year) the cash and equity awards (amount and manner or method of payment) to be made to non-employee
	directors for such fiscal year. In making this determination, the Compensation Committee shall utilize such market standard metrics
	as it deems appropriate, including, without limitation, an analysis of cash compensation paid to independent directors of our peer
	group.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The Compensation Committee shall also have the
	power and discretion to determine in the future whether non-employee directors should receive annual or other grants of options
	to purchase shares of common stock or other equity incentive awards in such amounts and pursuant to such policies as the Compensation
	Committee may determine utilizing such market standard metrics as it deems appropriate, including, without limitation, an analysis
	of equity awards granted to independent directors of our peer group.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Participation of Employee Directors; New Directors
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Unless separately and specifically approved
	by the Compensation Committee in its discretion, no employee director of our company shall be entitled to receive any remuneration
	for service as a director (other than expense reimbursement as per prevailing policy).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	New directors joining our Board of Directors
	shall be entitled to a pro rated portion (based on months to be served in the fiscal year in which they join) of cash and stock
	option or other equity incentive awards (if applicable) for the applicable fiscal year at the time they join the board.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 69; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	69
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage70"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Summary Director Compensation Table
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The following table summarizes the annual compensation
	paid to our non-employee directors for the fiscal year ended December 31, 2015:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	Name&nbsp;and
<BR>
	Principal
<BR>
<FONT STYLE="FONT-SIZE: 8PT">
	Position
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Year
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Fees&nbsp;Paid
<BR>
	or
<BR>
	Earned&nbsp;in
<BR>
	Cash
<BR>
<FONT STYLE="FONT-SIZE: 8PT">
	($)
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Stock
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 8PT">
	Awards
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Option
<BR>
	Awards
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 8PT">
	($)*
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Non-equity
<BR>
	incentive
<BR>
	plan
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 8PT">
	compensation
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Non-
<BR>
	qualified
<BR>
	deferred
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 8PT">
	compensation
	earnings
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	All&nbsp;other
<BR>
	compensation
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 8PT">
	($)
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Total&nbsp;($)
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; WIDTH: 17%">
<FONT STYLE="FONT-SIZE: 8PT">
	Malcolm Hoenlein
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	2015
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	41,000
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	(1)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	54,720
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	(2)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	95,720
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Dennis McGrath
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	2015
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	41,000
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	(3)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	54,720
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	(4)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	95,720
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Prof. Richard B. Stone
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	2015
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	41,000
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	(5)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	54,720
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	(6)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	95,720
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Rami Yehudiha
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	2015
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	41,000
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	(7)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	54,720
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	(8)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	95,720
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Dr. Peter M. Kash**
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	2015
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Hila Karah
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	2015
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	41,000
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	(9)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	54,720
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	(10)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	95,720
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%">
<FONT STYLE="FONT-SIZE: 10PT">
	*
</FONT>
</TD>
<TD STYLE="WIDTH: 95%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amount shown does not reflect dollar amount actually received. Instead, this amount reflects the aggregate grant date fair value of each stock option granted in the fiscal year ended December 31, 2015, computed in accordance with the provisions of ASC 718. Assumptions used in accordance with ASC 718 are included in Note 9 to our consolidated financial statements included in this Annual Report.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	**
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	On February 23, 2015, Dr. Kash resigned from the Board of Directors.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	284,574 stock awards are outstanding as of December 31, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(2)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	353,600 option awards are outstanding as of December 31, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(3)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	152,308 stock awards are outstanding as of December 31, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(4)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	308,600 option awards are outstanding as of December 31, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(5)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	151,518 stock awards are outstanding as of December 31, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(6)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	303,600 option awards are outstanding as of December 31, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(7)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	129,047 stock awards are outstanding as of December 31, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(8)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	273,600 option awards are outstanding as of December 31, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(9)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	95,029 stock awards are outstanding as of December 31, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(10)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	273,600 option awards are outstanding as of December 31, 2015.
</FONT>
</TD>
</TR>
</TABLE>
</EFX_COMPENSATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A NAME="V430703_10K_HTM_A_021">
</A>
	Item&nbsp;12.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%; FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -1IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The following table sets forth information regarding
	the beneficial ownership of our common stock as of February 8, 2016 by:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	each person known by us to
	be the beneficial owner of more than 5% of our outstanding shares of common stock;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	each of our named executive
	officers and directors; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	all our executive officers
	and directors as a group.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Beneficial ownership is determined in accordance
	with the rules of the SEC and includes voting or investment power with respect to the securities. Except as otherwise indicated,
	each person or entity named in the table has sole voting and investment power with respect to all shares of our capital shown as
	beneficially owned, subject to applicable community property laws.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 70; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	70
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage71"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	In computing the number and percentage of shares
	beneficially owned by a person, shares that may be acquired by such person within 60 days of the date of this Annual Report are
	counted as outstanding, while these shares are not counted as outstanding for computing the percentage ownership of any other person.
	Unless otherwise indicated, the address of each person listed below is c/o LabStyle Innovations Corp., 9 Halamish Street, Caesarea
	Industrial Park, 3088900, Israel.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_BENEFICIAL_OWNERS>
<A NAME="FIS_BENEFICIAL_OWNERS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Percent&nbsp;of
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Shares&nbsp;of
<BR>
	Common
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Common
<BR>
	Stock
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Beneficially
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Beneficially
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	Name&nbsp;of&nbsp;Beneficial&nbsp;Owner
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Stock&nbsp;Owned
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Owned&nbsp;
<SUP>
	(1)
</SUP>
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	Officers and Directors
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 74%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	Erez Raphael&nbsp;
<SUP>
	(2)
</SUP>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,420,926
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.2
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: #CCEEFF">
	Zvi Ben David&nbsp;
<SUP>
	(3)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,032,707
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7.3
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	Malcolm Hoenlein&nbsp;
<SUP>
	(4)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	525,640
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.0
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: #CCEEFF">
	Dennis M. McGrath&nbsp;
<SUP>
	(5)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	348,374
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;&nbsp;*
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	Prof. Richard B. Stone&nbsp;
<SUP>
	(6)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,620,363
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.6
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: #CCEEFF">
	Rami Yehudiha&nbsp;
<SUP>
	(7)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	290,161
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;*
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	Hila Karah&nbsp;
<SUP>
	(8)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	356,143
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	&nbsp;*
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	All Executive Officers and Directors as a group (7 persons)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12,594,314
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	23
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	5% Stockholders
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: #CCEEFF">
	Dicilyon Consulting and Investment Ltd.
<SUP>
	(9)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	17,830,577
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	26.6
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	Shmuel Farhi
<SUP>
	(10)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,666,666
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	11.7
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_BENEFICIAL_OWNERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%">
<FONT STYLE="FONT-SIZE: 10PT">
	*
</FONT>
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Less than 1%.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Percentage ownership is based on 53,498,649 shares of our common stock outstanding as of February 8, 2016 and, for each person or entity listed above, warrants or options to purchase shares of our common stock which exercisable within 60 days of the such date.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(2)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Includes 1,709,634 vested options and 40,000 warrants to purchase common stock.&nbsp;&nbsp;Excludes 1,530,633 options which are not vested.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(3)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Includes 387,649 vested options to purchase common stock and 1,037,500 warrants to purchase common stock. Excludes 387,651 options which are not vested.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(4)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Includes 216,800 vested options to purchase common stock. Excludes 136,800 options which are not vested.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(5)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Includes 171,800 vested options to purchase common stock. Excludes 136,800 options which are not vested.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(6)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Includes 1,222,223 warrants to purchase common stock, and 166,800 vested options to purchase common stock. Excludes 136,800 options which are not vested.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(7)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Includes 136,800 vested options to purchase common stock. Excludes 136,800 options which are not vested.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(8)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Includes 136,800 vested options to purchase common stock. Excludes 136,800 options which are not vested.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(9)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Includes 30,000 shares of our Series A Convertible Preferred Stock which are currently convertible into 7,568,114 shares of our common stock and 6,087,463 warrants&nbsp;to purchase common stock.&nbsp;David Edery&nbsp;is the natural person with voting and dispositive power over our securities held by&nbsp;Dicilyon Consulting and Investment Ltd. The address of Dicilyon Consulting and Investment Ltd. is 7 B'Chshvan St No. 8, Ramat HaSharon, Israel.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(10)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	Includes
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	3,333,333 warrants to purchase common stock issued to Mr. Farhi. Mr. Farhi&rsquo;s address is 484 Richmond St., London, England, N6A 3E6.&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 71; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	71
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_SECURITY_OWNERS>
<A NAME="eolPage72"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_OFFICER_TRANSACTIONS>
<A NAME="FIS_OFFICER_TRANSACTIONS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A NAME="V430703_10K_HTM_A_022">
</A>
	Item&nbsp;13.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Certain Relationships and Related Party Transactions
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Executive Officers and Directors
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;We
	have entered into employment and consulting agreements and granted stock awards to our executive officers and directors as more
	fully described in &ldquo;Executive Compensation&rdquo; above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	September 2014 Private Placement
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On September 23, 2014, we entered into and closed
	the transactions contemplated by a definitive Securities Purchase Agreement. The lead investor in the financing memorialized in
	such agreement was Dicilyon, an affiliate of Israeli investor David Edery who invested $3 million in the private placement purchasing
	30,000 shares of our Series A Convertible Preferred Stock which are currently convertible into 7,568,114 shares of our common stock
	and 4,162,463 warrants&nbsp;to purchase common stock following the entry into a warrant replacement agreement with Dicilyon whereby
	Dicilyon replaced 3,784,057 warrants issued in 2014 which contained a net settlement cash feature and liquidated damages penalties
	with 4,162,463 warrants which contain a standard anti-dilution clause, both groups of warrants with an exercise price of $0.4755
	per share and exercisable until September 23, 2018. Pursuant to the Securities Purchase Agreement, Mr. Edery and his controlled
	affiliates have been granted certain special rights, including, among other things, (i) a two year pre-emptive right to participate
	in our future financings, subject to certain exceptions, in an amount which would allow Mr. Edery to maintain his fully-diluted
	percentage ownership of the Company, and (ii) a right that, for so long as Mr. Edery holds 25%, 15% and 10% of the outstanding
	shares of Common Stock, Mr. Edery shall have the right to appoint, respectively, three, two or one member of our seven person Board
	of Directors. Mr. Edery currently holds the right to appoint three members of the Board of Directors. In connection with the closing
	of the transactions contemplated by the Securities Purchase Agreement, Mr. Edery&rsquo;s company appointed Rami Yehudiha to serve
	as a member of the Board of Directors and on November 18, 2014, Mr. Edery&rsquo;s company exercised its right to appoint two members
	to the Board of Directors by requesting that Dr. Oren Fuerst and Dr. Steven A. Kaplan resign from the Board of Directors. Accordingly,
	Dr. Kaplan resigned from the Board of Directors effective as of November 21, 2014 and Dr. Fuerst resigned from the Board of Directors
	effective as of November 23, 2014. On November 23, 2014, the remaining members of the Board of Directors acted by unanimous written
	consent to name two appointees of Mr. Edery&rsquo;s company, Dr. Peter M. Kash and Ms. Hila Karah, as members of the Board of Directors.
	On February 25, 2015, Dr. Peter M. Kash resigned from his position as a member of the Board of Directors for personal reasons.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Statement of Policy
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	All transactions (if any) between us and our
	officers, directors or five percent stockholders, and respective affiliates will be on terms no less favorable than could be obtained
	from unaffiliated third parties and will be approved by a majority of our independent directors who do not have an interest in
	the transactions and who had access, at our expense, to our legal counsel or independent legal counsel.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	To the best of our knowledge, other than as
	set forth above, there were no material transactions, or series of similar transactions, or any currently proposed transactions,
	or series of similar transactions, to which we were or are to be a party, in which the amount involved exceeds the lesser of $120,000
	or 1% of the average of our total assets at year end for the last two completed fiscal years, and in which any director or executive
	officer, or any security holder who is known by us to own of record or beneficially more than 5% of any class of our common stock,
	or any member of the immediate family of any of the foregoing persons, has an interest (other than compensation to our officers
	and directors in the ordinary course of business).
</P>
</EFX_OFFICER_TRANSACTIONS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<A NAME="V430703_10K_HTM_A_023">
</A>
	Item&nbsp;14.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Principal Accounting Fees and Services
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The following table sets forth fees billed to
	us by Kost Forer Gabbay &amp; Kasierer, a member of Ernst &amp; Young Global, our independent registered public accounting firm,
	during the fiscal years ended December 31, 2015 and December 31, 2014 for: (i) services rendered for the audit of our annual financial
	statements and the review of our quarterly financial statements; (ii) services by our independent registered public accounting
	firms that are reasonably related to the performance of the audit or review of our financial statements and that are not reported
	as audit fees; (iii) services rendered in connection with tax compliance, tax advice and tax planning; and (iv) all other fees
	for services rendered.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 72; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	72
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage73"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December&nbsp;31,&nbsp;2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December&nbsp;31,&nbsp;2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 74%; FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	Audit Fees
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	83,000
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	83,000
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	Audited Related Fees
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	Tax Fees (1)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	17,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	All Other Fees (2)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	Total
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	103,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	112,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD>
	Consists of fees relating to our tax compliance and tax planning.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)
</TD>
<TD>
	Consists of fees relating to our private placements.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Audit Committee Policies
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The Audit Committee of our Board of Directors
	is solely responsible for the approval in advance of all audit and permitted non-audit services to be provided by the independent
	auditors (including the fees and other terms thereof), subject to the de minimus exceptions for non-audit services provided by
	Section 10A(i)(1)(B) of the Exchange Act, which services are subsequently approved by the Board of Directors prior to the completion
	of the audit. None of the fees listed above are for services rendered pursuant to such de minimus exceptions.
</P>
</EFX_ACCOUNTANT_FEES>
</EFX_PART_III>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<EFX_PART_IV>
<A NAME="FIS_PART_IV"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<A NAME="V430703_10K_HTM_A_024">
</A>
<B>
	PART IV
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD">
<A NAME="V430703_10K_HTM_A_025">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item&nbsp;15.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Exhibits, Financial Statement Schedules.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The following exhibits are filed with this Annual
	Report.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; WIDTH: 12%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Exhibit No.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; WIDTH: 86%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	3.1
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Composite copy of Certificate of Incorporation, as amended&nbsp;&nbsp;(1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	3.2
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock of the Company (2)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	3.3
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Bylaws (3)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	4.1
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Warrant issued to investors in the Company&rsquo;s 2011-2012 Private Placement (3)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	4.2
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Warrant for shares of common stock issued to Spencer Trask Ventures, Inc. (3)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	4.3
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Warrant for shares of common stock issued to Spencer Trask Ventures, Inc. (3)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	4.4
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Warrant issued to investors in the Company&rsquo;s August 2012 Private Placement (3)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	4.5
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Finder Warrant issued in connection with the Company&rsquo;s October 2012 Private Placement (3)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	4.6
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Warrant issued to investors in the Company&rsquo;s May 2013 Private Placement (4)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	4.7
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Registration Rights Agreement, dated as of February 12, 2014, by and among the Company and the Buyers named therein in connection with the Company&rsquo;s February 2014 Private Placement (5)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	4.8
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Warrant issued to investors in the Company&rsquo;s September 2014 Private Placement (6)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	4.9
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Registration Rights Agreement, dated as of September 24, 2014, by and among the Company and the Purchasers named therein in connection with the Company&rsquo;s September 2014 Private Placement (6)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	4.10
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Series A Warrant issued to investors in the Company&rsquo;s February 2015 Private Placement (14)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	4.11
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Series B Warrant issued to investors in the Company&rsquo;s February 2015 Private Placement (14)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	4.12
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Registration Rights Agreement, dated as of February 25, 2015, by and among the Company and the Purchasers named therein in connection with the Company&rsquo;s February 2015 Private Placement (14)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	4.13
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Warrant issued in connection with warrant exercise and replacement agreement (15)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 73; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	73
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage74"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 12%">
<FONT STYLE="FONT-SIZE: 10PT">
	4.14
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 86%">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Series A Warrant issued to investors in the Company&rsquo;s July 2015 Private Placement (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	4.15
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Series B Warrant issued to investors in the Company&rsquo;s July 2015 Private Placement (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;4.16
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of placement agent common stock warrant issued in the Company&rsquo;s July 2015 Private Placement (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	4.17
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of placement agent Series A warrant issued in the Company&rsquo;s July 2015 Private Placement (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	4.18
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of placement agent Series B warrant issued in the Company&rsquo;s July 2015 Private Placement (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	4.19
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Warrant issued in connection with warrant replacement agreement (18)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	4.20
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Series A Warrant issued to investors in the Company&rsquo;s November 2015 Private Placement (18)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	4.21
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Series B Warrant issued to investors in the Company&rsquo;s November 2015 Private Placement (18)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	4.22
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Warrant issued to investors in the Company&rsquo;s December 2015 Private Placement*
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.1
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Employment Agreement, dated October 11, 2012, between LabStyle Israel and Erez Raphael+ (8)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.2
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment to Employment Agreement, dated April 1, 2013, between LabStyle Israel and Erez Raphael+ (8)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.3
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment to Employment Agreement, dated August 30, 2013, between LabStyle Israel and Erez Raphael+ (8)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.4
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Securities Purchase Agreement for the Company&rsquo;s August 2012 Private Placement (3)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.5
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Addendum to Securities Purchase Agreement, dated February 11, 2013, for the Company&rsquo;s August 2012 Private Placement (9)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.6
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Subscription Agreement for the Company&rsquo;s October 2012 private placement (3)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.7
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Distribution Agreement, dated April 25, 2013, by and between the Labstyle Innovation Ltd. and Farla Medical Limited (10)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.8
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Subscription Agreement for the Company&rsquo;s May 2013 Private Placement (4)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.9
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Securities Purchase Agreement, dated as of February 12, 2014, by and among the Company and the Buyers named therein in connection with the Company&rsquo;s February 2014 Private Placement (5)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.10
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment, dated as of March 20, 2014, by and among the Company and the Buyers named therein in connection with the Company&rsquo;s February 2014 Private Placement (11)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.11
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Amendment and Exchange Agreement, dated August 15, 2014, entered into between the Company and the several investors in the Company&rsquo;s February 2014 Private Placement (12)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.12
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Securities Purchase Agreement, dated as of September 24, 2014, by and among the Company and the Purchaser named therein in connection with the Company&rsquo;s September 2014 Private Placement (2)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.13
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Personal Employment Agreement, dated January 8, 2015, between the Company and Zvi Ben David+ (13)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.14
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Securities Purchase Agreement, dated as of February 25, 2015, by and among the Company and the Purchaser named therein in connection with the Company&rsquo;s February 2015 Private Placement (14)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.15
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Warrant Exercise and Replacement Agreement (15)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.16
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	2012 Equity Incentive Plan of the Company+ (3)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.17
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment No. 1 to 2012 Equity Incentive Plan of the Company+*
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.18
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment No. 2 to 2012 Equity Incentive Plan of the Company+ (7)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.19
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment No. 3 to the 2012 Equity Incentive Plan of the Company+ (16)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.20
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Securities Purchase Agreement by and among the Company and the Purchasers named therein in connection with the Company&rsquo;s July 2015 Private Placement (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.21
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Warrant Replacement Agreement (17)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.22
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Securities Purchase Agreement by and among the Company and the Purchasers named therein in connection with the Company&rsquo;s November 2015 Private Placement (18)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.23
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Securities Purchase Agreement by and among the Company and the Purchasers named therein in connection with the Company&rsquo;s December 2015 Private Placement*
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	21.1
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	List of Subsidiaries of the Company*
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	23.1
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<P STYLE="MARGIN: 0PT 0">
	Consent of Kost Forer Gabbay and Kaiserer*
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	31.1
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934.*
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	31.2
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Certification of the Chief Financial Officer pursuant to
	Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934.*
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	32.1
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Certification of the Chief Executive Officer and Chief Financial
	Officer pursuant to 18 U.S.C. 1350.**
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	101
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Interactive Data File (XBRL)*
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 74; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	74
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage75"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%">
<FONT STYLE="FONT-SIZE: 10PT">
	+
</FONT>
</TD>
<TD STYLE="WIDTH: 95%">
<FONT STYLE="FONT-SIZE: 10PT">
	Management contract or compensatory plan or arrangement
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	*
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Filed herewith
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	**
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Furnished herewith
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%">
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD STYLE="WIDTH: 92%">
<FONT STYLE="FONT-SIZE: 10PT">
	Incorporated by reference to the Company&rsquo;s Quarterly Report on Form 10-Q filed August 12, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(2)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Incorporated by reference to the Company&rsquo;s Current Report on Form 8-K, filed September 24, 2014.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(3)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Incorporated by reference to the Company&rsquo;s Registration Statement on Form S-1, filed January 16, 2013.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(4)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Incorporated by reference to the Company&rsquo;s Current Report on Form 8-K, filed May 13, 2013.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(5)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Incorporated by reference to the Company&rsquo;s Current Report on Form 8-K, filed February 13, 2014.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(6)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Incorporated by reference to the Company&rsquo;s Current Report on Form 8-K, filed September 24, 2014.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(7)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Incorporated by reference to the Company&rsquo;s Current Report on Form 8-K, filed June 18, 2014.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(8)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Incorporated by reference to the Company&rsquo;s Current Report on Form 8-K, filed September 6, 2013.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(9)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Incorporated by reference to the Company&rsquo;s Registration Statement on Form S-1, filed February 12, 2013.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(10)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Incorporated by reference to the Company&rsquo;s Current Report on Form 8-K, filed April 30, 2013.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(11)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Incorporated by reference to the Company&rsquo;s Registration Statement on Form S-1, filed March 20, 2014.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(12)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Incorporated by reference to the Company&rsquo;s Current Report on Form 8-K, filed August 18, 2014.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(13)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Incorporated by reference to the Company&rsquo;s Current Report on Form 8-K, filed January 9, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(14)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Incorporated by reference to the Company&rsquo;s Current Report on Form 8-K, filed February 26, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(15)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Incorporated by reference to the Company&rsquo;s Current Report on Form 8-K filed on May 20, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(16)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Incorporated by reference to the Company&rsquo;s Current Report on Form 8-K filed on June 16, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(17)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Incorporated by reference to the Company&rsquo;s Current Report on Form 8-K filed on November 2, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(18)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Incorporated by reference to the Company&rsquo;s Current Report on Form 8-K filed on November 19, 2015.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 75; VALUE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	75
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage76"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	AS OF DECEMBER 31, 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	INDEX
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 90%; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.75PT SOLID">
<B>
	Page
</B>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<A HREF="#V430703_10K_HTM_FIN_027">
<B>
	Report of Independent Registered Public Accounting Firm
</B>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<B>
	F-2
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<A HREF="#V430703_10K_HTM_FIN_028">
<B>
	Consolidated Balance Sheets
</B>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<B>
	F-3 - F-4
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<A HREF="#V430703_10K_HTM_FIN_029">
<B>
	Consolidated Statements of Comprehensive Loss
</B>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<B>
	F-5
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<A HREF="#V430703_10K_HTM_FIN_030">
<B>
	Statements of Changes in Stockholders' Deficiency
</B>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<B>
	F-6
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<A HREF="#V430703_10K_HTM_FIN_031">
<B>
	Consolidated Statements of Cash Flows
</B>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<B>
	F-7
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<A HREF="#V430703_10K_HTM_FIN_032">
<B>
	Notes to Consolidated Financial Statements
</B>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<B>
	F-8 - F-39
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
	- - - - - - - - - - - - - - -
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
	&nbsp;&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 76 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage77"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD ROWSPAN="7" NOWRAP STYLE="WIDTH: 75%; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/02/08/0001144204-16-079581_LOGO.JPG" ALT="">
</TD>
<TD NOWRAP STYLE="WIDTH: 25%; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #666666">
<B>
	Kost Forer Gabbay &amp; Kasierer
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD NOWRAP STYLE="COLOR: #666666">
<FONT STYLE="FONT-SIZE: 10PT">
	3 Aminadav St.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD NOWRAP STYLE="COLOR: #666666">
<FONT STYLE="FONT-SIZE: 10PT">
	Tel-Aviv 6706703, Israel
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD NOWRAP STYLE="COLOR: #666666">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD NOWRAP STYLE="COLOR: #666666">
	Tel:
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
	972 (3)6232525
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD NOWRAP STYLE="COLOR: #666666">
	Fax: 972 (3)5622555
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD NOWRAP STYLE="COLOR: #666666">
	www.ey.com/il
</TD>
</TR>
</TABLE>
</EFX_EXHIBITS>
</EFX_PART_IV>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<A NAME="V430703_10K_HTM_FIN_027">
</A>
<B>
	REPORT OF INDEPENDENT REGISTERED PUBLIC
	ACCOUNTING FIRM
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	To the Shareholders and Board of Directors
	of
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	LABSTYLE INNOVATIONS CORP.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have audited the
	accompanying consolidated balance sheets of LabStyle Innovations Corp. (the &quot;Company&quot;) and its subsidiaries as of December
	31, 2015 and 2014, and the related consolidated statements of comprehensive loss, changes in stockholders' deficiency and cash
	flows for each of the two years in the period ended December&nbsp;31, 2015. These consolidated financial statements are the responsibility
	of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our
	audits.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT">
	We conducted our
	audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require
	that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.
	We were not engaged to perform an audit of the Company&rsquo;s internal control over financial reporting. Our audits included consideration
	of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances,
	but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting.
	Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and
	disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management,
	and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT">
	In our opinion, the
	financial statements referred to above, present fairly, in all material respects, the consolidated financial position of the Company
	and its subsidiaries as of December&nbsp;31, 2015 and 2014, and the consolidated results of their operations and their cash flows
	for each of the two years in the period ended December&nbsp;31, 2015, in conformity with U.S. generally accepted accounting principles.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT">
	The accompanying
	consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in
	Note 1c to the consolidated financial statements, the Company has recurring losses from operations and has limited liquidity resources
	that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are
	also described in Note 1c. The consolidated financial statements do not include any adjustments that might result from the outcome
	of this uncertainty.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="WIDTH: 70%; TEXT-ALIGN: JUSTIFY">
	Tel-Aviv, Israel
</TD>
<TD NOWRAP STYLE="WIDTH: 30%; TEXT-ALIGN: LEFT">
	/s/ KOST FORER GABBAY &amp; KASIERER
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
	February 8, 2016
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	A Member of Ernst &amp; Young Global
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 77; OPTIONS: NEWSECTION; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_AUDITORS_OPINION>
<A NAME="eolPage78"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;&nbsp;
</B>
</P>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<A NAME="V430703_10K_HTM_FIN_028">
</A>
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	CONSOLIDATED BALANCE SHEETS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 0.25IN">
	ASSETS
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	CURRENT ASSETS:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 64%; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9PT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	2,671
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	1,453
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9PT">
	Short-term bank deposits
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	80
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	83
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9PT">
	Inventories
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	601
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	234
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9PT">
	Other accounts receivable and prepaid expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	935
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	286
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
<U>
	Total
</U>
	current assets
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	4,287
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,056
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	LEASE DEPOSITS
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	41
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	47
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	PROPERTY AND EQUIPMENT, NET
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	749
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	978
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT">
<U>
	Total
</U>
	assets
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	5,077
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	3,081
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_BALANCE_SHEET>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The accompanying notes are an integral
	part of the consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 78; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage79"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET_2"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	CONSOLIDATED BALANCE SHEETS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 0.25IN">
	LIABILITIES AND STOCKHOLDERS' DEFICIENCY
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	CURRENT LIABILITIES:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.15IN">
	Trade payables
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	978
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	708
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.15IN">
	Deferred revenues
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	31
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	24
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.15IN">
	Other accounts payable and accrued expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	681
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	884
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
<U>
	Total
</U>
	current liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,690
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,616
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	LIABILITY RELATED TO WARRANTS
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,610
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	4,003
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_BALANCE_SHEET>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	COMMITMENTS AND CONTINGENT LIABILITIES
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	CONVERTIBLE PREFERRED SHARES:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 16.2PT">
	Series A Preferred Stock of $0.0001 par value&nbsp;-&nbsp;Authorized: 60,000 shares at December 31, 2015 and 2014; Issued and Outstanding: 35,600 and 41,652 shares at December 31, 2015 and 2014, respectively; Aggregate liquidation preference of $3,560 and $4,165 at December 31, 2015 and 2014, respectively
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,357
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,757
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
	STOCKHOLDERS' DEFICIT
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 16.2PT">
	Common Stock of $0.0001 par value - Authorized: 160,000,000 and 80,000,000 shares at December 31, 2015 and 2014, respectively; Issued and Outstanding: 52,407,057 and 16,233,430 shares at December 31, 2015 and 2014, respectively
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 16.2PT">
	Preferred Stock of $0.0001 par value - Authorized: 4,940,000 shares at December 31, 2015 and 2014; Issued and Outstanding: None at December 31, 2015 and 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9PT">
	Additional paid-in capital
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	41,769
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	30,761
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9PT">
	Accumulated deficit
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(43,354
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(36,058
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
<U>
	Total
</U>
	stockholders' deficiency
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,580
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(5,295
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT">
<U>
	Total
</U>
	liabilities and stockholders' deficiency
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	5,077
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	3,081
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The accompanying notes are an integral
	part of the consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 79; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage80"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<B>
<A NAME="V430703_10K_HTM_FIN_029">
</A>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
<B>
	Year
	ended
<BR>
<B>
	December 31,
</B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; TEXT-ALIGN: LEFT">
	Revenues
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	823
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	51
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cost of revenues and ramp up of manufacturing
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,678
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,274
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Impairment of production line
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	489
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Gross loss
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	855
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,712
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Operating expenses:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 11.5PT">
	Research and development
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,565
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,943
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 11.5PT">
	Sales, Marketing and pre-production costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,330
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,063
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 11.5PT">
	General and administrative
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,948
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	3,640
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total operating expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	6,843
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	8,646
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Operating loss
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,698
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,358
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 11.5PT">
	Financial expenses (income), net:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 11.5PT">
	Revaluation of warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(571
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,194
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 11.5PT">
	Other financial expense, net
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	15
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	3,713
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total financial expenses (income), net
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(556
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,519
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	7,142
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	12,877
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 18.7PT">
	Deemed dividend related to May 2015 exchange agreement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	154
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 18.7PT">
	Deemed dividend related to February 2014 exchange agreement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	279
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 18.7PT">
	Deemed dividend related to Series A Preferred Stock
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,899
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net loss attributable to holders of Common Stock
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	7,296
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	16,055
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net loss per share:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Basic and diluted loss per share
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	0.21
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1.85
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 0.1IN">
	Weighted average number of Common Stock used in computing basic and diluted net loss per share
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	34,159,595
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	8,678,953
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The accompanying notes are an integral
	part of the consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 80; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage81"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;&nbsp;
</B>
</P>
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<A NAME="V430703_10K_HTM_FIN_030">
</A>
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIENCY
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Common stock
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	Additional
<BR>
	paid-in
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	Accumulated
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	Total
<BR>
	stockholders'
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amount
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	capital
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	deficit
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	deficiency
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 50%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Balance as of December 31, 2013
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	4,014,478
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	19,917
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	(20,003
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	(86
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Issuance of Common Stock in February 2014 at $2.75 per unit, net of issuance cost
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	445,392
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*) -
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,013
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,013
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Issuance of Common Stock in July 2014 upon reset price mechanism
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	496,884
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*) -
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*) -
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;*) -
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Deemed dividend related to exchange agreement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	279
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(279
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Issuance of additional shares upon Exchange Agreement in August 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,957,515
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,556
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,558
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Deemed dividend related to Series A Preferred Stock
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,899
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,899
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Conversion of Series A Preferred Stock
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	176,137
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*) -
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	46
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	46
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Exercise of warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	68,524
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*) -
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	352
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	352
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Exercise of options
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	74,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*) -
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Stock-based compensation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,692
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,692
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(12,877
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(12,877
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Balance as of December 31, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,233,430
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	30,761
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(36,058
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(5,295
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Issuance of Common Stock and warrants in February 2015 at $0.18 per unit, net of issuance cost
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,286,444
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,955
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,956
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Issuance of Common Stock in July and August 2015 at $0.30 per unit, net of issuance cost
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,646,203
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,324
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,325
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Issuance of Common stock in November 2015 at $0.30 per unit, net of issuance cost
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,031,734
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,293
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,294
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Issuance of Common stock in December 2015 at $0.34 per unit, net of issuance cost
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,461,988
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*) -
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Issuance of Common Stock in April, August and December 2015 to service provider
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	300,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*) -
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	118
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	118
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Issuance of Common Stock in September 2015 to employees as compensation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,748,166
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*) -
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	591
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	591
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Issuance of Common Stock in September 2015 to service provider
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	50,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*) -
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Payment for executives and directors under Salary Program
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	998,403
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*) -
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	304
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	304
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Exercise&nbsp;&nbsp;of warrants into Common Stock in May 2015, net of issuance cost
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,923,636
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*) -
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	453
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	453
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Deemed dividend related to inducement of warrant exercise in May 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	154
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(154
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Issuance of warrants related to warrant replacement agreement in November and December 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	822
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	822
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Receipts on Account of shares
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Conversion of Series A Preferred Stock into Common Stock
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,526,609
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*) -
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	400
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	400
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Exercise of warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	194,444
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*) -
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	60
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	60
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Exercise of options
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*) -
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*) -
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;*) -
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Stock-based compensation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	998
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	998
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(7,142
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(7,142
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Balance as of December 31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	52,407,057
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	5
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	41,769
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(43,354
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(1,580
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_STOCKHOLDERS_EQUITY>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	*) Represents an amount lower than $1.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The accompanying notes are an integral
	part of the consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 81; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage82"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<A NAME="V430703_10K_HTM_FIN_031">
</A>
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	CONSOLIDATED STATEMENT OF CASH FLOWS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Year ended
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	December 31,
</B>
</P>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: LEFT">
	Cash flows from operating activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 64%; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Net loss
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	(7,142
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	(12,877
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Adjustments required to reconcile net loss to net cash used in operating activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
	Stock-based compensation and Common Stock to service providers
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,723
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,692
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
	Issuance cost related to warrants to investors and service provider
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	533
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
	Depreciation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	335
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	549
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
	Write-off of a production line
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	489
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
	Increase in deferred revenues
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	24
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
	Decrease (increase) in other accounts receivable and prepaid expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(649
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	158
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
	Increase in inventories
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(366
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(234
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
	Increase (decrease) in trade payables
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	292
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(186
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
	Decrease in other accounts payable and accrued expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	102
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	341
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
	Incremental value to February 2014 Investors that resulted from Exchange Agreement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,124
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
	Change in the fair value of warrants to purchase shares of Common Stock
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(571
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,194
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN; PADDING-BOTTOM: 1PT">
	Loss from disposal of fixed assets
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Net cash used in operating activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(6,277
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(8,581
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: LEFT">
	Cash flows from investing activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Investment in short-term bank deposits
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(282
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(91
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Proceeds of maturities of short-term bank deposit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	285
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	231
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Investment in lease deposit, net
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(6
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(6
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT; PADDING-BOTTOM: 1PT">
	Purchase of property and equipment
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(110
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(563
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Net cash used in investing activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(113
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(429
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: LEFT">
	Cash flows from financing activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Proceeds from issuance of Common Stocks and warrants, net of issuance cost
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,075
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,754
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Proceeds from issuance of Series A Preferred Stock and warrants, net of issuance cost
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,096
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT; PADDING-BOTTOM: 1PT">
	Proceeds from exercise of options and warrants
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	533
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	350
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Net cash provided by financing activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	7,608
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	8,200
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Increase (decrease) in cash and cash equivalents
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,218
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(810
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Cash and cash equivalents at beginning of year
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	1,453
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2,263
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Cash and cash equivalents at end of year
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	2,671
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	1,453
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: LEFT">
	Non-cash investing and financing activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Purchase of property and equipment
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	27
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	308
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 0.1IN; PADDING-BOTTOM: 2.5PT">
	Classification of liability related to warrants as a result of September 2014 round Replacement Agreement
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	822
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 0.1IN; PADDING-BOTTOM: 2.5PT">
	Conversion of liability related to warrants to Common stock as a result of 2011-2012 Private Placement round warrants conversion
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Conversion of Series A Preferred Stock to Common stock
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	400
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	46
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Payment for executives and directors under Salary Program
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	304
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The accompanying notes are an integral
	part of the consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 82; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage83"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<A NAME="V430703_10K_HTM_FIN_032">
</A>
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 1:-
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	GENERAL
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	a.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	LabStyle Innovations Corp. (the &quot;Company&quot;) was incorporated in Delaware and commenced
	operations on August 11, 2011. The Company is a digital health (mHealth) company that is developing and commercializing a patented
	and proprietary technology providing consumers with laboratory-testing capabilities using smart phones and other mobile devices.&nbsp;
	The Company's flagship product, Dario&trade;, also referred to as the Dario&trade; Smart Diabetes Management Solution, is a mobile,
	real-time, cloud-based, diabetes management solution based on an innovative, multi-feature software application combined with a
	stylish, &lsquo;all-in-one&rsquo;, pocket-sized, blood glucose monitoring device, which we call the Dario&trade; Smart Meter.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 92.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	b.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Company's wholly owned subsidiary, LabStyle Innovation Ltd. (&quot;Ltd.&quot; or &quot;Subsidiary&quot;),
	was incorporated and commenced operations on September 14, 2011 in Israel. Its principal business activity is to hold the Company&rsquo;s
	intellectual property and to perform research and development, manufacturing, marketing and other business activities. Ltd. has
	a wholly-owned subsidiary, LabStyle Innovations US LLC, a Delaware limited liability company (&quot;LabStyle US&quot;), which was
	established in 2014, however it has not started its operations to date.&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	c.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	During the year ended December 31, 2015, the Company incurred operating losses and negative cash
	flows from operating activities amounting to $7,698 and $6,277, respectively. The Company will be required to obtain additional
	liquidity resources in the near term in order to support the commercialization of its products and maintain its research and development
	activities. The Company is addressing its liquidity needs by seeking additional funding from public and/or private sources and
	by ramping up its commercial sales. There are no assurances, however, that the Company will be able to obtain an adequate level
	of financial resources that are required for the short and long-term development and commercialization of its product. According
	to management estimates, the Company has sufficient liquidity resources to continue its planned activity&nbsp;into April 2016.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 55PT">
</TD>
<TD STYLE="WIDTH: 30.05PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	These conditions
	raise substantial doubt about the Company's ability to continue as a going concern. The accompanying consolidated financial statements
	do not include any adjustments to reflect the possible future effects on recoverability and classification of assets or the amounts
	and classification of liabilities that may result from the outcome of this uncertainty.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	d.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On June 17, 2014, the Company held its 2014 Annual Meeting of Stockholders in which, among other
	matters, Company stockholders approved an amendment to the Company's Certificate of Incorporation (&quot;COI&quot;) to increase
	the number of authorized shares of Common Stock from 45,000,000 to 80,000,000 and to effect a reverse stock split of the Common
	Stock at a ratio of between one-for-two and one-for-five with such ratio to be determined at the sole discretion of the Company's
	Board of Directors (the &quot;Reverse Split&quot;).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 83; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage84"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 1:-
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	GENERAL (Cont.)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	On September
	18, 2014, the Company's Board of Directors approved the Reverse Split at a ratio of one-for-five. Such Reverse Split was implemented
	on October 6, 2014. The amount of authorized Common Stock as well as the par value for the Common Stock was not affected. Any fractional
	shares resulting from the Reverse Split were rounded up to the nearest whole share.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	All Common
	Stock, warrants, options and per share amounts set forth herein are presented to give retroactive effect to the Reverse Split for
	all periods presented.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	e.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On June 15, 2015, the Company held its 2015 Annual Meeting of Stockholders in which, among other
	matters, Company stockholders approved an amendment to the Company's Certificate of Incorporation to increase the number of authorized
	shares of Common Stock from 80,000,000 to 160,000,000 and to amend the Company&rsquo;s 2012 Equity Incentive Plan, to increase
	the number of shares authorized for issuance under such Plan by 11,925,000 shares from 1,500,000 to 13,425,000.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	f.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	In February 2015, the Company obtained National Pharmaceutical Product Interface approval and registered
	Dario&trade; for sale in South Africa.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	g.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	In March 2015, the Company started marketing the Dario&trade; Smart Diabetes Management Solution
	in the Netherlands and New Zealand as a private, out of pocket offering (no reimbursement).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	h.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	In May 2015, the Company received Health Canada approval to market and sell Dario&trade; in Canada
	and commenced sales in Canada in June 2015. The majority of Canadian medical plans are currently providing reimbursement coverage
	for Dario&trade;.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	i.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	In December 2015, the United States Food and Drug Administration (&quot;FDA&quot;) granted the
	Subsidiary 510(k) clearance for the Dario Blood Glucose Monitoring System, including its components, the Dario Blood Glucose Meter,
	Dario Blood Glucose Test Strips, Dario Glucose Control Solutions and the Dario app on the Apple iOS 6.1 platform and higher.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 84; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage85"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 2:-
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	SIGNIFICANT ACCOUNTING POLICIES
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The consolidated
	financial statements are prepared according to United&nbsp;States generally accepted accounting principles (&quot;U.S.&nbsp;GAAP&quot;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	a.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Use of estimates:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	The preparation of the consolidated
	financial statements and related disclosures in conformity with U.S. generally accepted accounting principles (&ldquo;GAAP&rdquo;)
	and the Company&rsquo;s discussion and analysis of its financial condition and operating results require the Company&rsquo;s management
	to make judgments, assumptions and estimates that affect the amounts reported in its consolidated financial statements and accompanying
	notes. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under
	the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities.
	Actual results may differ from these estimates, and such differences may be material.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Management
	believes the Company&rsquo;s critical accounting policies and estimates are reasonable based upon information available at the
	time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure
	of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses
	during the reporting period. Actual results could differ from those estimates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT; TEXT-ALIGN: LEFT">
	b.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Financial statements in U.S. dollars (&quot;$&quot;, &quot;dollar&quot;
	or &quot;dollars&quot;):
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	The accompanying consolidated
	financial statements have been prepared in dollars.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	The Company&rsquo;s financing
	activities are incurred in U.S. dollars. Although a portion of the Subsidiary's expenses is denominated in New
<FONT STYLE="COLOR: #222222">
	Israeli
	Shekels
</FONT>
	(&quot;NIS&quot;) (mainly cost of personnel), a substantial portion of its expenses is denominated in dollars. Accordingly,
	the Company's management believes that the currency of the primary economic environment in which the Company and its subsidiary
	operate is the dollar; thus, the dollar is the functional currency of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	Transactions and balances denominated
	in dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured
	into dollars in accordance with Accounting Standard Codification (&quot;ASC&quot;) 830, &quot;Foreign Currency Matters&quot;. All
	transaction gains and losses of the re-measurement of monetary balance sheet items are reflected in the consolidated statements
	of comprehensive loss as financial income or expenses, as appropriate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	c.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Principles of consolidation:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	The consolidated financial
	statements include the accounts of the Company, its Subsidiary and LabStyle US. Intercompany accounts and transactions have been
	eliminated.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 85; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage86"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 2:-
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	SIGNIFICANT ACCOUNTING POLICIES (Cont.)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 74.75PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	d.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Cash and cash equivalents:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	The Company considers all highly
	liquid investments, which are readily convertible to cash with a maturity of three months or less at the date of acquisition, to
	be cash equivalents.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	e.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Short-term bank deposits:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	Short-term bank deposits are
	restricted deposits with maturities of up to one year and are pledged in favor of the bank as a security for the Company's rent
	and credit payments. The short-term bank deposits are denominated in NIS and bear interest at an average rate of 0.01% and 0.42%
	as of December 31, 2015 and 2014, respectively. The short-term bank deposits are presented at their cost, including accrued interest.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	f.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Inventories:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Inventories
	are stated at the lower of cost plus allocable indirect costs or net realized value. Cost is determined on a &quot;moving average&quot;
	basis. Inventory write-down is provided to cover technological obsolescence, excess inventories and discontinued products. Inventory
	write-down represents the difference between the cost of the inventory and net realizable value. Inventory write-down is charged
	to the cost of revenues and ramp up of manufacturing when a new lower cost basis is established. Subsequent changes in facts and
	circumstances do not result in the restoration or increase in that newly established cost basis.
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Work-in-process
	is immaterial, given the typically short manufacturing cycle, and therefore is disclosed in conjunction with raw materials.
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Total
	write-offs during the years ended December 31, 2015 and 2014 amounted to $193 and $1,046, respectively.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT; TEXT-ALIGN: LEFT">
	g.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Long-term lease deposits:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	Long-term lease deposits include
	mainly long-term deposits for the Company's leased vehicles.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 86; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage87"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 2:-
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	SIGNIFICANT ACCOUNTING POLICIES (Cont.)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	h.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Property and equipment:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	Property and equipment are
	stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful
	lives of the assets at the following annual rates:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-LEFT: 85.05PT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	Property
	and equipment (Cont.):
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 83%; BORDER-COLLAPSE: COLLAPSE; MARGIN-LEFT: 85.05PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 60%; PADDING-LEFT: 2.85PT; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-LEFT: 2.85PT; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<B>
	%
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 8.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT">
	Computers, and peripheral equipment
</TD>
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: CENTER">
	15-33
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 8.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT">
	Office furniture and equipment
</TD>
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: CENTER">
	6
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 8.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT">
	Production lines
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 2.85PT; TEXT-ALIGN: CENTER">
	33
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 8.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT">
	Leasehold improvements
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 2.85PT; TEXT-ALIGN: CENTER">
	Over the shorter of the lease term or useful economic life
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	i.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Impairment of long-lived assets:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Property and equipment are reviewed for impairment in accordance with ASC 360, &quot;Property,
	Plant and Equipment,&quot; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be
	recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the
	future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment
	to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During
	the year ended December&nbsp;31, 2015, no impairment loss has been recorded. During the year ended December&nbsp;31, 2014, the
	Company decided to cease the operation of one of its production lines and performed a recoverability test for such long-lived assets.
	Based on its analysis, the Company recorded a non-cash charge with respect to impairment of its production line in the amount of
	$489. This charge was recorded as separate line in the consolidated statements of comprehensive loss.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	j.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Revenue recognition:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.5PT; TEXT-ALIGN: JUSTIFY">
	Revenues from product sales
	are recognized in accordance with ASC 605-10 &ldquo;Revenue Recognition&rdquo;, when delivery has occurred, persuasive evidence
	of an agreement exists, the vendor&rsquo;s fee is fixed or determinable, no further obligation exists and collectability is probable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 112.5PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	The Company derives revenues
	from the sale of its Dario&trade; Smart Meter and its related device-specific disposables test strip cartridges and lancets through
	independent distributors or directly to end users. The Dario&trade; software application is offered for a free download and the
	Company does not obtain a recurring hosting commitment towards the end users relating specifically to the application.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 87; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage88"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 2:-
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	SIGNIFICANT ACCOUNTING POLICIES (Cont.)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	Revenue recognition (Cont.):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	The Company generally has a
	standard contract with its distributors. According to the agreements, all sales to distributors are final, no rights of return
	or price protection right is granted to such distributors and the Company is not a party of the agreements between distributors
	and their customers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	Through the year ended December
	31, 2015, product sales to distributors are recognized as revenues upon receipt of payment. The Company will apply this policy
	until it will have sufficient historical experience with each distributor in order to conclude that fee is fixed or determinable
	and collectability is probable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 112.5PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.5PT; TEXT-ALIGN: JUSTIFY">
	The Company also generates revenues
	from arrangements with health care providers which include supply of Dario&trade; Smart Meters and software platform that requires
	certain customization followed by monthly service, support and maintenance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	When a sales arrangement contains
	multiple elements, such as software and non-software components, the Company allocates revenue to each element based on a selling
	price hierarchy as required according to ASC 605-25, &ldquo;Multiple-Element Arrangements&rdquo;. The selling price for a deliverable
	is based on its Vendor Specific Objective Evidence (&ldquo;VSOE&rdquo;), if available, third party evidence (&ldquo;TPE&rdquo;)
	if VSOE is not available, or estimated selling price (&ldquo;ESP&rdquo;) if neither VSOE nor TPE is available. The best estimate
	of selling price is established considering several internal factors including, but not limited to, historical sales, pricing practices
	and geographies in which the Company offers its products. The determination of ESP is judgmental.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	Revenues from software components
	in sales arrangement contains multiple elements are recognized when all criteria outlined in ASC 985-605, &ldquo;Software Revenue
	Recognition&rdquo; (&ldquo;ASC 985-605&rdquo;), are met. Revenue from services is recognized when persuasive evidence of an arrangement
	exists, delivery of the product has occurred or the services have been rendered, the fee is fixed or determinable and collectability
	is probable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	For multiple element arrangements
	within ASC 985-605, revenues are allocated to the different elements in the arrangement under the &ldquo;residual method&rdquo;
	when VSOE of fair value exist for all undelivered elements and no VSOE exists for the delivered elements. Under the residual method,
	at the outset of the arrangement with the customer, the fair value of the undelivered elements is deferred and the remaining portion
	of the arrangement fee is allocated to the delivered elements and is recognized as revenue when the basic criteria in ASC 985-605
	have been met. Any discount in the arrangement is allocated to the delivered element.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	Since VSOE does not exist for
	undelivered elements, revenues are recognized as one unit of accounting, on a straight-line basis over the term of the last deliverable
	based on ASC 605-15, &ldquo;Products&rdquo; and ASC 985-605.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 88; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage89"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 2:-
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	SIGNIFICANT ACCOUNTING POLICIES (Cont.)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	Revenue recognition (Cont.):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	Deferred revenues include advances
	and payments received from customers, for which revenue has not yet been recognized.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	k.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Cost of revenues and ramp up of manufacturing:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	Cost of revenues is comprised
	of the cost of production, shipping and handling inventory, personnel and related overhead costs, depreciation of production line
	and related equipment costs and inventory write-downs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	l.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Concentrations of credit risk:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	Financial instruments that
	potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and short-term
	bank deposits.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	All of the cash and cash equivalents
	and short-term bank deposits of the Company and its Subsidiary are invested in deposits and current accounts with major U.S. and
	Israeli banks. Such cash and cash equivalents and short-term bank deposits may be in excess of insured limits and are not insured
	in other jurisdictions. Generally, cash and cash equivalents and short-term bank deposits may be redeemed and therefore a minimal
	credit risk exists with respect to these deposits and investments.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	m.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Income taxes:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	The Company accounts for income
	taxes in accordance with ASC 740, &quot;Income Taxes&quot; (&quot;ASC 740&quot;). This guidance prescribes the use of the liability
	method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting
	and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences
	are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to amounts that
	are more likely than not to be realized. As of December 31, 2015 and 2014, a full valuation allowance was provided by the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	ASC 740 contains a two-step
	approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken
	or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than
	not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related
	appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely
	to be realized upon ultimate settlement. As of December 31, 2015 and 2014, no liability for unrecognized tax benefits was recorded
	as a result of the implementation of ASC 740.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 89; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage90"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 2:-
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	SIGNIFICANT ACCOUNTING POLICIES (Cont.)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 63.8PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -7.1PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	n.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Research and development costs:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Research
	and development costs are charged to the consolidated statements of comprehensive loss, as incurred.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	o.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Series A Preferred Stock:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The
	Company classifies the Series A Preferred Stock (as defined in Note 9b) outside of Stockholders' deficiency because certain features
	of the COI would require redemption of some or all of the Series A Preferred Stock upon events not solely within the control of
	the Company.
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	p.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Warrants:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The
	Company accounts for certain warrants held by investors and the Company&rsquo;s previous placement agent and its permitted designees
	which include priced-based anti-dilution protection or certain net settlement cash features and liquidated damages penalties as
	a liability according to the provisions of ASC 815-40, &quot;Derivatives and Hedging - Contracts in Entity's Own Equity&quot; (&quot;ASC
	815&quot;), which provides a new two-step model to be applied in determining whether a financial instrument or an embedded feature
	is indexed to an issuer's own stock and thus able to qualify to be a derivative financial instrument. The Company measures the
	warrants at fair value by using Binomial option-pricing model in each reporting period until they are exercised or expired, with
	changes in the fair values being recognized in the Company's statement of comprehensive loss as financial income or expense.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT; TEXT-ALIGN: LEFT">
	q.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Accounting for stock-based compensation:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	The Company accounts for stock-based
	compensation in accordance with ASC 718, &quot;Compensation - Stock Compensation&quot; (&quot;ASC 718&quot;), which requires companies
	to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the
	portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the
	Company's consolidated statement of comprehensive loss.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	The Company recognizes compensation
	expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the
	awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary,
	in subsequent periods if actual forfeitures differ from those estimates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 90; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage91"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 2:-
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	SIGNIFICANT ACCOUNTING POLICIES (Cont.)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	Accounting
	for stock-based compensation (Cont.):
</FONT>
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	The
	Company estimates the fair value of stock options granted using the Black-Scholes-Merton option-pricing model. The option-pricing
	model requires a number of assumptions, of which the most significant are the expected stock price volatility and the expected
	option term. Expected volatility was calculated based upon historical volatilities of similar entities in the related sector index
	until the Company's own volatility data will be reliable. The expected option term represents the period that the Company's stock
	options are expected to be outstanding and is determined based on the simplified method until sufficient historical exercise data
	will support using expected life assumptions. The risk-free interest rate is based on the yield from U.S. treasury bonds with
	an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.
</FONT>
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	The
	Company applies ASC 505-50, &quot;Equity-Based Payments to Non-Employees&quot; with respect to options and warrants issued to
	non-employees.
</FONT>
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	Until
	the Company received a ticker symbol for its Common Stock and caused the Common Stock to be eligible for trading on April 9, 2013,
	The fair value of the shares of Common Stock underlying the options and warrants granted through such date, had been determined
	by the Company's management with assistance of an independent valuation firm by applying of market approach using recent third-party
	transactions in the equity of the Company.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	r.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Fair value of financial instruments:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The Company
	applies ASC 820, &quot;Fair Value Measurements and Disclosures&quot; (&ldquo;ASC 820&rdquo;). Under this standard, fair value is
	defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &quot;exit price&quot;)
	in an orderly transaction between market participants at the measurement date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	In determining
	fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value
	that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable
	inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability
	developed based on market data obtained from sources independent from the Company. Unobservable inputs are inputs that reflect
	the Company's assumptions about the assumptions market participants would use in pricing the asset or liability developed based
	on the best information available in the circumstances.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 91; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage92"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 2:-
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	SIGNIFICANT ACCOUNTING POLICIES (Cont.)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Fair value
	of financial instruments (Cont.):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The hierarchy
	is broken down into three levels based on the inputs as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 141.75PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 83%; BORDER-COLLAPSE: COLLAPSE; MARGIN-LEFT: 85.05PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Level 1 -
</TD>
<TD STYLE="WIDTH: 88%; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Level 2 -
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Level 3 -
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Valuations based on inputs that are unobservable and significant to the overall fair value measurement.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 141.75PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The availability
	of observable inputs can vary from investment to investment and is affected by a wide variety of factors, including, for example,
	the type of investment, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation
	is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more
	judgment and the investments are categorized as Level 3.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The carrying
	amounts of cash and cash equivalents, short-term bank deposits, other accounts receivable and prepaid expenses, trade payables
	and other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments.
	Warrants are classified within Level 3 because they are valued using valuation techniques. Some of the inputs to these models are
	unobservable in the market and are significant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 141.75PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	s.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Basic and diluted net loss per share:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Basic net
	loss per share is computed based on the weighted average number of shares of Common Stock outstanding during each year. Diluted
	net loss per share is computed based on the weighted average number of shares of Common Stock outstanding during each year, plus
	dilutive potential Common Stock considered outstanding during the year, in accordance with ASC 260, &quot;Earnings Per Share&quot;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The total
	weighted average number of shares related to the outstanding warrants and options excluded from the calculations of diluted net
	loss per share due to their anti-dilutive effect was 18,479,898 and 8,243,762 for the year ended December 31, 2015 and 2014, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 92; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage93"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 2:-
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	SIGNIFICANT ACCOUNTING POLICIES (Cont.)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -85.05PT">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	t.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Severance pay:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -27.3PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	Since
	inception date, all of Ltd.'s employees who are entitled to receive severance pay in accordance with the applicable law in Israel
	are included under section 14 of the Israeli Severance Compensation Law (&quot;Section 14&quot;). Under this section, they are
	entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made on their behalf with insurance companies.
	Payments in accordance with Section 14 release Ltd. from any future severance payments in respect of those employees. Deposits
	under Section 14 are not recorded as an asset in the Company's balance sheet
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT; TEXT-ALIGN: LEFT">
	u.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Legal and other contingencies:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	From
	time to time the Company is involved in claims and legal proceedings. The Company reviews the status of each matter and assesses
	its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and the amount
	can be reasonably estimated, the Company accrues a liability for the estimated loss.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT; TEXT-ALIGN: LEFT">
	v.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Impact of recently issued accounting pronouncements:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	In May 2014, the Financial
	Accounting Standards Board (&quot;FASB&quot;) issued ASU 2014-09, &quot;Revenue from Contracts with Customers&quot; (&quot;ASU
	2014-09&quot;), which will replace most of the existing revenue recognition guidance under U.S. GAAP. The core principle of ASU
	2014-09 is that an entity should recognize revenue for the transfer of goods or services equal to the amount that it expects to
	be entitled to receive for those goods or services. ASU 2014-09 requires additional disclosure about the nature, amount, timing
	and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments.
	In August&nbsp;2015, the FASB issued ASU 2015-14, &quot;Revenue from Contracts with Customers (Topic 606),&quot; which defers the
	effective date of ASU 2014-09 by one year to fiscal years beginning after December&nbsp;15, 2018, and interim reporting periods
	within annual reporting periods beginning after December 15, 2019, with early adoption permitted. The Company is in the process
	of determining the method of adoption and assessing the impact of ASU 2014-09 on the Company&rsquo;s consolidated financial position,
	results of operations and cash flows.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	In August
	2014, the FASB issued ASU 2014-15 (&quot;ASU 2014-15&quot;), &quot;Presentation of Financial Statements-Going Concern&quot; (Subtopic
	205-40): &quot;Disclosure of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern&quot; (&quot;ASU 2014-15&quot;),
	which defines management&rsquo;s responsibility to assess an entity&rsquo;s ability to continue as a going concern, and to provide
	related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. ASU 2014-15 is effective
	for annual reporting periods ending after December 15, 2016 with early adoption permitted. The adoption of this guidance is not
	expected to have a material impact on the Company&rsquo;s financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 93; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage94"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 2:-
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	SIGNIFICANT ACCOUNTING POLICIES (Cont.)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Impact of
	recently issued accounting pronouncements (Cont.):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	In July 2015,
	the FASB issued ASU No. 2015-11, &quot;Inventory (Topic 330): Simplifying the Measurement of Inventory.&quot; Under this accounting
	guidance, inventory will be measured at the lower of cost and net realizable value and other options that currently exist for market
	value will be eliminated. ASU No. 2015-11 defines net realizable value as the estimated selling prices in the ordinary course of
	business, less reasonably predictable costs of completion, disposal, and transportation. No other changes were made to the current
	guidance on inventory measurement. ASU 2015-11 is effective for fiscal years beginning after December&nbsp;15, 2016, and interim
	periods within fiscal years beginning after December 15, 2017, with early adoption permitted. The adoption of this guidance is
	not expected to have a material impact on the Company&rsquo;s financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	In November 2015, the FASB
	issued ASU No. 2015-17, &quot;Income Taxes &ndash; Balance Sheet Classification of Deferred Taxes&rdquo; (&quot;ASU 2015-17&quot;).
	The purpose of the standard is to simplify the presentation of deferred taxes on a classified balance sheet.&nbsp;&nbsp;Under current
	GAAP, deferred income tax assets and liabilities are separated into current and noncurrent amounts in the balance sheet.&nbsp;&nbsp;The
	amendments in ASU 2015-17 require that all deferred tax assets and liabilities be classified as noncurrent in the balance sheet.&nbsp;
	ASU 2015-17 is effective for interim and annual periods beginning after December 15, 2017, and interim periods within annual periods
	beginning after December 15, 2018. Companies can adopt the guidance either prospectively or retrospectively. The Company does not
	expect the adoption of ASU 2015-17 to have a material impact on its consolidated financial statements or presentation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 3:-
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 89%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.78IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; TEXT-ALIGN: JUSTIFY">
	Prepaid expenses
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	622
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	159
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Government authorities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	33
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Deferred costs (*)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	291
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	94
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	935
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	286
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	(*)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Inventory delivered to customers for which revenue criteria have not been met.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 94; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage95"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 4:-
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	INVENTORIES
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 83%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 85.05PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Raw materials
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	469
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	68
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN">
	Finished products
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	132
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	166
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	601
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	234
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 5:-
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	PROPERTY AND EQUIPMENT, NET
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0.78IN">
	Composition
	of assets, grouped by major classification, is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 88%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.78IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Cost:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; TEXT-ALIGN: JUSTIFY">
	Computers and peripheral equipment
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	209
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	194
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Office furniture and equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	62
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	62
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Production lines
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	903
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	813
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Leasehold improvement
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	7
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	6
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,181
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,075
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Accumulated depreciation:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Computers and peripheral equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	140
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	88
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Office furniture and equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Production lines
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	276
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Leasehold improvement
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	4
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	432
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	97
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT">
	Property and equipment, net
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	749
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	978
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: NORMAL; FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	Depreciation
	expenses for the year ended December 31, 2015 and 2014 amounted to $335 and $549, respectively.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 95; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage96"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	NOTE
	6:-
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	OTHER
	ACCOUNTS PAYABLE AND ACCRUED EXPENSES
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE; WIDTH: 89%; MARGIN-LEFT: 0.75IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Employees and payroll accruals
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	247
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	205
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Accrued expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	434
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	679
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	681
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	884
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	NOTE
	7:-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	COMMITMENTS
	AND CONTINGENT LIABILITIES
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	a.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The facilities and motor vehicles of the Subsidiary are leased under several operating lease agreements.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Ltd. is party to a lease agreement in Israel for its offices for a period of 36 months commencing
	January 1, 2014 and scheduled to expire on December 31, 2016.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.5PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Commencing
	November 13, 2011 and through the year ended 2015, Ltd. also entered into several motor vehicle lease agreements for a period
	of 36 months. As of December 31, 2015 the Company maintains 11 leased cars.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	b.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	In December 2015 the Company entered into a lease agreement in the United States for its offices
	for a period of 12 months commencing February 1, 2016 and scheduled to expire on January 31, 2017.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 76.5PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	c.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	As of December 31, 2015, the future minimum aggregate lease commitments under non-cancelable operating
	lease agreements are as&nbsp;follows:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 82%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 1.22IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	As of ended December 31,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Facilities
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Motor
<BR>
	vehicles
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 46%; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	2016
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	139
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	81
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	220
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	2017
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	38
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	39
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	2018
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	15
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	15
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	140
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	134
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	274
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	Facility and motor vehicle
	lease expenses for the year ended December&nbsp;31, 2015 and 2014 were $232 and $273, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.5PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	d.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	As of December 31, 2015, Ltd. established guarantees to cover rent agreements and credit cards
	commitments that amounted to $50.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 96; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage97"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	NOTE
	8:-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	TAXES
	ON INCOME
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	a.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Company and Ltd. are separately taxed under the domestic tax laws of the state of incorporation
	of each entity. LabStyle US is a pass through entity for U.S. income tax purposes.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	b.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tax rates applicable to Ltd.:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Corporate
	tax rate in Israel in 2014 and 2015 is 26.5%.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	On January
	4, 2016, the Israeli Parliament's Plenum approved by a second and third reading the Bill for Amending the Income Tax Ordinance
	(No. 217) (Reduction of Corporate Tax Rate), 2015, which consists of the reduction of the corporate tax rate from 26.5% to 25%.
	The Company estimates that the effect of the change in tax rates will result in a decrease in deferred tax balances as of December
	31, 2015 in immaterial amounts.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	c.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Net operating loss carryforward:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Ltd.
	has accumulated net operating losses for Israeli income tax purposes as of December&nbsp;31, 2015 in the amount of approximately
	$18,675. The net operating losses may be carried forward and offset against taxable income in the future for an indefinite period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	As of
	December 31, 2015, the Company had a U.S. federal net operating loss carryforward of approximately $4,877 that can be carried forward
	and offset against taxable income and that expires during the years 2031 to 2035. Utilization of U.S. loss carryforward may be
	subject to substantial annual limitation due to the &quot;change in ownership&quot; provisions of the Internal Revenue Code of
	1986 and similar state provisions. The annual limitations may result in the expiration of losses before utilization.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	d.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Deferred income taxes:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Deferred
	income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
	purposes and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets are as follows:
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 82%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 1.23IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Deferred tax assets:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Net operating loss carry forward
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	6,900
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	5,099
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9PT">
	Temporary differences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	713
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	927
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Deferred tax assets before valuation allowance
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,613
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,026
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Valuation allowance
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(7,613
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(6,026
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net deferred tax asset
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 97; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage98"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.5PT; TEXT-INDENT: -85.5PT">
<B>
	NOTE 8:-&#9;TAXES ON INCOME
	(Cont.)
</B>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The
	deferred tax balances included in the financial statements as of December 31, 2015 are calculated according to the tax rates that
	were in effect as of the reporting date and do not take into account the potential effects of the reduction in the tax rate. Said
	effects will be included in the financial statements that will be issued starting from the date on which the new tax rate is substantially
	enacted, namely in the first quarter of 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The
	net change in the total valuation allowance for the year ended December 31, 2015 was an increase of $1,587 and is mainly relates
	to increase in deferred taxes on net operating loss for which a full valuation allowance was recorded. In assessing the realizability
	of deferred tax assets, management considers whether it is more likely than not that some or all of the deferred tax assets will
	not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the
	periods in which those temporary differences and tax loss carryforward are deductible. Management considers the projected taxable
	income and tax-planning strategies in making this assessment. In consideration of the Company's accumulated losses and the uncertainty
	of its ability to utilize its deferred tax assets in the future, management currently believes that it is more likely than not
	that the Company will not realize its deferred tax assets and accordingly recorded a valuation allowance to fully offset all the
	deferred tax assets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	e.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Loss before taxes on income consists of the following:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 82%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 1.22IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year ended
<BR>
	December 31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT">
	Domestic
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	783
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	3,598
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Foreign
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	6,359
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	9,279
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 2.85PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 2.85PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	7,142
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	12,877
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	f.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The main reconciling item between the statutory tax rate of the Company and the effective tax rate
	is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating losses carried forward
	due to the uncertainty of the realization of such deferred taxes.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 98; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage99"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
	NOTE 9:-
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	STOCKHOLDERS' DEFICIT AND CONVERTIBLE PREFERRED
	SHARES
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 27.75PT">
	a.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The holders of Common Stock have the right to one vote for each share of Common Stock held of record
	by such holder with respect to all matters on which holders of Common Stock are entitled to vote, to receive dividends as they
	may be declared in the discretion of the Company&rsquo;s Board of Directors and to participate in the balance of the Company's
	assets remaining after liquidation, dissolution or winding up, ratably in proportion to the number of shares of Common Stock held
	by them after giving effect to any rights of holders of preferred stock. Except for contractual rights of certain investors, the
	holders of Common Stock have no pre-emptive or similar rights and are not subject to redemption rights and carry no subscription
	or conversion rights.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 27.75PT">
	b.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On September 23, 2014, the Company consummated the final closing of a private placement with existing
	and new institutional and accredited investors (the &quot;September 2014 Private Placement&quot;) pursuant to which the Company
	raised $4,096 in net proceeds by issuance of aggregate 42,350 units which consist of 42,350 shares of newly designated Series A
	Convertible Preferred Stock (the &quot;Series A Preferred Stock&quot;) which are convertible into up to an aggregate of 10,683,662
	shares of Common Stock, and warrants to purchase 5,341,834 shares of Common Stock with an exercise price of $0.48 per share which
	is subject to a standard anti-dilution protection clause. Such warrants contain a net settlement cash feature and liquidated damages
	penalties and therefore accounted as a liability according to the provisions of ASC 815-40 &ldquo;Contracts in entity's own equity&rdquo;.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -27.75PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 27.75PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The holders of Series A Preferred Stock have rights, preferences and privileges, as follows:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 120.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<I>
	Liquidation
	preference
</I>
	&nbsp;- Based on preference of distribution, the holders of Series A Preferred Stock shall be entitled to receive,
	out of funds legally available thereof, as determined by the Company's Board of Directors, dividends at an amount per share which
	is equal (on an as converted to Common Stock basis) to and in the same form as dividends actually paid on shares of Common Stock,
	as and if such dividends are paid on shares of Common Stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Based
	on preference of any distribution, liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, including,
	without limitation, upon any deemed liquidation as determined in the COI, the Company's assets or surplus funds legally available
	for distribution shall be distributed to the holders of Series A Preferred Stock pursuant to which each Series A Preferred Stock
	will be entitled to receive the original issue price paid by each Series A Preferred stockholder, plus all accrued but unpaid dividends
	for each share of Common Stock. The aggregate liquidation preference as of December 31, 2015 amounted to $3,560.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 99; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage100"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	NOTE
	9:-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	STOCKHOLDERS'
	DEFICIT AND CONVERTIBLE PREFERRED SHARES (Cont.)
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<I>
	Preemptive
	rights
</I>
	&nbsp;- One Series A Preferred Stockholder has a preemptive right to participate in future financings for a period of
	two years in an amount necessary to maintain such investor&rsquo;s fully-diluted percentage interest in the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<I>
	Voting
</I>
	&nbsp;-
	Each stockholder shall have one vote for each share of Common Stock held by such stockholder of record of such Common Stock as
	would be held by each holder of Series A Preferred Stock if all shares of Series A Preferred Stock were converted to Common Stock
	at the then effective conversion rate, on every resolution.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<I>
	Conversion
</I>
	&nbsp;-
	Each holder of a Series A Preferred Stock shall be entitled to convert, at any time and from time to time, and without
	payment of additional consideration, into such number of fully paid and non-assessable shares of Common Stock in ratio as
	determined in the COI. The conversion price shall be subject to standard anti-dilution adjustments as described in the
	COI.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Upon
	the written election of the holders of a majority of the outstanding Series A Preferred Stock, all shares of Series A Preferred
	Stock shall automatically be converted into fully paid and non-assessable shares of Common Stock.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	During 2015, 6,052 shares of
	Series A Preferred Stock have been converted into 1,526,609 shares of Common Stock and therefore an amount of $400 was credited
	to additional paid in capital in the Company's statement of changes in stockholders' deficiency.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 39.3PT">
</TD>
<TD STYLE="WIDTH: 45.75PT">
	c.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On February 25, 2015 and March 16, 2015, the Company completed two closings of a private placement
	(the &ldquo;February 2015 Private Placement&rdquo;) with existing and new institutional and accredited investors and raised $1,956
	in net proceeds through the issuance of 11,286,444 shares of Common Stock, and series A warrants to purchase 2,821,613 shares of
	Common Stock (the &ldquo;Series A Warrants&rdquo;) and series B warrants to purchase 2,821,613 shares of Common Stock (the &ldquo;Series
	B Warrants&rdquo;). Out of the above issuance, 1,150,000 shares of Common Stock, 287,500 Series A Warrants and 287,500 Series B
	Warrants were purchased by the Chief Financial Officer of the Company for gross proceeds of $207 and 1,111,111 shares of Common
	Stock, 277,778 Series A Warrants and 277,778 Series B Warrants were purchased by one of the directors of the Company for gross
	proceeds of $200.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The Series
	A Warrants are immediately exercisable at an exercise price of $0.24 per share and expire 9 months from the closing of the February
	2015 Private Placement in which such warrants were purchased. The Series B Warrants are immediately exercisable at an exercise
	price of $0.30 per share and expire 36 months from the closing of the February 2015 Private Placement in which such warrants were
	purchased. The Series A Warrants and Series B Warrants are eligible also for &ldquo;cashless exercise&rdquo; only if the underlying
	shares of Common Stock are not registered for resale. The Series A Warrants and the Series B Warrants contain a standard anti-dilution
	protection clause.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 100; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage101"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	NOTE
	9:-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	STOCKHOLDERS'
	DEFICIT AND CONVERTIBLE PREFERRED SHARES (Cont.)
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The Series
	B Warrants are callable by the Company for nominal consideration in the event that the share price of the Common Stock trades over
	$0.80 (adjusted for splits and the like) for 20 consecutive trading days.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	With respect
	to the February 2015 Private Placement the Company entered into a finder&rsquo;s fee agreement with a finder according to which
	the finder shall receive a cash fee of approximately $43 and immediately exercisable warrants to purchase: i) 241,423 shares of
	Common Stock with an exercise price of $0.18, with a &ldquo;cashless exercise&rdquo; feature and which are exercisable by February
	25, 2018; ii) 60,356 shares of Common Stock with an exercise price of $0.24 which expired on November 25, 2015; and iii) 60,356
	shares of Common Stock with an exercise price of $0.30 and which are exercisable by February 25, 2018. All finders' warrants contain
	a standard anti-dilution protection clause.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The Company
	was required to file a registration statement for the resale of the shares and warrants shares issued in the February 2015 Private
	Placement within&nbsp;60&nbsp;days following the closing date and to use its reasonable best efforts to cause such registration
	statement to be declared effective within&nbsp;75 days following the closing date (or&nbsp;150 days following the closing date
	if the Securities and Exchange Commission determines to review the registration statement). The Company could incur liquidated
	damages if it did not meet the registration obligations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	On April
	8, 2015, the Company filed a registration statement covering the public resale of up to 11,286,444 shares of Common Stock, 2,821,613
	shares of Common Stock underlying the Series A Warrants and 2,821,613 shares of Common Stock underlying the Series B Warrants,
	sold in the February 2015 Private Placement (the &ldquo;Fifth Registration Statement&rdquo;). The Fifth Registration Statement
	was declared effective on April 24, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.4IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 39.3PT">
</TD>
<TD STYLE="WIDTH: 45.75PT; TEXT-ALIGN: LEFT">
	d.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On April 3, 2015, the Company's Board of Directors approved
	the following:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 85.05PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	To reserve 400,000 shares of Common Stock under the terms of an engagement agreement with a service
	provider (&ldquo;Service Provider Agreement&rdquo;) dated March 15, 2015 (the &ldquo;Effective Date&rdquo;) offering investor relations
	services (&ldquo;Services&rdquo;) to the Company. The Service Provider Agreement is for a period of one year beginning with the
	Effective Date (the &ldquo;Term&rdquo;), pursuant to which in addition to monthly retainer Company shall issue 100,000 shares of
	Common Stock on a quarterly basis over the Term in consideration for the Services. The Company recorded General and Administrative
	expenses amounting to $118 in connection with 300,000 shares of Common Stock that have been issued during the year ended December
	31, 2015.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 101; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage102"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	NOTE
	9:-
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	STOCKHOLDERS'
	DEFICIT AND CONVERTIBLE PREFERRED SHARES (Cont.)
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 85.05PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	A salary program pursuant to which the Company will issue up to 2,200,000 compensation shares of
	restricted Common Stock (&ldquo;Compensation Shares&rdquo;) to directors, officers and employees of the Company as consideration
	for a reduction in or waiver of cash salary or fees owed to such individuals. The waiver of cash salary will be done upon the average
	closing price of the Common Stock for the 30 trading days prior to the date the Compensation Shares are granted.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	During the
	year ended December 31, 2015, the Company issued 998,403 Compensation Shares to certain members of the Board of Directors and officers
	as consideration for a waiver of cash owed to such individuals amounting to $304.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	e.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On May 5, 2015 (the &quot;Commitment Date&quot;), the Company&rsquo;s Board of Directors approved
	a warrant exercise and replacement agreement according to which upon the Company's request for a period of eight business days
	the holders of warrants from the February 2015 Private Placement were able to exercise for cash their outstanding 2,881,694 warrants.
	Upon such exercise, the Company issued the participating holders additional warrants to purchase the same number of additional
	shares of Common Stock, for an exercise price of $0.24 per share, having the same terms and conditions of the exercised warrants.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The
	transaction was accounted for in accordance with ASC 470-20 &quot;Debt with Conversion and Other Options&quot; (&ldquo;ASC 470&rdquo;),
	pursuant to which the induced conversion privileges are exercisable only for a limited period of time and includes the issuance
	of all of the equity securities issuable pursuant to conversion privileges included in the terms of the warrants at issuance for
	each warrant instrument that is converted. Therefore, the induced conversion was accounted for as a deemed dividend and measured
	at the Commitment Date in a total amount of $154.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Under
	this offer, 1,923,636 warrants were exercised into 1,923,636 shares of Common Stock for a total net consideration of $453.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 76.5PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	f.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On July 23, 2015 and August 28, 2015, the Company completed two closings of a private placement
	(the &ldquo;July 2015 Private Placement&rdquo;) with existing and new institutional and retail investors and raised approximately
	$2,325 in net proceeds through the issuance of 8,646,203 shares of Common Stock, and series A warrants to purchase 4,709,821 shares
	of Common Stock (the &ldquo;2015 Series A Warrants&rdquo;) and Series B Warrants to purchase 4,709,821 shares of Common Stock (the
	&ldquo;2015 Series B Warrants&rdquo;) and 449,157 shares of Common Stock underlying Placement Agent Warrants. Out of the above
	issuance, 750,000 shares of Common Stock, 375,000 2015 Series A Warrants and 375,000 2015 Series B Warrants were purchased by the
	Chief Financial Officer of the Company for gross proceeds of $225 and 40,000 shares of Common Stock, 20,000 2015 Series A Warrants
	and 20,000 2015 Series B Warrants were purchased by the Chief Executive Officer of the Company for gross proceeds of $12. Out of
	the above issuances, 245,333 and 50,000 restricted shares of Common Stock were issued to finders and to a placement agent, respectively.
	In addition, the Company also issued to a finder 439,630 non-plan stock options.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 102; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage103"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	NOTE
	9:-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	STOCKHOLDERS'
	DEFICIT AND CONVERTIBLE PREFERRED SHARES (Cont.)
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The
	2015 Series A Warrants are immediately exercisable at an exercise price of $0.35 per share and expire 12 months from the closing
	date. The 2015 Series B Warrants are immediately exercisable at an exercise price of $0.40 per share and expire 36 months from
	the closing date. The 2015 Series A and Series B Warrants are exercisable for cash or on a cashless basis if a registration statement
	covering the shares issuable upon exercise of the Warrants is unavailable. The non-plan stock options issued to the finder are
	fully vested and exercisable after the lapse of four months from the grant date in December 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	With
	respect to the July 2015 Private Placement, the Company entered into finder's fee agreements with certain finders according to
	which the finders received 245,333 restricted shares of Common Stock and 619,606 warrants, evenly divided between &ldquo;Series
	A Finders Warrants&rdquo; and &ldquo;Series B Finders Warrants&rdquo;. The Series A Finders Warrants are exercisable at an exercise
	price of $0.35 per share and expire 12 months from the date of the closing of the July 2015 Private Placement at which such warrants
	were issued. The Series B Finders Warrants are exercisable at an exercise price of $0.40 per share and expire 3 years from the
	date of the closing of the July 2015 Private Placement at which such warrants were issued.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Issuance
	costs related to the July 2015 Private Placement were approximately $181 ($122 out of which related to the placement agent). In
	addition, the Company issued to the placement agent 50,000 restricted shares of Common Stock and an aggregate of 898,313
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	warrants
	to the placement agent and to a selected dealer (the &ldquo;Placement Agent Warrants&rdquo;). The Company issued three types of
	Placement Agent Warrants, of which (i) the first will have an exercise price of $0.30 per share exercisable over a period of three
	years, (ii) the second will have an exercise price of $0.35 per share, exercisable over a period of one year; and (iii) the third
	will have an exercise price of $0.40 per share, exercisable over a period of three years. The Placement Agent Warrants are exercisable
	for cash or on a cashless basis and have similar registration rights as the shares but also include piggyback registration rights.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The
	Company was required to file a registration statement for the resale of the shares and warrants shares issued in the July 2015
	Private Placement within&nbsp;60&nbsp;days following the closing date and to use its reasonable best efforts to cause such registration
	statement to be declared effective within&nbsp;75 days following the closing date (or&nbsp;150 days following the closing date
	if the Securities and Exchange Commission determines to review the registration statement).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	On September
	21, 2015, the Company filed a registration statement covering the public resale of up to 8,350,870 shares of Common Stock, 4,400,018
	shares of Common Stock underlying the 2015 Series A Warrants, 4,400,018 shares of Common Stock underlying the 2015 Series B Warrants
	and 449,157 shares of Common Stock underlying the Placement Agent Warrants issued in the July 2015 Private Placement (the &ldquo;Sixth
	Registration Statement&rdquo;) which was declared effective on October 2, 2015.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 103; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage104"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	NOTE
	9:-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	STOCKHOLDERS'
	DEFICIT AND CONVERTIBLE PREFERRED SHARES (Cont.)
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The
	July 2015 Private Placement triggered the anti-dilution mechanism of the warrants issued in the 2011-2012 Private Placement by
	adjusting the current exercise price of the warrants for the investors and placement agent from $0.64 to $0.45 per share and an
	additional 2,307,106 and 439,347 shares became subject to such warrants, respectively. In addition, the exercise price of the placement
	agent's warrants in the 2011-2012 Private Placement, was adjusted from $0.53 to $0.38 per share and an additional 311,874 warrants
	were issued.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	g.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On September 3, 2015, the Company's Board of Directors approved the issuance of 1,748,166 shares
	of Common Stock under the 2012 Equity Incentive Plan to certain employees according to the Israeli sub-plan. Consequently, the
	Company recorded General and Administrative and Research and Development expenses amounting to $514 and $77, respectively.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	h.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On September 17, 2015, the Company's Board of Directors approved the issuance of 50,000 shares
	of Common Stock to a service provider. Consequently, the Company recorded General and Administrative expenses amounting to $16
	in the statements of comprehensive loss.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	i.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On November 19, 2015 the Company completed a closing of a private placement (the &quot;November
	2015 Private Placement&quot;) with existing shareholders and private investors and raised approximately $2,924 in net proceeds
	through the issuance of 8,031,734 shares of Common Stock, 5,929,955 Series A Warrants (the &quot;November 2015 Series A Warrants&quot;)
	and 2,541,409 Series B Warrants (the &quot;November 2015 Series B Warrants&quot;). Out of the above
	issuances, 383,467 restricted shares of Common Stock, 576,168 November 2015 Series A Warrants and 246,929 November 2015 Series
	B Warrants were issued to finders. In connection with the November 2015 Private Placement the Company also issued to a finder 439,630
	non-plan stock options.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The
	November 2015 Series A Warrants are immediately exercisable at an exercise price of $0.37 per share and expire 16 months from the
	closing date. The November 2015 Series B Warrants are immediately exercisable at an exercise price of $0.43 per share and expire
	36 months from the closing date. The November 2015 Series A Warrants and November 2015 Series B Warrants are eligible also for
	&ldquo;cashless exercise&rdquo; only if the underlying shares of Common Stock are not registered for resale.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	With
	respect to the November 2015 Private Placement the Company entered into a finder&rsquo;s fee agreements with certain finders according
	to which the finders received 383,467 restricted shares of Common Stock, 576,168 November 2015 Series A Warrants, 246,929 November
	2015 Series B Warrants and 439,630 fully vested non-plan stock options having an exercise price of $0.0001. The non-plan stock
	options are fully vested and exercisable after the lapse of four months from the grant date in December 2015. The warrants issued
	to the finders are subject to the same terms as those issued to the investors.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 104; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage105"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	NOTE
	9:-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	STOCKHOLDERS'
	DEFICIT AND CONVERTIBLE PREFERRED SHARES (Cont.)
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The
	November 2015 Private Placement triggered the anti-dilution mechanism of the warrants issued in the 2011-2012 Private Placement
	by adjusting the current exercise price of the warrants for the investors and placement agent from $0.45 to $0.36 per share and
	an additional 1,930,017 and 367,526 shares became subject to such warrants, respectively. In addition, the exercise price of the
	placement agent's warrants in the 2011-2012 Private Placement, was adjusted from $0.38 to $0.31 per share and an additional 249,977
	warrants were issued.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT; TEXT-ALIGN: LEFT">
	j.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On October 22 2015, the Company's Board of Directors
	approved a warrant replacement agreement (the &quot;September 2014 round Replacement Agreement&quot;) with the September 2014
	Private Placement Purchasers pursuant to which up to 5,341,834 outstanding warrants that contain a net settlement cash feature
	will be replaced by new warrants to acquire up to an aggregate of 5,876,021 shares of common stock at an exercise price of $0.4755
	per share, which warrants are subject to standard anti-dilution protections. Consequently, certain investors replaced 4,320,135
	outstanding warrants that contain certain net settlement cash features by 4,752,147 new warrants to acquire an aggregate of 4,752,147
	shares of Common Stock at an exercise price of $0.4755 per share which are subject to standard anti-dilution protections and do
	not contain a net settlement cash feature. As of December 31, 2015 the Company's offer to the warrant holders expired.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The
	above replacement is considered as a modification of the warrants' terms of the September 2014 Private Placement. As a result,
	and in accordance with ASC 470 the incremental value that was generated to the particular Purchasers from the aforementioned exchanged
	warrants was recorded as financial expenses in the amount of $75 in the consolidated statement of comprehensive loss.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The
	September 2014 round Replacement Agreement triggered the anti-dilution mechanism of the warrants issued in the 2011-2012 Private
	Placement and an additional 81,840 and 15,581 shares became subject to such warrants, respectively. In addition, 13,159 additional
	shares became subject to the warrants issued to the placement agent of the 2011-2012 Private Placement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The
	table below presents the September 2014 Private Placement carrying value of the warrants issued in such placement:
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 82%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 1.23IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year ended
<BR>
	December 31,
<BR>
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -11.35PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 80%; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -11.35PT; PADDING-LEFT: 11.35PT">
	Fair value of warrants at December 31, 2014
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 17%; TEXT-ALIGN: RIGHT">
	101
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -11.35PT; PADDING-LEFT: 11.35PT">
	Revaluation of warrants during 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,099
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 0.1IN">
	Reclassification of warrants to additional paid-in capital upon warrant replacement agreement in November and December 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(822
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -11.35PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -11.35PT; PADDING-LEFT: 11.35PT">
	Fair value of warrants at December 31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	378
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -11.35PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: PAGE; SEQUENCE: 105; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage106"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: -1.15PT; FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 9:-
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	STOCKHOLDERS'
	DEFICIT AND CONVERTIBLE PREFERRED SHARES (Cont.)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT; TEXT-ALIGN: LEFT">
	k.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On December 24, 2015, the Company completed a private
	placement (the &ldquo;December 2015 Private Placement&rdquo;) with a new investor and raised $500 in net proceeds through the
	issuance of 1,461,988 shares of Common Stock and warrants to purchase 1,461,988 shares of Common Stock (the &quot;December 2015
	Warrants&quot;). The December 2015 Warrants are immediately exercisable at an exercise price of $0.34 per share and expire 6 months
	from the closing of the December 2015 Private Placement. The December 2015 Warrants are eligible also for &ldquo;cashless exercise&rdquo;
	only if the underlying shares of Common Stock are not registered for resale.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The
	December 2015 Private Placement triggered the anti-dilution mechanism of the warrants issued in the 2011-2012 Private Placement
	to the investors and placement agent by adjusting the current exercise price of the warrants from $0.36 to $0.35 per share and
	an additional 283,068 and 53,906 shares became subject to such warrants, respectively.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 106; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage107"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: -1.15PT; FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 9:-
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	STOCKHOLDERS'
	DEFICIT AND CONVERTIBLE PREFERRED SHARES (Cont.)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	l.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The table below summarizes the outstanding warrants as of December 31, 2015:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 84%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 1.2IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Warrants
<BR>
	outstanding as of
<BR>
	December 31, 2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	Exercise price
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Expiration date
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	Investors of the 2011-2012 Private Placement
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	10,090,941
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	0.35
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 18%; TEXT-ALIGN: CENTER">
	October 26, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	Placement agent of the 2011-2012 Private Placement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,921,642
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.35
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	April 8, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	Placement agent of the 2011-2012 Private Placement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,374,773
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.31
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	April 8, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	October 2012 Private Placement FINRA member
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	29,585
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	October 16, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	April-May 2013 Private Placement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	400,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	25.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	April 4, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	Placement agent of the April-May 2013 Private Placement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	80,003
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12.50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	April 4, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	Placement agent of the April-May 2013 Private Placement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	40,005
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	25.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	April 4, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	Investors of the September 2014 Private Placement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,021,699
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.48
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	September 23, 2018
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	September 2014 PPM-Warrant Replacement Agreement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,752,147
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.48
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	September 23, 2018
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	February 2015 PPM A (*)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	83,334
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.24
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	November 25,2015
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	February 2015 PPM B
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,266,057
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.30
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	February 25,2018
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	February 2015 PPM A-Finders
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	241,422
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.18
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	February 25,2018
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	February 2015 PPM - C Finders
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	60,356
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.30
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	February 25,2018
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	February 2015 PPM - B 2nd closing
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	555,556
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.30
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	March 16, 2018
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	May 2015 replacement warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,863,280
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.24
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	February 15, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	May 2015 replacement warrants (PA)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	60,356
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.24
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	February 15, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	July 2015 PPM - 2015 Series A Warrants - 1st Closing
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,375,135
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.35
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	July 23, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	July 2015 PPM - 2015 Series B Warrants - 1st Closing
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,500,135
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.40
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	July 23, 2018
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	July 2015 PPM - 2015 Series A Warrants (Finder's warrants)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	309,803
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.35
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	August 28, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	July 2015 PPM - 2015 Series B Warrants (Finder's warrants)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	309,803
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.40
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	August 28, 2018
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	July 2015 PPM - 2015 Series B Warrants-2nd Closing
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,675,305
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.40
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	August 28, 2018
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	July 2015 PPM (PA) - 1st Closing
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	425,022
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.30
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	July 23, 2018
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	July 2015 PPM (PA) - 2015 Series A Warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	212,511
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.35
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	July 23, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	July 2015 PPM (PA) - 2015 Series B Warrants - 2nd Closing
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,067
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.35
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	August 28, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	July 2015 PPM (PA) - 2nd Closing
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	212,511
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.40
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	July 23, 2018
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	July 2015 PPM - 2015 Series A Warrants-2nd Closing
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,675,305
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	July 2015 PPM (PA) - 2015 Series B Warrants - 2nd Closing
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,067
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.40
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	August 28, 2018
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	July 2015 PPM (PA) - 2nd Closing
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	24,135
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.30
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	August 28, 2018
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	November 2015 PPM - 2015 Series A Warrants (Finder's warrants)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	576,168
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.37
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	March 19, 2017
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	November 2015 PPM - 2015 Series B Warrants (Finder's warrants)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	246,929
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.43
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	November 19, 2018
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	November 2015 PPM - Series A Warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,353,787
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.37
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	March 19, 2017
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	November 2015 PPM - Series B Warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,294,480
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.43
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	November 19, 2018
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	December 2015 PPM - Warrants
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,461,988
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	0.34
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	June 24, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -5.75PT; PADDING-LEFT: 5.75PT">
	Total outstanding
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	44,518,307
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<BR CLEAR="ALL">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 1.2IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
	(*)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Warrants for which cash has been received by the Company
	but no securities issued.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 107; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage108"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: -1.15PT; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
	NOTE 9:-
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	STOCKHOLDERS' DEFICIT AND CONVERTIBLE PREFERRED
	SHARES (Cont.)
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	During
	the year ended December 31, 2015, proceeds from warrants exercised amounted to $513 following the issuance of 2,118,080 shares
	of Common Stock out of which none were issued utilizing a cashless exercise feature. During the year ended December 31, 2014, proceeds
	from warrants exercised amounted to $343 following the issuance of 68,524 shares of Common Stock out of which none were issued
	utilizing a cashless exercise feature.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	m.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Stock-based compensation:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 85.05PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On January&nbsp;23, 2012, an equity incentive plan (the &quot;2012 Plan&quot;) was adopted by the
	Board of Directors of the Company and approved by a majority of the Company's stockholders, under which options to purchase up
	to 572,000 shares of Common Stock have been reserved. Under the 2012 Plan, options to purchase shares of Common Stock may be granted
	to employees and non-employees of the Company or any affiliate, each option granted can be exercised to one share of Common Stock.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 85.05PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On January&nbsp;23, 2012, the 2012 Israeli equity sub plan (the &quot;Sub Plan&quot;) was adopted
	by the Board of Directors of the Company, which set forth the terms for the grant of stock awards to Israeli employees or Israeli
	non-employees. The Sub Plan was adopted in accordance with the amended sections 102 and 3(i) of Israel's Income Tax Ordinance.
	The Sub Plan is part of the 2012 Plan and subject to the same terms and conditions.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 85.05PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	During February 2013, the Board of Directors and majority stockholders of the Company approved
	an increase in the size of the 2012 Plan from 572,000 shares of Common Stock to 1,000,000 shares of Common Stock.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 85.05PT">
</TD>
<TD STYLE="WIDTH: 28.35PT; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On June 17, 2014, the Board of Directors and majority stockholders of the Company approved an
	increase in the size of the 2012 Plan from 1,000,000 shares of Common Stock to 1,500,000 shares of Common Stock.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 85.05PT">
</TD>
<TD STYLE="WIDTH: 28.35PT; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On June 15, 2015, the Company held its 2015 Annual Meeting of Stockholders in which, among
	other matters, Company stockholders approved an amendment to the 2012 Plan to increase the number of shares authorized for
	issuance under the 2012 Plan by 11,925,000 shares from 1,500,000 to 13,425,000 shares of Common Stock.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 85.05PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On September 3, 2015, the Company's Compensation Committee of the Board of Directors approved the
	grants of 6,308,634, 1,368,000 and 650,000 options to employees, directors and consultants of the Company, respectively, at an
	exercise price of $0.32 per share. 2,360,543 of such stock options are vested upon grant and the remainder shall vest over a period
	of two to three years commencing on the grant date. All of the aforementioned options have six year term. 7,345,834 options were
	issued under the 2012 Plan and 980,800 options are non-plan.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 108; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage109"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: -1.15PT; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
	NOTE 9:-
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	STOCKHOLDERS' DEFICIT AND CONVERTIBLE PREFERRED
	SHARES (Cont.)
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	On December
	17, 2015, the Company's Compensation Committee of the Board of Directors approved the grants of 652,500, and 657,000 options to
	employees and consultants of the Company, respectively, at an exercise price of $0.39 per share. The options shall vest over a
	period of three years commencing on the grant date. All of the aforementioned options have a six year term. 1,259,500 options were
	issued under the 2012 Plan and 50,000 options were issued to a member of the Company&rsquo;s Scientific Advisory Board which are
	non-plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Transactions
	related to the grant of options to employees, directors and non-employees under the above plans during the year ended December
	31, 2015 were as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 77%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 113.4PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of
<BR>
	options
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted
<BR>
	average
<BR>
	exercise
<BR>
	price
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted
<BR>
	average
<BR>
	remaining
<BR>
	contractual
<BR>
	life
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Aggregate
<BR>
	Intrinsic
<BR>
	value
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Years
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.65PT; PADDING-LEFT: 8.5PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 48%; TEXT-ALIGN: LEFT; TEXT-INDENT: -10.1PT; PADDING-LEFT: 10.1PT">
	Options outstanding at beginning of year
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	1,317,400
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	6.59
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	6.98
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10.1PT; PADDING-LEFT: 10.1PT">
	Options granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,636,134
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.33
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10.1PT; PADDING-LEFT: 10.1PT">
	Options exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.01
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10.1PT; PADDING-LEFT: 10.1PT">
	Options expired
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	172,775
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.78
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -10.1PT; PADDING-LEFT: 10.1PT">
	Options forfeited
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	198,225
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	2.05
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10.1PT; PADDING-LEFT: 10.1PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -10.1PT; PADDING-LEFT: 10.1PT">
	Options outstanding at end of year
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	10,576,534
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	0.94
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	5.80
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,264
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10.1PT; PADDING-LEFT: 10.1PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -10.1PT; PADDING-LEFT: 10.1PT">
	Options vested and expected to vest at end of year
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	9,870,821
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	0.97
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	0.67
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,173
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10.1PT; PADDING-LEFT: 10.1PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -10.1PT; PADDING-LEFT: 10.1PT">
	Exercisable at end of year
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	3,975,581
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1.85
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	5.85
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	441
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<B>
	&nbsp;&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Weighted
	average fair value of options granted during the year ended December&nbsp;31, 2015 and 2014 is $0.33 and $2.82, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The aggregate
	intrinsic value in the table above represents the total intrinsic value (the difference between the Company's closing stock price
	on the last day of fiscal 2015 and the exercise price, multiplied by the number of in-the-money options) that would have been received
	by the option holders had all option holders exercised their options on December 31, 2015. This amount is impacted by the changes
	in the fair market value of the Common Stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 109; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	34
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage110"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: -1.15PT; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
	NOTE 9:-
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	STOCKHOLDERS' DEFICIT AND CONVERTIBLE PREFERRED
	SHARES (Cont.)
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The following
	table presents the assumptions used to estimate the fair values of the options granted in the period presented:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: YELLOW">
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 76%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 113.4PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="COLOR: BLACK; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP STYLE="COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" NOWRAP STYLE="COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year ended
<BR>
	December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="COLOR: BLACK; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP STYLE="COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="COLOR: BLACK; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="COLOR: BLACK">
	&nbsp;
</TD>
<TD NOWRAP STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: JUSTIFY">
	Volatility
</TD>
<TD STYLE="COLOR: BLACK">
	&nbsp;
</TD>
<TD NOWRAP STYLE="COLOR: BLACK; TEXT-ALIGN: CENTER">
	82.39%-87.28%
</TD>
<TD NOWRAP STYLE="COLOR: BLACK">
	&nbsp;
</TD>
<TD NOWRAP STYLE="COLOR: BLACK; TEXT-ALIGN: CENTER">
	54.57%-64.74%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: JUSTIFY">
	Risk-free interest rate
</TD>
<TD STYLE="COLOR: BLACK">
	&nbsp;
</TD>
<TD NOWRAP STYLE="COLOR: BLACK; TEXT-ALIGN: CENTER">
	1.00%-1.54%
</TD>
<TD NOWRAP STYLE="COLOR: BLACK">
	&nbsp;
</TD>
<TD NOWRAP STYLE="COLOR: BLACK; TEXT-ALIGN: CENTER">
	1.65%-2.84%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 68%; COLOR: BLACK; TEXT-ALIGN: JUSTIFY">
	Dividend yield
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 15%; COLOR: BLACK; TEXT-ALIGN: CENTER">
	0%
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; COLOR: BLACK">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 15%; COLOR: BLACK; TEXT-ALIGN: CENTER">
	0%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: JUSTIFY">
	Expected life (years)
</TD>
<TD STYLE="COLOR: BLACK">
	&nbsp;
</TD>
<TD NOWRAP STYLE="COLOR: BLACK; TEXT-ALIGN: CENTER">
	5.68-8.51
</TD>
<TD NOWRAP STYLE="COLOR: BLACK">
	&nbsp;
</TD>
<TD NOWRAP STYLE="COLOR: BLACK; TEXT-ALIGN: CENTER">
	5-10
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 56.7PT 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	As of December
	31, 2015, the total unrecognized estimated compensation cost related to non-vested stock options granted prior to that date was
	$1,415, which is expected to be recognized over a weighted average period of approximately 1.16 years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The total
	compensation cost related to all of the Company's equity-based awards, recognized during year ended December 31, 2015 and 2014
	were comprised as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 76%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 113.4PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year ended
<BR>
	December 31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Cost of revenues
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	49
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	39
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Research and development
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	185
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	409
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Sales, Marketing and pre-production costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	111
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	29
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	General and administrative
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	653
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,215
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Total stock-based compensation expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	998
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,692
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 10:-
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	FAIR VALUE
	MEASURMENTS
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	a.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On March 30, 2012, the Company consummated the final closing of the 2011-2012 Private Placement
	pursuant to which certain accredited investors purchased an aggregate of 492,200 shares of Common Stock and warrants to purchase
	492,200 shares of Common Stock at an exercise price of $7.50 per share for total consideration of $2,461.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	The placement agent for the
	2011-2012 Private Placement and its permitted designees were granted warrants to purchase an aggregate of (i) 96,440 shares of
	Common Stock at the exercise price of $5.00 per share and (ii) 96,440 shares of Common Stock at the exercise price of $7.50 per
	share.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 110; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	35
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage111"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: -1.15PT; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 10:-
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	FAIR VALUE
	MEASURMENTS (Cont.)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Subsequent
	to the issuance of the 2011-2012 Private Placement warrants the original exercise price of the warrants for the investors and placement
	agent was adjusted from $7.50 per share to $0.35 per share and an additional 9,626,982 and 1,833,624 warrants were
</FONT>
	issued,
<FONT STYLE="FONT-SIZE: 10PT">
	respectively. In addition, the exercise price for the placement agent warrants of the 2011-2012 Private
	Placement, with an original exercise price of $5.00 per share was adjusted to $0.30 per share and an additional 1,289,376 warrants
	were issued.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	b.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On September 23, 2014, the Company consummated the September 2014 Private Placement (see also Notes
	9b and 9j).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The
	warrants of the 2011-2012 Private Placement and the warrants of the September 2014 Private Placement contain certain net
	settlement cash features and liquidated damages penalties and therefore the Company accounts for such warrants as a liability
	according to the provisions of ASC 815-40 and re-measured using the Binomial option-pricing model as described below.
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	In estimating
	the warrants' fair value, the Company used the following assumptions:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Investors'
	warrants in 2011-2012 Private Placement:
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 82%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 85.05PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
<BR>
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
<BR>
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: JUSTIFY">
	Risk-free interest rate (1)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	0.60
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	0.59
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Expected volatility (2)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	74.64
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	47.72
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Expected life (in years) (3)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.82
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.82
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Expected dividend yield (4)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Fair value per warrant
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.17
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.05
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Placement
	agent's warrants 2011-2012 Private Placement:
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 82%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 85.05PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
<BR>
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
<BR>
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: JUSTIFY">
	Risk-free interest rate (1)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	0.19
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	0.36
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Expected volatility (2)
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	86.65
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	46.46
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Expected life (in years) (3)
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	0.27
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	1.27
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Expected dividend yield (4)
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Fair value per warrant
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.14-0.18
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.83-1.06
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 111; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	36
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage112"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: -1.15PT; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 10:-
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	FAIR VALUE
	MEASURMENTS (Cont.)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Investors'
	warrants in September 2014 Private Placement:
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 82%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 85.05PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
<BR>
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Issuance
<BR>
	date
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: JUSTIFY">
	Risk-free interest rate (1)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1.24
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1.42
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Expected volatility (2)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	158.68
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	48.75
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Expected life (in years) (3)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.73
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Expected dividend yield (4)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Fair value per warrant
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.37
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.25
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 92.15PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 85.05PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Risk-free interest rate - based on yield rates of non-index linked U.S. Federal Reserve treasury
	bonds.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 85.05PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	(2)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Expected volatility - was calculated
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	based
	on actual historical stock price movements of the Company and other companies in the same industry over a
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	term that is equivalent to the expected term of the option.
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 92.15PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -35.45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 85.05PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	(3)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Expected life - the expected life was based on the expiration date of the warrants.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 92.15PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -35.45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 85.05PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	(4)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Expected dividend yield - was based on the fact that the Company has not paid dividends to its
	shareholders in the past and does not expect to pay dividends to its shareholders in the future.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The
	changes in Level 3 liabilities associated with the 2011-2012 Private Placement and the September 2014 Private Placement warrants
	are measured at fair value on a recurring basis. The following tabular presentation reflects the components of the liability associated
	with such warrants as of December 31, 2015:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 82%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 85.05PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Fair value
<BR>
	of liability
<BR>
	related to
<BR>
	warrants
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -11.35PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 85%; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -11.35PT; PADDING-LEFT: 11.35PT">
	Balance at December 31, 2014
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	4,003
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -11.35PT; PADDING-LEFT: 11.35PT">
	Exchange of warrants in November-December 2015 (see also Note 9j)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(822
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; TEXT-INDENT: -11.35PT; PADDING-LEFT: 11.35PT">
	Change in fair value of warrants during the period
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(571
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -11.35PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -11.35PT; PADDING-LEFT: 11.35PT">
	Balance at December 31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	2,610
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	As of December
	31, 2015, there were outstanding warrants to purchase 14,409,055 shares of Common Stock from the above issuances which were recorded
	as a liability.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 112; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	37
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage113"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: -1.15PT; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 11:-
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	SELECTED
	STATEMENTS OF OPERATIONS DATA
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	a.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	General and administrative:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 82%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 85.05PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year ended
<BR>
	December 31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT">
	Payroll, office and related
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,150
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	945
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Legal and professional fees
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	408
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,103
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Stock-based compensation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,169
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,215
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Issuance of Common Stock and warrants to service provider
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	134
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Other
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	87
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	377
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Total General and administrative
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	2,948
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	3,640
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	b.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Financial expenses, net:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 74.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_32"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 82%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 85.05PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year ended
<BR>
	December 31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Bank charges
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	22
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	23
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Foreign currency adjustments losses (gain)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	33
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Issuance cost related to warrants to investors and service provider
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	533
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Incremental value to the February 2014 Investors that resulted from Exchange Agreement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,124
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Change in the fair value of warrants
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(571
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,194
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 8.65PT">
	Total Financial expenses (income), net
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(556
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,519
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 113; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	38
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage114"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<B>
	LABSTYLE INNOVATIONS CORP. AND ITS SUBSIDIARIES
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: -1.15PT; TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-WEIGHT: BOLD">
<B>
	U.S. dollars in thousands (except stock and stock data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<EFX_SUBSEQUENT_EVENTS>
<A NAME="FIS_SUBSEQUENT_EVENTS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 0.78IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 12:-
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	SUBSEQUENT
	EVENTS
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT; TEXT-ALIGN: LEFT">
	a.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	In January 2016, 177,216 Compensation Shares of Common
	Stock were issued to certain members of the Board of Directors and Officers of the Company as consideration for a reduction in
	or waiver of cash salary or fees owed to such individuals. The waiver of cash salary is based upon the average closing price of
	the Common Stock for the 30 trading days prior to the date the Compensation Shares are granted.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	b.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	In January 2016, the Company issued 100,000 restricted shares of Common Stock under the terms of
	the Service Provider Agreement (See Note 9d).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	c.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	In January and February 2016 the Company issued 814,377 shares of Common Stock in connection with
	the exercise of 1,249,001 warrants, 765,861 of which were exercised on a cashless basis, that were issued as part of the warrants
	exercise and replacement agreement discussed in Note 9e for $116. Out of the above issuance, 287,500 shares of Common Stock were
	issued to the Chief Financial Officer of the Company for gross proceeds of $69.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	- - - - - - - - - - - - - - -
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 114; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	- F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	39
<!-- FIELD: /SEQUENCE -->
	-&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_SUBSEQUENT_EVENTS>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="eolPage115"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<A NAME="V430703_10K_HTM_A_026">
</A>
<B>
	SIGNATURES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	In
	accordance with Section&nbsp;13 or 15(d) of the Exchange Act, the registrant has duly caused this report to be signed on its behalf
	by the undersigned, thereunto duly authorized.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	Date: February
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	8
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	, 2016
</FONT>
</FONT>
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	LABSTYLE INNOVATIONS CORP.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD COLSPAN="3">
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	By:
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	/s/
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	Erez Raphael
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%">
<FONT STYLE="FONT-SIZE: 10PT">
	Name:
</FONT>
</TD>
<TD STYLE="WIDTH: 39%">
<FONT STYLE="FONT-SIZE: 10PT">
	Erez Raphael
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Title:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	President and Chief Executive Officer
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	By:
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	/s/
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	Zvi Ben David
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Name:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Zvi Ben David
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Title:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Financial Officer, Secretary and Treasurer
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In accordance with the
	Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and
	on the dates indicated.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; WIDTH: 30%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Person
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; WIDTH: 38%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Capacity
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; WIDTH: 30%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Date
</B>
</FONT>
</TD>
</TR>
<TR>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Erez Raphael
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	President, Chief Executive Officer and
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	February 8, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Erez Raphael
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Chairman of the Board (Principal Executive Officer)
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Zvi Ben David
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Financial Officer, Secretary and
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	February 8, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Zvi Ben David
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Treasurer (Principal Financial and Accounting Officer)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Richard B. Stone
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	February 8, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Richard B. Stone
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Malcolm Hoenlein
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	February 8, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Malcolm Hoenlein
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Rami Yehudiha
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	February 8, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Rami Yehudiha
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Dennis M. McGrath
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	February 8, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Dennis M. McGrath
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Hila Karah
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	February 8, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Hila Karah
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 115; OPTIONS: NEWSECTION LAST; VALUE: 76 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	76
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_SIGNATURES>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage116"></A>
<A NAME="V430703_EX4-22_HTM"></A>
<EFX_EXHIBIT_4>
<A NAME="FIS_EXHIBIT_4"></A>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 4.22
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	NEITHER THIS SECURITY NOR
	THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
	COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;
<U>
	SECURITIES
	ACT
</U>
	&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE
	SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF
	THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE COMPANY
	TO SUCH EFFECT.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Warrant No.
</FONT>
</TD>
<TD STYLE="WIDTH: 50%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	December 24, 2015
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	LABSTYLE INNOVATIONS CORP.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Series
	A Common Stock Purchase Warrant
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	THIS CERTIFIES THAT
</B>
	,
	for value received,
<B>
	[_______]
</B>
	(the &ldquo;
<B>
<U>
	Holder
</U>
</B>
	&rdquo;), is entitled to subscribe for and purchase,
	at the Exercise Price (as defined below), from LabStyle Innovations Corp., a Delaware corporation (the &ldquo;
<B>
<U>
	Company
</U>
</B>
	&rdquo;),
	shares of the Company&rsquo;s common stock, par value $0.0001 (the &ldquo;
<B>
<U>
	Common Stock
</U>
</B>
	&rdquo;), at any time prior
	to 5:00 p.m., New York time, on June 24, 2016 (the &ldquo;
<B>
<U>
	Warrant Exercise Term
</U>
</B>
	&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	This Warrant is issued
	in accordance with, and subject to, the terms and conditions described in the Securities Purchase Agreement, dated December 24,
	2015, between the initial Holder and the Company (the &ldquo;
<B>
<U>
	Purchase Agreement
</U>
</B>
	&rdquo;) entered into in connection
	with the private placement offering of the Company (the &ldquo;
<B>
<U>
	Offering
</U>
</B>
	&rdquo;) described in the Purchase Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	All capitalized terms
	used but not defined herein shall have the meanings ascribed to them in the Purchase Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	This Warrant is subject to the following
	terms and conditions:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Shares
</U>
	.
	The Holder has, subject to the terms set forth herein, the right to purchase up to an aggregate of 1,461,988 shares of Common Stock
	(the &ldquo;
<B>
<U>
	Warrant
</U>
</B>
<U>
<B>
	Shares
</B>
</U>
	&rdquo;) at a per share exercise price of $0.342, subject to adjustment as
	provided for herein (the &ldquo;
<B>
<U>
	Exercise Price
</U>
</B>
	&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Exercise
	of Warrant
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
<FONT STYLE="FONT-SIZE: 10PT">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Exercise
</U>
	.
	This Warrant may be exercised by the Holder at any time prior to the Warrant Exercise Term, in whole or in part, by delivering
	the notice of exercise attached as
<U>
	Exhibit A
</U>
	hereto (the &ldquo;
<B>
<U>
	Notice of Exercise
</U>
</B>
	&rdquo;), duly executed
	by the Holder to the Company at its principal office, or at such other office as the Company may designate, accompanied by payment,
	by wire transfer of immediately available funds to the order of the Company to an account designated by the Company, of the amount
	obtained by multiplying the number of Warrant Shares designated in the Notice of Exercise by the Exercise Price (the &ldquo;
<B>
<U>
	Purchase
	Price
</U>
</B>
	&rdquo;). For purposes hereof, &ldquo;
<B>
	Exercise Date
</B>
	&rdquo; shall mean the date on which all deliveries required
	to be made to the Company upon exercise of this Warrant pursuant to this Section 2(a) shall have been made.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	The
	Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. No originals of the Notice
	of Exercise shall be required to be delivered, nor shall any medallion guarantee (or any other type of guarantee or notarization)
	of any Notice of Exercise shall be required.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage117"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Issuance
	of Certificates
</U>
	. As soon as practicable after the exercise of this Warrant, in whole or in part, in accordance with Section
	2(a) hereof (and in no event later than two (2) Trading Days following the delivery of the Notice of Exercise), the Company, at
	its expense, shall cause to be issued in the name of and delivered to the Holder: (i) a certificate or certificates for (or, if
	applicable, by delivery through the facilities of the Depository Trust Company in electronic form of) the number of fully paid
	and non-assessable Warrant Shares to which the Holder shall be entitled upon such exercise and, if applicable, (ii) a new warrant
	of like tenor to purchase all of the Warrant Shares that may be purchased pursuant to the portion, if any, of this Warrant not
	exercised by the Holder. The Holder shall for all purposes hereof be deemed to have become the Holder of record of such Warrant
	Shares on the date on which the Notice of Exercise and payment of the Purchase Price in accordance with Section 2(a) hereof were
	delivered and made, respectively, irrespective of the date of delivery of such certificate or certificates, except that if the
	date of such delivery, notice and payment is a date when the stock transfer books of the Company are closed, such person shall
	be deemed to have become the holder of record of such Warrant Shares at the close of business on the next succeeding date on which
	the stock transfer books are open.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Taxes
</U>
	.
	The issuance of the Warrant Shares upon the exercise of this Warrant, and the delivery of certificates or other instruments representing
	such Warrant Shares, shall be made without charge to the Holder for any tax or other charge of whatever nature in respect of such
	issuance and the Company shall bear any such taxes in respect of such issuance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Adjustment
	of Exercise Price
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Adjustment
	for Reclassification, Consolidation or Merger
</U>
	. If while this Warrant, or any portion hereof, remains outstanding and unexpired
	there shall be (i) a reorganization or recapitalization (other than a combination, reclassification, exchange or subdivision of
	shares otherwise provided for herein), (ii) a merger or consolidation of the Company with or into another corporation or other
	entity in which the Company shall not be the surviving entity, or a reverse merger in which the Company shall be the surviving
	entity but the shares of the Company&rsquo;s capital stock outstanding immediately prior to the merger are converted by virtue
	of the merger into other property, whether in the form of securities, cash or otherwise, or (iii) a sale or transfer of the Company&rsquo;s
	properties and assets as, or substantially as, an entirety to any other corporation or other entity in one transaction or a series
	of related transactions, then, as a part of such reorganization, recapitalization, merger, consolidation, sale or transfer, unless
	otherwise directed by the Holder, all necessary or appropriate lawful provisions shall be made so that the Holder shall thereafter
	be entitled to receive upon exercise of this Warrant, during the period specified herein and upon payment of the Exercise Price
	then in effect, the greatest number of shares of capital stock or other securities or property that a holder of the Warrant Shares
	deliverable upon exercise of this Warrant would have been entitled to receive in such reorganization, recapitalization, merger,
	consolidation, sale or transfer if this Warrant had been exercised immediately prior to such reorganization, recapitalization,
	merger, consolidation, sale or transfer, all subject to further adjustment as provided in this Section 3. If the per share consideration
	payable to the Holder for Warrant Shares in connection with any such transaction is in a form other than cash or marketable securities,
	then the value of such consideration shall be determined in good faith by the Company&rsquo;s Board of Directors. The foregoing
	provisions of this paragraph shall similarly apply to successive reorganizations, recapitalizations, mergers, consolidations, sales
	and transfers and to the capital stock or securities of any other corporation that are at the time receivable upon the exercise
	of this Warrant. In all events, appropriate adjustment shall be made in the application of the provisions of this Warrant with
	respect to the rights and interests of the Holder after the transaction, to the end that the provisions of this Warrant shall be
	applicable after that event, as near as reasonably may be, in relation to any shares or other property deliverable or issuable
	after such reorganization, recapitalization, merger, consolidation, sale or transfer upon exercise of this Warrant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage118"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Adjustments
	for Split, Subdivision or Combination of Shares
</U>
	. If while this Warrant, or any portion hereof, remains outstanding and unexpired
	the Company shall subdivide (by any stock split, stock dividend, recapitalization, reorganization, reclassification or otherwise)
	the shares of Common Stock subject to acquisition hereunder, then, upon the effective date of such subdivision, the Exercise Price
	in effect immediately prior to such subdivision will be proportionately reduced and the number of shares of Common Stock subject
	to acquisition upon exercise of the Warrant will be proportionately increased. If the Company at any time combines (by reverse
	stock split, recapitalization, reorganization, reclassification or otherwise) the shares of Common Stock subject to acquisition
	hereunder, then, upon the effective date of such combination, the Exercise Price in effect immediately prior to such combination
	will be proportionately increased and the number of shares of Common Stock subject to acquisition upon exercise of the Warrant
	will be proportionately decreased.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Notice
	of Adjustments
</U>
	. Upon any adjustment of the Exercise Price and any increase or decrease in the number of Warrant Shares purchasable
	upon the exercise of this Warrant, then, and in each such case, the Company, within 15 days thereafter, shall give written notice
	thereof to the Holder at the address of such Holder as shown on the books of the Company, which notice shall state the Exercise
	Price as adjusted and, if applicable, the increased or decreased number of Warrant Shares purchasable upon the exercise of this
	Warrant, setting forth in reasonable detail the method of calculation of each.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Notices
</U>
	.
	Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be delivered in accordance
	with Section 5.4 of the Purchase Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Legends
</U>
	.
	Unless the Warrant Shares are registered for resale with the Commission, each certificate evidencing the Warrant Shares issued
	upon exercise of this Warrant shall be stamped or imprinted with a legend required pursuant to the Purchase Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Removal
	of Legend
</U>
	. Upon request of a holder of a certificate with the legends required by Section 5 hereof, the Company shall issue
	to such holder a new certificate therefor free of any transfer legend, if, with such request, the Company shall have received an
	opinion of counsel satisfactory to the Company in form and substance to the effect that any transfer by such holder of the Warrant
	Shares evidenced by such certificate will not violate the Securities Act or any applicable state securities laws.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Fractional
	Shares
</U>
	. No fractional Warrant Shares will be issued in connection with any exercise hereunder. Instead, the Company shall round
	up, as nearly as practicable to the nearest whole Share, the number of Warrant Shares to be issued.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Rights
	of Stockholders
</U>
	. Except as expressly provided herein, the Holder, as such, shall not be entitled to vote or be deemed the holder
	of the Warrant Shares or any other securities of the Company that may at any time be issuable on the exercise hereof for any purpose,
	nor shall anything contained herein be construed to confer upon the Holder, as such, any of the rights of a stockholder of the
	Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof,
	or to give or withhold consent to any corporate action (whether upon any recapitalization, issuance of stock, reclassification
	of stock, change of par value, consolidation, merger, conveyance, or otherwise) or to receive notice of meetings, or otherwise
	until this Warrant shall have been exercised and the Warrant Shares purchasable upon the exercise hereof shall have been issued,
	as provided herein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage119"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	No
	Transfer
</U>
	. This Warrant shall be assignable and transferable, provided that no such assignment and transfer shall be valid unless
	(a) the same shall be valid under and undertaken in accordance with applicable law, rule or regulation and (b) the provisions of
	Sections 4.1 and 5.7 of the Purchase Agreement shall be adhered to as a condition to such transfer or assignment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Miscellaneous
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
	Warrant and disputes arising hereunder shall be governed by and construed and enforced in accordance with the laws of the State
	of Delaware applicable to agreements made and to be performed wholly within such State, without regard to its conflict of law rules.
	Any action brought by either party against the other concerning the transaction contemplated by this Warrant shall be brought only
	in the state courts of Delaware or in the federal courts located in the state of Delaware. The parties to this Warrant hereby irrevocably
	waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack
	of jurisdiction or venue or based upon forum non conveniens. The Company and Holder waive trial by jury.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the terms hereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	covenants of the respective parties contained herein shall survive the execution and delivery of this Warrant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	terms of this Warrant shall be binding upon and shall inure to the benefit of any successors or permitted assigns of the Company
	and of the Holder and of the Warrant Shares issued or issuable upon the exercise hereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
	Warrant and the other documents delivered pursuant hereto constitute the full and entire understanding and agreement between the
	parties with regard to the subject hereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company shall not, by amendment of its Certificate of Incorporation or Bylaws, or through any other means, directly or indirectly,
	avoid or seek to avoid the observance or performance of any of the terms of this Warrant and shall at all times in good faith assist
	in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect
	the rights of the Holder contained herein against impairment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
	receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in
	the case of any such loss, theft or destruction, upon delivery of an indemnity agreement reasonably satisfactory in form and amount
	to the Company, or, in the case of any such mutilation, upon surrender and cancellation of such Warrant, the Company, at its expense,
	will execute and deliver to the Holder, in lieu thereof, a new Warrant of like date and tenor.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
	Warrant and any provision hereof may be amended, waived or terminated only by an instrument in writing signed by the Company and
	the Holder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant and the
	other Transaction Documents, at law or in equity (including a decree of specific performance and/or other injunctive relief), and
	nothing herein shall limit the right of the Holder to pursue actual damages for any failure by the Company to comply with the terms
	of this Warrant. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder
	and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach
	or threatened breach, the holder of this Warrant shall be entitled, in addition to all other available remedies, to an injunction
	restraining any breach, without the necessity of showing economic loss and without any bond or other security being required.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage120"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	IN WITNESS WHEREOF
</B>
	,
	the Company has caused this Warrant to be signed by its duly authorized officer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 3IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT">
	LABSTYLE INNOVATIONS CORP.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-DECORATION: NONE">
<FONT STYLE="FONT-SIZE: 10PT">
	By:
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Name:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Zvi Ben-David
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Title:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Financial Officer
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage121"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
<U>
	Exhibit A
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	NOTICE OF EXERCISE
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	TO:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LabStyle Innovations Corp., attention:
	President
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The undersigned hereby
	elects to purchase the below referenced shares (the &ldquo;
<U>
	Warrant Shares
</U>
	&rdquo;) of Common Stock of LabStyle Innovations
	Corp. (the &ldquo;
<U>
	Company
</U>
	&rdquo;) pursuant to the terms of the attached Warrant, and tenders herewith payment of the purchase
	price of such Warrant Shares in full. Payment of the purchase price is being made by:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	____________&#9;a cash
	exercise with respect to _________________ Warrant Shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Please issue a certificate
	or certificates representing said shares in the name of the undersigned or in such other name as is specified below:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 7%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 3%">
<FONT STYLE="FONT-SIZE: 10PT">
	1.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 90%">
<FONT STYLE="FONT-SIZE: 10PT">
	Name: __________________________________________________
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	2.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Address: ________________________________________________
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	3.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	DWAC Instructions (if applicable): ___________________________________________
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	The undersigned
	hereby represents and warrants the following:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It (i) has
	such knowledge and experience in financial and business affairs that he/she/it is capable of evaluating the merits and risks involved
	in purchasing the Warrant Shares, (ii) is able to bear the economic risks involved in purchasing the Warrant Shares, and (iii)
	is a &ldquo;non-US person&rdquo; as defined in Regulation S promulgated under the Securities Act of 1933, as amended;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	making the decision to purchase the Warrant Shares, it has relied solely on independent investigations made by it and has had the
	opportunity to ask questions of, and receive answers from, the Company concerning the Warrant Shares, the financial condition,
	prospective business and operations of the Company and has otherwise had an opportunity to obtain any additional information, to
	the extent that the Company possess such information or could acquire it without unreasonable effort or expense;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Its overall
	commitment to investments that are not readily marketable is not disproportionate to its net worth and income, and the purchase
	of the Warrant Shares will not cause such overall commitment to become disproportionate; it can afford to bear the loss of the
	purchase price of the Warrant Shares;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
	has no present need for liquidity in its investment in the Warrant Shares; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
	acknowledges that the transaction contemplated in connection with the purchase of the Warrant Shares has not been reviewed or approved
	by the Securities and Exchange Commission or by any administrative agency charged with the administration of the securities laws
	of any state, and that no such agency has passed on or made any recommendation or endorsement of any of the securities contemplated
	hereby.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 50%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	(Signature and Date)
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
</EFX_EXHIBIT_4>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage122"></A>
<A NAME="V430703_EX10-17_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: TRANSPARENT">
<B>
	Exhibit
	10.17
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: TRANSPARENT">
<B>
	AMENDMENT
	NO. 1
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: TRANSPARENT">
<B>
	TO
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: TRANSPARENT">
<B>
	LABSTYLE
	INNOVATIONS CORP.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: TRANSPARENT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: TRANSPARENT">
<B>
	2012 EQUITY
	INCENTIVE PLAN
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 6PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 32PT; BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 6PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 32PT; BACKGROUND-COLOR: TRANSPARENT">
	Pursuant
	to Section 12 of the 2012 Equity Incentive Plan (the
<B>
	&ldquo;Plan&rdquo;
</B>
	) of LabStyle Innovations Corp. (the
<B>
	&ldquo;Corporation&rdquo;
</B>
	),
	the Board of Directors of the Corporation and the holders of a majority of the outstanding shares of common stock, par value $0.0001
	of the Corporation (the
<B>
	&ldquo;Common Stock&rdquo;
</B>
	)
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	have
</FONT>
	duly approved this Amendment No. 1 to the Plan to increase the total number of shares of Common Stock reserved and available
	for issuance under the Plan as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 6PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 32PT; BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 6PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 32PT; BACKGROUND-COLOR: TRANSPARENT">
	Section
	4(a) of Plan is hereby amended to read in its entirety as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 6PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 32PT; BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 6PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 32PT; BACKGROUND-COLOR: TRANSPARENT">
	&ldquo;(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B>
	Share
	Reserve.
</B>
	Subject to the provisions of Section 10 relating to adjustments upon changes in Common
	Stock, the Common Stock that may be issued pursuant to Option Awards shall not exceed in the aggregate of
<B>
	5,000,000
</B>
	shares
	of Common Stock. During the terms of the Option Awards, the Company shall keep available at all times the number
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	of
</FONT>
	shares of Common Stock required to satisfy such Awards.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 6PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 32PT; BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 6PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 32PT; BACKGROUND-COLOR: TRANSPARENT">
	All
	other terms and provisions of the Plan shall remain unchanged and in full force and
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	effect
	as
</FONT>
	written.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 6PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 32PT; BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 6PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 32PT; BACKGROUND-COLOR: TRANSPARENT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: NEWSECTION LAST; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: TRANSPARENT">
<B>
	&nbsp;
</B>
</P>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage123"></A>
<A NAME="V430703_EX10-23_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_2"></A>
<P STYLE="MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 10.23
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	SECURITIES PURCHASE AGREEMENT
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	This
<B>
	SECURITIES
	PURCHASE AGREEMENT
</B>
	(this &ldquo;
<U>
	Agreement
</U>
	&rdquo;) is dated as of December 24, 2015, by and among LabStyle Innovations
	Corp., a Delaware corporation (the &ldquo;
<U>
	Company
</U>
	&rdquo;), and each purchaser identified on the signature pages hereto (each,
	including its successors and assigns, a &ldquo;
<U>
	Purchaser
</U>
	&rdquo; and collectively, the &ldquo;
<U>
	Purchasers
</U>
	&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	WHEREAS
</B>
	, subject
	to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended
	(the &ldquo;
<U>
	Securities Act
</U>
	&rdquo;), and Rule 903 of Regulation S promulgated thereunder, the Company desires to issue and
	sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the
	Company as more fully described in this Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	NOW, THEREFORE,
	IN CONSIDERATION
</B>
	of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
	and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	ARTICLE I.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	DEFINITIONS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Definitions
</U>
	.
	In addition to the terms defined elsewhere in this Agreement, the following capitalized terms have the meanings set forth in this
	Section 1.1:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Affiliate
</U>
	&rdquo;
	means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
	control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Board
	of Directors
</U>
	&rdquo; means the board of directors of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Business
	Day
</U>
	&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
	any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to
	close.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Closing
</U>
	&rdquo;
	means the closing of the purchase and sale of the Securities pursuant to Section 2.1.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Closing
	Date
</U>
	&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable
	parties thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii)
	the Company&rsquo;s obligations to deliver the Securities, in each case, have been satisfied or waived.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Commission
</U>
	&rdquo;
	means the United States Securities and Exchange Commission.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Common
	Stock
</U>
	&rdquo; means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which
	such securities may hereafter be reclassified or changed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Common
	Stock Equivalents
</U>
	&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
	acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
	that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common
	Stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage124"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Exchange
	Act
</U>
	&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	FCPA
</U>
	&rdquo;
	means the Foreign Corrupt Practices Act of 1977, as amended.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Liens
</U>
	&rdquo;
	means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Person
</U>
	&rdquo;
	means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
	company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Proceeding
</U>
	&rdquo;
	means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
	proceeding, such as a deposition), whether commenced or threatened.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Purchase
	Price
</U>
	&rdquo; means $0.342 per Unit.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Registration
	Statement
</U>
	&rdquo; means a registration statement covering the resale of the Shares and the Warrant Shares by each Purchaser.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Rule
	144
</U>
	&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
	from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
	and effect as such Rule.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Securities
</U>
	&rdquo;
	means the Shares, the Warrants and the Warrant Shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Securities
	Act
</U>
	&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Short
	Sales
</U>
	&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Subscription
	Amount
</U>
	&rdquo; shall mean, as to each Purchaser, the aggregate amount to be paid for the Shares and Warrants purchased hereunder
	as specified below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription
	Amount,&rdquo; in United States dollars and in immediately available funds.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Subsidiary
</U>
	&rdquo;
	means (i) LabStyle Innovation Ltd., an Israeli company and (ii) LabStyle Innovations US LLC, a Delaware limited liability company,
	and &ldquo;
<U>
	Subsidiaries
</U>
	&rdquo; means each Subsidiary collectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Trading
	Day
</U>
	&rdquo; means a day on which the principal Trading Market is open for trading.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Trading
	Market
</U>
	&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
	the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New
	York Stock Exchange or the OTC Bulletin Board or OTCQB Marketplace operated by OTC Markets Group, Inc. (or any successors to any
	of the foregoing).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage125"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Transaction
	Documents
</U>
	&rdquo; means this Agreement, the Warrants, all exhibits and schedules thereto and hereto and any other documents
	or agreements executed in connection with the transactions contemplated hereunder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Transfer
	Agent
</U>
	&rdquo; means VStock Transfer, LLC, the current transfer agent of the Company, and any successor transfer agent of the
	Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Units
</U>
	&rdquo;
	means units sold in the transaction contemplated hereunder, each consisting of (i) one (1) share (the
	&ldquo;
<U>
	Shares
</U>
	&rdquo;) of Common Stock, par value $0.0001 per share (the &ldquo;
<U>
	Common Stock
</U>
	&rdquo;), and (ii) a
	Series A warrant to purchase one share of Common Stock at an exercise price of $0.342 per share exercisable over a period of
	6 months (the &ldquo;
<U>
	Series A Warrant
</U>
	&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Warrants
</U>
	&rdquo;
	means, the Series A Warrant in the form of Exhibit A attached hereto.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Warrant
	Shares
</U>
	&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	ARTICLE II.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	PURCHASE AND SALE
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Closing
</U>
	.
	On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution
	and delivery of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly,
	agree to purchase, an aggregate of $500,000 of Units with an aggregate value for each Purchaser equal to such Purchaser&rsquo;s
	Subscription Amount as set forth on the signature page hereto executed by such Purchaser, and Warrants as determined pursuant to
	Section 2.2(a). The aggregate number of Units sold hereunder shall be up to 1,461,988. Prior to Closing, each Purchaser shall deliver
	to the Company, via wire transfer of immediately available funds, pursuant to the wire transfer instructions set forth as
<U>
	Exhibit
	C
</U>
	, cash equal to its Subscription Amount, and as of the Closing (i) the Company shall deliver to each Purchaser the Units as
	determined pursuant to Section 2.2(a), and (ii) the Company and each Purchaser shall deliver the other items set forth in Section
	2.2 deliverable at the Closing, provided that it shall not be a condition for the Closing as to any Purchaser that any other Purchaser
	shall have delivered the items set forth in Section 2.2 to be delivered by such other Purchaser. Upon satisfaction of the covenants
	and conditions set forth in Sections 2.2 and 2.3, the Closing shall occur at the offices of legal counsel to the Company or such
	other location as the parties shall mutually agree (and such Closing may be undertaken remotely by electronic exchange of documentation).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Deliveries
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	connection with the Closing, the Company shall deliver or cause to be delivered to each Purchaser the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 2IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 2IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;on
	or prior to the Closing Date, this Agreement duly executed by the Company;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;within
	five (5) Business Days of the Closing Date, a stock certificate evidencing a number of Shares equal to such Purchaser&rsquo;s Subscription
	Amount divided by the Purchase Price, registered in the name of such Purchaser (it being agreed, however, that each Purchaser shall,
	upon consummation of the Closing, be the record holder of such Shares);
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage126"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;within
	five (5) Business Days of the Closing Date, the Warrants registered in the name of such Purchaser.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition to delivering the Subscription Amount as contemplated by Section 2.1, on or prior to the Closing Date, each Purchaser
	shall deliver or cause to be delivered to the Company the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this
	Agreement duly executed by such Purchaser;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
	you are an individual, provide a copy of your photo identification (eg., Driver&rsquo;s License or Passport); and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
	other subscription documents requested by the Company, duly executed by such Purchaser.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Closing
	Conditions
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
	accuracy in all material respects on the Closing Date of the representations and warranties of the Purchasers contained herein
	(unless as of a specific date therein in which case they shall be accurate as of such date);
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
	obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
	performed; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
	delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being
	met:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-SIZE: 10PT">
	the
	accuracy in all material respects when made and on the Closing Date of the representations and warranties of the Company contained
	herein (unless as of a specific date therein, which shall be true and correct as of such specified date);
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-SIZE: 10PT">
	all
	obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-SIZE: 10PT">
	the
	Company shall have received all governmental, regulatory or third party consents and approvals, if any, necessary for the sale
	of the Securities; and
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-SIZE: 10PT">
	the
	delivery by the Company of the items set forth in Section 2.2(a) of this Agreement
<B>
	.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage127"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	ARTICLE III.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	REPRESENTATIONS AND WARRANTIES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Representations
	and Warranties of the Company
</U>
	. The Company hereby makes the following representations and warranties to each Purchaser:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Subsidiaries
</U>
	.
	The Subsidiaries are the only direct or indirect subsidiaries of the Company. The Company owns, directly or indirectly, all of
	the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding
	shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar
	rights to subscribe for or purchase securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Organization
	and Qualification
</U>
	. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly
	existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
	and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company
	nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation,
	bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business
	and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted
	or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as
	the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity
	or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business or
	condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on
	the Company&rsquo;s ability to perform in any material respect on a timely basis its obligations under any Transaction Document
	(any of (i), (ii) or (iii), a &ldquo;
<U>
	Material Adverse Effect
</U>
	&rdquo;) and no Proceeding has been instituted in any such jurisdiction
	revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Authorization;
	Enforcement
</U>
	. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
	by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder
	and to issue the Securities in accordance with the term hereof and thereof. The execution and delivery of this Agreement and each
	of the other Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby
	have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company,
	the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith, other than in connection with the
	Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or upon delivery will have
	been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid
	and binding obligation of the Company enforceable against the Company in accordance with its terms, except: (i) as limited by general
	equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting
	enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
	injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by
	applicable law.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage128"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	No
	Conflicts
</U>
	. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
	which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby
	and thereby do not and will not: (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate
	or articles of incorporation, bylaws or other organizational or charter documents, (ii) conflict with, or constitute a default
	(or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any
	of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration
	or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing
	a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which
	any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
	with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court
	or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
	or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of clause (ii), such
	as could not have or reasonably be expected to result in a Material Adverse Effect.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Filings,
	Consents and Approvals
</U>
	. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice
	to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
	Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i)
	notices to existing investors in connection with affording such investors any existing pre-emptive or participation rights held
	by such existing investors (the &ldquo;
<U>
	Participation Rights
</U>
	&rdquo;), and (ii) the notice and/or application(s) to each applicable
	Trading Market for the issuance and sale of the Securities and the listing of the Shares and Warrant Shares for trading thereon
	in the time and manner required thereby, (collectively, the &ldquo;
<U>
	Required Approvals
</U>
	&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Issuance
	of the Securities
</U>
	. The Units and Shares are duly authorized and, when issued and paid for in accordance with the applicable
	Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the
	Company other than restrictions on transfer provided for in the Transaction Documents and (ii) the Warrant Shares, when paid for
	and issued in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable, free and clear of
	all Liens imposed by the Company other than restrictions on transfer provided for in the Transaction Documents and (iii) the Company
	has reserved from its duly authorized capital stock a number of shares of Common Stock for issuance of the Warrant Shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Capitalization
</U>
	.
	As of the date hereof the authorized capital stock of the Company consists of (i) 160,000,000 shares of Common Stock, of which,
	42,993,162 are issued and outstanding, and 51,735,689 shares are reserved for issuance pursuant to securities (other than the Warrants)
	exercisable or exchangeable for, or convertible into, shares of Common Stock and (ii) 5,000,000 shares of preferred stock, of which
	35,600 are issued and outstanding and classified as Series A Convertible Preferred Stock. No shares of Common Stock are held in
	treasury. All of such outstanding shares are duly authorized and have been, or upon issuance will be, validly issued and are fully
	paid and nonassessable. Except as set forth in the SEC Reports or as a result of the purchase and sale of the Securities, there
	are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to,
	or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe
	for or acquire any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company or any
	Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents. All of the outstanding
	shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance
	with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights
	or similar rights to subscribe for or purchase securities. No further approval or authorization of any stockholder, the Board of
	Directors or others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting agreements
	or other similar agreements with respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge
	of the Company, between or among any of the Company&rsquo;s stockholders.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage129"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	SEC
	Reports; Financial Statements
</U>
	. The Company has filed all reports, schedules, forms, statements and other documents required
	to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof,
	for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such
	material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively
	referred to herein as the &ldquo;
<U>
	SEC Reports
</U>
	&rdquo;) on a timely basis or has received a valid extension of such time of
	filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC
	Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and
	none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required
	to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were
	made, not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act. The financial statements
	of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules
	and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been
	prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods
	involved (&ldquo;
<U>
	GAAP
</U>
	&rdquo;), except as may be otherwise specified in such financial statements or the notes thereto and
	except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects
	the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations
	and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit
	adjustments.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Material
	Changes; Undisclosed Events, Liabilities or Developments
</U>
	. Since the date of the latest audited financial statements included
	within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof: (i) there has
	been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect,
	(ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses
	incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the
	Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not
	altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property
	to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v)
	the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock
	option or incentive plans.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage130"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Litigation
</U>
	.
	There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company,
	threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator,
	governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &ldquo;
<U>
	Action
</U>
	&rdquo;)
	which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities
	or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. There
	has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving
	the Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other
	order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act
	or the Securities Act.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Labor
	Relations
</U>
	. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of
	the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
	employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither
	the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
	that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or
	any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure
	or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant
	in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of
	its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance
	with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and
	conditions of employment and wages and hours.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Compliance
</U>
	.
	Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been
	waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the
	Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
	loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is
	bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any
	court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation
	of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental
	protection, occupational health and safety, product quality and safety and employment and labor matters.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Regulatory
	Permits
</U>
	. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
	state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
	except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;
<U>
	Material
	Permits
</U>
	&rdquo;), and neither the Company nor any Subsidiary has received any written notice of proceedings relating to the
	revocation or modification of any Material Permit.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage131"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Title
	to Assets
</U>
	. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them
	and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
	in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not
	materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens
	for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP
	and, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by
	the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the
	Subsidiaries are in compliance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Intellectual
	Property
</U>
	. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark
	applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
	and similar rights necessary or required for use in connection with their respective businesses (collectively, the &ldquo;
<U>
	Intellectual
	Property Rights
</U>
	&rdquo;). None of, and neither the Company nor any Subsidiary has received a written notice that any of, the
	Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned,
	within two (2) years from the date of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the
	latest audited financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge
	that the Intellectual Property Rights violate or infringe upon the rights of any Person. To the knowledge of the Company, all such
	Intellectual Property Rights are enforceable. With the possible exception of one third-party company that is selling a product
	that may infringe the Company's patent rights, to the knowledge of the Company, there is no existing infringement by another Person
	of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect
	the secrecy, confidentiality and value of all of their intellectual properties. The Company, and to the Company&rsquo;s knowledge
	its patent counsel, have complied with the duty of candor and good faith in dealing with the U.S. Patent and Trademark Office and
	any similar duties in dealing with similar foreign intellectual property office. There are no material defects in the preparation
	and filing of any of the Company&rsquo;s patents and patent applications. The Company is not obligated to pay a royalty, grant
	a license, or provide other consideration to any third party in connection with the Intellectual Property Rights. The Company has
	not infringed (or would infringe) or otherwise violated (or would violate) any intellectual property rights of any third party
	by conducting its business in the manner in which it is contemplated as set forth in the SEC Reports.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Insurance
</U>
	.
	The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and
	in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Transactions
	With Affiliates and Employees
</U>
	. Except as set forth in
<U>
	Schedule 3(q)
</U>
	hereto and in the SEC Reports, none of the officers
	or directors of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any
	Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers
	and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing
	for rental of real or personal property to or from, providing for the borrowing of money from or lending of money too or otherwise
	requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any
	officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or
	partner, in each case in excess of $120,000 other than for: (i) payment of salary or consulting fees for services rendered, (ii)
	reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements
	under any stock option plan of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 9; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage132"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Sarbanes-Oxley;
	Internal Accounting Controls
</U>
	. The Company and the Subsidiaries are in material compliance with any and all applicable requirements
	of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated
	by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries
	maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed
	in accordance with management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to permit
	preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted
	only in accordance with management&rsquo;s general or specific authorization, and (iv) the recorded accountability for assets is
	compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The
	Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
	15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information
	required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized
	and reported, within the time periods specified in the Commission&rsquo;s rules and forms. The Company&rsquo;s certifying officers
	have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of
	the period covered by the most recently filed periodic report under the Exchange Act (such date, the &ldquo;
<U>
	Evaluation Date
</U>
	&rdquo;).
	The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers
	about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the
	Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange
	Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal
	control over financial reporting of the Company and its Subsidiaries.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Private
	Placement
</U>
	. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, no registration
	under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers as contemplated
	hereby.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Investment
	Company.
</U>
	The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will
	not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as
	amended. The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject
	to registration under the Investment Company Act of 1940, as amended.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Registration
	Rights
</U>
	. Except as disclosed in the SEC Reports, no Person has any right to cause the Company to effect the registration under
	the Securities Act of any securities of the Company or any Subsidiary.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Listing
	and Maintenance Requirements
</U>
	. The Company has not, in the 12 months preceding the date hereof, received written notice from
	any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance
	with the listing or maintenance requirements of such Trading Market.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Disclosure
</U>
	.
	All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their
	respective businesses and the transactions contemplated hereby is true and correct in all material respects and does not contain
	any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein,
	in light of the circumstances under which they were made, not misleading.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 10; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage133"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	No
	Integrated Offering
</U>
	. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2,
	neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made
	any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering
	of the Securities to be integrated with prior offerings by the Company for purposes of the Securities Act which would require the
	registration of any such securities under the Securities Act.
<U>
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Tax
	Status
</U>
	. The Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all
	foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has
	paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such
	returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material
	taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in
	any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary
	know of no basis for any such claim.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	No
	General Solicitation
</U>
	. Neither the Company nor any person acting on behalf of the Company has offered or sold any of the Securities
	by any form of general solicitation or general advertising. The Company has offered the Securities for sale only to the Purchasers
	and certain other (i) &ldquo;accredited investors&rdquo; within the meaning of Rule 501 under the Securities Act, and (ii) &ldquo;non-US
	persons&rdquo; as defined in Regulation S as promulgated under the Securities Act.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(aa)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Foreign
	Corrupt Practices.
</U>
	Neither the Company nor any Subsidiary, nor any director, officer, employee, agent or other person acting
	on behalf of the Company or any Subsidiary, has: (i) directly or indirectly, used any funds for unlawful contributions, gifts,
	entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign
	or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds,
	(iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
	of which the Company is aware) which is in violation of law or (iv) violated any provision of FCPA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(bb)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Regulation
	M Compliance
</U>
	.&nbsp; The Company has not, and to its knowledge no one acting on its behalf has: (i) taken, directly or indirectly,
	any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
	the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of,
	any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other
	securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company&rsquo;s placement
	agent or finders in connection with the placement of the Securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(cc)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Office
	of Foreign Assets Control
</U>
	. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent,
	employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of
	Foreign Assets Control of the U.S. Treasury Department (&ldquo;
<U>
	OFAC
</U>
	&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 11; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage134"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(dd)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Money
	Laundering
</U>
	. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
	applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
	as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;
<U>
	Money
	Laundering Laws
</U>
	&rdquo;), and no action, suit or proceeding by or before any court or governmental agency, authority or body
	or any arbitrator involving the Company and any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge
	of the Company or any Subsidiary, threatened.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(ee)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Application
	of Takeover Protections; Rights Agreement.
</U>
	The Company and its board of directors have taken all necessary action, if any,
	in order to render inapplicable any control share acquisition, interested stockholder, business combination, poison pill (including,
	without limitation, any distribution under a rights agreement) or other similar anti-takeover provision under the Certificate of
	Incorporation, Bylaws or other organizational documents or the laws of the jurisdiction of its formation which is or could become
	applicable to any Purchaser as a result of the transactions contemplated by this Agreement, including, without limitation, the
	Company's issuance of the Securities and any Purchaser's ownership of the Securities. The Company and its Board of Directors have
	taken all necessary action, if any, in order to render inapplicable any stockholder rights plan or similar arrangement relating
	to accumulations of beneficial ownership of shares of Common Stock or a change in control of the Company or any of its Subsidiaries.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(ff)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Off
	Balance Sheet Arrangements
</U>
	. There is no transaction, arrangement, or other relationship between the Company or any of its Subsidiaries
	and an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company in its Exchange Act filings
	and is not so disclosed or that otherwise could be reasonably likely to have a Material Adverse Effect.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Representations
	and Warranties of the Purchasers
</U>
	. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as
	of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Organization;
	Authority
</U>
	. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and (where such
	concept is applicable) in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate,
	partnership, limited liability company or similar power and authority to enter into and to consummate the transactions contemplated
	by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of
	the Transaction Documents and performance by such Purchaser of the transactions contemplated by the Transaction Documents have
	been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the
	part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered
	by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser,
	enforceable against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy,
	insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally,
	(ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and
	(iii) insofar as indemnification and contribution provisions may be limited by applicable law.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 12; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage135"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Own
	Account
</U>
	. Such Purchaser understands that the Securities are &ldquo;restricted securities&rdquo; and have not been registered
	under the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own account
	and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act
	or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities
	Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons to
	distribute or regarding the distribution of such Securities in violation of the Securities Act or any applicable state securities
	law (this representation and warranty not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to a Registration
	Statement or otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities
	hereunder in the ordinary course of its business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Purchaser
	Status
</U>
	. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on
	which it exercises any Warrants for cash, it will be a &ldquo;non-US person&rdquo; as defined in Regulation S (&ldquo;
<U>
	Regulation
	S
</U>
	&rdquo;) as promulgated under the Securities Act.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Experience
	of Such Purchaser
</U>
	. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and
	experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
	in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk
	of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment. Such Purchaser
	acknowledges that as of the date hereof, the Company has very limited financial resources, and thus an investment in the Securities
	is subject to significant risk.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-SIZE: 10PT">
<U>
	General
	Solicitation
</U>
	. Such Purchaser is not purchasing the Securities (i) as a result of any advertisement, article, notice or other
	communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio
	or presented at any seminar or any other general solicitation or general advertisement; or (ii) as a result of any of the Current
	Reports on Form 8-K filed by the Company with the Commission on July 23, 2015, August 28, 2015, November 2, 2015 and November 19,
	2015 or anything contained therein; or (iii) as a result of the Company&rsquo;s Quarterly Reports on Form 10-Q filed by the Company
	with the Commission on August 12, 2015 and on November 13, 2015 or anything contained therein. In purchasing the Securities hereunder,
	such Purchaser is relying only on the representations and warranties contained herein and the other Transaction Documents provided
	by the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-SIZE: 10PT">
<U>
	Access
	to Information
</U>
	. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
	all exhibits and schedules thereto) and the SEC Reports and has been afforded (i) the opportunity to ask such questions as it has
	deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering
	of the Units and the merits and risks of investing in the Units; (ii) access to information about the Company and its financial
	condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment;
	and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable
	effort or expense that is necessary to make an informed investment decision with respect to the investment.&nbsp; Such Purchaser
	acknowledges and agrees that neither the Company nor any Affiliate of the Company has provided such Purchaser with any information
	or advice with respect to the Securities nor is such information or advice necessary or desired.&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 13; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage136"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-SIZE: 10PT">
<U>
	Additional
	Representations and Warranties of Non-U.S. Persons
</U>
	. Each Purchaser indicating that it is not a U.S. person on its signature
	page to this Agreement, severally and not jointly, further makes the representations and warranties to the Company set forth on
<U>
	Exhibit B-
</U>
	1.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-SIZE: 10PT">
<U>
	Certain
	Transactions and Confidentiality
</U>
	. Other than consummating the transactions contemplated hereunder, such Purchaser has not directly
	or indirectly, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, executed any purchases
	or sales, including Short Sales,&nbsp;of the securities of the Company during the period commencing as of the time that such Purchaser
	first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material
	terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing,
	in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions
	of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio
	managers managing other portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect
	to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered
	by this Agreement. Other than to other Persons party to this Agreement or its legal counsel or other advisors, such Purchaser has
	maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms
	of this transaction).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-SIZE: 10PT">
<U>
	Other
	Company Holdings
</U>
	. As of the Closing Date, and prior to the consummation of the transactions contemplated by this Agreement,
	such Purchaser is not, collectively with its Affiliates or any Person with whom such Purchaser is acting in concert, a holder of
	Common Stock or Common Stock Equivalents in an amount equal to more than 9.99% of the outstanding shares of Common Stock (assuming
	full exercise or conversion of any such Common Stock Equivalents).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	ARTICLE IV.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	OTHER AGREEMENTS OF THE PARTIES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Transfer
	Restrictions
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Securities may only be disposed of in compliance with U.S. state and U.S. federal securities laws. In connection with any transfer
	of Securities other than pursuant to an effective Registration Statement or Rule 144, to the Company or to an Affiliate of a Purchaser
	or in connection with a pledge as contemplated in Section 4.1(b), the Company may require the transferor thereof to provide to
	the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of
	which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of
	such transferred Securities under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to
	be bound by the terms of this Agreement and shall have the rights and obligations of a Purchaser under this Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
	certificate representing the Shares, the Warrants and Warrant Shares and if appropriate, securities issued upon conversion or exercise
	thereof, shall be stamped or otherwise imprinted with a legend substantially in the following form (in addition to any legend required
	by applicable state securities or &ldquo;blue sky&rdquo; laws):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 14; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage137"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&ldquo;THE SECURITIES REPRESENTED
	BY THIS CERTIFICATE (THE &ldquo;
<U>
	SECURITIES
</U>
	&rdquo;) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
	(THE &ldquo;
<U>
	SECURITIES ACT
</U>
	&rdquo;), OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED
	OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR THE COMPANY SHALL HAVE RECEIVED AN
	OPINION OF COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES
	LAWS IS NOT REQUIRED.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	Each certificate representing
	the Shares, the Warrants and Warrant Shares and if appropriate, securities issued upon conversion or exercise thereof, if such
	securities are being offered to Purchasers in reliance upon Regulation S, shall be stamped or otherwise imprinted with a legend
	substantially in the following form (in addition to any legend required by applicable state securities or &ldquo;blue sky&rdquo;
	laws):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&ldquo;THE SECURITIES REPRESENTED
	BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;
<U>
	SECURITIES ACT
</U>
	&rdquo;),
	OR ANY STATE SECURITIES LAWS AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE
	TRANSFERRED EXCEPT (1) IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S PROMULGATED UNDER THE SECURITIES ACT, AND BASED ON AN
	OPINION OF COUNSEL, WHICH COUNSEL AND OPINION ARE REASONABLY SATISFACTORY TO THE COMPANY, THAT THE PROVISIONS OF REGULATION S HAVE
	BEEN SATISFIED, (2) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS
	OR (3) PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND APPLICABLE STATE SECURITIES
	LAWS, IN WHICH CASE THE HOLDER MUST, PRIOR TO SUCH TRANSFER, FURNISH TO THE COMPANY AN OPINION OF COUNSEL, WHICH COUNSEL AND OPINION
	ARE REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED
	IN THE MANNER CONTEMPLATED PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND APPLICABLE
	STATE SECURITIES LAWS. HEDGING TRANSACTIONS INVOLVING THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE CONDUCTED UNLESS
	IN COMPLIANCE WITH THE SECURITIES ACT.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certificates
	evidencing the Warrant Shares shall not be required to contain any legend (including the legend set forth in Section 4.1(b) hereof):
	(i) while a Registration Statement is effective under the Securities Act, (ii) following any sale of such Warrant Shares pursuant
	to Rule 144, (iii) if such Warrant Shares are eligible for sale under Rule 144, without the requirement for the Company to be in
	compliance with the current public information required under Rule 144 as to such Warrant Shares and without volume or manner-of-sale
	restrictions or (iv) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations
	and pronouncements issued by the staff of the Commission).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 15; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage138"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
	Purchaser, severally and not jointly with the other Purchasers, agrees with the Company that such Purchaser will sell any Securities
	pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements,
	or an exemption therefrom, and that if Securities are sold pursuant to a Registration Statement, they will be sold in compliance
	with the plan of distribution set forth therein, and acknowledges that the removal of the restrictive legend from certificates
	representing Securities as set forth in this Section 4.1 is predicated upon the Company&rsquo;s reliance upon this understanding.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Furnishing
	of Information
</U>
	. For so long as any Purchaser is an &ldquo;affiliate&rdquo; (as defined in Rule 144) of the Company, the Company
	covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required
	to be filed by the Company after the date hereof pursuant to the Exchange Act, and the Company shall not terminate its status as
	an issuer required to file reports under the Exchange Act even if the Exchange Act or the rules and regulations thereunder would
	no longer require or otherwise permit such termination, and the Company shall take all reasonable actions to maintain its eligibility
	to register the Common Stock and Warrant Shares for resale by the Purchasers on Form S-3.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Integration
</U>
	.
	The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined
	in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require
	the registration under the Securities Act of the sale of the Securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Exercise
	Procedures
</U>
	. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required of the
	Purchasers in order to exercise the Warrants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Use
	of Proceeds
</U>
	. The Company shall use the net proceeds from the sale of the Securities hereunder for working capital and general
	corporate purposes and shall not use such proceed: (a) for the satisfaction of any portion of the Company&rsquo;s debt (other than
	payment of trade payables in the ordinary course of the Company&rsquo;s business and prior practices), (b) for the redemption of
	any Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA
	or OFAC regulations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Certain
	Transactions and Confidentiality
</U>
	. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither
	it, nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
	Short Sales, of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending
	at such time that the transactions contemplated by this Agreement are first publicly announced.&nbsp; Each Purchaser, severally
	and not jointly with the other Purchasers, and the Company covenants that until such time as the transactions contemplated by this
	Agreement are publicly disclosed by the Company, it will maintain the confidentiality of the existence and terms of this transaction
	and the information included in the Transaction Documents.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Listing
</U>
	.
	The Company shall promptly secure the listing of all of the Shares and the Warrant Shares upon each national securities exchange
	and automated quotation system, if any, upon which the Common Stock is then listed (subject to official notice of issuance) and
	shall maintain such listing of all Shares and Warrant Shares from time to time issuable under the terms of the Transaction Documents.
	The Company shall maintain the authorization for quotation of the Common Stock on the Trading Market. Neither the Company nor any
	of its Subsidiaries shall take any action which would be reasonably expected to result in the delisting or suspension of the Common
	Stock on the Trading Market. The Company shall pay all fees and expenses in connection with satisfying its obligations under this
	Section 4.9.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 16; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage139"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Indemnification
	by Purchasers
</U>
	. Each Purchaser, severally and not jointly, indemnifies and holds harmless the Company, its directors, officers,
	agents and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section
	20 of the Exchange Act), and the directors, officers, agents or employees of such controlling Persons, to the fullest extent permitted
	by applicable law, from and against all losses, as incurred, to the extent arising out of or based solely upon: (x) such Purchaser&rsquo;s
	failure to comply with any applicable prospectus delivery requirements of the Securities Act through no fault of the Company or
	(y) any untrue or alleged untrue statement of a material fact contained in any Registration Statement, any prospectus, preliminary
	prospectus, free writing prospectus, or in any amendment or supplement thereto, or arising out of or relating to any omission or
	alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any
	prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading (i) to the extent, but
	only to the extent, that such untrue statement or omission is contained in any information so furnished in writing by such Purchaser
	to the Company expressly for inclusion in such Registration Statement or such prospectus or (ii) to the extent, but only to the
	extent, that such information relates to such Purchaser&rsquo;s proposed method of distribution of the Securities and was reviewed
	and expressly approved in writing by such Purchaser expressly for use in a Registration Statement (it being understood that the
	Purchaser has approved the contents of the &ldquo;Selling Stockholder Questionnaire&rdquo; for this purpose), such prospectus,
	preliminary prospectus, free writing prospectus, or in any amendment or supplement thereto or (iii) to the extent, but only to
	the extent, related to the use by such Purchaser of an outdated, defective or otherwise unavailable prospectus after the Company
	has notified such Purchaser in writing that the prospectus is outdated, defective or otherwise unavailable for use by such Purchaser.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	ARTICLE V.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	MISCELLANEOUS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Termination
</U>
	.&nbsp;
	This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without any effect
	whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing
	has not been consummated on or before 5:00 p.m., New York time, on December 31, 2015
<U>
	provided
</U>
	,
<U>
	however
</U>
	, that such
	termination will not affect the right of any party to sue for any breach by any other party (or parties).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Fees
	and Expenses
</U>
	. Each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and
	all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this
	Agreement. The Company shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing
	of any instruction letter delivered by the Company and any conversion or exercise notice delivered by a Purchaser), stamp taxes
	and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Entire
	Agreement
</U>
	. The Transaction Documents, together with the exhibits thereto, contain the entire understanding of the parties with
	respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect
	to such matters, which the parties acknowledge have been merged into such documents and exhibits.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 17; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage140"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Notices
</U>
	.
	Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
	shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered
	via facsimile at the facsimile number or email attachment as set forth on the signature pages attached hereto (or, with respect
	to an assignee or transferee of Securities as contemplated by Section 5.7, at the contact information of such Person provided to
	the Company in connection with such assignment or transfer) at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b)
	the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile
	number or email attachment as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than
	5:30 p.m. (New York City time) on any Trading Day, (c) the second (2
<SUP>
	nd
</SUP>
	) Trading Day following the date of mailing, if
	sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required
	to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Amendments;
	Waivers
</U>
	. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed,
	in the case of an amendment, by the Company and the holder of 51% of the Shares and Warrants purchased from the Company hereunder
	or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought. No waiver of any default
	with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future
	or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay
	or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Headings
</U>
	.
	The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
	any of the provisions hereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Successors
	and Assigns
</U>
	. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted
	assigns. Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or
	transfers any Securities, provided that such transferee agrees in writing as a pre-condition to such assignment or transfer to
	be bound, with respect to the transferred Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	5.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	No
	Third-Party Beneficiaries
</U>
	. This Agreement is intended for the benefit of the parties hereto and their respective successors
	and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	5.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Governing
	Law
</U>
	. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall
	be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the
	principles of conflicts of law thereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	5.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Arbitration
	of Claims
</U>
	. Any dispute, controversy or claim arising in relation to this this Agreement or any Transaction Document, including
	with regard to their validity, invalidity, breach, enforcement or termination, will be referred to a single arbitrator, who shall
	be appointed by the Head of the Israel Bar Association. The arbitrator will not be bound by rules of evidence or procedure and
	will give the reasons for his or her judgment in writing. Any such arbitration shall be conducted in Tel Aviv, Israel. The arbitrator's
	decision shall be final and enforceable in any court. This Section 5.10 shall constitute an arbitration agreement between the parties.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 18; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage141"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	5.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Survival
</U>
	.
	The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	5.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Execution
</U>
	.
	This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
	agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being
	understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
	or by e-mail delivery of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the
	party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf&rdquo;
	signature page were an original thereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	5.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Severability
</U>
	.
	If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
	void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full
	force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
	reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
	by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
	they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
	hereafter declared invalid, illegal, void or unenforceable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	5.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Replacement
	of Securities
</U>
	. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company
	shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or
	in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory
	to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall
	also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	5.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Independent
	Nature of Purchasers&rsquo; Obligations and Rights
</U>
	. The obligations of each Purchaser under any Transaction Document are several
	and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
	or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any
	other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the
	Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers
	are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction
	Documents. Each Purchaser shall be entitled to independently protect and enforce its rights, including, without limitation, the
	rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser
	to be joined as an additional party in any proceeding for such purpose. Each Purchaser has been represented by its own separate
	legal counsel in its review and negotiation of the Transaction Documents.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	5.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Saturdays,
	Sundays, Holidays, etc.
</U>
	If the last or appointed day for the taking of any action or the expiration of any right required or
	granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding
	Business Day.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 19; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage142"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	5.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Construction
</U>
	.
	The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction
	Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting
	party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and
	every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
	and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after
	the date of this Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<I>
	(Signature Pages Follow)
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 20; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage143"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	IN WITNESS WHEREOF,
	the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
	as of the date first indicated above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
<B>
	LABSTYLE INNOVATIONS CORP.
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD; WIDTH: 4%">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; WIDTH: 46%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	By:
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Name:&nbsp; Erez Raphael
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Title: &nbsp;&nbsp;&nbsp;Chairman and CEO
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Address for Notice
</U>
	:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	9 Halamish Street
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Caesarea Industrial Park
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	3088900, Israel
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Fax Number: +(972)-(4) 770 4060
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	With a copy to (which shall not constitute notice):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	ZAG/S&amp;W LLP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	1633 Broadway
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	New York, NY 10019
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Fax Number: (212) 660-3001
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Attention: Oded Har-Even, Esq.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
	[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
	SIGNATURE PAGE FOR PURCHASER FOLLOWS]
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 21; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage144"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	PURCHASER SIGNATURE PAGES
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	(FOR NON-U.S. PERSONS)
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	IN WITNESS WHEREOF,
	the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as
	of the date first indicated above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Subscription Amount:
</B>
<B>
<U>
	$500,000
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	# of Units Purchased (@ $0.342 per Unit):
</B>
<B>
<U>
	1,461,988
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	If Investor is an entity, sign here:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 40%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 60%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT">
	(Name of entity)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%">
	By:
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; WIDTH: 46%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%">
	Name:
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; WIDTH: 43%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
	Title:
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; WIDTH: 44%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	If Investor is an individual, sign here:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 10%">
	Signature:
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; WIDTH: 42%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 48%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 11%">
	Print Name:
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; WIDTH: 41%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 48%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	PLEASE COMPLETE FOLLOWING INFORMATION
	FOR NOTICES:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Email Address: ___________________________________________
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Facsimile Number: _________________________________________
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Address for Notice to
</FONT>
	Investor
<FONT STYLE="FONT-SIZE: 10PT">
	:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Offshore Address for Delivery
	of Securities to
</FONT>
	Investor
<FONT STYLE="FONT-SIZE: 10PT">
	(if not same as address for notice):
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 22; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage145"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	EXHIBIT A
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Form of Series A Warrant
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	NEITHER THIS SECURITY NOR THE SECURITIES
	INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
	OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;
<U>
	SECURITIES
	ACT
</U>
	&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE
	SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF
	THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE COMPANY
	TO SUCH EFFECT.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 52%">
<FONT STYLE="FONT-SIZE: 10PT">
	Warrant No. __________
</FONT>
</TD>
<TD STYLE="WIDTH: 48%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	December [___], 2015
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	LABSTYLE INNOVATIONS CORP.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Series
	A Common Stock Purchase Warrant
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	THIS CERTIFIES THAT
</B>
	,
	for value received,
<B>
	[___________________________]
</B>
	(the &ldquo;
<B>
<U>
	Holder
</U>
</B>
	&rdquo;), is entitled to subscribe for
	and purchase, at the Exercise Price (as defined below), from LabStyle Innovations Corp., a Delaware corporation (the &ldquo;
<B>
<U>
	Company
</U>
</B>
	&rdquo;),
	shares of the Company&rsquo;s common stock, par value $0.0001 (the &ldquo;
<B>
<U>
	Common Stock
</U>
</B>
	&rdquo;), at any time prior
	to 5:00 p.m., New York time, on June __, 2016 (the &ldquo;
<B>
<U>
	Warrant Exercise Term
</U>
</B>
	&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	This Warrant is issued in accordance with, and subject to, the
	terms and conditions described in the Securities Purchase Agreement, dated December [__], 2015, between the initial Holder and
	the Company (the &ldquo;
<B>
<U>
	Purchase Agreement
</U>
</B>
	&rdquo;) entered into in connection with the private placement offering
	of the Company (the &ldquo;
<B>
<U>
	Offering
</U>
</B>
	&rdquo;) described in the Purchase Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	All capitalized terms
	used but not defined herein shall have the meanings ascribed to them in the Purchase Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	This Warrant is subject to the following
	terms and conditions:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Shares
</U>
	.
	The Holder has, subject to the terms set forth herein, the right to purchase up to an aggregate of 1,461,988 shares of Common Stock
	(the &ldquo;
<B>
<U>
	Warrant
</U>
</B>
<U>
<B>
	Shares
</B>
</U>
	&rdquo;) at a per share exercise price of $0.342, subject to adjustment as
	provided for herein (the &ldquo;
<B>
<U>
	Exercise Price
</U>
</B>
	&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 23; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage146"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Exercise
	of Warrant
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
<FONT STYLE="FONT-SIZE: 10PT">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Exercise
</U>
	.
	This Warrant may be exercised by the Holder at any time prior to the Warrant Exercise Term, in whole or in part, by delivering
	the notice of exercise attached as
<U>
	Exhibit A
</U>
	hereto (the &ldquo;
<B>
<U>
	Notice of Exercise
</U>
</B>
	&rdquo;), duly executed
	by the Holder to the Company at its principal office, or at such other office as the Company may designate, accompanied by payment,
	by wire transfer of immediately available funds to the order of the Company to an account designated by the Company, of the amount
	obtained by multiplying the number of Warrant Shares designated in the Notice of Exercise by the Exercise Price (the &ldquo;
<B>
<U>
	Purchase
	Price
</U>
</B>
	&rdquo;). For purposes hereof, &ldquo;
<B>
	Exercise Date
</B>
	&rdquo; shall mean the date on which all deliveries required
	to be made to the Company upon exercise of this Warrant pursuant to this Section 2(a) shall have been made.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	The
	Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. No originals of the Notice
	of Exercise shall be required to be delivered, nor shall any medallion guarantee (or any other type of guarantee or notarization)
	of any Notice of Exercise shall be required.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Issuance
	of Certificates
</U>
	. As soon as practicable after the exercise of this Warrant, in whole or in part, in accordance with Section
	2(a) hereof (and in no event later than two (2) Trading Days following the delivery of the Notice of Exercise), the Company, at
	its expense, shall cause to be issued in the name of and delivered to the Holder: (i) a certificate or certificates for (or, if
	applicable, by delivery through the facilities of the Depository Trust Company in electronic form of) the number of fully paid
	and non-assessable Warrant Shares to which the Holder shall be entitled upon such exercise and, if applicable, (ii) a new warrant
	of like tenor to purchase all of the Warrant Shares that may be purchased pursuant to the portion, if any, of this Warrant not
	exercised by the Holder. The Holder shall for all purposes hereof be deemed to have become the Holder of record of such Warrant
	Shares on the date on which the Notice of Exercise and payment of the Purchase Price in accordance with Section 2(a) hereof were
	delivered and made, respectively, irrespective of the date of delivery of such certificate or certificates, except that if the
	date of such delivery, notice and payment is a date when the stock transfer books of the Company are closed, such person shall
	be deemed to have become the holder of record of such Warrant Shares at the close of business on the next succeeding date on which
	the stock transfer books are open.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Taxes
</U>
	.
	The issuance of the Warrant Shares upon the exercise of this Warrant, and the delivery of certificates or other instruments representing
	such Warrant Shares, shall be made without charge to the Holder for any tax or other charge of whatever nature in respect of such
	issuance and the Company shall bear any such taxes in respect of such issuance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Adjustment
	of Exercise Price
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Adjustment
	for Reclassification, Consolidation or Merger
</U>
	. If while this Warrant, or any portion hereof, remains outstanding and unexpired
	there shall be (i) a reorganization or recapitalization (other than a combination, reclassification, exchange or subdivision of
	shares otherwise provided for herein), (ii) a merger or consolidation of the Company with or into another corporation or other
	entity in which the Company shall not be the surviving entity, or a reverse merger in which the Company shall be the surviving
	entity but the shares of the Company&rsquo;s capital stock outstanding immediately prior to the merger are converted by virtue
	of the merger into other property, whether in the form of securities, cash or otherwise, or (iii) a sale or transfer of the Company&rsquo;s
	properties and assets as, or substantially as, an entirety to any other corporation or other entity in one transaction or a series
	of related transactions, then, as a part of such reorganization, recapitalization, merger, consolidation, sale or transfer, unless
	otherwise directed by the Holder, all necessary or appropriate lawful provisions shall be made so that the Holder shall thereafter
	be entitled to receive upon exercise of this Warrant, during the period specified herein and upon payment of the Exercise Price
	then in effect, the greatest number of shares of capital stock or other securities or property that a holder of the Warrant Shares
	deliverable upon exercise of this Warrant would have been entitled to receive in such reorganization, recapitalization, merger,
	consolidation, sale or transfer if this Warrant had been exercised immediately prior to such reorganization, recapitalization,
	merger, consolidation, sale or transfer, all subject to further adjustment as provided in this Section 3. If the per share consideration
	payable to the Holder for Warrant Shares in connection with any such transaction is in a form other than cash or marketable securities,
	then the value of such consideration shall be determined in good faith by the Company&rsquo;s Board of Directors. The foregoing
	provisions of this paragraph shall similarly apply to successive reorganizations, recapitalizations, mergers, consolidations, sales
	and transfers and to the capital stock or securities of any other corporation that are at the time receivable upon the exercise
	of this Warrant. In all events, appropriate adjustment shall be made in the application of the provisions of this Warrant with
	respect to the rights and interests of the Holder after the transaction, to the end that the provisions of this Warrant shall be
	applicable after that event, as near as reasonably may be, in relation to any shares or other property deliverable or issuable
	after such reorganization, recapitalization, merger, consolidation, sale or transfer upon exercise of this Warrant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 24; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage147"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Adjustments
	for Split, Subdivision or Combination of Shares
</U>
	. If while this Warrant, or any portion hereof, remains outstanding and unexpired
	the Company shall subdivide (by any stock split, stock dividend, recapitalization, reorganization, reclassification or otherwise)
	the shares of Common Stock subject to acquisition hereunder, then, upon the effective date of such subdivision, the Exercise Price
	in effect immediately prior to such subdivision will be proportionately reduced and the number of shares of Common Stock subject
	to acquisition upon exercise of the Warrant will be proportionately increased. If the Company at any time combines (by reverse
	stock split, recapitalization, reorganization, reclassification or otherwise) the shares of Common Stock subject to acquisition
	hereunder, then, upon the effective date of such combination, the Exercise Price in effect immediately prior to such combination
	will be proportionately increased and the number of shares of Common Stock subject to acquisition upon exercise of the Warrant
	will be proportionately decreased.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Notice
	of Adjustments
</U>
	. Upon any adjustment of the Exercise Price and any increase or decrease in the number of Warrant Shares purchasable
	upon the exercise of this Warrant, then, and in each such case, the Company, within 15 days thereafter, shall give written notice
	thereof to the Holder at the address of such Holder as shown on the books of the Company, which notice shall state the Exercise
	Price as adjusted and, if applicable, the increased or decreased number of Warrant Shares purchasable upon the exercise of this
	Warrant, setting forth in reasonable detail the method of calculation of each.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Notices
</U>
	.
	Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be delivered in accordance
	with Section 5.4 of the Purchase Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Legends
</U>
	.
	Unless the Warrant Shares are registered for resale with the Commission, each certificate evidencing the Warrant Shares issued
	upon exercise of this Warrant shall be stamped or imprinted with a legend required pursuant to the Purchase Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Removal
	of Legend
</U>
	. Upon request of a holder of a certificate with the legends required by Section 5 hereof, the Company shall issue
	to such holder a new certificate therefor free of any transfer legend, if, with such request, the Company shall have received an
	opinion of counsel satisfactory to the Company in form and substance to the effect that any transfer by such holder of the Warrant
	Shares evidenced by such certificate will not violate the Securities Act or any applicable state securities laws.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Fractional
	Shares
</U>
	. No fractional Warrant Shares will be issued in connection with any exercise hereunder. Instead, the Company shall round
	up, as nearly as practicable to the nearest whole Share, the number of Warrant Shares to be issued.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 25; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage148"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Rights
	of Stockholders
</U>
	. Except as expressly provided herein, the Holder, as such, shall not be entitled to vote or be deemed the holder
	of the Warrant Shares or any other securities of the Company that may at any time be issuable on the exercise hereof for any purpose,
	nor shall anything contained herein be construed to confer upon the Holder, as such, any of the rights of a stockholder of the
	Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof,
	or to give or withhold consent to any corporate action (whether upon any recapitalization, issuance of stock, reclassification
	of stock, change of par value, consolidation, merger, conveyance, or otherwise) or to receive notice of meetings, or otherwise
	until this Warrant shall have been exercised and the Warrant Shares purchasable upon the exercise hereof shall have been issued,
	as provided herein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	No
	Transfer
</U>
	. This Warrant shall be assignable and transferable, provided that no such assignment and transfer shall be valid unless
	(a) the same shall be valid under and undertaken in accordance with applicable law, rule or regulation and (b) the provisions of
	Sections 4.1 and 5.7 of the Purchase Agreement shall be adhered to as a condition to such transfer or assignment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Miscellaneous
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
	Warrant and disputes arising hereunder shall be governed by and construed and enforced in accordance with the laws of the State
	of Delaware applicable to agreements made and to be performed wholly within such State, without regard to its conflict of law rules.
	Any action brought by either party against the other concerning the transaction contemplated by this Warrant shall be brought only
	in the state courts of Delaware or in the federal courts located in the state of Delaware. The parties to this Warrant hereby irrevocably
	waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack
	of jurisdiction or venue or based upon forum non conveniens. The Company and Holder waive trial by jury.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the terms hereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	covenants of the respective parties contained herein shall survive the execution and delivery of this Warrant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	terms of this Warrant shall be binding upon and shall inure to the benefit of any successors or permitted assigns of the Company
	and of the Holder and of the Warrant Shares issued or issuable upon the exercise hereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
	Warrant and the other documents delivered pursuant hereto constitute the full and entire understanding and agreement between the
	parties with regard to the subject hereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company shall not, by amendment of its Certificate of Incorporation or Bylaws, or through any other means, directly or indirectly,
	avoid or seek to avoid the observance or performance of any of the terms of this Warrant and shall at all times in good faith assist
	in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect
	the rights of the Holder contained herein against impairment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
	receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in
	the case of any such loss, theft or destruction, upon delivery of an indemnity agreement reasonably satisfactory in form and amount
	to the Company, or, in the case of any such mutilation, upon surrender and cancellation of such Warrant, the Company, at its expense,
	will execute and deliver to the Holder, in lieu thereof, a new Warrant of like date and tenor.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
	Warrant and any provision hereof may be amended, waived or terminated only by an instrument in writing signed by the Company and
	the Holder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 26; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage149"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant and the
	other Transaction Documents, at law or in equity (including a decree of specific performance and/or other injunctive relief), and
	nothing herein shall limit the right of the Holder to pursue actual damages for any failure by the Company to comply with the terms
	of this Warrant. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder
	and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach
	or threatened breach, the holder of this Warrant shall be entitled, in addition to all other available remedies, to an injunction
	restraining any breach, without the necessity of showing economic loss and without any bond or other security being required.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	IN WITNESS WHEREOF
</B>
	,
	the Company has caused this Warrant to be signed by its duly authorized officer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
<FONT STYLE="FONT-SIZE: 10PT">
	LABSTYLE INNOVATIONS CORP.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 46%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	By:
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Name:
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Title:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 238.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 27; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage150"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
<U>
	Exhibit A
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	NOTICE OF EXERCISE
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
	TO:
</TD>
<TD>
	LabStyle Innovations Corp., attention: President
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The undersigned hereby
	elects to purchase the below referenced shares (the &ldquo;
<U>
	Warrant Shares
</U>
	&rdquo;) of Common Stock of LabStyle Innovations
	Corp. (the &ldquo;
<U>
	Company
</U>
	&rdquo;) pursuant to the terms of the attached Warrant, and tenders herewith payment of the purchase
	price of such Warrant Shares in full. Payment of the purchase price is being made by:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 2IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; MARGIN-LEFT: 1IN; TEXT-INDENT: 0IN">
	____________
	a cash exercise with respect to _________________ Warrant Shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Please issue a certificate
	or certificates representing said shares in the name of the undersigned or in such other name as is specified below:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
	1.
</TD>
<TD>
	Name: __________________________________________________
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
	2.
</TD>
<TD>
	Address: ________________________________________________
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
	3.
</TD>
<TD>
	DWAC Instructions (if applicable): ___________________________________________
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	The undersigned
	hereby represents and warrants the following:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It (i) has such
	knowledge and experience in financial and business affairs that he/she/it is capable of evaluating the merits and risks involved
	in purchasing the Warrant Shares, (ii) is able to bear the economic risks involved in purchasing the Warrant Shares, and (iii)
	is a &ldquo;non-US person&rdquo; as defined in Regulation S promulgated under the Securities Act of 1933, as amended;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	making the decision to purchase the Warrant Shares, it has relied solely on independent investigations made by it and has had the
	opportunity to ask questions of, and receive answers from, the Company concerning the Warrant Shares, the financial condition,
	prospective business and operations of the Company and has otherwise had an opportunity to obtain any additional information, to
	the extent that the Company possess such information or could acquire it without unreasonable effort or expense;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Its overall commitment
	to investments that are not readily marketable is not disproportionate to its net worth and income, and the purchase of the Warrant
	Shares will not cause such overall commitment to become disproportionate; it can afford to bear the loss of the purchase price
	of the Warrant Shares;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
	has no present need for liquidity in its investment in the Warrant Shares; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
	acknowledges that the transaction contemplated in connection with the purchase of the Warrant Shares has not been reviewed or approved
	by the Securities and Exchange Commission or by any administrative agency charged with the administration of the securities laws
	of any state, and that no such agency has passed on or made any recommendation or endorsement of any of the securities contemplated
	hereby.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 50%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-DECORATION: NONE; TEXT-ALIGN: JUSTIFY; WIDTH: 35%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 15%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	(Signature and Date)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 28; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage151"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	EXHIBIT B-1 TO THE
<BR>
	SECURITIES PURCHASE AGREEMENT
</B>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	NON U.S. PERSON REPRESENTATIONS
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Each Purchaser indicating that it is not
	a U.S. person, severally and not jointly, further represents and warrants to the Company as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
	1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	At the time of (a) the offer by the Company and (b) the
	acceptance of the offer by such person or entity, of the Units, such person or entity was outside the United States.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
	2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Such person or entity is acquiring the Units for such
	Purchaser&rsquo;s own account, for investment and not for distribution or resale to others and is not purchasing the Units for
	the account or benefit of any U.S. person, or with a view towards distribution to any U.S. person, in violation of the registration
	requirements of the Securities Act.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
	3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Such person or entity will make all subsequent offers
	and sales of the Units either (x) outside of the United States in compliance with Regulation S; (y) pursuant to a registration
	under the Securities Act; or (z) pursuant to an available exemption from registration under the Securities Act. Specifically,
	such person or entity will not resell the Units to any U.S. person or within the United States prior to the expiration of a period
	commencing on the Closing Date and ending on the date that is one year thereafter (the &ldquo;
<U>
	Distribution Compliance Period
</U>
	&rdquo;),
	except pursuant to registration under the Securities Act or an exemption from registration under the Securities Act.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
	4.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Such person or entity has no present plan or intention
	to sell the Units in the United States or to a U.S. person at any predetermined time, has made no predetermined arrangements to
	sell the Units and is not acting as a distributor of such securities.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
	5.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Neither such person or entity, its affiliates nor
	any person acting on behalf of such person or entity, has entered into, has the intention of entering into, or will enter into
	any put option, short position or other similar instrument or position in the U.S. with respect to the Units at any time after
	the Closing Date through the Distribution Compliance Period except in compliance with the Securities Act.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
	6.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Such person or entity consents to the placement of
	a legend on any certificate or other document evidencing the Units substantially in the form set forth in Section&nbsp;4.1.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
	7.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Such person or entity is not acquiring the Units in
	a transaction (or an element of a series of transactions) that is part of any plan or scheme to evade the registration provisions
	of the Securities Act.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
	8.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Such person or entity has sufficient knowledge and
	experience in finance, securities, investments and other business matters to be able to protect such person&rsquo;s or entity&rsquo;s
	interests in connection with the transactions contemplated by this Agreement.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
	9.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Such person or entity has consulted, to the extent
	that it has deemed necessary, with its tax, legal, accounting and financial advisors concerning its investment in the Units.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 29; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage152"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
	10.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Such person or entity understands the various risks
	of an investment in the Units and can afford to bear such risks for an indefinite period of time, including, without limitation,
	the risk of losing its entire investment in the Units.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
	11.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Such person or entity has had access to the Company&rsquo;s
	publicly filed reports with the Commission and has been furnished during the course of the transactions contemplated by this Agreement
	with all other public information regarding the Company that such person or entity has requested and all such public information
	is sufficient for such person or entity to evaluate the risks of investing in the Units.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
	12.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Such person or entity has been afforded the opportunity
	to ask questions of and receive answers concerning the Company and the terms and conditions of the issuance of the Units.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
	13.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Such person or entity is not relying on any representations
	and warranties concerning the Company made by the Company or any officer, employee or agent of the Company, other than those contained
	in this Agreement.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
	14.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Such person or entity will not sell or otherwise transfer
	the Securities unless either (A)&nbsp;the transfer of such securities is registered under the Securities Act or (B) an exemption
	from registration of such securities is available.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
	15.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Such person or entity represents that the address
	furnished on its signature page to this Agreement is the principal residence if he is an individual or its principal business
	address if it is a corporation or other entity.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
	16.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Such person or entity understands and acknowledges
	that the Units have not been recommended by any federal or state securities commission or regulatory authority, that the foregoing
	authorities have not confirmed the accuracy or determined the adequacy of any information concerning the Company that has been
	supplied to such person or entity and that any representation to the contrary is a criminal offense.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 30; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage153"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Company Wiring Instructions
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Bank Leumi USA -
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Account Name - Labstyle Innovations Corp
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Account No -
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Swift LUMIUS3N
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Bank address - 579 Fifth Avenue 5th Floor | New York
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 31; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage154"></A>
<A NAME="V430703_EX21-1_HTM"></A>
<EFX_EXHIBIT_21>
<A NAME="FIS_EXHIBIT_21"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 21.1
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Subsidiaries of the Registrant
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Labstyle Innovation Ltd., an Israeli company (&ldquo;Labstyle Israel&rdquo;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	LabStyle Innovations US LLC, a Delaware limited liability company,
	a subsidiary of Labstyle Israel
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
</EFX_EXHIBIT_21>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage155"></A>
<A NAME="V430703_EX23-1_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23"></A>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 23.1
</B>
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="MARGIN: 0">
</P>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Consent of Independent Registered Public
	Accounting Firm
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; TEXT-INDENT: 0.5IN">
	We consent to the incorporation by reference in the Registration Statement (Form S-1, No. 333-209002)
	of LabStyle Innovations Corp.
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(&ldquo;LabStyle&rdquo;)
	and in the related Prospectus of our report dated February 8, 2016, with respect to the consolidated financial statements of LabStyle
	included in this Annual Report (Form 10-K) for the year ended December 31, 2015.
</FONT>
</P>
<P STYLE="MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 60%; TEXT-ALIGN: LEFT; DIRECTION: RTL; UNICODE-BIDI: EMBED; FONT-SIZE: 10PT">
	Tel-Aviv, Israel
</TD>
<TD STYLE="WIDTH: 40%; TEXT-ALIGN: LEFT; DIRECTION: RTL; UNICODE-BIDI: EMBED; FONT-SIZE: 10PT">
	/s/ Kost Forer Gabbay &amp; Kasierer
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; DIRECTION: RTL; UNICODE-BIDI: EMBED; FONT-SIZE: 10PT">
	February 8, 2016
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; DIRECTION: RTL; UNICODE-BIDI: EMBED; FONT-SIZE: 10PT">
	A Member of Ernst &amp; Young Global
</TD>
</TR>
</TABLE>
</EFX_EXPERTS_CONSENT>
<P STYLE="MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
</EFX_EXHIBIT_23>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage156"></A>
<A NAME="V430703_EX31-1_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 31.1
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATION
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	OF PRINCIPAL EXECUTIVE OFFICER
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	PURSUANT TO RULE 13A-14(A) AND 15D-14(A)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	UNDER THE SECURITIES EXCHANGE ACT OF 1934
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	I, Erez Raphael, certify that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	1. I have reviewed this Annual Report on Form
	10-K of LabStyle Innovations Corp. (the &ldquo;Registrant&rdquo;);
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	2. Based on my knowledge, this report does
	not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
	light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	3. Based on my knowledge, the financial statements,
	and other financial information included in this report, fairly present in all material respects the financial condition, results
	of operations and cash flows of the registrant as of, and for, the periods presented in this report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	4. The registrant&rsquo;s other certifying
	officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
	Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a13a-15(f) and
	15d-15(f)) for the registrant and have:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	a)&nbsp;&nbsp;&nbsp; Designed
	such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision,
	to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
	others within those entities, particularly during the period in which this report is being prepared;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	b)&nbsp;&nbsp; &nbsp;Designed
	such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
	supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
	statements for external purposes in accordance with generally accepted accounting principles;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	c)&nbsp;&nbsp;&nbsp;&nbsp;
	Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures; and presented in this report our conclusions
	about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such
	evaluation; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	d)&nbsp;&nbsp; &nbsp;Disclosed
	in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
	most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
	or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	5. The registrant&rsquo;s other certifying
	officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
	auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	a)&nbsp;&nbsp;&nbsp; All
	significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
	are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
	and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	b)&nbsp;&nbsp;&nbsp;&nbsp;Any
	fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
	internal control over financial reporting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Date: February 8, 2016
</FONT>
</TD>
<TD STYLE="WIDTH: 50%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Erez Raphael
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Erez Raphael
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	President, Chief Executive Officer and Acting Chairman of the Board (Principal Executive Officer)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage157"></A>
<A NAME="V430703_EX31-2_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 31.2
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATION
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	OF PRINCIPAL FINANCIAL OFFICER
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	PURSUANT TO RULE 13A-14(A) AND 15D-14(A)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	UNDER THE SECURITIES EXCHANGE ACT OF 1934
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	I, Zvi Ben David, certify that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	1. I have reviewed this Annual Report on Form
	10-K of LabStyle Innovations Corp. (the &ldquo;Registrant&rdquo;);
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	2. Based on my knowledge, this report does
	not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
	light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	3. Based on my knowledge, the financial statements,
	and other financial information included in this report, fairly present in all material respects the financial condition, results
	of operations and cash flows of the registrant as of, and for, the periods presented in this report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	4. The registrant&rsquo;s other certifying
	officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
	Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a13a-15(f) and
	15d-15(f)) for the registrant and have:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	a)&nbsp;&nbsp;&nbsp;&nbsp;
	Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision,
	to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
	others within those entities, particularly during the period in which this report is being prepared;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	b)&nbsp;&nbsp;&nbsp;&nbsp;
	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
	under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
	financial statements for external purposes in accordance with generally accepted accounting principles;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	c)&nbsp;&nbsp;&nbsp;&nbsp;
	Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures; and presented in this report our conclusions
	about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such
	evaluation; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	d)&nbsp;&nbsp;&nbsp;&nbsp;
	Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the
	registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that
	has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
	and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	5. The registrant&rsquo;s other certifying
	officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
	auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	a)&nbsp;&nbsp;&nbsp;&nbsp;
	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
	are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
	and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	b)&nbsp;&nbsp;&nbsp;&nbsp;
	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
	internal control over financial reporting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Date: February 8, 2016
</FONT>
</TD>
<TD STYLE="WIDTH: 50%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Zvi Ben David
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Zvi Ben David
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Financial Officer, Secretary and Treasurer
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(Principal Financial Officer)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
</P>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage158"></A>
<A NAME="V430703_EX32-1_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 32.1
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_3"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATION
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	OF PRINCIPAL EXECUTIVE OFFICER AND
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	PRINCIPAL FINANCIAL OFFICER
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	PURSUANT TO 18 U. S. C. SECTION 1350,
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In connection with the
	Annual Report of LabStyle Innovations Corp. (the &ldquo;Company&rdquo;) on Form 10-K for the period ended December 31, 2015 (the
	&ldquo;Report&rdquo;), I, Erez Raphael, Chief Executive Officer of the Company, and I, Zvi Ben David, Chief Financial Officer of
	the Company, hereby certify pursuant to 18 U.S.C. Section 1350, that to my knowledge:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	1.&nbsp;&nbsp;&nbsp; The Report fully complies
	with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	2.&nbsp;&nbsp;&nbsp; The information contained
	in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Date: February 8, 2016
</FONT>
</TD>
<TD STYLE="WIDTH: 50%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Erez Raphael
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Erez Raphael
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-LEFT: 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	President, Chief Executive Officer and Acting Chairman of the Board
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-LEFT: 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(Principal Executive Officer)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-LEFT: 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Date: February 8, 2016
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Zvi Ben David
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Zvi Ben David
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Financial Officer, Secretary and Treasurer
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(Principal Financial Officer)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_32>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
